20.10.2023

10:15 - 11:45 **Type: Industry Satellite Symposium**
Title: AstraZeneca - Evolving Paradigms in Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates
Salamanca Auditorium - Hall 3

Chair(s): Javier Cortés, ES

10:15 - 10:20 **Welcome and Introduction**

J. Cortés, Hospital Ruber Internacional, Madrid, ES

10:20 - 10:45 **Antibody-Drug Conjugates for HR-Positive Breast Cancer: Where Are We Today?**

P. Fasching, University Hospital Erlangen, Erlangen, DE

10:45 - 11:10 **Next-Generation Antibody-Drug Conjugates in Practice: A Case-Based Discussion**

S. Hurvitz, University of Washington, Seattle, US

11:10 - 11:30 **New Antibody-Drug Conjugates on the Horizon**

P. Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

11:30 - 11:40 **Audience Q&A**

J. Cortés[1], P. Fasching[2], S. Hurvitz[3], P. Schmid[4], [1]Hospital Ruber Internacional, Madrid, ES, [2]University Hospital Erlangen, Erlangen, DE, [3]University of Washington, Seattle, US, [4]Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

11:40 - 11:45 **Concluding Remarks**

J. Cortés, Hospital Ruber Internacional, Madrid, ES

10:15 - 11:45 **Type: Industry Satellite Symposium** **Málaga Auditorium - Hall 10**

Title: Seagen - HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?

Chair(s): Salvatore Siena, IT

10:15 - 10:20 **Welcome and Introduction**

S. Siena, UNIMI - Università degli Studi di Milano Statale, Milan, IT

10:20 - 10:35 **HER2 as an Actionable Target in HER2+ mCRC**

K. Ng, Dana Farber Cancer Institute, Boston, US

10:35 - 10:55 **The Role of HER2 Testing in mCRC**

R. Adams, Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB

10:55 - 11:15 **Exploring New Opportunities to Improve Outcomes in Patients with HER2+ mCRC**

S. Siena, UNIMI - Università degli Studi di Milano Statale, Milan, IT

11:15 - 11:40 **Panel Discussion and Interactive Q&A**

S. Siena[1], K. Ng[2], R. Adams[3], [1]UNIMI - Università degli Studi di Milano Statale, Milan, IT, [2]Dana Farber Cancer Institute, Boston, US, [3]Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB

11:40 - 11:45 **Closing Remarks**

S. Siena, UNIMI - Università degli Studi di Milano Statale, Milan, IT

10:15 - 11:40 **Type: Industry Satellite Symposium** **Santander Auditorium - Hall 9**

Title: Deciphera - Expert perspectives: management of advanced GIST –now and in the future

Chair(s): Cesar Serrano, ES

10:15 - 10:20 **Welcome and introduction**

C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

10:20 - 10:40 **Overview of advanced GIST: understanding the pathogenesis for this rare cancer**

A. Napolitano, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

10:40 - 11:00 **Reviewing advanced GIST management and addressing current challenges to care**

S. Watson, Institut Curie, Paris, FR

11:00 - 11:20 **Individualising treatment, ctDNA and future advanced GIST management**

C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

11:20 - 11:40 **Discussion and conclusions**

C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

10:15 - 11:45 **Type: Industry Satellite Symposium** **Toledo Auditorium - Hall 3**
Title: Astellas Pharma Europe Ltd - The evolving treatment landscape in LA/mUC
Chair(s): Ignacio Duran Martinez, ES

10:15 - 10:20 **Housekeeping and introductions**
I. Duran Martinez, HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES

10:20 - 10:30 **First-line therapy for patients with LA/mUC: The transformation of the treatment landscape and current unmet needs**
I. Duran Martinez, HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES

10:30 - 10:50 **Overview of current trials investigating first-line treatment of LA/mUC**
T. Friedlander, UCSF - University of California San Francisco, San Francisco, US

10:50 - 11:30 **Clinical experiences with first-line treatment of LA/mUC**
F. Schlürmann[1], T. Friedlander[2], [1]CHRU Brest - Hopital Augustin Morvan, Brest, FR, [2]UCSF - University of California San Francisco, San Francisco, US

11:30 - 11:40 **Panel discussion**
I. Duran Martinez[1], F. Schlürmann[2], T. Friedlander[3], [1]HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES, [2]CHRU Brest - Hopital Augustin Morvan, Brest, FR, [3]UCSF - University of California San Francisco, San Francisco, US

11:40 - 11:45 **Summary and close**
I. Duran Martinez, HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES

10:15 - 11:45 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 7**

Title: Bristol Myers Squibb - Immuno-Oncology Landscape for GI Cancers: Perspectives on Current Practices and Recent Advances

Chair(s): John Bridgewater, GB

10:15 - 10:20 **Immuno-Oncology Landscape for GI Cancers: Perspectives on Current Practices and Recent Advances**

J. Bridgewater, UCL Cancer Institute - Paul O'Gorman Building, London, GB

10:20 - 10:40 **Immunotherapeutic Advances in the Treatment of Esophageal Cancer**

P. Thuss-Patience, Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE

10:40 - 11:00 **Update on Immuno-Oncology for the Treatment of Gastric Cancer**

T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES

11:00 - 11:20 **Advances in Immuno-Oncology for the Treatment of Colorectal Cancer**

M.E. Elez Fernandez, Vall d'Hebron University Hospital, Barcelona, ES

11:20 - 11:40 **Roundtable Case Discussion, Q&A**

J. Bridgewater[1], M.E. Elez Fernandez[2], P. Thuss-Patience[3], T. Fleitas[4], [1]UCL Cancer Institute - Paul O'Gorman Building, London, GB, [2]Vall d'Hebron University Hospital, Barcelona, ES, [3]Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE, [4]Hospital Clinico Universitario de Valencia, Valencia, ES

11:40 - 11:45 **Summary and Close**

J. Bridgewater, UCL Cancer Institute - Paul O'Gorman Building, London, GB

10:15 - 11:45	**Type: Industry Satellite Symposium** **Title: Servier - Are brain cancer patients finally able to benefit from precision medicine approaches?** Chair(s): Carmen Balana, ES	**León Auditorium - Hall 7**

10:15 - 10:25 **Introduction: The Sword of Damocles hanging over each patient**

C. Balana, ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES

10:25 - 10:45 **IDH Mutated Glioma: A Decade's journey from bench to bedside**

T. Cloughesy, Ronald Reagan UCLA Medical Center University of California, Los Angeles, US

10:45 - 11:00 **Connecting the dots: Understanding recent clinical evidence in the framework of previous studies and current practice**

M. Van Den Bent, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL

11:00 - 11:15 **The evolving paradigm for clinical management of glioma**

S. Erridge, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, GB

11:15 - 11:30 **Navigating the paradigm shift: Thriving in the new era glioma care**

G. Tabatabai, Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE

11:30 - 11:45 **Q&A Session**

C. Balana[1], G. Tabatabai[2], T. Cloughesy[3], M. Van Den Bent[4], S. Erridge[5], [1]ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, [2]Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE, [3]Ronald Reagan UCLA Medical Center University of California, Los Angeles, US, [4]Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL, [5]Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, GB

12:00 - 13:45 **Type: Opening session** **Madrid Auditorium - Hall 6**
Title: Opening session

12:00 - 12:17 **Welcome and Presidential address**

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

12:17 - 12:22 **Scientific Chair address**

S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

12:22 - 12:27 **Presentation of the ESMO awards 2023**

12:27 - 12:46 **ESMO Award 2023**

I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

12:46 - 13:05 **ESMO Award for Translational Research 2023**

N. Turner, The Royal Marsden Hospital - Chelsea, London, GB

13:05 - 13:24 **ESMO Women for Oncology Award 2023**

G. Long, University of Sydney, Sydney, AU

13:24 - 13:43 **ESMO Lifetime Achievement Award 2023**

A.T. Chan, The Chinese University of Hong Kong, Hong Kong, CN

13:43 - 13:45 **Closure of the Opening Ceremony**

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

14:00 - 15:40 **Type: Proffered Paper session** **Barcelona Auditorium - Hall 9**
Title: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive

Chair(s): Elizabeth Smyth, GB; Magnus Nilsson, SE

14:00 - 14:10 **LBA74 - Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study**

K. Shitara[1], S.Y. Rha[2], L. Wyrwicz[3], T. Oshima[4], N. Karaseva[5], M. Osipov[6], H. Yasui[7], H. Yabusaki[8], S. Afanasyev[9], Y.-K. Park[10], S.-E. Al-Batran[11], T. Yoshikawa[12], P. Yanez Weber[13], M. Di Bartolomeo[14], S. Lonardi[15], X. Fang[16], C.-S. Shih[16], P. Bhagia[16], Y.-J. Bang[17], [1]National Cancer Center Hospital East, Kashiwa, JP, [2]Yonsei Cancer Center, Yonsei University Health System & Songdang Institute for Clinical Research, Seoul, KR, [3]Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, PL, [4]Kanagawa Cancer Center, Yokohama, JP, [5]SPb SBHI Clinical Oncology Dispensary, Saint-Petersburg, RU, [6]Leningrad Regional Clinical Hospital, Saint-Petersburg, RU, [7]Kobe City Medical Center General Hospital, Kobe, JP, [8]Niigata Cancer Center Hospital, Niigata, JP, [9]Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk,

RU, [10]Chonnam National University Hwasun Hospital, Hwasun, KR, [11]Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, DE, [12]National Cancer Center Hospital, Tokyo, JP, [13]Universidad de La Frontera, James Lind Cancer Research Center, Temuco, CL, [14]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [15]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [16]Merck & Co., Inc., Rahway, US, [17]Seoul National University College of Medicine, Seoul, KR

14:10 - 14:20

LBA73 - Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Y. Janjigian[1], S.-E. Al-Batran[2], Z. Wainberg[3], E. Van Cutsem[4], D. Molena[1], K. Muro[5], W.J. Hyung[6], L. Wyrwicz[7], D.-Y. Oh[8], T. Omori[9], M. Moehler[10], M. Garrido[11], S. Cunha Sousa Oliveira[12], M. Liberman[13], V. Castro Oliden[14], M. Bilici[15], J. Kurland[16], I. Xynos[17], H. Mann[17], J. Tabernero[18], [1]Memorial Sloan Kettering Cancer Center, New York, US, [2]Krankenhaus Nordwest, University Cancer Center, Frankfurt, DE, [3]David Geffen School of Medicine at UCLA, Los Angeles, US, [4]University Hospitals Leuven and KU Leuven, Leuven, BE, [5]Aichi Cancer Center Hospital, Nagoya, JP, [6]Yonsei University College of Medicine, Seoul, KR, [7]Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, [8]Seoul National University Hospital; Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, [9]Osaka International Cancer Institute, Osaka, JP, [10]Johannes Gutenberg-University Clinic, Mainz, DE, [11]SAGA Clinical Trial Centre and Universidad Mayor, Santiago, CL, [12]Northern Riograndense League Against Cancer, Natal, Rio Grande do Norte, BR, [13]Centre Hospitalier de l'Université de Montréal, Centre de Recherche du CHUM, Montreal, CA, [14]National Institute of Neoplastic Diseases (INEN), Lima, PE, [15]Atatürk University Faculty of Medicine, Erzurum, TR, [16]AstraZeneca, Gaithersburg, US, [17]AstraZeneca, Cambridge, GB, [18]Vall d'Hebron Hospital Campus & Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, ES

14:20 - 14:30

Invited Discussant LBA74 and LBA73

E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB

14:30 - 14:40

Q&A

14:40 - 14:50

LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial

B. Van Der Wilk[1], B.M. Eyck[1], B. Wijnhoven[2], S. Lagarde[3], C. Rosman[4], B.J. Noordman[5], M. Valkema[1], P.-P. Coene[6], J.-W. Dekker[7], H. Hartgrink[8], J. Heisterkamp[9], E. Kouwenhoven[10], G. Nieuwenhuijzen[11], J.-P. Pierie[12], J. Van Sandick[13], M. Sosef[14], M. Spaander[2], E. Van Der Zaag[15], E. Steyerberg[8], J. Van Lanschot[1], [1]Erasmus MC - Erasmus University Rotterdam, Rotterdam, NL, [2]Erasmus MC, Rotterdam, NL, [3]Erasmus Medical Center, Rotterdam, NL, [4]Radboud University Medical Center, Nijmegen, NL, [5]Erasmus University Medical Center, Rotterdam, NL, [6]Maasstad Ziekenhuis, Rotterdam, NL, [7]Reinier de Graaf Hospital (Gasthuis), Delft, NL, [8]LUMC-Leiden University Medical Center, Leiden, NL, [9]ETZ - Elisabeth-TweeSteden Hospital, Tilburg, NL,

[10]Ziekenhuisgroep Twente (ZGT), Almelo, NL, [11]Catharina Hospital Eindhoven, Eindhoven, NL, [12]MCL - Medisch Centrum Leeuwarden, Leeuwarden, NL, [13]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [14]Zuyderland Medical Center, Heerlen, NL, [15]Gelre Ziekenhuizen, Apeldoorn, NL

14:50 - 15:00 **Invited Discussant LBA75**

M. Nilsson, Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE

15:00 - 15:10 **Q&A**

15:10 - 15:20 **1511O - Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study**

Y. Janjigian[1], A. Kawazoe[2], Y. Bai[3], J. Xu[4], S. Lonardi[5], J.-P. Metges[6], P. Yanez Weber[7], L. Wyrwicz[8], L. Shen[9], Y. Ostapenko[10], M. Bilici[11], H.C. Chung[12], K. Shitara[13], S. Qin[14], E. Van Cutsem[15], J. Tabernero[16], K. Li[17], C.-S. Shih[18], P. Bhagia[18], S.Y. Rha[12], [1]Memorial Sloan Kettering Cancer Center and Weill Cornel Medical College, New York, US, [2]National Cancer Center Hospital East, Kashiwa, JP, [3]Harbin Medical University Hospital, Harbin, CN, [4]Fifth Medical Center, Chinese PLA General Hospital, Beijing, CN, [5]Istituto Oncologico Veneto IOV-IRCCS, Padova, IT, [6]University Hospital of Brest, Brest, FR, [7]Universidad de La Frontera, James Lind Cancer Research Center, Temuco, CL, [8]Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, PL, [9]Peking University Cancer Hospital & Institute, Beijing, CN, [10]Clinic of National Cancer Institute, Kyiv, UA, [11]Atatürk University, Erzurum, TR, [12]Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, [13]National Cancer Hospital East, Kashiwa, JP, [14]Cancer Center of People’s Liberation Army, Nanjing, CN, [15]University Hospitals Gasthuisberg and KU Leuven, Leuven, BE, [16]Vall d’Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, ES, [17]Merck & Co. Inc., Rahway, US, [18]Merck & Co., Inc., Rahway, US

15:20 - 15:30 **Invited Discussant 1511O**

F. Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE

15:30 - 15:40 **Q&A**

14:00 - 15:45 **Type: Proffered Paper session** **Sevilla Auditorium - Hall 9**
Title: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies

Chair(s): Rafal Dziadziuszko, PL; Fiona Blackhall, GB

14:00 - 14:10 **1261O - Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial**

M. Awad[1], P. Forde[2], N. Girard[3], J. Spicer[4], C. Wang[5], S. Lu[6], T. Mitsudomi[7], E. Felip[8], S. Broderick[2], S.J. Swanson[1], J. Brahmer[2], K. Kerr[9], G. Saylors[10], K.-N. Chen[11], J.L. Cai[12], J. Mahmood[12], J. Neely[12], D. Balli[12], N. Hu[12], M. Provencio Pulla[13], [1]Dana-Farber Cancer Institute, Boston, US, [2]The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, [3]Institut Curie, Paris, FR, [4]McGill University Health Centre, Montreal, CA, [5]Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, [6]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN, [7]Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, JP, [8]Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, ES, [9]Aberdeen Royal Infirmary, Aberdeen, GB, [10]Charleston Oncology, Charleston, US, [11]Peking University School of Oncology, Beijing Cancer Hospital, Beijing, CN, [12]Bristol Myers Squibb, Princeton, US, [13]Hospital Universitario Puerta de Hierro, Madrid, ES

14:10 - 14:20

LBA56 - Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

J. Spicer[1], S. Gao[2], M. Liberman[3], T. Kato[4], M. Tsuboi[5], S.-H. Lee[6], K.-N. Chen[7], C. Dooms[8], M. Majem[9], E. Eigendorff[10], G. Martinengo[11], O. Bylicki[12], M. Garassino[13], D. Rodriguez Abreu[14], J. Chaft[15], S. Novello[16], J. Yang[17], S. Keller[18], A. Samkari[18], H. Wakelee[19], [1]McGill University, Montréal, CA, [2]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijng, CN, [3]Centre Hospitalier de Universite to Montréal (CHUM), Montreal, CA, [4]Kanagawa Cancer Center, Yokohama, JP, [5]National Cancer Center Hospital East, Kashiwa, JP, [6]Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, KR, [7]Peking University Cancer Hospital and Institute, Beijing, CN, [8]UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, [9]Hospital de la Santa Creu i Sant Pau, Barcelona, ES, [10]Zentralklinik Bad Berka GmbH, Bad Berka, DE, [11]Sanatorio Parque, Rosario, AR, [12]Hôpital d'Instruction des Armées Sainte Anne Toulon, Toulon, Cedex, FR, [13]Knapp Center for Biomedical Discovery, The University of Chicago, Chicago, US, [14]Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES, [15]Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, US, [16]University of Turin, A.O.U. San Luigi Gonzaga di Orbassano, Orbassano, IT, [17]Merck & Co., Inc. - Rahway, Rahway, US, [18]Merck & Co., Inc., Rahway, US, [19]Stanford University School of Medicine, Stanford Cancer Institute, Stanford, US

14:20 - 14:30

Invited Discussant 1261O and LBA56

J. Naidoo, Beaumont Hospital, Dublin, IE

14:30 - 14:35

Q&A

14:35 - 14:45

LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer

Z.-R. Zhao[1], S. Liu[2], T. Zhou[1], G. Chen[1], Z.-H. Ye[3], Z.-C. Li[1], J.-D. Wu[1], Y. Yang[1], M. Xi[1], Y.-B. Lin[1], H. Yang[1], [1]Sun Yat-sen University Cancer Center, Guangzhou, CN, [2]Sun Yat-sen

University Cancer Center, Guangzhou, CN, [3]The University of Hong Kong - Shenzhen Hospital, Shenzhen, CN

14:45 - 14:55 **1291O - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): A prospective multicentre, open-label, randomised, controlled trial**

P. Vera[1], F. Le Tinier[2], P. Chaumet-Riffaud[3], E. Martin[4], N. Pourel[5], P. Boisselier[6], N. Salem[7], C. Le Pechoux[8], E. Giroux-Leprieur[9], S. Guillerm[10], C. Audigier Valette[11], D. Lerouge[12], C. Massabeau[13], P. Moisson[14], A. Larrouy[15], S. Hapdey[1], A. Langlais[16], E. Amour[16], G. Zalcman[17], P. Giraud[18], S. Thureau[1], [1]Centre Henri Becquerel, ROUEN, FR, [2]Centre Oscar Lambret, Lille, FR, [3]Hôpital National des 15-20, Paris, FR, [4]Centre Georges-François Leclerc (Dijon), Dijon, FR, [5]Institut Sainte-Catherine, Avignon, Cedex, FR, [6]ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, [7]Institut Paoli-Calmettes, Marseille, Cedex, FR, [8]Institut Gustave Roussy, Villejuif, Cedex, FR, [9]University Paris-Saclay, UVSQ, APHP – Ambroise Paré Hospital, Boulogne-Billancourt, FR, [10]Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Paris, FR, [11]CHITS Toulon Sainte-Musse, Toulon, FR, [12]Centre Francois Baclesse, Caen, Cedex, FR, [13]Institut Claudius Regaud - IUCT Oncopole, Toulouse, Cedex, FR, [14]Hopital René Huguenin - Institut Curie, Saint-Cloud, FR, [15]ICPN - Centre de Cancerologie Paris Nord, Sarcelles, FR, [16]French Cooperative Thoracic Intergroup, Paris, FR, [17]Hopital Bichat - Claude-Bernard AP-HP, Paris, FR, [18]HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR

14:55 - 15:05 **Invited Discussant LBA60 and 1291O**

R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

15:05 - 15:10 **Q&A**

15:10 - 15:20 **LBA98 - Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial**

C. Proto[1], S. Manglaviti[1], G. Galli[1], M. Imbimbo[2], M.F. Alvisi[3], F. Zollo[3], M. Perrino[4], M. Giuliano[5], E. Pietroluongo[5], Z. Ballatore[6], A. Chella[7], A. Fabbri[1], R. Vigorito[1], F.G.M. De Braud[8], G. Pasello[9], I. Petrini[7], R. Berardi[10], P. Zucali[4], M. Ganzinelli[1], M. Garassino[11], G. Lo Russo[1], [1]Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, [2]Fondazione IRCCS Istituto Nazionale dei Tumori, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, [3]Istituto Di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, IT, [4]IRCCS Humanitas Research Hospital, Rozzano, IT, [5]AOU "Federico II", Napoli, IT, [6]AOU delle Marche, Torrette di Ancona, IT, [7]AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, [8]Fondazione IRCCS Istituto Nazionale dei Tumori, Università di Milano, Milan, IT, [9]University of Padova Medical School, Padova, Italy; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, IT, [10]Università Politecnica delle Marche, AOU delle Marche, Ancona, IT, [11]Fondazione IRCCS Istituto Nazionale dei Tumori, The University of Chicago, Chicago, US

15:20 - 15:30 **LBA92 - Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study**

L. Paz-Ares[1], M.-J. Ahn[2], E. Felip[3], S. Handzhiev[4], I. Korantzis[5], H. Izumi[6], K. Ohashi[7], M. Majem[8], J. Wolf[9], M. Reck[10], H.-D. Hummel[11], F. Blackhall[12], A.-M. Dingemans[13], T. Owonikoko[14], S. Ramalingam[15], J. Sands[16], T. Jiang[17], S. Mukherjee[17], E. Anderson[17], B.C. Cho[18], [1]Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO-H12o Lung Cancer Unit and Ciberonc, Madrid, ES, [2]Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, [3]Vall d'Hebron University Hospital, Barcelona, ES, [4]Universitätsklinikum Krems, Krems an der Donau, AT, [5]St Luke's Hospital-Agios Loukas Clinic, Thessaloniki, GR, [6]National Cancer Center Hospital East, Kashiwa, JP, [7]Okayama University Hospital, Okayama, JP, [8]Hospital de la Santa Creu i Sant Pau, Barcelona, ES, [9]Universitätsklinikum Köln (AöR), Cologne, DE, [10]Airway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, DE, [11]Universitätsklinikum Würzburg, Comprehensive Cancer Center Mainfranken, Wuerzburg, DE, [12]The Christie NHS Foundation Trust, Manchester, GB, [13]Erasmus MC Cancer Institute, University Medical Center, Rotterdam, NL, [14]UPMC Hillman Cancer Center, Pittsburgh, US, [15]Winship Cancer Institute of Emory University, Atlanta, US, [16]Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, [17]Amgen Inc., Thousand Oaks, US, [18]Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, KR

15:30 - 15:40 **Invited Discussant LBA98 and LBA92**

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

15:40 - 15:45 **Q&A**

14:00 - 15:40 **Type: Proffered Paper session** **Bilbao Auditorium - NCC**
Title: Proffered Paper session - Breast cancer, early stage

Chair(s): Stephen Johnston, GB; Sara Tolaney, US

14:00 - 14:10 **LBA17 - Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes**

N. Harbeck[1], P. Rastogi[2], J. O'Shaughnessy[3], F. Boyle[4], J. Cortés[5], H. Rugo[6], M. Goetz[7], E. Hamilton[8], C. Huang[9], E. Senkus-Konefka[10], A. Tryakin[11], P. Neven[12], J. Huober[13], R.J. Wei[14], V. Andre[14], M. Muñoz[14], B. San Antonio[14], A. Shahir[14], M. Martin Jimenez[15], S. Johnston[16], [1]Ludwig Maximilians University Hospital, Munich, DE, [2]University of Pittsburgh Medical Center, Pittsburgh, US, [3]Baylor University Medical Center, Dallas, US, [4]University of Sydney, Sydney, AU, [5]Hospital Ruber Internacional, Madrid, ES, [6]UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, [7]Mayo Clinic, Rochester, US, [8]Sarah Cannon Research Institute-Cancer Centre, Nashville, US, [9]NTUH - National Taiwan University Hospital, Taipei City, TW, [10]Medical University of Gdansk, Gdansk, PL, [11]Altai Branch of N. N. Blokhin Russian Cancer Research Centre, Barnaul, RU, [12]University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, [13]Kantonsspital St. Gallen, St. Gallen, CH, [14]Eli Lilly and Company, Indianapolis, US, [15]Gregorio Marañón General University Hospital, Madrid, ES, [16]Royal Marsden NHS Foundation Trust, London, GB

14:10 - 14:20 **LBA18 - Pembrolizumab or placebo plus chemotherapy followed by**

pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study

P. Schmid[1], J. Cortés[2], R. Dent[3], L. Pusztai[4], H. Mcarthur[5], S. Kummel[6], C. Denkert[7], Y.H. Park[8], R. Hui[9], N. Harbeck[10], M. Takahashi[11], T. Foukakis[12], M.A. Mouret Reynier[13], M. Ferreira[14], S.-A. Im[15], F. Cardoso[16], Y. Ding[17], W. Pan[17], K. Tryfonidis[17], J. O'Shaughnessy[18], [1]Barts Cancer Institute, Queen Mary University of London, London, GB, [2]Quironsalud Group, Barcelona, Spain and Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, ES, [3]Duke – National University of Singapore Medical School, Singapore, SG, [4]Yale Cancer Center, New Haven, US, [5]University of Texas Southwestern Medical Center, Dallas, US, [6]Kliniken Essen-Mitte, Essen, Germany and Charité – Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, DE, [7]Philipps-University Marburg and University Hospital Marburg, Marburg, DE, [8]Sungkyunkwan University School of Medicine, Seoul, KR, [9]Westmead Hospital and the University of Sydney, Sydney, NSW, Australia and Centre of Cancer Medicine, School of Clinical Medicine, University of Hong Kong, Hong Kong, HK, [10]LMU University Hospital, Munich, DE, [11]Hokkaido University Hospital, Sapporo, JP, [12]Karolinska Institutet and Breast Cancer Centre, Cancer theme, Karolinska University Hospital, Solna, SE, [13]Centre Jean Perrin, Clermont-Ferrand, FR, [14]Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, PT, [15]Seoul National University Hospital, Seoul, KR, [16]Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, PT, [17]Merck & Co., Inc., Rahway, US, [18]Texas Oncology, US Oncology Network, Dallas, US

14:20 - 14:30

LBA19 - Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

L. Gianni[1], C. Huang[2], D. Egle[3], B. Bermejo[4], C. Zamagni[5], M. Thill[6], A. Anton Torres[7], G. Bianchini[8], E. Sevillano Fernandez[9], S. Russo[10], E. Ciruelos[11], R. Greil[12], V. Semiglazov[13], M. Colleoni[14], C. Kelly[15], G. Mariani[16], L. Del Mastro[17], R. Spezia[1], H. Ali[18], G. Viale[14], [1]Fondazione Michelangelo, Milan, IT, [2]National Taiwan University Hospital and Taiwan Breast Cancer Consortium, Taipei, TW, [3]BrustGesundheitZentrum Tirol, Medical University, Innsbruck, AT, [4]Hospital Clínico Universitario de Valencia, INCLIVA; Department of Medicine, Universidad de Valencia; CIBERONC-ISCIII, Madrid, ES, [5]IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT, [6]Agaplesion Markus Krankenhaus,, Frankfurt am Main, DE, [7]Hospital Universitario Miguel Servet Instituto Investigación Sanitaria de Aragon Universidad de Zaragoza, Zaragoza, ES, [8]IRCCS San Raffaele Hospital, Milan, IT, [9]Hospital Universitario HM Sanchinarro, Centro Integral Oncológico Clara Campal, Unidad Central de Ensayos Clínicos, Madrid, ES, [10]Azienda Sanitaria Friuli Centrale, Udine, IT, [11]Hospital Universitario 12 de octubre, Madrid, ES, [12]Paracelsus Medical University; Salzburg Cancer Research Institute-CCCIT and Cancer cluster, Salzburg, AT, [13]NN Petrov Research Inst of Oncology, Saint-Petersburg, RU, [14]IEO Istituto Europeo di Oncologia IRCCS, Milan, IT, [15]Cancer Trials Ireland & Mater Misericordiae University Hospital, Dublin, IE, [16]IRCCS Istituto Nazionale Tumori, Milan, IT, [17]IRCCS Ospedale Policlinico San Martino, Università degli Studi di Genova, Genova, IT, [18]Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, GB

14:30 - 14:45

Invited Discussant LBA17, LBA18 and LBA19

K. Kalinsky, Winship Cancer Institute of Emory University, Atlanta, US

14:45 - 14:55 **Q&A**

14:55 - 15:05 **LBA20 - A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)**

S. Loi[1], G. Curigliano[2], R. Salgado[3], R.I. Romero Diaz[4], S. Delaloge[5], C. Rojas[6], M. Kok[7], C. Saura Manich[8], N. Harbeck[9], E. Mittendorf[10], D. Yardley[11], L. Pusztai[12], A. Suarez Zaizar[13], A. Ungureanu[14], F. Ades[15], R. Chandra[16], R. Nathani[17], M. Pacius[16], J. Wu[16], H. Mcarthur[18], [1]Peter MacCallum Cancer Centre, Melbourne, AU, [2]European Institute of Oncology, IRCCS; University of Milano, Milan, IT, [3]GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, BE, [4]Consultorio de Oncólogo Médico, Tlalnepantla de Baz, MX, [5]Institut Gustave Roussy, Villejuif, FR, [6]Bradford Hill, Independencia, CL, [7]Netherlands Cancer Institute, Amsterdam, NL, [8]Vall d'Hebron University Hospital, Barcelona, ES, [9]Ludwig Maximilians University Hospital, Munich, DE, [10]Dana Farber/Brigham and Women's Cancer Center, Boston, US, [11]Sarah Cannon Research Center and Tennessee Oncology, Chattanooga, US, [12]Smilow Cancer Hospital at Yale University School of Medicine, New Heaven, US, [13]CENEIT Oncologicos, Ciudad de Mexico, MX, [14]Amethyst Radiotherapy Center Cluj, Floresti, RO, [15]Bristol-Myers Squibb, Lawrenceville, US, [16]BMS - Bristol-Myers Squibb, Cambridge, US, [17]Bristol Myers Squibb, Cambridge, US, [18]University of Texas Southwestern Medical Center, Dallas, US

15:05 - 15:15 **LBA21 - KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer**

F. Cardoso[1], H. Mcarthur[2], P. Schmid[3], J. Cortés[4], N. Harbeck[5], M. Telli[6], D. Cescon[7], J. O'Shaughnessy[8], P. Fasching[9], Z. Shao[10], D. Loirat[11], Y.H. Park[12], M. González Fernández[13], Z. Liu[14], H. Yasojima[15], Y. Ding[16], L. Jia[16], V. Karantza[16], K. Tryfonidis[16], A. Bardia[17], [1]Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, PT, [2]University of Texas Southwestern Medical Center, Dallas, US, [3]Barts Cancer Institute, Queen Mary University of London, London, GB, [4]Quironsalud Group, Barcelona, Spain and Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, ES, [5]LMU University Hospital, Munich, DE, [6]Stanford University School of Medicine, Stanford, US, [7]Princess Margaret Cancer Centre, Toronto, CA, [8]Texas Oncology, US Oncology Network, Dallas, US, [9]Comprehensive Cancer Center Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Erlangen, DE, [10]Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, CN, [11]Institut Curie, Paris, FR, [12]Sungkyunkwan University School of Medicine, Seoul, KR, [13]IMAT-Oncomedica, Montería, CO, [14]Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, CN, [15]NHO Osaka National Hospital, Osaka, JP, [16]Merck & Co., Inc., Rahway, US, [17]Harvard Medical School, Boston, US

15:15 - 15:25 **Invited Discussant LBA20 and LBA21**

S. Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

15:25 - 15:40 **Q&A**

14:00 - 15:30 **Type: Educational session** **Granada Auditorium - Hall 3**
Title: Optimising overall survival in advanced renal cancer
Chair(s): Cristina Suarez Rodriguez, ES; Thomas Powles, GB

14:00 - 14:25 **Evolving frontline treatment paradigms**
T. Choueiri, Dana Farber Cancer Institute, Boston, US

14:25 - 14:50 **What is the role of localised therapies in metastatic RCC?**
A. Bex, Royal Free London NHS Foundation Trust, London, GB

14:50 - 15:15 **Data from sequencing trials and new therapeutic targets**
C. Suarez Rodriguez, Vall d'Hebron University Hospital, Barcelona, ES

15:15 - 15:30 **Discussion**

14:00 - 15:30 **Type: Educational session** **Burgos Auditorium - Hall 3**
Title: Therapeutic view on tumour immune microenvironment: It's TIME
Chair(s): Tanja de Gruijl, NL; Gary Middleton, GB

14:00 - 14:20 **Immune suppressive cell populations in TME**
V. Bronte, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

14:20 - 14:40 **How tumour-draining lymph nodes inform the content of the TME and vice versa**
T. De Gruijl, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

14:40 - 15:00 **Modulating TME to overcome primary and acquired resistance**
S. Zelenay, Cancer Research UK Manchester Institute, Manchester, GB

15:00 - 15:10 **Q&A and Discussion**

14:00 - 15:30	**Type: Educational session** **Title: First-line therapy in advanced melanoma: What is my preferred choice?** Chair(s): Teresa Petrella, CA; Reinhard Dummer, CH	**Salamanca Auditorium - Hall 3**

14:00 - 14:25 **My preferred choice is PD-1 monotherapy, and these are the reasons why**
T. Petrella, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA

14:25 - 14:50 **My preferred choice is combined immunotherapy with PD1+CTLA-4, and these are the reasons why**
A.M. Arance Fernandez, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

14:50 - 15:15 **I prefer the combination of anti-PD-1 and anti-LAG-3, and these are the reasons why**
R. Dummer, USZ - University Hospital Zürich, Zurich, CH

15:15 - 15:30 **Q&A and Discussion**

14:00 - 15:30	**Type: Educational session** **Title: Neuro-Oncology 101: All you need to know to take care of brain tumour patients** Chair(s): Matthias Holdhoff, US; Emeline Tabouret, FR	**Santander Auditorium - Hall 9**

14:00 - 14:20 **WHO classification simplified for the busy clinician**
M. Holdhoff, Johns Hopkins University, Baltimore, US

14:20 - 14:40 **Glioma beyond TMZ/RT**
E. Galanis, Mayo Clinic - Rochester, Rochester, US

14:40 - 15:00 **Brain metastases: When radiation is (not!) indicated**
S. Lukacova, Aarhus University Hospital, Aarhus, DK

15:00 - 15:20 **Supportive care: Antiepileptics, steroids and anticoagulation**
A. Pace, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT

15:20 - 15:30 **Q&A and Discussion**

14:00 - 15:30	**Type: Special session** **Title: In collaboration with SIOG: Fundamentals in geriatric oncology in clinical practice** Chair(s): Ravindran Kanesvaran, SG; Etienne Brain, FR	**León Auditorium - Hall 7**

14:00 - 14:20 **Geriatric assessment: It is primetime now?**

L. Biganzoli, Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT

14:20 - 14:40 **Optimizing oncologic care in older patients with advanced lung cancer**

E. Quoix, Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, FR

14:40 - 15:00 **Optimizing oncologic care in older patients with advanced breast cancer**

E. Brain, Hopital René Huguenin - Institut Curie, Saint-Cloud, FR

15:00 - 15:20 **Optimizing oncologic care in older patients with advanced colorectal cancer**

D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY

15:20 - 15:30 **Discussion**

14:00 - 15:30	**Type: Patient Advocacy session** **Title: The importance to address the caregivers' needs: The perspective of the caregivers** Chair(s): Bettina Ryll, SE; Katie Rizvi, RO	**Cádiz Auditorium - NCC**

14:00 - 14:15 **Caregiver? Carer? Who are they?**
S. Yghemonos, Eurocarers, Brussels, BE

14:15 - 14:30 **Caregivers' needs along the patient journey: What do oncologists need to know?**
B. Ryll, Melanoma Patient Network Europe MPNE, Uppsala, SE

14:30 - 14:45 **Caregivers' needs along the patient journey: What do nurses need to know?**
K. Rizvi, YCE - Youth Cancer Europe, Cluj-Napoca, RO

14:45 - 15:00 **Caregivers after patient end of life: The caregivers' role continues...as do their needs!**
S. Chaturvedi, King's College Hospital - NHS Foundation Trust, London, GB

15:00 - 15:15 **Cancer patient groups and their help to support caregivers: Guide for healthcare professionals**
M. Leal, Portuguese League Against Cancer, Lisbon, PT

15:15 - 15:25 **Discussion**

15:25 - 15:45 **Conclusion**

14:00 - 15:30	**Type: Special session** **Title: ESMO-MCBS: 2023 revolution** Chair(s): Nathan Cherny, IL; Dario Trapani, IT	**Ávila Auditorium - NCC**

14:00 - 14:05 **Introduction**

D. Trapani, Università degli Studi di Milano, Milan, IT

14:05 - 14:30 **A guide through the new ESMO-MCBS v2.0**

N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

14:30 - 14:55 **ESMO-Magnitude of Clinical Scale for Haematological Malignancies (ESMO-MCBS:H)**

B. Kiesewetter-Wiederkehr, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

14:55 - 15:20 **Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI): Two years update**

M. Pe, EORTC, Brussels, BE

15:20 - 15:30 **Conclusions and perspectives, discussion and Q&A**

D. Trapani, Università degli Studi di Milano, Milan, IT

14:15 - 15:00	**Type: Challenge your Expert** **Title: First-line treatment of oncogene-addicted mutated NSCLC: Choosing between many options** Chair(s): Enriqueta Felip, ES	**Valencia Auditorium - Hall 10**

14:15 - 14:30 **Presentation by Expert EGFR**

Z. Piotrowska, MGH - Massachusetts General Hospital, Boston, US

14:30 - 14:45 **Presentation by Expert ALK**

G. Pasello, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

14:45 - 15:00 **Discussion led by Chair**

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

14:15 - 15:30	**Type: Multidisciplinary session** **Title: Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients** Chair(s): Lisa Carey, US; Adam Sonabend, US	**Málaga Auditorium - Hall 10**

14:15 - 14:20 **Presentation of case with extra cranial met / condition**

M. Banys- Paluchowski, UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE

14:20 - 14:35 **Integrating locoregional and systemic therapies for non-CNS metastatic disease**

A. Kirby, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

14:35 - 14:40 **Presentation of case with CNS met / condition**

A. Fitzpatrick, King's College London, London, GB

14:40 - 14:55 **Integrating locoregional and systemic therapies for CNS metastatic disease**

T. Bachelot, Centre Léon Bérard, Lyon, FR

14:55 - 15:10 **Beyond medical oncology in the management of metastatic disease: When to involve a surgeon or a radiation doctor or interventional radiologist**

L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US

15:10 - 15:30 **Discussion**

14:15 - 15:00	**Type: Challenge your Expert** **Title: East meets West in the management of head and neck cancer: Learning from each other** Chair(s): Jean-Pascal Machiels, BE	**Toledo Auditorium - Hall 3**

14:15 - 14:35 **Presentation by Expert**

B. Keam, Seoul National University Hospital, Seoul, KR

14:35 - 15:00 **Discussion led by Chair**

J.-P. Machiels, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE

16:00 - 17:30	**Type: Proffered Paper session** **Title: Proffered Paper session - NSCLC, metastatic** Chair(s): Marina Garassino, US; Yi-Long Wu, CN	**Barcelona Auditorium - Hall 9**

16:00 - 16:10 **LBA63 - SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)**

H. Borghaei[1], M. Johnson[2], E. Garon[3], K. He[4], D. Planchard[5], M. Reck[6], S. Popat[7], R.S. Herbst[8], T. Leal[9], D. Dumoulin[10], F. De Marinis[11], C. Reynolds[12], W. Theelen[13], I. Percent[14], V. Gutierrez Calderon[15], A.-C. Madroszyk Flandin[16], R. Shazer[17], X. Yan[17], R. Harrigan[17], S. Peters[18], [1]Fox Chase Cancer Center, Philadelphia, US, [2]Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, [3]University of California, Los Angeles, US, [4]The Ohio State University, Columbus, US, [5]Institut Gustave Roussy, Villejuif, FR, [6]LungenClinic Grosshansdorf, Grosshansdorf, DE, [7]The Royal Marsden Hospital NHS Foundation Trust, London, GB, [8]Yale University, New Haven, US, [9]Emory University, Atlanta, US, [10]Erasmus Medisch Centrum, Rotterdam, NL, [11]European Institute of Oncology, IRCC, Milan, IT, [12]Florida Cancer Specialists and Research Institute - North Region (SCRI), Ocala, US, [13]Netherlands Cancer Institute, Amsterdam, NL, [14]Florida Cancer Specialists and Research Institute - South Region (SCRI), Fort Myers, US, [15]Hospital Regional Universitario de Malaga, Malaga, ES, [16]Institut Paoli-Calmettes, Marseille, FR, [17]Mirati Therapeutics, Inc., San Diego, US, [18]Centre Hospitalier Universitaire Vaudois, Lausanne, CH

16:10 - 16:20 **LBA64 - Overall survival from a phase II randomised double-blind trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC**

S. Peters[1], A.L. Ortega Granados[2], F. De Marinis[3], G. Lo Russo[4], M. Schenker[5], E. Arriola[6], J. Puig[7], D.H. Lee[8], M. Reck[9], Z. Szijgyarto[10], E. Buss[11], N. Stjepanovic[11], S.M. Lim[12], [1]Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, CH, [2]Hospital Universitario de Jaén, Jaén, ES, [3]Istituto Europeo di Oncologia (IRCCS), Milan, IT, [4]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [5]Policlinica Sf. Nectarie, Centrul de Oncologie, Craiova, RO, [6]Hospital del Mar, Parc de Salut Mar, Barcelona, ES, [7]Centro Polivalente de Asistencia e Investigación Clínica, CER San Juan, San Juan, AR, [8]University of Ulsan, College of Medicine, Asan Medical Center, Seoul, KR, [9]Lungen Clinic, Airway Research Center North, Center for Lung Research, Grosshansdorf, DE, [10]GSK, Stevenage, GB, [11]GSK, Baar, CH, [12]Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, KR

16:20 - 16:30 **Invited Discussant LBA63 and LBA64**

N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

16:30 - 16:40 **Q&A**

16:40 - 16:50 **LBA65 - KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation**

M. Garassino[1], W. Theelen[2], R. Jotte[3], J. Laskin[4], F. De Marinis[5], C. Aguado[6], F. Badin[7], I. Chmielewska[8], M. Hochmair[9], S. Lu[10], E. Nadal[11], G. Ostoros[12], E. Felip[13], A. Spira[14], C. Lane[15], J. He[15], R. Chao[15], P. Jänne[16], [1]The University of Chicago, Chicago, US, [2]The Netherlands Cancer Institute, Amsterdam, NL, [3]Rocky Mountain Cancer Centers, Greenwood Village, US, [4]BC Cancer Vancouver Centre, University of British Columbia, Vancouver, CA, [5]Istituto Europeo di Oncologia, Milan, IT, [6]Hospital Universitario Clínico San Carlos, Madrid, ES, [7]Baptist Health Medical Group, Lexington, US, [8]Medical University of Lublin, Lublin, PL, [9]Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Vienna, AT, [10]Shanghai Lung Cancer Center, Shanghai Jiao Tong

University, Shanghai, CN, [11]Institut Català d'Oncologia (ICO), Barcelona, ES, [12]National Korányi Institute of Pulmonology, Budapest, HU, [13]Vall d'Hebron University Hospital, Barcelona, ES, [14]Virginia Cancer Specialists, Fairfax, VA; US Oncology Research, The Woodlands, US, [15]Mirati Therapeutics, Inc., San Diego, US, [16]Dana Farber Cancer Institute, Boston, US

16:50 - 17:00 **LBA66 - Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)**

S. Miura[1], H. Tanaka[1], T. Misumi[2], H. Yoshioka[3], T. Kurata[3], T. Tokito[4], T. Fukuhara[5], Y. Sato[6], Y. Shiraishi[7], S. Kusuhara[8], S. Teraoka[9], T. Kato[10], H. Horinouchi[11], Y. Takiguchi[12], Y. Goto[13], K. Tanaka[14], M. Kanazu[15], S. Ikeda[16], E. Ichihara[17], H. Okamoto[18], [1]Niigata Cancer Center Hospital, Niigata, JP, [2]Yokohama City University Hospital, Yokohama, JP, [3]Kansai Medical University, Hirakata, JP, [4]Kurume University, Kurume, JP, [5]Miyagi Cancer Center, Natori, JP, [6]Kobe City Medical Center General Hospital, Kobe, JP, [7]Kyushu University Hospital, Fukuoka, JP, [8]Kitasato University Hospital, Sagamihara, JP, [9]Wakayama Medical University, Wakayama, JP, [10]Kanagawa Cancer Center, Yokohama, JP, [11]National Cancer Center - Tsukiji Campus, Chuo-ku, JP, [12]Chiba University, School of Medicine, Chiba, JP, [13]Fujita Health University, Toyoake, JP, [14]Kyushu university hospital, Fukuoka, JP, [15]National Hospital Organization Toneyama Hospital, Toyonaka, JP, [16]Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, [17]Okayama University Hospital, Okayama, JP, [18]Yokohama Municipal Citizen's Hospital, Yokohama, JP

17:00 - 17:10 **LBA67 - A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)**

M.-J. Ahn[1], S. Park[2], T.M. Kim[3], J.-Y. Han[4], G.-W. Lee[5], B. Shim[6], Y.-G. Lee[7], S.-W. Kim[8], I.-H. Kim[9], S. Lee[10], Y.J. Kim[11], J.H. Park[12], S.G. Park[13], K. Lee[14], E.J. Kang[15], J.W. Kim[16], S.-H. Shin[17], [1]Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, [2]Samsung Medical Center, Seoul, KR, [3]Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR, [4]National Cancer Center - Graduate School of Cancer Science and Policy, Goyang, KR, [5]Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, Jinju, KR, [6]The Catholic University of Korea - St. Vincent's Hospital, Suwon, KR, [7]Samsung Medical Center (SMC)-Kangbuk Samsung Hospital, Seoul, KR, [8]Asan Medical Center - University of Ulsan, Seoul, KR, [9]Inje University Haeundae Paik Hospital, Busan, KR, [10]Dong-A University Medical Center, Busan, KR, [11]SNUBH - Seoul National University Bundang Hospital, Seongnam, KR, [12]Konkuk University Medical Center, Seoul, KR, [13]Chosun University Hospital, Gwangju, KR, [14]Chungbuk National University Hospital, Cheongju, KR, [15]Korea University Guro Hospital, Seoul, KR, [16]Korea University Anam Hospital, Seoul, KR, [17]Kosin Univeristy Gospel Hospital, Busan, KR

17:10 - 17:20 **Invited Discussant LBA65, LBA66 and LBA67**

F. Blackhall, The Christie NHS Foundation Trust, Manchester, GB

17:20 - 17:30 **Q&A**

16:00 - 17:30 **Type: Proffered Paper session** **Sevilla Auditorium - Hall 9**
Title: Proffered Paper session 1 - Gynaecological cancers

Chair(s): David SP Tan, SG; Ana Oaknin, ES

16:00 - 16:10

LBA36 - Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebo-controlled, phase III trial

X. Wu[1], J. Liu[2], X. Wang[3], J. Wang[4], L. Wang[5], J. Zhu[6], B. Kong[7], J. Fei[8], Y. Tang[9], B. Xia[10], Z. Liang[11], K. Wang[12], Z. Lin[13], Y. Huang[14], H. Zheng[15], A. Lin[16], K. Jiang[17], W. Wang[18], X. Wang[19], G. Lou[20], [1]Fudan University Shanghai Cancer Center, Shanghai, CN, [2]Sun Yat-sen University Cancer Center, Guangzhou, CN, [3]Liaoning Cancer Hospital & Institute, Shenyang, CN, [4]Hunan Cancer Hospital, Changsha, CN, [5]Henan Cancer Hospital, Zhengzhou, CN, [6]Cancer hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hanghou, CN, [7]Qilu Hospital of Shandong University, Jinan, CN, [8]The First Hospital of Jilin University, Changchun, CN, [9]Chongqing University Cancer Hospital, Chongqing, CN, [10]Anhui Provincial Cancer Hospital aka West Branch of Anhui Province Hospital, Hefei, CN, [11]South West Hospital, Third Military Medical University, Chongqing, CN, [12]TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, [13]The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN, [14]Hubei Cancer Hospital, Wuhan, CN, [15]Beijing Cancer Hospital, Beijing, CN, [16]Fujian Provincial Cancer Hospital, Fuzhou, CN, [17]The Second Affiliated Hospital of Dalian Medical University, Dalian, CN, [18]The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, [19]Zhongshan Hospital Xiamen University, Xiamen, CN, [20]Harbin Medical University Cancer Hospital, Harbin, CN

16:10 - 16:20

LBA37 - Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial

A. Gonzalez Martin[1], M.J. Rubio Perez[2], F. Heitz[3], R.D. Christensen[4], N. Colombo[5], T. Van Gorp[6], A. Oaknin[7], A. Leary[8], L. Gaba Garcia[9], C. Lebreton[10], L.M. De Sande González[11], M. Romeo Marin[12], A. Redondo[13], M.P. Barretina Ginesta[14], J.A. Perez Fidalgo[15], A. Santaballa Bertran[16], M.J. Bermejo-Pérez[17], I. Bruchim[18], I. Ray-Coquard[19], F. Selle[20], [1]Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Madrid, ES, [2]Reina Sofía University Hospital of Cordoba, Cordoba, ES, [3]KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE, [4]Copenhagen University Hospital, Copenhagen, DK, [5]Department of Medicine and Surgery, University of Milan-Bicocca, Milan, IT, [6]University Hospital Leuven, Leuven Cancer Institute, Leuven, BE, [7]Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, ES, [8]Gustave Roussy, Villejuif, FR, [9]Hospital Clinic and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, ES, [10]Institut Bergonié – Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, [11]Complejo Asistencial Universitario de León - Hospital de León, León, ES, [12]Institut Català d'Oncologia, Badalona, ES, [13]Hospital Universitario La Paz-IdiPAZ, Madrid, ES, [14]Institut Català d'Oncologia, IDIBGI, Girona, ES, [15]Hospital Clinico Universitario de Valencia, Valencia, ES, [16]Hospital Universitari i Politècnic La Fe, Valencia, ES, [17]Hospitales Universitarios Regional y Virgen Victoria, Málaga, ES, [18]Hillel Yaffe Medical Center Israel, affiliated with the Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Hadera, IL,

[19]Centre Léon Bérard, Lyon, FR, [20]Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, FR

16:20 - 16:30 **Invited Discussant LBA36 and LBA37**

C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB

16:30 - 16:45 **Q&A**

16:45 - 16:55 **LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study**

D. Lorusso[1], Y. Xiang[2], K. Hasegawa[3], G. Scambia[4], M. Leiva Galves[5], P. Ramos Elias[6], A. Acevedo[7], J. Vizkeleti[8], A.J. Gomes[9], F. Contreras Mejia[10], A. Reiss[11], A. Ayhan[12], J.-Y. Lee[13], V. Saevets[14], F. Zagouri[15], K. Li[16], K. Ussui Yamada[16], S. Toker[16], S. Pignata[17], L. Duska[18], [1]Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of Sacred Heart, Rome, IT, [2]Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, CN, [3]Saitama Medical University International Medical Center, Hidaka, Saitama, JP, [4]Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of the Sacred Heart, Rome, IT, [5]Instituto de Oncologia y Radioterapia Clinica Ricardo Palma, Lima, PE, [6]Edificio Integra Medical Center, Guatemala City, GT, [7]Oncocentro, Valparaiso, CL, [8]Centre of Radiotherapy, Budapest, HU, [9]Liga Norte Riograndense Contra o Câncer Rio Grande do Norte, Natal, BR, [10]Instituto Nacional de Cancerologia, Bogota, CO, [11]Gyneco-oncology Unit, Haifa, IL, [12]Başkent University, Ankara, TR, [13]Yonsei University College of Medicine, Seoul, KR, [14]Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine, Chelyabinsk, RU, [15]Alexandra Hospital, Athens, GR, [16]Merck & Co., Inc., Rahway, US, [17] Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, IT, [18]University of Virginia School of Medicine, Charlottesville, US

16:55 - 17:05 **Invited Discussant LBA38**

B. Monk, The University of Arizona, Tucson, US

17:05 - 17:20 **Q&A**

16:00 - 17:30 **Type: Special symposium** **Bilbao Auditorium - NCC**
Title: HER2 positive gastroesophageal cancer
Chair(s): Elizabeth Smyth, GB; Sylvie Lorenzen, DE

16:00 - 16:05 **Introduction and scientific background**
E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB

16:05 - 16:20 **Novel therapies in HER2 in advanced gastroesophageal cancer**
Y. Janjigian, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

16:20 - 16:35 **Targeting HER2 in operable gastroesophageal cancer**
F. Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE

16:35 - 16:50 **Lessons from the biology of HER2 positive gastroesophageal cancer**
H. Van Laarhoven, Academic Medical Center, University of Amsterdam, Amsterdam, NL

16:50 - 17:05 **HER2 and beyond: What's next?**
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP

17:05 - 17:25 **Discussion**

17:25 - 17:30 **Conclusions and perspectives**
S. Lorenzen, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

16:00 - 17:20 **Type: Proffered Paper session** **Granada Auditorium - Hall 3**
Title: Proffered Paper session - Genitourinary tumours, prostate
Chair(s): Karim Fizazi, FR; Shahneen Sandhu, AU

16:00 - 16:10 **1764O - Timing of radiotherapy (RT) after radical prostatectomy (RP): Final results of RADICALS RT randomised controlled trial**
C. Parker[1], N. Clarke[2], A. Cook[3], H. Kynaston[4], P. Meidahl Petersen[5], W. Cross[6], R. Persad[7], C. Catton[8], J. Logue[9], H. Payne[10], F. Saad[11], K. Brasso[12], C. Heath[13], H. Lindberg[14], R. Raman[15], M.A. Røder[12], A. Zarkar[16], W. Parulekar[17], M. Parmar[18], M. Sydes[3], [1]The Royal Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton, GB, [2]The University of Manchester, Manchester, GB, [3]Medical Research Council Clinical Trials Unit, London, GB, [4]Cardiff & Vale UHB, Cardiff, GB, [5]Copenhagen University, Copenhagen, DK, [6]University of Leeds - Leeds Institute of Molecular Medicine (LIMM), Leeds, GB, [7]University Hospitals Bristol NHS Foundation Trust, Bristol, GB, [8]Princess Margaret Cancer Center, Toronto, CA, [9]The Christie NHS Foundation Trust, Manchester, GB, [10]University College London Hospitals NHS Foundation Trust, London, GB, [11]Hospital St. Luc du CHUM, Montreal, CA, [12]Rigshospitalet, Copenhagen, DK, [13]Southampton General Hospital - University Hospital Southampton NHS Trust,

Southampton, GB, [14]Herlev and Gentofte Hospital, Herlev, DK, [15]Kent Oncology Centre - Maidstone and Tunbridge NHS Trust, Maidstone, GB, [16]Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, [17]Canadian Cancer Trials Group, Kingston, CA, [18]MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB

16:10 - 16:20 **1765O - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)**

W. Kelly[1], D. Danila[2], C.-C. Lin[3], J.-L. Lee[4], N. Matsubara[5], P. Ward[6], A. Armstrong[7], D. Pook[8], M. Kim[9], T. Dorff[10], S. Fischer[11], Y.-C. Lin[12], L. Horvath[13], C. Sumey[14], Z. Yang[15], G. Jurida[15], J. Connarn[15], H. Penny[15], J. Stieglmaier[16], L. Appleman[17], [1]Thomas Jefferson University, Philadelphia, US, [2]MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, [3]NTUH - National Taiwan University Hospital, Taipei City, TW, [4]Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, [5]National Cancer Center Hospital East, Kashiwa, JP, [6]Oncology Hematology Care, Cincinnati, US, [7]Duke Cancer Center, Durham, US, [8]Monash Health - Monash Cancer Centre, Bentleigh East, AU, [9]SNUH - Seoul National University Hospital, Seoul, KR, [10]City of Hope Comprehensive Cancer Center, Duarte, US, [11]Kantonsspital St. Gallen, St. Gallen, CH, [12]Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, [13]Chris O'Brien Lifehouse, Camperdown, AU, [14]Sanford Cancer Center, Sioux Falls, US, [15]AMGEN (Headquarters) - USA, Thousand Oaks, US, [16]AMGEN Research (Munich) GmbH, Munich, DE, [17]UPMC Hillman Cancer Center, Pittsburgh, US

16:20 - 16:30 **Invited Discussant 1764O and 1765O**

S. Sandhu, Peter MacCallum Cancer Centre, Melbourne, AU

16:30 - 16:40 **Q&A**

16:40 - 16:50 **LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)**

L. Emmett[1], S. Subramaniam[2], M. Crumbaker[3], A. Joshua[4], A. Weickhardt[5], S.T. Lee[6], S. Ng[7], R. Francis[8], J. Goh[9], D. Pattison[9], H. Tan[10], I. Kirkwood[10], S. Sandhu[11], A. Nguyen[1], C. Gedye[12], N. Rutherford[13], M. Hofman[14], A. Martin[2], M. Stockler[15], I. Davis[16], [1]St. Vincent's Hospital, Darlinghurst, AU, [2]University of Sydney, Sydney, AU, [3]The Kinghorn Cancer Centre, Sydney, AU, [4]St Vincents Hospital Sydney, Sydney, AU, [5]Austin Health, Melbourne, AU, [6]Austin Health - Austin Hospital, Heidelberg, AU, [7]Sir Charles Gairdner Hospital, Nedlands, AU, [8]University of Western Australia, Perth, AU, [9]Royal Brisbane and Women's Hospital, Herston, AU, [10]Royal Adelaide Hospital, Adelaide, AU, [11]Peter MacCallum Cancer Centre, Melbourne, AU, [12]Calvary Mater Hospital Newcastle, Newcastle, AU, [13]Hunter New England Health Imaging Service, New Lambton, AU, [14]Victorian Comprehensive Cancer Centre, Melbourne, AU, [15]University of Sydney, Camperdown, AU, [16]Monash University and Eastern Health, Box Hill, AU

16:50 - 17:00 **1770O - Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-**

PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium

P. Ravi[1], W. Xie[1], M. Buyse[2], S. Halabi[3], P. Kantoff[4], O. Sartor[5], G. Attard[6], N. Clarke[7], A. D'Amico[1], J. Dignam[8], N. James[9], K. Fizazi[10], S. Gillessen[11], W. Parulekar[12], H. Sandler[13], D. Spratt[14], M. Sydes[15], B. Tombal[16], S. Williams[17], C. Sweeney[18], [1]Dana Farber Cancer Institute, Boston, US, [2]International Drug Development Institute, Louvain-la-Neuve, BE, [3]Duke University Medical Center, Durham, US, [4]Convergent Therapeutics, Inc., Cambridge, US, [5]Mayo Clinic - Rochester, Rochester, US, [6]University College London, London, GB, [7]The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, [8]NRG Oncology Statistics and Data Management Center, Philadelphia, US, [9]ICR - Institute of Cancer Research, London, GB, [10]Institut Gustave Roussy, Villejuif, Cedex, FR, [11]EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, [12]Canadian Cancer Trials Group, Kingston, CA, [13]Cedars Sinai Medical Center, Los Angeles, US, [14]Case Western Reserve University / University Hospitals, Cleveland, US, [15]Medical Research Council Clinical Trials Unit, London, GB, [16]Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, [17]Peter MacCallum Cancer Center, Melbourne, AU, [18]The University of Adelaide, Adelaide, AU

17:00 - 17:10 **Invited Discussant LBA84 and 1770O**

D. Heinrich, Sykehuset Innlandet HF, Brumunddal, NO

17:10 - 17:20 **Q&A**

16:00 - 17:20 **Type: Proffered Paper session** **Burgos Auditorium - Hall 3**
Title: Proffered Paper session - Supportive and palliative care

Chair(s): Anne Letsch, DE; Christina Ruhlmann, DK

16:00 - 16:10 **2030O - Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for metastatic cancer: Results from the PRO-TECT trial (Alliance AFT-39)**

E. Basch[1], D. Schrag[2], J. Jansen[3], B. Ginos[4], P. Spears[5], M. Jonsson[3], P. Carr[3], A. Deal[3], G. Thanarajasingam[6], B. Reeve[7], C. Snyder[8], D. Bruner[9], D. Cella[10], V. Blinder[11], L. Kottschade[12], J. Perlmutter[13], C. Geoghegan[13], G. Mazza[6], A. Weiss[14], A. Dueck[4], [1]UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, [2]MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, [3]University of North Carolina - Chapel Hill, Chapel Hill, US, [4]Mayo Clinic Cancer Center, Phoenix, US, [5]UNC - Lineberger Cancer Center, Chapel Hill, US, [6]Mayo Clinic - Rochester, Rochester, US, [7]Duke Cancer Center - Duke University Medical Center, Durham, US, [8]Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, [9]Winship Cancer Institute of Emory University, Atlanta, US, [10]Northwestern University, Chicago, US, [11]Memorial Sloan Kettering Cancer Center, Commack, US, [12]Mayo Clinic, Jacksonville, US, [13]Independent, Philadelphia, US, [14]University of Rochester Cancer Center, Rochester, US

16:10 - 16:20 **2031O - Randomized trial of a telephone-based weight loss intervention in overweight and obese patients (pts) with breast cancer (BC): The MEDEA trial**

I. Vaz Luis[1], A. Di Meglio[1], E. Martin[1], L. Vanlemmens[2], C. Segura-Djezzar[3], C. Bouleuc[4], O. Tredan[5], B. Pistilli[1], T. Crane[6], D. Soldato[1], C. Charles[1], A. Barbier[1], B. Raynard[7], A. Mangin[1], B. Coquet[8], G. Jacob[9], J. Bonastre[10], S. Michiels[1], D. Chaltiel[1], J. Ligibel[11], [1]Institut Gustave Roussy, Villejuif, Cedex, FR, [2]Centre Oscar Lambret, Lille, FR, [3]Centre Francois Baclesse, Caen, Cedex, FR, [4]Institut Curie, Paris, FR, [5]Centre Léon Bérard, Lyon, FR, [6]University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, US, [7]Gustave Roussy - Cancer Campus, Villejuif, FR, [8]Ligue Nationale Contre le Cancer, Paris, FR, [9]Seintinelles, Paris, FR, [10]Institut Gustave Roussy, Villejuif, FR, [11]Dana Farber Cancer Institute, Boston, US

16:20 - 16:30 **Invited Discussant 2030O and 2031O**

A. Letsch, Universitätsklinikum Schleswig Holstein Campus Kiel II, Kiel, DE

16:30 - 16:40 **Q&A**

16:40 - 16:50 **LBA94 - Effects of short-term fasting on quality of life as an add-on option during chemotherapy**

D. Koppold[1], C. Kessler[1], M. Wischnewsky[2], I.M. Alvarado-Rupflin[1], C. Kempter[3], M. Paul[4], B. Brueckner[3], D. Fischer[5], N. Steckhan[6], M. Jeitler[1], E. Hanslian[1], B. Kunz[1], A. Michalsen[1], [1]Charité - Universitätsmedizin Berlin, Berlin, DE, [2]University of Bremen, Bremen, DE, [3]Waldfriede Krankenhaus, Berlin, DE, [4]Vivantes Klinikum am Urban, Berlin, DE, [5]Klinikum Ernst von Bergmann, Potsdam, DE, [6]Hasso-Plattner-Institut, Potsdam, DE

16:50 - 17:00 **LBA95 - Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia: Efficacy and safety in the multinational phase III SCALA program**

D. Currow[1], S. Chessari[2], P. Bonomi[3], R. Giorgino[4], R. Skipworth[5], [1]University of Wollongong, Wollongong, AU, [2]Helsinn Healthcare SA, Pazzallo-Lugano, CH, [3]Rush University, Chicago, US, [4]Triallism GmbH, Allschwill, CH, [5]University of Edinburgh, Edinburgh, GB

17:00 - 17:10 **Invited Discussant LBA94 and LBA95**

J. Arends, Universitätsklinikum Freiburg - Klinik für Innere Medizin I/Klinik für Tumorbiologie, Freiburg im Breisgau, DE

17:10 - 17:20 **Q&A**

16:00 - 17:30 **Type: Proffered Paper session** **Santander Auditorium - Hall 9**
Title: Proffered Paper session - CNS tumours
Chair(s): Dieta Brandsma, NL; Evanthia Galanis, US

16:00 - 16:10 **498O - INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma**

D. Blumenthal[1], I. Mellinghoff[2], M. Van Den Bent[3], M. Touat[4], K. Peters[5], J. Clarke[6], J.

Mendez[7], L. Welsh[8], W. Mason[9], A. Hottinger[10], J.M. Sepulveda Sanchez[11], W. Wick[12], R. Soffietti[13], A. Tron[14], D. Zhao[14], S. Pandya[14], L. Steelman[14], I. Hassan[14], P. Wen[15], T. Cloughesy[16], [1]Tel-Aviv Medical Center, Tel-Aviv University, Tel Aviv, IL, [2]Memorial Sloan-Kettering Cancer Center, New York, US, [3]Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, NL, [4]Sorbonne Université, Institut du Cerveau, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière, Charles Foix, Paris, FR, [5]Duke University Medical Center, Durham, US, [6]University of California, San Francisco, US, [7]Huntsman Cancer Institute at the University of Utah, Salt Lake City, US, [8]The Royal Marsden Hospital, London, GB, [9]Princess Margaret Cancer Centre, and University of Toronto, Toronto, CA, [10]Lundin Family Brain Tumor Research Center, University Hospital of Lausanne, and University of Lausanne, Lausanne, CH, [11]Hospital Universitario 12 de Octubre, Madrid, ES, [12]Universitatsklinikum Heidelberg, Heidelberg, DE, [13]University of Turin, Torino, IT, [14]Servier Pharmaceuticals, Boston, US, [15]Dana-Farber Cancer Institute, Boston, US, [16]University of California, Los Angeles, US

16:10 - 16:20 **Invited Discussant 498O**

D. Brandsma, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:20 - 16:30 **Q&A**

16:30 - 16:40 **499O - A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated**

W. Li[1], Y. Mao[2], Z. Kang[1], W. Hua[2], S. Li[1], Z. Wu[3], H. Liu[4], J. Hu[4], J. Guo[4], W. Zhong[4], X. Wang[5], [1]Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, [2]Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, CN, [3]Beijing Fosun Pharmaceutical Research and Development Co., Ltd., Beijing, CN, [4]Beijing Fosun Pharmaceutical Research and Development Co., Ltd., Shanghai, CN, [5]Shanghai Fosun Pharmaceutical Development Co.,Ltd, Shanghai, CN

16:40 - 16:50 **500O - Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study**

M. Vieito Villar[1], J.M. Sepúlveda Sánchez[2], V. Moreno Garcia[3], G. Lombardi[4], A. Stradella[5], R.H. Dahlrot[6], C. Haslund[7], M. Geurts[8], E. Pineda[9], P. Brandal[10], F. De Vos[11], M.A. Vaz Salgado[12], M. Martinez Garcia[13], M. Macchini[14], B. Amoroso[15], T. Sanchez[15], B. Hanna[16], X. Li[16], Z. Nikolova[15], M. Simonelli[17], [1]Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, [2]Hospital Universitario 12 de Octubre, Madrid, ES, [3]Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, [4]Istituto Oncologico Veneto, Oncologia 1, IOV-IRCCS, Padua, IT, [5]Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, ES, [6]Odense University Hospital, Odense, DK, [7]Aalborg University Hospital, Aalborg, DK, [8]Erasmus MC Cancer Institute, Rotterdam, NL, [9]Hospital Clínic de Barcelona, Barcelona, ES, [10]Oslo University Hospital, Oslo, NO, [11]University Medical Center Utrecht, Utrecht, NL, [12]Hospital Universitario Ramon y Cajal, Madrid, ES, [13]Hospital del Mar, Barcelona, ES, [14]IRCCS San Raffaele Scientific Institute, Milan, IT, [15]Centre for Innovation and Translational Research Europe, a Bristol Myers Squibb Company, Seville, ES, [16]Bristol Myers Squibb, Princeton, US, [17]IRCCS Humanitas

Research Hospital and Department of Biomedical Sciences, Humanitas University, Milan, IT

16:50 - 17:00 **501O - Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial**

M.A. Vaz Salgado[1], S. Del Barco[2], J.M. Sepúlveda[3], M. Alonso[4], E. Pineda[5], C. Balana[6], M. Martínez-García[7], R. Gironés[8], [1]Hospital Universitario Ramón y Cajal, Madrid, ES, [2]Institut Català d'Oncologia Girona, Girona, ES, [3]Hospital Universitario 12 de Octubre, Madrid, ES, [4]Hospital Virgen del Rocío, Sevilla, ES, [5]Hospital Clínic de Barcelona, Barcelona, ES, [6]Institut Català d'Oncologia, Badalona, ES, [7]Hospital del Mar, Barcelona, ES, [8]Hospital Universitario y Politécnico la Fe de Valencia, Valencia, ES

17:00 - 17:15 **Invited Discussant 499O, 500O and 501O**

A.S. Berghoff, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

17:15 - 17:30 **Q&A**

16:00 - 17:30 **Type: Educational session** **León Auditorium - Hall 7**
Title: Harnessing innate immunity to fight cancer

Chair(s): Adrian Hayday, GB; Daniela Thommen, NL

16:00 - 16:25 **Are Gamma Delta T cells the protagonists of cancer attack by the innate immune system?**

A. Hayday, King's College London Guy's Hospital - NHS Foundation Trust, London, GB

16:25 - 16:50 **DNA sensing by innate immunity**

A. Ablasser, EPFL - Ecole Polytechnique Federale de Lausanne - Interfaculty (EPFL-SV-IBI), Lausanne, CH

16:50 - 17:15 **The Type 2 immune axis in the marrow directs pro-tumorigenic myelopoiesis**

T. Marron, Icahn School of Medicine at Mount Sinai, New York, US

17:15 - 17:30 **Q&A and Discussion**

16:00 - 17:30	**Type: Patient Advocacy session** **Title: How to improve access to medicines through patient engagement?** Chair(s): Jana Pelouchova, CZ; André Deschamps, BE	**Cádiz Auditorium - NCC**

16:00 - 16:15 **The improvement of the regulatory process through the consideration of patients' reported outcomes during the medicines' development**

A. Deschamps, Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE

16:15 - 16:30 **A gap analysis on access to modern medicines and treatments: A comparison between West and Eastern Europe**

K.E. Morgan, Myeloma Patients Europe AISBL, Brussels, BE

16:30 - 16:45 **Incorporating patient organizations' expertise into the healthcare legislation**

J. Pelouchova, Diagnoza leukemie, z.s, Prague, CZ

16:45 - 17:00 **Patient engagement and collaboration with national regulatory agencies**

L.-L. Eriksson, The Swedish Blood Cancer Association, Sundbyberg, SE

17:00 - 17:15 **Leukaemia care and the collaboration with NICE**

Z. Pemberton-Whiteley, Leukaemia Care - National Worcester, Worcester, GB

17:15 - 17:25 **Discussion**

17:25 - 17:30 **Conclusion**

16:00 - 18:00	**Type: Special session** **Title: 8th ESMO Designated Centres of Integrated Oncology and Palliative Care Session and Awards: Approaches to the integration of palliative care in oncology services** Chair(s): Jayne Wood, GB; Anna Reyners, NL	**Ávila Auditorium - NCC**

16:00 - 16:05 **Introduction**

J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

16:05 - 16:20 **Importance of integration of palliative care into mainstream oncology**

J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

16:20 - 16:35 **Designated centres virtual visits pilot**

A. Reyners, UMCG - University Medical Center Groningen, Groningen, NL

16:35 - 16:50 **MyPath update and introduction to the JANE network**

S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

16:50 - 17:05 **Symptom screening with Targeted Early Palliative care (STEP) intervention**

C. Zimmermann, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

17:05 - 17:25 **Q&A**

17:25 - 17:30 **Conclusion and next steps**

A. Reyners, UMCG - University Medical Center Groningen, Groningen, NL

17:30 - 18:00 **Designated Centres Awards**

J. Wood[1], A. Reyners[2], [1]The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, [2]UMCG - University Medical Center Groningen, Groningen, NL

16:00 - 17:30	**Type: Young Oncologists session** **Title: YO Mentorship sessions**	**Pamplona Auditorium - Hall 9**

16:00 - 16:00 **Table 1: Clinical research in the general oncology practice setting**

J. Cortés[1], H. Zhu[2], [1]Hospital Ruber Internacional, Madrid, ES, [2]Fudan University Shanghai Cancer Center, Shanghai, CN

16:00 - 16:00 **Table 2: How to build your own lab and research group in academia**

C. Saura Manich[1], R. Pihlak[2], [1]Vall d'Hebron University Hospital, Barcelona, ES, [2]St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

16:00 - 16:00 **Table 3: How to build your own lab and research group in academia**

J. Haanen[1], M. Moutafi[2], [1]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [2]Attikon University Hospital, Haidari, GR

16:00 - 16:00 **Table 4: Career opportunities for oncologists in the pharmaceutical industry**

L. Mühlenhoff[1], E. Kocakavuk[2], [1]AstraZeneca GmbH, Wedel, DE, [2]University Hospital Essen, Essen, DE

16:00 - 16:00 **Table 5: A career in supportive and palliative care**

K. Jordan[1], D.C. Guven[2], [1]Ernst von Bergmann Klinikum Potsdam, Potsdam, DE, [2]Hacettepe University Oncology Hospital, Ankara, TR

16:00 - 16:00 **Table 6: Leadership and management in oncology**

T. Amaral[1], K. Punie[2], [1]Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE, [2]UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

16:00 - 16:00 **Table 7: A career in neuro-oncology for medical oncologists**

R. Stupp[1], A. Starzer[2], [1]Northwestern University Feinberg School of Medicine, Chicago, US, [2]Medizinische Universitaet Wien, Vienna, AT

16:15 - 17:00	**Type: Challenge your Expert** **Title: Immunotherapy in colorectal cancer: Where do we stand and what do we expect?** Chair(s): Chiara Cremolini, IT	**Valencia Auditorium - Hall 10**

16:15 - 16:35 **Presentation by Expert**

G. Argiles Martinez, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

16:35 - 17:00 **Discussion led by Chair**

C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

16:15 - 17:00	**Type: Challenge your Expert** **Title: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?** Chair(s): Ryan Sullivan, US	**Salamanca Auditorium - Hall 3**

16:15 - 16:35 **Presentation by Expert**

C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR

16:35 - 17:00 **Discussion led by Chair**

R. Sullivan, MGH - Massachusetts General Hospital, Boston, US

16:15 - 17:00	**Type: Challenge your Expert** **Title: Is there still a place for anthracyclines in early breast cancer?** Chair(s): Evandro de Azambuja, BE	**Málaga Auditorium - Hall 10**

16:15 - 16:35 **Presentation by Expert**

S. Hurvitz, University of Washington, Seattle, US

16:35 - 17:00 **Discussion led by Chair**

E. De Azambuja, Institute Jules Bordet, Brussels, BE

16:15 - 17:00	**Type: Challenge your Expert** **Title: When can we cure patients with metastatic sarcoma?** Chair(s): Silvia Stacchiotti, IT	**Toledo Auditorium - Hall 3**

16:15 - 16:35 **Presentation by Expert**

W. Van Houdt, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:35 - 17:00 **Discussion led by Chair**

S. Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

16:15 - 17:30	**Type: Multidisciplinary session** **Title: Building an academic cell therapy programme** Chair(s): Elena Garralda, ES; Inge-Marie Svane, DK	**Oviedo Auditorium - Hall 7**

16:15 - 16:20 **Presentation of case/condition**

E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES

16:20 - 16:40 **Lab requirements and translational opportunities**

I.-M. Svane, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK

16:40 - 17:00 **Clinical requirements**

A. Furness, The Royal Marsden Hospital - Chelsea, London, GB

17:00 - 17:20 **Regulatory requirements**

A. Hidalgo-Simon, EMA - European Medicines Agency, Amsterdam, NL

17:20 - 17:30 **Q&A and Discussion**

17:30 - 18:30	**Type: Young Oncologists session** **Title: YO Vesalius talk: Diversity, equity and inclusion: Tips to move forward in your career** Chair(s): Kok Haw Jonathan Lim, GB; Elene Mariamidze, GE	**Networking Hub - NCC**

17:30 - 17:40 **Intorduction by the Chair**

K.H.J. Lim[1], E. Mariamidze[2], [1]The Francis Crick Institute, London, GB, [2]Todua Clinic, Tbilisi, GE

17:40 - 18:30 **Diversity, equity and inclusion: Tips to move forward in your career**

P. Vuylsteke[1], S. Peters[2], P. Garrido Lopez[3], T.S.K. Mok[4], [1]University of Botswana, Gaborone, BW, [2]CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, [3]Hospital Universitario Ramon y Cajal, Madrid, ES, [4]Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

18:00 - 19:30	**Type: Industry Satellite Symposium** **Title: AstraZeneca - Clinical Perspectives in mCRPC: Practical Considerations on Incorporating PARPi plus Next-generation Hormonal Agents into the Clinic** Chair(s): Elena Castro, ES	**Salamanca Auditorium - Hall 3**

18:00 - 18:05 **Welcome and introduction**

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

18:05 - 18:20 **Examining the evidence: PARPi plus NHA combination therapy in mCRPC**

G. Von Amsberg, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

18:20 - 19:00 **Clinical considerations: case-based scenarios for patient selection and AE management with combination PARPi plus NHAs**

E. Castro[1], F. Saad[2], [1]Hospital Universitario 12 de Octubre, Madrid, ES, [2]Hospital St. Luc du CHUM, Montreal, CA

19:00 - 19:25 **Exploring the patient perspective: practical approaches for shared decision making**

R. Mckay, University of California San Diego - UCSD, La Jolla, US

19:25 - 19:30 **Summary and close**

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

18:00 - 19:30	**Type: Industry Satellite Symposium** **Title: Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence** Chair(s): Aurelius Omlin, CH; Alison Birtle, GB	**Málaga Auditorium - Hall 10**

18:00 - 18:05 **Opening remarks & introduction**

A. Omlin[1], A. Birtle[2], [1]OnkoZentrum Zürich, Zurich, CH, [2]Royal Preston Hospital, Preston, GB

18:05 - 18:25 **How can we balance efficacy and QoL in mHSPC treatment? Why it's time to tailor treatments**

F. Schlürmann[1], L.-M. Krabbe[2], [1]CHRU Brest - Hopital Augustin Morvan, Brest, FR, [2]UKM - University Hospital Muenster, Muenster, DE

18:25 - 18:45 **Germ line testing and genomic profiling - isn't it time for personalised prostate cancer care?**

D. Olmos[1], N. Mehra[2], [1]Hospital Universitario 12 de Octubre, Madrid, ES, [2]Radboud University Medical Center, Nijmegen, Nijmegen, NL

18:45 - 19:05 **Revolutionising urothelial carcinoma care: Discovering the value of targeted therapy**

G.A. De Velasco Oria, Hospital Universitario 12 de Octubre, Madrid, ES

19:05 - 19:25 **Interactive Q&A session**

A. Omlin[1], A. Birtle[2], F. Schlürmann[3], D. Olmos[4], N. Mehra[5], L.-M. Krabbe[6], G.A. De Velasco Oria[4], [1]OnkoZentrum Zürich, Zurich, CH, [2]Royal Preston Hospital, Preston, GB, [3]CHRU Brest - Hopital Augustin Morvan, Brest, FR, [4]Hospital Universitario 12 de Octubre, Madrid, ES, [5]Radboud University Medical Center, Nijmegen, Nijmegen, NL, [6]UKM - University Hospital Muenster, Muenster, DE

19:25 - 19:30 **Closing remarks**

A. Omlin[1], A. Birtle[2], [1]OnkoZentrum Zürich, Zurich, CH, [2]Royal Preston Hospital, Preston, GB

18:00 - 19:30	**Type: Industry Satellite Symposium** **Title: Servier - A journey through IDH1mutated Cholangiocarcinoma - Unveiling clinical and therapeutic perspectives** Chair(s): Michel Ducreux, FR	**Santander Auditorium - Hall 9**

18:00 - 18:10 **Introduction**

M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

18:10 - 18:15 **Introducing a patient case with IDH1 mutated CCA**

T. Macarulla, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

18:15 - 18:35 **CCA diagnosis: current practice and challenges**

T. Macarulla[1], E. Martinelli[2], [1]Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, [2]Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT

18:35 - 18:55 **Molecular profiling in CCA: where do we stand?**

T. Macarulla[1], A. Stenzinger[2], [1]Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, [2]University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE

18:55 - 19:15 **Treatment landscape in CCA and future perspectives**

B. Westphalen[1], T. Macarulla[2], [1]LMU Klinikum der Universität München, Munich, DE, [2]Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

19:15 - 19:25 **Panel discussion Q&A**

M. Ducreux[1], T. Macarulla[2], E. Martinelli[3], A. Stenzinger[4], B. Westphalen[5], [1]Gustave Roussy - Cancer Campus, Villejuif, FR, [2]Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, [3]Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, [4]University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, [5]LMU Klinikum der Universität München, Munich, DE

19:25 - 19:30 **Conclusion**

M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

18:00 - 19:30	**Type: Industry Satellite Symposium** **Title: Bayer - Delivering on the Promise of Precision Oncology: From the Big Bang to Tangible Impact on Patients' Lives** Chair(s): Vivek Subbiah, US	**Toledo Auditorium - Hall 3**

18:00 - 18:05 **Welcome**

V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US

18:05 - 18:10 **The Voice That Matters - A Patient Perspective**

V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US

18:10 - 18:25 **The Big Bang of Precision Oncology: Creating Milestones in Medicine**

V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US

18:25 - 18:40 **Theory to Reality: Overcoming Challenges and Raising the Value of Precision Oncology**

V. Subbiah[1], J. Hernandez-Losa[2], [1]The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US, [2]Vall d'Hebron University Hospital, Barcelona, ES

18:40 - 19:05 **Making It Stick: Implementing the Advances in Precision Oncology into Clinical Practice**

V. Subbiah[1], J. Naidoo[2], D.S.W. Tan[3], [1]The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US, [2]Beaumont Hospital, Dublin, IE, [3]NCCS - National Cancer Centre Singapore, Singapore, SG

19:05 - 19:15 **Open Panel Audience Q&A**

V. Subbiah[1], J. Naidoo[2], D.S.W. Tan[3], J. Hernandez-Losa[4], [1]The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US, [2]Beaumont Hospital, Dublin, IE, [3]NCCS - National Cancer Centre Singapore, Singapore, SG, [4]Vall d'Hebron University Hospital, Barcelona, ES

19:15 - 19:25 **Impact From Within: Patient Advocacy and the Voices That Bring Progress**

A. Moore, LUNGevity Foundation, Chicago, US

19:25 - 19:30 **Closing Remarks**

V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US

18:00 - 19:30	**Type: Industry Satellite Symposium** **Title: Boehringer Ingelheim - Rethinking Cancer Therapies: Fresh Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Cancer** Chair(s): Charles Rudin, US	**Oviedo Auditorium - Hall 7**

18:00 - 18:05 **Welcome and Introduction of Agenda and Speakers**

C. Rudin, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

18:05 - 18:25 **Restoring p53 by Antagonizing MDM2-p53 in Soft Tissue Sarcoma**

P. Schoeffski, KU Leuven - Laboratory of Experimental Oncology, Leuven, BE

18:25 - 18:50 **Improving HER2 Targeting in NSCLC with Selective TKI**

Z. Piotrowska, MGH - Massachusetts General Hospital, Boston, US

18:50 - 19:15 **T-cell Engagers: Fighting Solid Tumors from Within**

C. Rudin, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

19:15 - 19:30 **Panel Discussion and Audience Q&A, Key Takeaways and Closing Remarks**

C. Rudin[1], P. Schoeffski[2], Z. Piotrowska[3], [1]MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, [2]KU Leuven - Laboratory of Experimental Oncology, Leuven, BE, [3]MGH - Massachusetts General Hospital, Boston, US

18:00 - 19:30 **Type: Industry Satellite Symposium** **León Auditorium - Hall 7**
Title: Regeneron Pharmaceuticals, Inc. - Putting the Patient First: The Value of Personalized Medicine for Nonmelanoma Skin Cancers
Chair(s): Vishal Patel, US

18:00 - 18:05 **Welcome and Introduction**

V. Patel, Birmingham City University - City South Campus, Washington, DC, US

18:05 - 18:20 **The CSCC and BCC Essentials**

D.M. Miller, Beth Israel Deaconess Medical Center, Boston, US

18:20 - 18:50 **Navigating the Patient Journey for CSCC**

V. Patel[1], D.M. Miller[2], T. Guo[3], [1]Birmingham City University - City South Campus, Washington, DC, US, [2]Beth Israel Deaconess Medical Center, Boston, US, [3]University of California San Diego - UCSD, San Diego, US

18:50 - 19:20 **Leveraging the Patient Voice in BCC**

V. Patel[1], D.M. Miller[2], T. Guo[3], [1]Birmingham City University - City South Campus, Washington, DC, US, [2]Beth Israel Deaconess Medical Center, Boston, US, [3]University of California San Diego - UCSD, San Diego, US

19:20 - 19:30 **Audience Q&A**

V. Patel[1], D.M. Miller[2], T. Guo[3], [1]Birmingham City University - City South Campus, Washington, DC, US, [2]Beth Israel Deaconess Medical Center, Boston, US, [3]University of California San Diego - UCSD, San Diego, US

21.10.2023

08:30 - 09:50 **Type: Proffered Paper session** **Barcelona Auditorium - Hall 9**
Title: Proffered Paper session 1 - Genitourinary tumours, non-prostate

Chair(s): Thomas Powles, GB; Srikala Sridhar, CA

08:30 - 08:40 **2359O - Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)**

A. Siefker-Radtke[1], N. Matsubara[2], S.H. Park[3], R. Huddart[4], E. Burgess[5], M. Ozguroglu[6], B. Perez Valderrama[7], S. Triantos[8], S. Akapame[8], Y. Kean[8], K. Deprince[9], S. Mukhopadhyay[10], Y. Loriot[11], [1]The University of Texas MD Anderson Cancer Center, Houston, US, [2]National Cancer Center Hospital East, Chiba, JP, [3]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [4]Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, GB, [5]Levine Cancer Institute, Charlotte, US, [6]Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, TR, [7]Hospital Universitario Virgen del Rocío, Seville, ES, [8]Janssen Research & Development, Spring House, US, [9]Janssen Research & Development, Beerse, BE, [10]Janssen Research & Development, Lexington, US, [11]INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, Cedex, FR

08:40 - 08:50 **LBA102 - THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment**

J. Catto[1], B. Tran[2], M. Roupret[3], J. Gschwend[4], Y. Loriot[5], H. Nishiyama[6], J. Palou[7], S. Daneshmand[8], S. Hussain[1], H. Cutuli[9], G. Procopio[10], V. Guadalupi[10], N. Vasdev[11], V. Naini[12], L. Crow[13], S. Triantos[13], M. Baig[13], G. Steinberg[14], [1]University of Sheffield; Sheffield Teaching Hospitals NHS Trust, Sheffield, GB, [2]Peter MacCallum Cancer Centre, Melbourne, AU, [3]GRC 5 Predictive Onco-Uro, Hôpital Pitié-Salpêtrière, Sorbonne University, Paris, Cedex, FR, [4]Rechts der Isar Hospital, Technical University of Munich, Munich, DE, [5]INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, Cedex, FR, [6]University of Tsukuba, Tsukuba, JP, [7]Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, ES, [8]Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, US, [9]Sirio Libanes Hospital, Buenos Aires, AR, [10]Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, [11]Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, GB, [12]Janssen Research & Development, San Diego, US, [13]Janssen Research & Development, Spring House, US, [14]Rush University Medical Center, Chicago, US

08:50 - 09:00 **Invited Discussant 2359O and LBA102**

M. Van Der Heijden, Netherlands Cancer Institute, Amsterdam, NL

09:00 - 09:10 **Q&A**

09:10 - 09:20 **2360O - The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)**

B. Mcgregor[1], G. Sonpavde[2], L. Kwak[1], X. Gao[3], C. Mantia[1], X. Wei[1], J. Berchuck[1], P. Ravi[1], M.D. Michaelson[4], T. Choueiri[1], J. Bellmunt[1], [1]Dana Farber Cancer Institute, Boston, US, [2]AdventHealth Medical Group - Internal Medicine at Orlando, Orlando, US, [3]Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, [4]MGH - Massachusetts General Hospital, Boston, US

09:20 - 09:30 **LBA103 - ICRA: Efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1**

S.M.H. Einerhand[1], J. Van Dorp[1], J. De Feijter[1], A. Daletzakis[1], S. Oosting[2], C. Bruijnen[3], B. Suelmann[3], M. Van Der Heijden[1], [1]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [2]UMCG - University Medical Center Groningen, Groningen, NL, [3]UMC - University Medical Center Utrecht, Utrecht, NL

09:30 - 09:40 **Invited Discussant 2360O and LBA103**

T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

09:40 - 09:50 **Q&A**

08:30 - 10:00 **Type: Special symposium** **Sevilla Auditorium - Hall 9**
Title: Advancing strategies for cancer immunotherapy
Chair(s): Inge-Marie Svane, DK; Ignacio Melero, ES

08:30 - 08:35 **Introduction and scientific background**
I.-M. Svane, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK

08:35 - 08:50 **Activation of innate cells through Treg targeting**
S. Quezada, University College London, London, GB

08:50 - 09:05 **CAR-T and TCR-T approaches for solid cancers**
S. Kobold, LMU Klinikum der Universität München, Munich, DE

09:05 - 09:20 **Intra-tumoural immunotherapy**
I. Melero, Clinica Universidad de Navarra, Pamplona, ES

09:20 - 09:35 **New approaches in cancer vaccines**
S. Van Der Burg, LUMC - Leids Universitair Medisch Centrum, Leiden, NL

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**

08:30 - 10:00 **Type: Mini Oral session** **Granada Auditorium - Hall 3**
Title: Mini oral session 1 - NSCLC, metastatic
Chair(s): Daniel Shao Weng Tan, SG; Yi-Long Wu, CN; Lizza Hendriks, NL; Jordi Remon Masip, FR

08:30 - 08:35 **LBA68 - FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC**
D. Planchard[1], P. Jänne[2], Y. Cheng[3], C. Lee[4], K. Laktionov[5], T.-Y. Yang[6], Y. Yu[7], T. Kato[8], L. Jiang[9], B. Chewaskulyong[10], S. Lucien Geater[11], J.-M. Maurel[12], C. Rojas[13], L. Havel[14], F.A. Shepherd[15], K. Tanaka[16], D. Ghiorghiu[17], E. Armenteros Monterroso[17], X. Huang[17], J.C.-H. Yang[18], [1]Institut Gustave Roussy, Thoracic Unit, Villejuif, Paris, FR, [2]Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, US, [3]Jilin Cancer Hospital, Changchun, CN, [4]Cancer Care Centre, St. George Hospital, Kogarah, AU, [5]Ministry of Health of the Russian Federation, Moscow, RU, [6]Taichung Veterans General Hospital, Taichung, TW, [7]Harbin Medical University Cancer Hospital, Harbin, CN, [8]Kanagawa Cancer Center, Asahi Ward, Yokohama, JP, [9]Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, [10]Faculty of Medicine, Chiang Mai University, Chiang Mai, TH, [11]Prince of Songkla University, Hat Yai District, Songkhla, TH, [12]Cancercare, Rondebosch Oncology Centre, Rondebosch, Cape Town, ZA, [13]Bradford Hill Clinical

Research Center, Santiago, CL, [14]First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, CZ, [15]University Health Network, Princess Margaret Cancer Centre, Toronto, CA, [16]Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, [17]AstraZeneca, Cambridge, GB, [18]National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW

08:35 - 08:40

LBA69 - Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study

Y. Hu[1], F. Zhang[1], M. Zhao[2], Z. Zheng[3], H. Zhang[4], T. Jiang[5], Z. Liu[6], J. Wen[7], X. Gan[8], H. Wang[9], L. Wu[10], S. Cang[11], J. Zhao[12], X. Li[13], L. Peng[14], Z. Fan[15], G. Shen[16], Q. Zhou[17], J. Zou[18], [1]Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, [2]The First Affiliated Hospital of China Medical University, Shenyang, CN, [3]General Hospital of Northern Theater Command, Shenyang, CN, [4]Air Force Medical University, xi‘an, CN, [5]The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital, Xi'an, CN, [6]The Third Medical Center of Chinese PLA General Hospital, beijing, CN, [7]The Sixth Medical Center of Chinese PLA General Hospital, Beijing, CN, [8]The First Affiliated Hospital of Nanchang University, Nanchang, CN, [9]The Affiliated Hospital of Qingdao University, Qingdao, CN, [10]Hunan Cancer Hospital, Changsha, CN, [11]Henan Province People’s Hospital, Zhengzhou, CN, [12]Changzhi People's Hospital of Changzhi Medical College, Changzhi, CN, [13]The Seventh Medical Center of Chinese PLA General Hospital, Beijing, CN, [14]The Fourth Medical Center of Chinese PLA General Hospital, Beijing, CN, [15]Air Force General Hospital (PLA), Beijing, CN, [16]Beijing Fengtai Youanmen Hospital, Beijing, CN, [17]Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, CN, [18]Renmin Hospital of Wuhan University/ Hubei General Hospital, Wuhan, CN

08:40 - 08:50

Invited Discussant LBA68 and LBA69

D.S.W. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

08:50 - 08:55

LBA70 - OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)

Y. Nakahara[1], T. Kato[2], R. Isomura[2], T. Misumi[3], M. Tamiya[4], K. Yoh[3], N. Furuya[5], A. Ono[6], Y. Takiguchi[7], K. Koyama[8], S. Ikeda[9], K. Watanabe[10], T. Tokito[11], N. Seki[12], H. Imai[13], T. Shukuya[14], Y. Shibata[15], S. Hosokawa[16], T. Kozuki[17], H. Okamoto[18], [1]Kitasato University School of Medicine, Sagamihara, JP, [2]Kanagawa Cancer Center, Yokohama, JP, [3]National Cancer Center Hospital East, Kashiwa, JP, [4]Osaka International Cancer Institute, Osaka, JP, [5]St.Marianna University School of Medicine, Kawasaki, JP, [6]Shizuoka Cancer Center, Shizuoka, JP, [7]Chiba University Hospital, Chiba, JP, [8]Niigata Cancer Center Hospital, Niigata, JP, [9]Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, [10]Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, [11]Kurume University Hospital, Kurume, JP, [12]Teikyo University Hospital, Tokyo, JP, [13]Gunma Prefectural Cancer Center, Ota, JP, [14]Juntendo University Hospital, Tokyo, JP, [15]National Hospital Organization Yokohama Medical Center, Yokohama, JP, [16]Japanese Red Cross Okayama Hospital, Okayama, JP, [17]National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, [18]Yokohama Municipal Citizen's Hospital, Yokohama, JP

08:55 - 09:00

LBA71 - A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)

X. Le[1], J. Patel[2], E. Shum[3], R. Sanborn[4], C. Baik[5], C.A. Shu[6], C. Kim[7], M. Fidler[8], R. Hall[9], N. Hanna[10], N. Mohindra[11], J. Sabari[12], S. Heeke[13], M. Hernandez[14], J. Gray[15], J. Heymach[14], A. Saltos[15], [1]The University of Texas M. D. Anderson Cancer Center, Houston, US, [2]Northwestern University Feinberg School of Medicine, Chicago, US, [3]New York University Medical Center, New York, US, [4]Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, [5]University of Washington Seattle Cancer Care Alliance, Seattle, US, [6]Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, [7]Lombardi Cancer Center Georgetown University, Washington, US, [8]Rush Cancer Institute, Chicago, US, [9]The University of Virginia, Charlottesville, US, [10]Indiana University Simon Cancer Center, Indianapolis, US, [11]Northwestern University, Chicago, US, [12]NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, [13]University of Texas MD Anderson Cancer Center, Houston, US, [14]MD Anderson Cancer Center, Houston, US, [15]H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US

09:00 - 09:10

Invited Discussant LBA70 and LBA71

Y.-L. Wu, Guangdong Province People's Hospital, Guangzhou, CN

09:10 - 09:15

1312MO - Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)

E. Carcereny[1], E. Felip[2], M. Majem[3], B. Doger De Spéville[4], T. Clay[5], I. Bondarenko[6], J. Peguero[7], M. Cobo Dols[8], M. Forster[9], G. Ursol[10], E. Kalinka[11], G. Garcia Ledo[12], L. Vila Martinez[13], W. Iams[14], M. Krebs[15], J. Kefas[16], K. Efthymiadis[17], S. Perera[18], C. Mueller[19], F. Triebel[20], [1]ICO - Institut Català d'Oncologia Badalona -Hospital Germans Trias i Pujol, Badalona, ES, [2]Vall d'Hebron University Hospital (VHIO), Barcelona, ES, [3]Hospital de la Santa Creu i Sant Pau, Barcelona, ES, [4]Fundacion Jimenez Díaz, Madrid, ES, [5]Saint John of God Subiaco Hospital, Subiaco, AU, [6]City Clinical hospital Nr. 4, Dnipro, UA, [7]Oncology Consultants, Houston, US, [8]Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, [9]University College London Cancer Institute and University College London Hospital NHS Trust, London, GB, [10]St. Luke's Hospital - Medical and Diagnostic Center "Acinus'', Kropyvnytskyi, UA, [11]Instytut Centrum Zdrowia Matki Polki, Łódź, PL, [12]HM Universitario Sanchinarro, Madrid, ES, [13]Parc Taulí Sabadell Hospital Universitari, Barcelona, ES, [14]Vanderbilt Ingram Cancer Center, Nashville, US, [15]The University of Manchester and The Christie NHS Foundation Trust, Manchester, GB, [16]University College London Hospitals NHS Trust, London, GB, [17]UCLH NHS Foundation Trust, London, GB, [18]Immutep GmbH - Berlin, Berlin, DE, [19]Immutep GmbH, Leipzig, DE, [20]Immutep S.A.S, SAINT-AUBIN, FR

09:15 - 09:20

1313MO - Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy

B. Besse[1], A. Italiano[2], S. Cousin[2], G. Ruiter[3], E. Felip[4], E. Castanon Alvarez[5], S. Ramalingam[6], C. Rolfo[7], D.R. Spigel[8], D. Andrew[9], S. Cho[10], T. Collins[9], A. Hansen[10], G.

Hawkins[9], R. Kurek[9], N. Ceaicovscaia[10], M. Petruzzelli[9], E. Dean[9], A. Sacher[11], [1]Institut Gustave Roussy, Villejuif, FR, [2]Institute Bergonié, Bordeaux, FR, [3]The Netherlands Cancer Institute, Amsterdam, NL, [4]Vall d'Hebron Institute of Oncology, Barcelona, ES, [5]Clínica Universidad de Navarra, Madrid, ES, [6]Emory University - Winship Cancer Institute, Atlanta, US, [7]Mount Sinai Hospital, New York, US, [8]Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US, [9]AstraZeneca, Cambridge, GB, [10]AstraZeneca, Gaithersburg, US, [11]Princess Margaret Cancer Centre, Toronto, CA

09:20 - 09:30

Invited Discussant 1312MO and 1313MO

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

09:30 - 09:35

1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

L. Paz-Ares[1], M.-J. Ahn[2], A. Lisberg[3], S. Kitazono[4], B.C. Cho[5], G. Blumenschein[6], E. Shum[7], E. Pons-Tostivint[8], Y. Goto[9], K. Yoh[10], R. Heist[11], P. Baas[12], D. Planchard[13], M. Pérol[14], E. Felip[15], W.-C. Su[16], H. Zebger-Gong[17], L. Lan[18], C. Liu[18], J. Sands[19], [1]Hospital Universitario 12 de Octubre, Madrid, ES, [2]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [3]JDavid Geffen School of Medicine at UCLA, Los Angeles, US, [4]The Cancer Institute Hospital of JFCR, Tokyo, JP, [5]Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, [6]University of Texas MD Anderson Cancer Center, Houston, US, [7]NYU Perlmutter Cancer Center, New York, US, [8]University Hospital Nantes, Nantes, FR, [9]National Cancer Center Hospital, Tokyo, JP, [10]National Cancer Center Hospital East, Kashiwa, JP, [11]Massachusetts General Hospital Cancer Center, Boston, US, [12]The Netherlands Cancer Institute, Amsterdam, NL, [13]Institut Gustave Roussy, Villejuif, FR, [14]Léon Bérard Cancer Center, Lyon, FR, [15]Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, [16]National Cheng Kung University Hospital, Tainan City, TW, [17]Daiichi Sankyo Europe GmbH, Munich, DE, [18]Daiichi Sankyo, Inc, Basking Ridge, US, [19]Dana-Farber Cancer Institute, Harvard Medical School, Boston, US

09:35 - 09:40

1315MO - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

A. Schram[1], K. Goto[2], D.-W. Kim[3], A. Hollebecque[4], S.Y. Rha[5], K. Nishino[6], M. Duruisseaux[7], K. Umemoto[8], J.O. Park[9], N. Leighl[10], T. Macarulla[11], S. Liu[12], M.N. Al-Hallak[13], J. Cleary[14], C. Neuzillet[15], Y. Goto[16], A.K. Joe[17], S. Adeyemi[17], S. Jauhari[17], A. Drilon[18], [1]Memorial Sloan Kettering Cancer Center, New York, US, [2]National Cancer Center Hospital East, Kashiwa, JP, [3]Seoul National University Hospital and Seoul National University College of Medicine, Seoul, KR, [4]Gustave Roussy Cancer Campus, Villejuif, FR, [5]Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, [6]Osaka International Cancer Institute, Osaka, JP, [7]Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute; Cancer Research Centre of Lyon, UMR INSERM 1052 CNRS 5286; Claude Bernard University Lyon 1, University of Lyon, Lyon, FR, [8]St. Marianna University School of Medicine, Kawasaki, JP, [9]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [10]Princess Margaret Cancer Centre, Toronto, CA, [11]Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, ES, [12]Lombardi Comprehensive Cancer Center, Georgetown University, Washington, US, [13]Barbara Ann Karmanos Cancer Institute, Wayne State University

School of Medicine, Detroit, US, [14]Dana-Farber Cancer Institute, Boston, MA, United States of America, Harvard Medical School, Boston, US, [15]Versailles-Saint Quentin University, Saint-Cloud, FR, [16]National Cancer Center Hospital, Tokyo, JP, [17]Merus N.V, Utrecht, NL, [18]Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US

09:40 - 09:45 **1316MO - BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study**

L. Zhang[1], Y. Ma[1], Y. Zhao[2], W.F. Fang[1], H. Zhao[1], Y. Huang[1], Y. Yang[1], X. Hou[1], Z. Wen[3], S. Zhang[3], J. Wang[3], S. Xiao[3], H. Wang[4], H. Zhu[4], M. Olivo[4], Y. Zhu[4], [1]Sun Yat-sen University Cancer Center, Guangzhou, CN, [2]The Affiliated Hospital of Qingdao University, Qingdao, CN, [3]Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., Chengdu, CN, [4]SystImmune Inc., Redmond, US

09:45 - 10:00 **Invited Discussant 1314MO, 1315MO and 1316MO**

J. Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, FR

08:30 - 10:00 **Type: Educational session** **Burgos Auditorium - Hall 3**

Title: Fight the enemy as soon as possible: News and views in the management of early stages colorectal cancer (CRC)

Chair(s): Jenny Seligmann, GB; Dominik Modest, DE

08:30 - 08:50 **Screening programmes 20 years later: Lessons learned and how to move on?**

M. Van Leerdam, LUMC-Leiden University Medical Center, Leiden, NL

08:50 - 09:05 **How do we optimise imaging?**

E. Dresen, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

09:05 - 09:25 **Current systemic treatment of locally advanced colon cancer**

J. Seligmann, The University of Leeds, Leeds, GB

09:25 - 09:45 **Future directions neoadjuvant versus adjuvant**

D. Modest, Charité - Universitaetsmedizin Berlin, Berlin, DE

09:45 - 10:00 **Q&A and Discussion**

08:30 - 10:00 **Type: Special symposium** **Valencia Auditorium - Hall 10**

Title: Open questions in the management of mesothelioma

Chair(s): Jean Yannis Perentes, CH; Kenneth Rosenzweig, US

08:30 - 08:35 **Introduction and scientific background**

P. Baas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

08:35 - 08:50 **When and when not to operate**

J.Y. Perentes, UNIL - University of Lausanne, Lausanne, CH

08:50 - 09:05 **What is the optimal first-line treatment?**

A. Scherpereel, DRC / CHRU of Lille, Lille, FR

09:05 - 09:20 **Biomarker-selected therapy: Progress or delusion?**

P. Baas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

09:20 - 09:35 **Preoperative or postoperative radiation for mesothelioma**

K. Rosenzweig, Mount Sinai Hospital, New York, US

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**

08:30 - 10:00	**Type: Educational session** **Title: Unravelling choices for adjuvant endocrine therapy in HR+ early breast cancer** Chair(s): Stephen Johnston, GB; Nadia Harbeck, DE	**Salamanca Auditorium - Hall 3**

08:30 - 08:50 **Risk assessment stratification**

N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

08:50 - 09:10 **ER positive breast cancer: What endocrine therapy is needed in premenopausal patients?**

S. Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, IL

09:10 - 09:30 **ER positive breast cancer: What endocrine therapy is needed in menopausal patients?**

P. Neven, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

09:30 - 09:50 **Beyond chemo and endocrine therapy**

S. Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

09:50 - 10:00 **Q&A and Discussion**

08:30 - 10:00 **Type: Special symposium** **Málaga Auditorium - Hall 10**
Title: New targets on the horizon
Chair(s): Ruth Plummer, GB; Alexander Drilon, US

08:30 - 08:35 **Introduction and scientific background**
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

08:35 - 08:50 **POLTheta inhibitors and USP1 inhibitors for BRCA-deficient cancers**
A. D'Andrea, Dana Farber Cancer Institute, Boston, US

08:50 - 09:05 **Innovative/novel delivery of immunotherapeutics**
A. Marabelle, Institut Gustave Roussy, Villejuif, FR

09:05 - 09:20 **Peptide-based cancer vaccines**
J. Walz, University Clinic Tübingen, Tuebingen, DE

09:20 - 09:35 **Mutant specific inhibitors**
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**
R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB

08:30 - 09:50	**Type: Special symposium** **Title: Protein degrading cancer drugs: The promises of the new generation** Chair(s): Madelon Maurice, NL; David Spiegel, US	**Santander Auditorium - Hall 9**

08:30 - 08:35 **Introduction and scientific background**

M. Maurice, UMC - University Medical Center Utrecht, Utrecht, NL

08:35 - 08:50 **Degrading oncogenic transcription factors**

N. Thomä, Friedrich Miescher Institute for Biomedical Research, Basel, CH

08:50 - 09:05 **Degrading cancer targets on the cell surface (SureTACs)**

M. Maurice, UMC - University Medical Center Utrecht, Utrecht, NL

09:05 - 09:20 **Bifunctional small molecules that mediate the degradation of extracellular proteins**

D. Spiegel, Yale University School of Medicine - Yale Cancer Center, New Haven, US

09:20 - 09:45 **Discussion**

09:45 - 09:50 **Conclusions and perspectives**

D. Spiegel, Yale University School of Medicine - Yale Cancer Center, New Haven, US

08:30 - 10:00	**Type: Special symposium** **Title: Next generation diagnostics of blood cancer: An optimistic view on the future of cancer testing** Chair(s): Thorsten Zenz, CH; Iñaki Martin Subero, ES	**Oviedo Auditorium - Hall 7**

08:30 - 08:35 **Introduction and scientific background**

I. Martin Subero, IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES

08:35 - 08:50 **Liquid biopsy in lymphoma**

D. Kurtz, Stanford University, Stanford, US

08:50 - 09:05 **Multi-omic profiling in lymphoid neoplasms**

I. Martin Subero, IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES

09:05 - 09:20 **Drug sensitivity testing in blood cancer**

T. Zenz, USZ - University Hospital Zürich, Zurich, CH

09:20 - 09:35 **How novel profiling methods impact trial design**

R. Schlenk, NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**

T. Zenz, USZ - University Hospital Zürich, Zurich, CH

08:30 - 10:00 **Type: Educational session** **Cádiz Auditorium - NCC**
Title: Making essential cancer drugs affordable
Chair(s): E.G. Elisabeth de Vries, NL; Nathan Cherny, IL

08:30 - 08:50 **Insights in essential medicine availability and accessibility from ESMO antineoplastic medicines study 2.0**
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

08:50 - 09:05 **Policy and intellectual property regulatory instruments as tools to enhance access to expensive essential cancer medicines**
E. 'T Hoen, Medicines Law & Policy, Amsterdam, NL

09:05 - 09:20 **Governmental policies to control cancer medicine prices**
K. Tay-Teo, WHO - World Health Organization, Geneva, CH

09:20 - 09:35 **India’s approach to advance access to cancer medicines**
M. Sengar, Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN

09:35 - 10:00 **Q&A and Discussion**

08:30 - 10:00	**Type: EONS session** **Title: EONS16: Opening session & Keynote lectures** Chair(s): Virpi Sulosaari, FI	**Alicante Auditorium - Hall 10**

08:30 - 08:35 **Welcome address**

V. Sulosaari, Turku University of Applied Sciences, Turku, FI

08:35 - 08:40 **Welcome from Spanish Oncology Nursing Society (Sociedad Española de Enfermería Oncológica, SEEO)**

J. De La Torre-Montero, Universidad Pontificia Comillas, Madrid, ES

08:40 - 08:45 **Welcome from ESMO**

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

08:45 - 09:05 **Keynote lecture: The effectiveness of nurse-led interventions for cancer symptom management**

D. Kelly, Cardiff University - School of Healthcare Sciences, Cardiff, GB

09:05 - 09:25 **Keynote lecture: Priorities for future research in cancer nursing**

G. Bagcivan, Koc University - School of Nursing, Istanbul, TR

09:25 - 09:40 **CN1 - Integrating an electronic patient reported outcome measure (ePROM) into a nurse-led rare cancer pathway**

J. Ireson[1], T. Holch[2], D. Greenfield[3], K. Singh[1], S. Gillett[1], S. Rollins[1], S. Radley[3], J. Tidy[1], G. Jones[2], [1]Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, [2]Leeds Beckett University, Leeds, GB, [3]Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB

09:40 - 09:50 **Lifetime Achievement Award, RECaN Award, NRDA Award**

09:50 - 10:00 **Q&A and discussion**

08:45 - 10:00	**Type: Proffered Paper session** **Title: Proffered Paper session 2 - Gynaecological cancers** Chair(s): Domenica Lorusso, IT; Sven Mahner, DE	**Bilbao Auditorium - NCC**

08:45 - 08:55 **LBA40 - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma**

N. Colombo[1], K. Harano[2], E. Hudson[3], F. Galli[4], Y. Antill[5], C.H. Choi[6], M. Rabaglio[7], F. Marmé[8], E. Petru[9], C.-H. Lai[10], E. Biagioli[11], L. Fariñas Madrid[12], K. Takehara[13], K.

Allan[14], Y.C. Lee[15], E. Piovano[16], C. Zamagni[17], G. Tasca[18], A. Ferrero[19], M.P. Barretina Ginesta[20], [1]European Institute of Oncology IRCCS, Milan, IT, [2]National Cancer Center Hospital East, Kashiwa, JP, [3]Velindre Cancer Centre, Cardiff, GB, [4]Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, IT, [5]Frankston Hospital, Melbourne, AU, [6]Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, [7]Inselspital - Universitatsspital, Bern, CH, [8]UMM - Universitaetsklinikum Mannheim - Medizinische Fakultaet, Mannheim, DE, [9]Medical University of Graz Division of Gynecology, Graz, AT, [10]Chang Gung Memorial Hospital, Linkou Branch, Taoyuan City, TW, [11]Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, IT, [12]Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, [13]National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, [14]University of Glasgow, Glasgow, GB, [15]The University of Sydney, Sydney, AU, [16]AOU Città della Salute e della Scienza - Presidio Sant'Anna, Torino, IT, [17]IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT, [18]Istituto Oncologico Veneto IOV, IRCCS, Padova, IT, [19]Azienda Ospedaliera Ordine Mauriziano - Presidio Umberto I, Torino, IT, [20]Institut Català d'Oncologia & IDIBGI, Girona, ES

08:55 - 09:05 **Invited Discussant LBA40**

D.S. Tan, NUHS - National University Health System, Singapore, SG

09:05 - 09:15 **Q&A**

09:15 - 09:25 **LBA41 - Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial**

S. Westin[1], K. Moore[2], H.S. Chon[3], J.-Y. Lee[4], J. Thomes Pepin[5], M. Sundborg[6], J. De La Garza[7], S. Nishio[8], K. Wang[9], K. Mcintyre[10], T. Tillmanns[11], F. Contreras Mejia[12], A. De Melo[13], D. Klasa-Mazurkiewicz[14], C. Papadimitriou[15], M. Gil Martín[16], B. Brasiuniene[17], C. Donnelly[18], X. Liu[19], E. Van Nieuwenhuysen[20], [1]The University of Texas MD Anderson Cancer Center, Houston, US, [2]Stephenson Cancer Center, University of Oklahoma Medical Center, Oklahoma City, US, [3]University of South Florida, Tampa, US, [4]Yonsei University College of Medicine, Seoul, KR, [5]Minnesota Oncology, Maplewood, US, [6]FirstHealth Moore Regional Hospital, Pinehurst, US, [7]Texas Oncology-San Antonio Medical Center, San Antonio, US, [8]Kurume University School of Medicine, Kurume, JP, [9]Medical University Cancer Institute & Hospital, Tianjin, CN, [10]Texas Health Presbyterian Hospital, Dallas, US, [11]West Cancer Center & Research Institute, Germantown, US, [12]National Cancer Institute of Colombia, Bogotá, CO, [13]Brazilian National Cancer Institute, Rio de Janeiro, BR, [14]Medical University of Gdańsk, and PGOG, Gdańsk, PL, [15]The National and Kapodistrian University of Athens, and HeCOG, Athens, GR, [16]Catalan Institute of Oncology-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L'Hospitalet-Barcelona, and GEICO, Barcelona, ES, [17]National Cancer Institute of Lithuania, Faculty of Medicine of Vilnius University, and NSGO, Vilnius, LT, [18]AstraZeneca, Cambridge, GB, [19]AstraZeneca, Gaithersburg, US, [20]UZ Leuven, and BGOG, Leuven, BE

09:25 - 09:35 **LBA42 - Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO**

randomized phase IIb UTOLA trial

F. Joly Lobbedez[1], A. Leary[2], I. Ray-Coquard[3], B. Asselain[4], M. Rodrigues[5], L. Gladieff[6], F. Bazan[7], S. Abadie Lacourtoisie[8], C. Lebreton[9], L. Bengrine Lefevre[10], K. Leroy[11], R. Leman[1], P. Fournel[12], R. Largillier[13], F. Selle[14], J.-S. Frenel[15], Y. Fernandez[16], C. Foa[17], B. You[18], J. Alexandre[19], [1]Centre Francois Baclesse, Caen, Cedex, FR, [2]Gustave Roussy, Villejuif, FR, [3]Centre Léon Bérard and University of Lyon, Lyon, FR, [4]ARCAGY-GINECO, Paris, FR, [5]Institut Curie, Paris, FR, [6]Institut Claudius Régaud, IUCT Oncopole, Toulouse, FR, [7]CHRU BESANCON - Hôpital Jean Minjoz, BESANCON, FR, [8]Institut de Cancérologie de l'Ouest - ICO - Site Paul Papin, Angers, FR, [9]Institut Bergonié, Bordeaux, FR, [10]Centre Georges-François Leclerc, Dijon, FR, [11]Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, Paris, FR, [12]Centre Hospitalier Universitaire de Saint-Etienne, pôle de cancérologie, Saint-Étienne, FR, [13]Centre Azuréen de Cancérologie, MOUGINS, FR, [14]Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, FR, [15]Institut de Cancérologie de l'Ouest – Site René Gauducheau, Saint-Herblain, FR, [16]Institut de Cancérologie de Lorraine - Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, [17]Hôpital Saint-Joseph, Marseille, FR, [18]Hospices Civil de Lyon – Centre Hospitalier Lyon Sud, PIERRE BENITE, Pierre-Bénite, FR, [19]Université de Paris Cité, AP-HP, Cochin Port-Royal, Paris, FR

09:35 - 09:45 **Invited Discussant LBA41 and LBA42**

D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT

09:45 - 10:00 **Q&A**

08:45 - 10:00	**Type: Multidisciplinary session** **Title: Relieving complex suffering in women with advanced cervical cancer** Chair(s): Snezana Bosnjak, RS; Giovanni Aletti, IT	**Toledo Auditorium - Hall 3**

08:45 - 08:50 **Presentation of case/condition**

S. Bosnjak, Institute for Oncology and Radiology of Serbia, Belgrade, RS

08:50 - 09:05 **Refractory pain**

J. Paice, Northwestern University, Chicago, US

09:05 - 09:20 **Ureteral and bowel obstruction, haemorrhage: A surgical perspective**

G. Aletti, IEO - Istituto Europeo di Oncologia, Milan, IT

09:20 - 09:35 **A psycho-oncologist's perspective**

M. Die-Trill, Atrium: Psycho-Oncology & Clinical Psychology, Madrid, ES

09:35 - 09:50 **Nausea and vomiting in advanced cervical cancer**

A. Baptista Capela, Centro Hospitalar Vila Nova de Gaia / Espinho, Vila Nova de Gaia, PT

09:50 - 10:00 **Discussion**

08:45 - 10:00	**Type: Multidisciplinary session** **Title: Interdisciplinary management of advanced and functional digestive neuroendocrine tumours** Chair(s): Rachel Riechelmann, BR; Stefano Partelli, IT	**León Auditorium - Hall 7**

08:45 - 08:50 **Presentation of case/condition**

S. De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

08:50 - 09:10 **Role of surgery in advanced disease**

S. Partelli, UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT

09:10 - 09:30 **Role of locoregional and ablative therapies**

R. Riechelmann, A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR

09:30 - 09:50 **Role of systemic therapies in the control of hormone-release**

S. Singh, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA

09:50 - 10:00 **Q&A and Discussion**

08:45 - 09:45 **Type: Young Oncologists session** **Ávila Auditorium - NCC**
Title: YO Boxing session
Chair(s): Maria Kfoury, FR; Emre Kocakavuk, DE

08:45 - 08:55 **Do you need a basic science rotation for your career in oncology? Yes**
J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

08:55 - 09:05 **Do you need a basic science rotation for your career in oncology? No**
S. Pilotto, University of Verona, Verona, IT

09:05 - 09:15 **Discussion led by Chairs**

09:15 - 09:25 **Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours - Yes**
B. Kiesewetter-Wiederkehr, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

09:25 - 09:35 **Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours - No**
Y. Metaxas, Spital Thurgau AG - Kantonsspital Muensterlingen, Muensterlingen, CH

09:35 - 09:45 **Discussion led by Chairs**

10:00 - 11:00	**Type: Special session** **Title: Climate Change Task Force - How to build more sustainable and environment-friendly oncology care** Chair(s): Mathilde Jalving, NL; Rebecca Lee, GB	**Pamplona Auditorium - Hall 9**

10:00 - 10:10 **Moving towards a sustainable academic society: Update from the ESMO Climate Change Task Force**

R. Lee, The University of Manchester, Manchester, GB

10:10 - 10:20 **Climate toxicity of cancer care**

S. O'Reilly, CUH - Cork University Hospital, Cork, IE

10:20 - 10:30 **A sustainable oncology department: Practical tips and tricks**

M. Jalving, UMCG - University Medical Center Groningen, Groningen, NL

10:30 - 10:40 **Rationale drug prescribing to reduce environmental impact**

M. Van De Poll, Maxima Medisch Centrum -Veldhoven, Veldhoven, NL

10:40 - 11:00 **Discussion**

10:15 - 11:35	**Type: Proffered Paper session** **Title: Proffered Paper session - Breast cancer, metastatic** Chair(s): Hervé Bonnefoi, FR; Janice Wing-Hang Tsang, HK	**Barcelona Auditorium - Hall 9**

10:15 - 10:25 **381O - First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors**

J. Wu[1], J. Zhang[2], H. Li[3], X. Wang[4], Q.Y. Zhang[5], Y. Shi[6], M. Yan[7], Y. Pan[8], A. Shen[9], Q. Chen[10], Q. Rao[10], H. Wei[11], C. Li[11], L. Yang[11], Q. Huang[11], Z. Cao[11], Q. Wu[11], [1]Fudan University Cancer Institute, Shanghai, CN, [2]Fudan University Shanghai Cancer Center, Shanghai, CN, [3]Peking University Cancer Hospital and Institute, Beijing, CN, [4]Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN, [5]3rd Affiliated Hospital of Harbin Medical University, Harbin, CN, [6]TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, [7]Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, [8]Anhui Provincial Hospital, Hefei, CN, [9]The First Affiliated Hospital of USTC/ Anhui Provincial Hospital, Hefei, CN, [10]Sun Yat-Sen Memorial Hospital, Guangzhou, CN, [11]Hansoh Pharma Group CO.,LTD., Shanghai, CN

10:25 - 10:35 **376O - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study**

S. Modi[1], W. Jacot[2], H. Iwata[3], Y.H. Park[4], M.J. Vidal Losada[5], W. Li[6], J. Tsurutani[7], K. Zaman[8], N. Ueno[9], A. Prat[10], K. Papazisis[11], H. Rugo[12], N. Harbeck[13], S.-A. Im[14], M. De Laurentiis[15], C. Orbegoso[16], L. Yung[17], F.-C. Cheng[17], Y. Cheng[17], D. Cameron[18], [1]Memorial Sloan Kettering Cancer Center, New York, US, [2]Institut du Cancer de

Montpellier, Montpellier, FR, [3]Aichi Cancer Center Hospital, Nagoya, JP, [4]Samsung Medical Center, Seoul, KR, [5]Hospital Clínic de Barcelona, Barcelona, ES, [6]The First Hospital of Jilin University, Changchun, CN, [7]Showa University, Shinagawa, JP, [8]Lausanne University Hospital CHUV, Lausanne, CH, [9]University of Hawaii Cancer Center, Honolulu, US, [10]Translational Genomics and Targeted Therapies Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, ES, [11]Euromedica General Clinic, Thessaloniki, GR, [12]UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, [13]LMU University Hospital, Munich, DE, [14]Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR, [15]Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, IT, [16]Daiichi Sankyo, Inc., Rueil-Malmaison, FR, [17]Daiichi Sankyo, Inc., Basking Ridge, US, [18]University of Edinburgh, Edinburgh, GB

10:35 - 10:45 **Invited Discussant 381O and 376O**

G. Bianchini, IRCCS Ospedale San Raffaele, Milan, IT

10:45 - 10:55 **Q&A**

10:55 - 11:05 **377O - A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03**

S. Hurvitz[1], S. Modi[2], W. Li[3], Y.H. Park[4], W. Chung[5], S.-B. Kim[6], J. Cortés[7], T. Yamashita[8], J. Pedrini[9], S.-A. Im[10], L.-M. Tseng[11], N. Harbeck[12], I. Krop[13], G. Curigliano[14], E. Mathias[15], J. Cathcart[16], A. Cagnazzo[15], S. Ashfaque[15], A. Egorov[15], F. André[17], [1]David Geffen School of Medicine at UCLA, Los Angeles, US, [2]Memorial Sloan Kettering Cancer Center, New York, US, [3]The First Hospital of Jilin University, Changchun, CN, [4]Samsung Medical Center, Seoul, KR, [5]National Cheng Kung University, Tainan City, TW, [6]Asan Medical Center, Seoul, KR, [7]International Breast Cancer Center, Barcelona, ES, [8]Kanagawa Cancer Center, Yokohama, JP, [9]Hospital Nossa Senhora da Conceicao, Porto Alegre, BR, [10]Seoul National University Hospital, Seoul, KR, [11]Taipei Veterans General Hospital, Taipei City, TW, [12]LMU University Hospital, Munich, DE, [13]Yale Cancer Center, New Haven, US, [14]European Institute of Oncology, IRCCS, and University of Milan, Milan, IT, [15]Daiichi Sankyo, Inc., Basking Ridge, US, [16]Daiichi Sankyo Inc., Basking Ridge, US, [17]Institiut Gustave Roussy, Villejuif, FR

11:05 - 11:15 **378O - Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC): First results of the randomized IMPACT trial comparing patient coaching with the MASCC oral agent teaching tool (MOATT) versus local routine patient coaching (LC)**

M. Welslau[1], P. Fasching[2], L. Mueller[3], E. Belleville[4], L. Rieger[5], M.-O. Zahn[6], B. Lex[7], L. Häberle[8], H. Tesch[1], [1]Klinikum Aschaffenburg, Aschaffenburg, DE, [2]Universitätsklinikum Erlangen, Erlangen, DE, [3]Onkologie Untere Ems - Leer Papenburg Emden, Leer, DE, [4]ClinSol, wuerzburg, DE, [5]Praxis Dr. Vehling-Kaiser, Landshut, DE, [6]MVZ Onkologische Kooperation Harz, Goslar, DE, [7]Department of Gynecology and Obstetrics, Kulmbach, DE, [8]Universitätsklinik Erlangen, Erlangen, DE

11:15 - 11:25 **Invited Discussant 377O and 378O**

J.W.-H. Tsang, HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK

11:25 - 11:35 **Q&A**

10:15 - 11:45 **Type: Special symposium** **Sevilla Auditorium - Hall 9**
Title: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge

Chair(s): Raffaele Califano, GB; Sanjay Popat, GB

10:15 - 10:20 **Introduction and scientific background**

R. Califano, The Christie NHS Foundation Trust, Manchester, GB

10:20 - 10:35 **Duration of IO treatment**

B. Besse, Institut Gustave Roussy, Villejuif, FR

10:35 - 10:50 **Immunotherapy re-challenge: Who, when and why**

N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

10:50 - 11:05 **When and how to combine PD-1/PD-L1?**

S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

11:05 - 11:20 **How to overcome IO resistance: New approaches**

E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

11:20 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**

S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

10:15 - 11:45 **Type: Special symposium** **Granada Auditorium - Hall 3**
Title: Upper GI cancers: From bench to bedside
Chair(s): Nicole van Grieken, NL; Kohei Shitara, JP

10:15 - 10:20 **Introduction and scientific background**
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP

10:20 - 10:35 **Heterogeneity, evolution, and outcomes in gastroesophageal cancer**
S. Klempner, MGH - Massachusetts General Hospital, Boston, US

10:35 - 10:50 **ctDNA: From theory to clinical translation**
J. Lee, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

10:50 - 11:05 **New directions in pancreas cancer**
C. Jorgensen, Cancer Research UK Manchester Institute, Manchester, GB

11:05 - 11:20 **Evolving diagnostics in gastroesophageal cancer**
N. Van Grieken, Vrije University Medical Centre (VUMC), Amsterdam, NL

11:20 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**
N. Van Grieken, Vrije University Medical Centre (VUMC), Amsterdam, NL

10:15 - 11:45 **Type: Special symposium** **Burgos Auditorium - Hall 3**
Title: What's the future in melanoma therapy? Novel targets, new drugs, reinvented approaches
Chair(s): Omid Hamid, US; Joanna Mangana, CH

10:15 - 10:20 **Introduction and scientific background**

10:20 - 10:40 **Revisiting old friends: New clinical developments of MEKi/BRAFi/NRASi combinations**
R. Sullivan, MGH - Massachusetts General Hospital, Boston, US

10:40 - 11:00 **Bispecific T-Cell engagers (TCE) and fusion protein carriers: Ready for prime-time in melanoma?**
O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US

11:00 - 11:20 **Clinical data, NGS, (x)-omics et al.: What is the ideal mixture to identify and overcome primary resistance to immune-checkpoint inhibitors?**
I. Pires Da Silva, Melanoma Institute Australia, Wollstonecraft, AU

11:20 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**

10:15 - 11:45 **Type: Proffered Paper session** **Salamanca Auditorium - Hall 3**
Title: Proffered Paper session 1 - Basic Science and Translational research
Chair(s): Federica Di Nicolantonio, IT; Stefan Fröhling, DE

10:15 - 10:25 **LBA55 - An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer**
J. Black[1], A. Frankell[1], S. Veeriah[2], M. Colopi[2], M. Hill[1], C. Abbott[3], S. Boyle[3], B. Li[3], R. Chen[3], M. Al Bakir[1], C. Martinez Ruiz[2], A. Huebner[2], M. Jamal-Hanjani[4], N. Mcgranahan[4], C. Swanton[1], [1]Francis Crick Institute, London, GB, [2]University College London, London, GB, [3]Personalis, Inc. - Headquarters (Office and Laboratory), Menlo Park, US, [4]UCL Cancer Institute - Paul O'Gorman Building, London, GB

10:25 - 10:35 **1206O - Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling**
S. Baca[1], J.-H. Seo[2], J. Berchuck[1], T. El Zarif[1], R. Saliby[1], K. Semaan[2], B. Fortunato[1], M. Awad[1], C. Chau[3], J.A. Decaprio[2], W.D. Figg[3], A. Hata[4], F.S. Hodi[5], K. Ligon[2], K. Ng[2], M. Oser[2], S. Tolaney[2], P. Wen[2], M. Freedman[1], T. Choueiri[1], [1]Dana-Farber Cancer Institute, Boston, US, [2]Dana Farber Cancer Institute, Boston, US, [3]NIH - National Institutes of Health, Bethesda, US, [4]MGH - Massachusetts General Hospital, Boston, US, [5]Dana

Farber Cancer Institute - Longwood Center, Boston, US

10:35 - 10:45 **LBA16 - Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)**

L. Mileshkin[1], T. Bochtler[2], C. Pauli[3], G. Durán-Pacheco[4], C. Arslan[5], F. Bigot[6], N. Chalabi[4], N. Cook[7], A. Italiano[8], F. Losa[9], J. Menezes[10], C. Michaud[4], M. Ozguroglu[11], R. Pazo Cid[12], J. Ross[13], K.-K. Shiu[14], M. Stahl[15], M. Thomas[4], H. Moch[3], A. Krämer[2], [1]The University of Melbourne, Melbourne, AU, [2]German Cancer Research Center (DKFZ) and University of Heidelberg, Heidelberg, DE, [3]University of Zürich and University Hospital Zürich, Zurich, CH, [4]F. Hoffmann-La Roche Ltd, Basel, CH, [5]Medical Park İzmir Hospital, İzmir, TR, [6]Institut de Cancérologie de l'Ouest, Nantes-Angers, FR, [7]The University of Manchester and the Christie NHS Foundation Trust, Manchester, GB, [8]Institute Bergonié, Bordeaux, FR, [9]Hospital de Sant Joan Despí Moisès Broggi, ICO Hospitalet, Barcelona, ES, [10]Centro Pesquisa Integrado em Oncologia, Porto Alegre, BR, [11]Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, TR, [12]Miguel Servet University Hospital, Zaragoza, ES, [13]Foundation Medicine, Inc./SUNY Upstate Medical University, Cambridge, US, [14]UCL Cancer Institute, London, GB, [15]Evang. Kliniken Essen-Mitte, Essen, DE

10:45 - 10:55 **Invited Discussant LBA55, 1206O and LBA16**

F. Di Nicolantonio, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT

10:55 - 11:05 **Q&A**

11:05 - 11:15 **1207O - Beyond 100,000 genomes project: Whole genome sequencing for cancer patients within NHS Genomic Medicine Service**

A. Sosinsky[1], S. Walker[1], J. Ambrose[1], R. Coleran[1], O. Yavorska[1], A. Hamblin[1], N. Murugaesu[1], P. Talley[2], S. `Hing[2], J. Starczynski[2], S. Deans[2], S. Hill[2], [1]Genomics England Ltd, London, GB, [2]NHS England, London, GB

11:15 - 11:25 **2231O - Pan-cancer assessment of the impact of intronic variants on cancer development and progression**

A. Safonov[1], M. Mehine[2], O. Ceyhan-Birsoy[2], D. Brown[2], C. Bandlamudi[1], A. Forbes[3], A. Gazzo[2], P. Selenica[2], R. Shen[2], E. Khurana[4], L. Norton[5], D. Solit[1], S. Chandarlapaty[1], P. Razavi[2], M. Robson[1], B. Weigelt[1], M. Berger[2], M. Ladanyi[1], J. Reis-Filho[1], D. Mandelker[2], [1]MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, [2]Memorial Sloan Kettering Cancer Center, New York, US, [3]Weill Cornell Medical College, New York, US, [4]Weill Cornell Medicine Sandra and Edward Meyer Cancer Center, New York, US, [5]Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

11:25 - 11:35 **Invited Discussant 1207O and 2231O**

C. Swanton, Francis Crick Institute, London, GB

11:35 - 11:45 **Q&A**

10:15 - 11:15 **Type: Mini Oral session** **Málaga Auditorium - Hall 10**
Title: Mini oral session - Head and neck cancer
Chair(s): Panagiota Economopoulou, GR; Marc Oliva, ES

10:15 - 10:20 **855MO - Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)**

J. Guerlain[1], N. Cozic[1], A. Daste[2], O. Malard[3], J. Fayette[4], F. Rolland[5], O. Mauvais[6], A. Johnson[7], S. Salas[8], M. Vinches[9], A. Bozec[10], S. Vergez[11], E. De Monès[12], I. Breuskin[1], M. Iacob[13], B. Archambaud[1], F. Janot[1], C. Even[13], [1]Gustave Roussy - Cancer Campus, Villejuif, FR, [2]CHU Bordeaux - Hopital St. André, Bordeaux, FR, [3]Chu Nantes Hotel Dieu, Nantes, FR, [4]Centre Léon Bérard, Lyon, FR, [5]ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, [6]CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, [7]Centre Francois Baclesse, Caen, FR, [8]AP-HM - CHU La Timone Enfants, Marseille, FR, [9]ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, [10]Centre Antoine Lacassagne (CLCC), Nice, FR, [11]IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, [12]CHU - Centre Universitaire Hospitalier de Bordeaux, Bordeaux, FR, [13]Institut Gustave Roussy, Villejuif, Cedex, FR

10:20 - 10:25 **856MO - A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis**

D. Zandberg[1], D. Clump[1], B. Isett[1], R. Bao[1], H. Wang[1], L. Vujanovic[1], H. Li[1], J. Ohr[1], M. Fenton[1], H. Skinner[1], R. Seethala[1], S. Chiosea[1], B. Jonathan[2], J. Bauman[3], R. Ferris[4], [1]UPMC Hillman Cancer Center, Pittsburgh, US, [2]Winship Cancer Institute of Emory University, Atlanta, US, [3]University of Arizona Cancer Center, Tucson, US, [4]University of Pittsburgh Cancer Institute, Pittsburgh, US

10:25 - 10:30 **LBA46 - SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy**

N. Mach[1], E. Fernandez[1], R. Vernet[1], O. Vonrohr[1], M. Urwyler[1], E. Charrier[1], M.-C. Belkouch[1], V. Saingier[1], F. Courtout[1], C. De Vito[1], O. Rubin[1], V. Ancrenaz[1], J. Grogg[2], J. Renaux[3], K. Gysel[4], G. Müller[4], T. Brezina[5], T. Rordorf[5], M. Joerger[6], O. Michielin[1], [1]Geneva University Hospital HUG, Geneva, CH, [2]MaxiVax SA, Geneva, CH, [3]MaxiVAX SA, Geneva, CH, [4]SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, [5]University Hospital Zurich (USZ), Zurich, CH, [6]Kantonsspital St. Gallen, St. Gallen, CH

10:30 - 10:45 **Invited Discussant 855MO, 856MO and LBA46**

P. Economopoulou, Attikon University Hospital, Haidari, GR

10:45 - 10:50 **859MO - Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from**

the phase II TROPiCS-03 basket trial

L. Michel[1], A. Jimeno[2], A. Sukari[3], T. Beck[4], J. Chiu[5], E. Ahern[6], J. Hilton[7], A. Hollebecque[8], S. Zanetta[9], J. Patel[10], S. Mekan[10], T. Wu[10], E. Dumbrava[11], [1]Memorial Sloan Kettering 64th Street Outpatient Center, New York, US, [2]University of Colorado Cancer Center & Charles C. Gates Center of Stem Cell Biology, Aurora, US, [3]Barbara Ann Karmanos Cancer Institute, Detroit, US, [4]Highlands Oncology Group - Rogers, Fayetteville, US, [5]The University of Hong Kong Queen Mary Hospital, Hong Kong, HK, [6]Monash Medical Centre, Clayton, AU, [7]The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, [8]Gustave Roussy, Villejuif, FR, [9]Centre Georges-François Leclerc (Dijon), Dijon, FR, [10]Gilead Sciences, Inc., Foster City, US, [11]The University of Texas M. D. Anderson Cancer Center, Houston, US

10:50 - 10:55

860MO - MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma

F. Han[1], F. Wang[1], Y.-R. Shi[2], Y. Guo[3], X.-L. Shu[4], S. Pan[5], S.-H. Qu[6], P. Zhang[7], Y. Jiang[8], M.-J. Xu[9], K. Lei[10], S. Qu[11], F. Lei[12], X. Lv[13], Y.-Q. Xiang[1], R.-H. Xu[1], [1]Sun Yat-sen University Cancer Center, Guangzhou, CN, [2]Hunan Cancer Hospital, Changsha, CN, [3]Shanghai East Hospital, Shanghai, CN, [4]Chongqing University Cancer Hospital, Chongqing, CN, [5]Yuebei People's Hospital, Shaoguan, CN, [6]The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, CN, [7]West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, [8]Cancer Hospital of Shantou University Medical College, Shantou, CN, [9]First Affiliated Hospital of Gannan Medical university, Ganzhou, CN, [10]The Second People's Hospital of Yibin City, YiBin, CN, [11]Guangxi Medical University Affiliated Tumour Hospital, Nanning, CN, [12]Zhongshan City People’s Hospital, Zhongshan, CN, [13]Sun Yat-Sen University Cancer Center, Guangzhou, CN

10:55 - 11:00

LBA47 - A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)

A. Ho[1], D. Adkins[2], G. Hanna[3], J. Bruce[4], M.-J. Ahn[5], L. Iglesias Docampo[6], H. Kang[7], D. Wong[8], A. Psyrri[9], M. Gillison[10], I. Brañа[11], Y.C. Liu[12], C.-Y. Hsieh[13], M.H. Hong[14], Z. Zhang[15], B. Balsara[15], A. Saunders[15], A. Gasco Hernandez[15], S. Dale[15], R. Haddad[3], [1]Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, [2]Washington University School of Medicine in St. Louis, St. Louis, US, [3]Dana Farber Cancer Institute, Boston, US, [4]University of Wisconsin Carbone Cancer Center, Madison, US, [5]Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, [6]Hospital Universitario 12 de Octubre, Madrid, ES, [7]University of California San Francisco, San Francisco, US, [8]UCLA - David Geffen School of Medicine, Los Angeles, US, [9]Attikon University Hospital, Haidari, GR, [10]University of Texas MD Anderson Cancer Center, Houston, US, [11]Vall d'Hebron University Hospital, Barcelona, ES, [12]Taichung Veterans General Hospital, Taichung City, TW, [13]China Medical University Hospital, Taichung City, TW, [14]Severance Hospital, Yonsei University College of Medicine, Seoul, KR, [15]Kura Oncology, Inc., Boston, US

11:00 - 11:15

Invited Discussant 859MO, 860MO and LBA47

M. Oliva, Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona, ES

10:15 - 11:45 **Type: Mini Oral session** **Toledo Auditorium - Hall 3**
Title: Mini oral session - Sarcoma

Chair(s): Piotr Rutkowski, PL; Kjetil Boye, NO; Nadia Hindi, ES

10:15 - 10:20 **1914MO - The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders: Single-arm phase II clinical trial**

B. Bharath[1], S. Rastogi[1], V. Garg[2], G. Tansir[1], E. Dhamija[1], A. Barwad[1], S. Kaur[1], S. Gamanagatti[1], S. Bhoriwal[1], M. Khan[1], [1]AIIMS - All India Institute of Medical Sciences, New Delhi, IN, [2]Princess Margaret Cancer Centre, Toronto, CA

10:20 - 10:25 **1915MO - Fear, anxiety and depression in gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study**

D. Van De Wal[1], D. Den Hollander[2], I. Desar[2], H. Gelderblom[3], A. Oosten[4], A. Reyners[5], N. Steeghs[1], W. Van Der Graaf[1], O. Husson[1], [1]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [2]Radboud University Medical Center, Nijmegen, NL, [3]LUMC - Leids University Medical Center, Leiden, NL, [4]Erasmus MC, Rotterdam, NL, [5]UMCG - University Medical Center Groningen, Groningen, NL

10:25 - 10:35 **Invited Discussant 1914MO and 1915MO**

P. Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL

10:35 - 10:40 **1916MO - A first-in-human phase I trial of NB003, a potent and selective KIT/PDGFRa inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)**

P. Chi[1], L. Shen[2], J. Li[3], J. Zhang[4], K. Hu[5], L. Zhang[5], Y. Xu[5], [1]Memorial Sloan Kettering Cancer Center, New York, US, [2]Peking University Cancer Hospital and Institute, Beijing, CN, [3]Peking University Cancer Hospital and Institute, beijing, CN, [4]Fudan University Shanghai Cancer Center, Shanghai, CN, [5]Ningbo Newbay Technology Development Co., Ltd., Ningbo, CN

10:40 - 10:45 **1917MO - CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor**

Y. Naito[1], Y. Komatsu[2], Y. Kurokawa[3], H. Hirano[4], T. Nishida[5], T. Doi[1], [1]National Cancer Center Hospital East, Kashiwa, JP, [2]Hokkaido University Hospital, Sapporo, JP, [3]Graduate School of Medicine / Faculty of Medicine, Osaka University, Suita, JP, [4]National Cancer Center Hospital, Tokyo, JP, [5]NCCH - National Cancer Center Hospital, Chuo-ku, JP

10:45 - 10:50 **1918MO - Circulating tumor DNA in relation to tumor volume in gastro-intestinal stromal tumors**

R. Bleckman[1], C. Haag[1], R. Mathijssen[2], N. Steeghs[3], H. Gelderblom[4], I. Desar[5], A. Ter Elst[1], E. Schuuring[1], A. Reyners[6], [1]UMCG - University Medical Center Groningen, Groningen, NL, [2]Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, [3]Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [4]LUMC - Leids Universitair Medisch Centrum, Leiden, NL, [5]Radboud University Medical Center, Nijmegen, Nijmegen, NL, [6]University Medical Center Groningen, University of

Groningen, Groningen, NL

10:50 - 11:00 **Invited Discussant 1916MO, 1917MO and 1918MO**

K. Boye, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

11:00 - 11:05 **1919MO - Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma**

B. Wilky[1], J. Trent[2], M. Gordon[3], A. El-Khoueiry[4], A. Bullock[5], B. Henick[6], G. Schwartz[6], M. Agulnik[7], D. Mahadevan[8], J. Patel[9], J. Grossman[9], K. Rosenthal[9], S. O'Day[10], A.M. Tsimberidou[11], [1]UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, [2]Sylvester Comprehensive Cancer Center - University of Miami, Miami, US, [3]HonorHealth Research Institute, Scottsdale, US, [4]USC - University of Southern California - Keck School of Medicine, Los Angeles, US, [5]Beth Israel Deaconess Medical Center, Boston, US, [6]Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, [7]City of Hope Comprehensive Cancer Center, Duarte, US, [8]UT Health San Antonio MD Anderson Cancer Center, San Antonio, US, [9]Agenus Inc - Corporate HQ, R&D and Vaccine Manufacturing, Lexington, US, [10]Agenus Inc, Lexington, US, [11]The University of Texas MD Anderson Cancer Center, Houston, US

11:05 - 11:10 **1920MO - Regomune: A phase II study of regorafenib + avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort**

S. Cousin[1], C. Bellera[2], J.-P. Guegan[3], T. Valentin[4], B. Verret[5], J.-P. Metges[6], A. Adenis[7], P. Cassier[8], F. Bouteiller[2], M. Spalato Ceruso[1], I. Korakis[9], A. Hollebecque[10], P.G. Poureau[11], J. Palussiere[12], M. Kind[2], I. Soubeyran[13], A. Bessede[3], A. Italiano[13], [1]Institut Bergonie, Bordeaux, FR, [2]Institut Bergonié, Bordeaux, FR, [3]Explicyte, Bordeaux, FR, [4]Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, [5]Institut Gustave Roussy, Villejuif, FR, [6]CHU Morvan - Institut de Cancerologie et d'Hematologie, Brest, FR, [7]ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, [8]Centre Léon Bérard, Lyon, FR, [9]Iuct Oncopole, Toulouse, FR, [10]Institut Gustave Roussy, Villejuif, Cedex, FR, [11]CHRU Brest - Hopital Augustin Morvan, Brest, FR, [12]Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, [13]Institute Bergonié, Bordeaux, FR

11:10 - 11:15 **1921MO - Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies two prognostic profiles: A cohort study from the French Sarcoma Group (FSG)**

H. Vanacker[1], F. Le Loarer[2], M. Karanian[1], A. Meurgey[1], A. Dufresne[1], S. El Zein[3], J.-Y. Blay[1], O. Collard[4], I. Ray-Coquard[1], W. Waissi[1], D. Pissaloux[1], S. Paindavoine[1], A. Houlier[1], G. Pierron[3], P. Meeus[1], F. Tirode[1], M. Brahmi[1], [1]Centre Léon Bérard, Lyon, FR, [2]Institut Bergonié, Bordeaux, FR, [3]Institut Curie, Paris, FR, [4]Institute de Cancerologie de la Loire, Saint-Priest-en-Jarez, FR

11:15 - 11:25 **Invited Discussant 1919MO, 1920MO and 1921MO**

N. Hindi, Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Madrid, ES

10:15 - 11:45 **Type: Special session** **Oviedo Auditorium - Hall 7**
Title: Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies

Chair(s): Hendrik van Halteren, NL; John Cairns, GB

10:15 - 10:30 **Which factors can cause an E-E gap?**

H. Van Halteren, Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL

10:30 - 10:45 **How often and to which extent does the E-E gap seriously affect treatment outcome in daily practice?**

G. Sonke, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

10:45 - 11:00 **Which adaptations in trials and daily practice could bridge the E-E gap?**

M. Koopman, UMC - University Medical Center Utrecht, Utrecht, NL

11:00 - 11:15 **Under which circumstances could effectiveness data be used for clinical guidelines?**

H. Groen, UMCG - University Medical Center Groningen, Groningen, NL

11:15 - 11:30 **Should effectiveness data be taken into consideration for drug appraisal by regulatory authorities?**

J. Cairns, London School of Hygiene & Tropical Medicine, London, GB

11:30 - 11:45 **Discussion**

10:15 - 11:45 **Type: Mini Oral session** **León Auditorium - Hall 7**
Title: Mini oral session: CNS tumours

Chair(s): Joan Seoane, ES; Andreas Hottinger, CH; Emeline Tabouret, FR

10:15 - 10:20 **502MO - Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: A real-life cohort analysis from Veneto Institute of Oncology, Padua (Italy)**

G. Cerretti[1], M. Padovan[1], C. De Toni[1], M. Maccari[1], A. Bosio[1], M. Caccese[1], M. Corrà[1], I. Cestonaro[1], A. Pittaro[1], A. Guerriero[2], M. Coppola[1], G. Lombardi[1], [1]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [2]Azienda Universitaria Ospedaliera di Padova, Padova, IT

10:20 - 10:25 **503MO - Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights**

O. Mirallas[1], G. Velilla[2], F. Ruiz-Pace[3], J. Yaringaño[1], T. Gorria[4], D. Gomez-Puerto[1], Á. Martínez[5], D. López Valbuena[1], M.A. Vaz Salgado[6], A. Hernandez Gonzalez[7], M. Aguado Sorolla[8], K. Raskina[9], M. Gonzalez Rodriguez[1], M. Martinez Garcia[5], J. Carles Galceran[1], C. Balana[10], E. Pineda[11], R. Dienstmann[12], J.M. Sepúlveda Sánchez[13], M. Vieito Villar[1], [1]Vall d'Hebron University Hospital, Barcelona, ES, [2]Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, ES, [3]Vall d'Hebron Institute of Oncology (VHIO)-

Cellex Center, Barcelona, ES, [4]Hospital Clinic of Barcelona, Barcelona, ES, [5]Hospital del Mar - Parc de Salut Mar, Barcelona, ES, [6]Hospital Universitario Ramon y Cajal, Madrid, ES, [7]Institut Catala d'Oncologia (ICO) Badalona, Badalona Applied Research Group in Oncology (B- ARGO Group), Badalona, ES, [8]Hospital de la Santa Creu i Sant Pau, Barcelona, ES, [9]VHIO - Vall d'Hebron Institute of Oncology, Barcelona, ES, [10]ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, [11]Hospital Clinic y Provincial de Barcelona, Barcelona, ES, [12]Grupo Oncoclinicas, Sao Paulo, BR, [13]Hosp. Doce de Octubre, Madrid, ES

10:25 - 10:30

504MO - Validation of a spectroscopic liquid biopsy for the earlier detection of brain cancer

J. Cameron[1], A. Sala[1], J. Conn[1], G. Antoniou[1], D. Palmer[1], M. Baker[2], [1]Dxcover Limited, Glasgow, GB, [2]University of Central Lancashire, Preston, GB

10:30 - 10:45

Invited Discussant 502MO, 503MO and 504MO

J. Seoane, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES

10:45 - 10:50

505MO - A phase 0/Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients

N. Sanai, S. Desai, T. Margaryan, C. Lo Cascio, M. Elliott, J. Molloy, J. Harmon, A. Hong, E. Luna Melendez, J. Wanebo, K. Braun, W. Kennedy, M. Garcia, W. Yoo, A. Tovmasyan, A.-C. Tien, S. Mehta, Barrow Neurological Institute, Phoenix, US

10:50 - 10:55

506MO - A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma

W. Li[1], Z. Kang[1], Z. Wu[1], S. Li[1], M. Huang[1], W. Pu[2], X. Yang[2], J. Lin[2], M. Liu[2], [1]Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, [2]CSPC Pharmaceutical Group Limited, Shijiazhuang, CN

10:55 - 11:10

Invited Discussant 505MO and 506MO

A. Hottinger, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

11:10 - 11:15

507MO - REGOMA-OS: A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients

G. Lombardi[1], I. Desideri[2], V. Villani[3], M. Simonelli[4], M. Buglione[5], S. Chiesa[6], E. Franceschi[7], P. Gaviani[8], I. Stasi[9], C. Caserta[10], S. Brugnara[11], I.R. Lolli[12], E. Bennicelli[13], P. Bini[14], A. Cuccu[15], S. Scoccianti[16], G. Magni[17], M. Caccese[1], G. De Salvo[1], V. Zagonel[1], [1]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [2]Università di Firenze- Dipartimento di Patologia e Oncologia Sperimentali, Firenze, IT, [3]IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT, [4]Humanitas University, Milan, IT, [5]UNIBS - Università degli Studi di Brescia - Facoltà di Medicina e Chirurgia, Brescia, IT, [6]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, [7]Ospedale Bellaria Carlo Alberto Pizzardi, Bologna, IT, [8]Fondazione IRCCS - Istituto Neurologico C.Besta, Milan, IT, [9]Azienda Toscana Nord-Ovest Livorno, LIvorno, IT, [10]Azienda Ospedaliera Santa Maria di Terni, Terni, IT, [11]Ospedale Santa Chiara, Trento, IT, [12]IRCCS Castellana Grotte, Castellana Grotte, IT, [13]Ospedale Policlinico San Martino, Genova, IT,

[14]IRCCS Mondino, Pavia, IT, [15]A.O.U di Sassari, Sassari, IT, [16]Ospedale Santa Maria Annunziata (Ponte a Niccheri) - USL Toscana Centro, Bagno a Ripoli, IT, [17]Veneto Institute of Oncology IOV – IRCCS, padua, IT

11:15 - 11:20 **508MO - Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial**

S. Leonardelli[1], J.P. Layer[1], L.L. Friker[1], R. Turiello[1], G. Van Der Voort[1], D. Corvino[1], C. Schaub[1], W. Müller[2], E. Sperk[3], L.C. Schmeel2[1], K. Sahm[3], S. Kebir[4], P. Hambsch[2], T. Pietsch[1], K. Thurley[1], M. Glas[5], C. Seidel[2], U. Herrlinger[6], F. Giordano[3], M. Hölzel[1], [1]University Hospital Bonn, Bonn, DE, [2]University Hospital Leipzig, Leipzig, DE, [3]Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE, [4]University Hospital Essen, Essen, DE, [5]University Hospital Essen - Westdeutsches Protonentherapiezentrum, Essen, DE, [6]Institute of Experimental Immunology - UKB University of Bonn, Bonn, DE

11:20 - 11:35 **Invited Discussant 507MO and 508MO**

E. Tabouret, CHU La Timone Adultes, Marseille, FR

10:15 - 11:45 **Type: Educational session** **Cádiz Auditorium - NCC**
Title: Do we enter a new era of oncology with big data and artificial intelligence?

Chair(s): Rudolf Fehrmann, NL; James McKay, FR

10:15 - 10:30 **Where are we in Oncology in relation to developments in digital health, big data, artificial intelligence...? Challenges and opportunities**

R. Fehrmann, UMCG - University Medical Center Groningen, Groningen, NL

10:30 - 10:45 **Wearable medical devices in oncology: Hopes and hypes for patients and health professionals**

H. Martins, UBI - Universidade da Beira Interior - Faculdade de Ciencias da Saude, Covilha, PT

10:45 - 11:05 **AI-based therapeutic algorithms in oncology**

L. Verlingue, Centre Léon Bérard, Lyon, FR

11:05 - 11:25 **What will the European Health Data Space bring us?**

S. Buttigieg, Ministry for Health, Valletta, MT

11:25 - 11:45 **Q&A and Discussion**

10:15 - 11:45 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Health promotion, prevention and screening
Chair(s): Constantina Cloconi, CY

10:15 - 10:30 **Genetics and cancer nurses prevention**
C. Diez De Los Rios De La Serna, University of Glasgow, Glasgow, GB

10:30 - 10:45 **PrEvCan – Preventing cancer across Europe**
L. Sharp, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE

10:45 - 11:00 **Perceptions of health promotion among young people**
N. Dodlek, University Hospital Center Osijek, Osijek, HR

11:00 - 11:15 **Promoting cancer screening among under-represented populations**
S. Mulcahy Symmons, University College Dublin, Dublin, IE

11:15 - 11:25 **CN18 - Impact of the medical record-based frailty index on the health outcomes of elderly patients with colorectal cancer**
H. Lee, Yonsei University, Seoul, KR

11:25 - 11:35 **CN76 - Consensus views on research priorities for cancer survivorship in older adulthood: A Delphi study**
A. Drury[1], A. O'Brien[2], L. O'Connell[3], S. Cosgrave[4], M. Hannan[5], C. Smyth[6], K. Fessele[7], S. Sheehan[1], M. Harkin[8], L. Rogers[2], [1]DCU - Dublin City University, Dublin, IE, [2]University College Dublin, Dublin, IE, [3]Tallaght University Hospital, Dublin, IE, [4]St. Vincent's University Hospital, Dublin, IE, [5]University Hospital Waterford, Waterford, IE, [6]HSE - Health Service Executive, Dublin, IE, [7]Memorial Sloan Kettering Cancer Center, New York, US, [8]Age and Opportunity, Dublin, IE

11:35 - 11:45 **Q&A and discussion**

10:30 - 11:45	**Type: Controversy session** **Title: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC** Chair(s): Tony S.K. Mok, HK	**Bilbao Auditorium - NCC**

10:30 - 10:35 **Welcome and "set the scene"**

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

10:35 - 10:50 **Adjuvant only**

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

10:50 - 11:05 **Neo adjuvant only**

R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

11:05 - 11:20 **Neo adjuvant follow by adjuvant**

F. Cappuzzo, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT

11:20 - 11:25 **First voting**

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

11:25 - 11:40 **Perspective from the Chair**

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

11:40 - 11:45 **Second voting**

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

10:30 - 11:15	**Type: Challenge your Expert** **Title: Immunotherapy in dMMR/MSI-H recurrent/metastatic endometrial cancer: Monotherapy or combination?** Chair(s): Domenica Lorusso, IT	**Valencia Auditorium - Hall 10**

10:30 - 10:50 **Presentation by Expert**

S. Banerjee, The Royal Marsden Hospital - Chelsea, London, GB

10:50 - 11:15 **Discussion led by Chair**

D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT

10:30 - 11:15	**Type: Challenge your Expert** **Title: All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment** Chair(s): Silke Gillessen, CH	**Santander Auditorium - Hall 9**

10:30 - 10:50 **Presentation by Expert**

S. Sandhu, Peter MacCallum Cancer Centre, Melbourne, AU

10:50 - 11:15 **Discussion led by Chair**

S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

11:00 - 11:45	**Type: Young Oncologists session** **Title: YO Brunch 1: Caring for the LGBTQ+ cancer patient** Chair(s): Pawel Sobczuk, PL	**Ávila Auditorium - NCC**

11:00 - 11:15 **Caring for the LGBTQ+ cancer patient**

A. Berner, Private Address - Dr. Alison Berner, Milton Keynes, GB

11:15 - 11:45 **Discussion led by Chair**

P. Sobczuk, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

11:15 - 12:15	**Type: Special session** **Title: Patient Guides: Let’s talk about oesophageal and stomach cancers**	**Networking Hub - NCC**

11:15 - 12:15 **Patient Guides: Let’s talk about oesophageal and stomach cancers**

F. Lordick[1], R. Obermannova[2], E. Smyth[3], T. Gašpert[4], Z. Maravic[5],
[1]Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE, [2]Masaryk Memorial Cancer Institute, Brno, CZ, [3]Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB, [4]University Hospital KBC Rijeka, Rijeka, HR, [5]DiCE - Digestive Cancers Europe vzw/asbl, Overijse, BE

12:00 - 12:30	**Type: Keynote lecture** **Title: The hallmarks of cancer in 2023** Chair(s): Charles Swanton, GB	**Barcelona Auditorium - Hall 9**

12:00 - 12:05 **Introduction by the Chair**

C. Swanton, Francis Crick Institute, London, GB

12:05 - 12:30 **The hallmarks of cancer in 2023**

D. Hanahan, Swiss Institute of Experimental Cancer Research, EPFL, Lausanne, CH

12:00 - 13:30	**Type: EONS Industry Satellite Symposium** **Title: MSD - Improving health literacy across the patient pathway from screening and prevention to treatment and care** Chair(s): Esra Urkmez Uzel, CH	**Alicante Auditorium - Hall 10**

12:00 - 12:05 **Opening remarks**

E. Urkmez Uzel, ESGO ENGAGe European Network of Gynecological Cancer Advocacy Group, Geneva, CH

12:05 - 12:15 **Cancer nursing's potential to address the growing cancer burden in Europe**

D. Protogiros, National Public Health Organisation, Athens, GR

12:15 - 12:25 **Role of cancer nurses in cancer screening and prevention**

L. Benito, Barcelona University, Barcelona, ES

12:25 - 12:35 **Exploring the conceptual underpinnings of cancer literacy and how it guides policy and action**

K. Sorensen, Global Health Literacy Association, Risskov, DK

12:35 - 13:25 **Panel discussion and Q&A**

E. Urkmez Uzel[1], D. Protogiros[2], L. Benito[3], K. Sorensen[4], [1]ESGO ENGAGe European Network of Gynecological Cancer Advocacy Group, Geneva, CH, [2]National Public Health Organisation, Athens, GR, [3]Barcelona University, Barcelona, ES, [4]Global Health Literacy Association, Risskov, DK

13:25 - 13:30 **Conclusion remarks**

E. Urkmez Uzel, ESGO ENGAGe European Network of Gynecological Cancer Advocacy Group, Geneva, CH

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Pfizer Oncology - Focus on Individualised Care With CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer** Chair(s): Javier Cortés, ES	**Burgos Auditorium - Hall 3**

13:00 - 13:05 **Welcome and Introductions**

J. Cortés, Hospital Ruber Internacional, Madrid, ES

13:05 - 13:15 **Beyond Therapy: How Can You Identify Women's Goals For Living with Metastatic Breast Cancer?**

J. Cortés, Hospital Ruber Internacional, Madrid, ES

13:15 - 14:25 **Leveraging Experience for a Personalised Approach in Patients with HR+/HER2- Metastatic Breast Cancer: An Interactive Discussion**

J. Cortés[1], H. Rugo[2], P. Fasching[3], [1]Hospital Ruber Internacional, Madrid, ES, [2]UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, [3]University Hospital Erlangen, Erlangen, DE

14:25 - 14:30 **Chair's sum up and Meeting Close**

J. Cortés, Hospital Ruber Internacional, Madrid, ES

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Medscape Oncology Global - Keeping the Outcome in Mind: Applying Best Practices for Managing HR+/HER2- EBC at High Risk of Recurrence** Chair(s): Sara Hurvitz, US	**Valencia Auditorium - Hall 10**

13:00 - 13:05 **Welcome and Introductions**

S. Hurvitz, University of Washington, Seattle, US

13:05 - 13:20 **Keeping the Outcome in Mind: The Patient With HR-Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence**

P. Neven, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

13:20 - 13:40 **Latest Developments for Oral Adjuvant Therapy: Analyzing the Latest Data, Guideline Recommendations and Best Practices**

S. Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

13:40 - 14:00 **Managing the Patient at Risk: Which Patients Will Benefit from Adjuvant Oral Anti-Cancer Therapies?**

P. Neven[1], S. Hurvitz[2], [1]University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, [2]University of Washington, Seattle, US

14:00 - 14:15 **How to Approach Nonadherence in Practice: Clinical Pearls for the Multidisciplinary Team**

E. Hamilton, Sarah Cannon Research Institute-Cancer Centre, Nashville, US

14:15 - 14:30 **Q&A Session**

S. Hurvitz[1], S. Johnston[2], P. Neven[3], E. Hamilton[4], [1]University of Washington, Seattle, US, [2]The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, [3]University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, [4]Sarah Cannon Research Institute-Cancer Centre, Nashville, US

13:00 - 14:20	**Type: Industry Satellite Symposium** **Title: Bristol Myers Squibb - Clinical Perspectives on the Evolution of NSCLC Treatment With I-O and ROS1 TKIs** Chair(s): Jürgen Wolf, DE	**Salamanca Auditorium - Hall 3**

13:00 - 13:10 **Welcome and Introductions**

J. Wolf, University Hospital of Cologne, Cologne, DE

13:10 - 13:30 **A Foundation for Survivorship With I-O and Potential New Approaches for Patients With ROS1+ NSCLC**

J. Wolf, University Hospital of Cologne, Cologne, DE

13:30 - 13:55 **Multidisciplinary Approach to Managing the Expanding Options With I-O in Non-Metastatic NSCLC**

T. Cascone[1], J.L. Campo Canaveral[2], [1]The University of Texas MD Anderson Cancer Center - Main Building, Houston, US, [2]University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES

13:55 - 14:18 **We Are NSCLC Clinicians: Ask Us Anything**

J. Wolf[1], T. Cascone[2], J.L. Campo Canaveral[3], [1]University Hospital of Cologne, Cologne, DE, [2]The University of Texas MD Anderson Cancer Center - Main Building, Houston, US, [3]University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES

14:18 - 14:20 **Closing Remarks**

J. Wolf, University Hospital of Cologne, Cologne, DE

13:00 - 14:30 **Type: Industry Satellite Symposium**
Title: Sanofi - Novel Targets in Advanced NSCLC: Leveraging Emerging Biomarkers in an Evolving Treatment Landscape
Málaga Auditorium - Hall 10

Chair(s): Silvia Novello, IT

13:00 - 13:05 **Welcome and Introduction**

S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

13:05 - 13:25 **Treatment in Advanced NSCLC: What Have We Learned and Where Are We Headed?**

S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

13:25 - 13:45 **Tailor-made: Guiding Treatment Choice With Emerging Biomarkers**

A. Ryska, University Hospital (Fakultni Nemocnice), Hradec Kralove, CZ

13:45 - 14:05 **What Does the Future Hold? Clinical Update on ADCs in Advanced NSCLC**

E. Nadal, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES

14:05 - 14:30 **Group Discussion**

S. Novello[1], E. Nadal[2], A. Ryska[3], [1]Università Degli Studi Di Torino - Orbassano, Orbassano, IT, [2]ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, [3]University Hospital (Fakultni Nemocnice), Hradec Kralove, CZ

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Servier - Shining the light on colorectal cancer: Advancing treatment strategies in mCRC** Chair(s): Eric Van Cutsem, BE; Julien Taieb, FR	**Santander Auditorium - Hall 9**

13:00 - 13:10 **Introduction**

E. Van Cutsem, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

13:10 - 13:30 **New approaches in treating patients with mCRC**

J. Seligmann, The University of Leeds, Leeds, GB

13:30 - 13:50 **Redefining the meaning of later lines of therapy**

J. Taieb, Hopital European George Pompidou, Paris, FR

13:50 - 14:20 **Patient cases in mCRC and panel discussion**

F. Ciardiello, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT

14:20 - 14:30 **Conclusion**

J. Taieb, Hopital European George Pompidou, Paris, FR

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Merck Healthcare KGaA - Putting Patients First: Cultivating Care in Bladder Cancer** Chair(s): Joaquim Bellmunt, US	**Toledo Auditorium - Hall 3**

13:00 - 13:10 **Chairman's introduction**

J. Bellmunt, Harvard Medical School, Boston, US

13:10 - 13:25 **Improving treatment standards in advanced UC: What can we learn from clinical practice?**

P. Grivas, University of Washington, Seattle, US

13:25 - 13:40 **Patient needs in UC: How to optimize treatment experience**

E. Grande Pulido, MD Anderson Cancer Center Madrid, Madrid, ES

13:40 - 13:55 **Open questions in UC: Which gaps can we address today?**

V. Gruenwald, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

13:55 - 14:25 **Hot topics in UC: What keeps the faculty awake at night**

J. Bellmunt[1], E. Grande Pulido[2], V. Gruenwald[3], P. Grivas[4], [1]Harvard Medical School, Boston, US, [2]MD Anderson Cancer Center Madrid, Madrid, ES, [3]University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, [4]University of Washington, Seattle, US

14:25 - 14:30 **Closing remarks**

J. Bellmunt, Harvard Medical School, Boston, US

13:00 - 14:30 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 7**

Title: Amgen - Targeting advanced GI cancer: new approaches on the horizon?

Chair(s): Fernando Rivera, ES

13:00 - 13:10 **Welcome and introduction**

F. Rivera, Hospital Universitario Marqués de Valdecilla, Santander, ES

13:10 - 13:30 **Optimising use of targeted therapy across the RAS WT mCRC continuum**

D. Modest, Charité - Universitaetsmedizin Berlin, Berlin, DE

13:30 - 13:50 **New therapeutic approaches in GI cancers: targeting KRAS mutations**

C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

13:50 - 14:10 **The pursuit of further actionable targets in advanced gastric and GEJ cancers**

E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB

14:10 - 14:30 **Panel discussion and Q&A**

F. Rivera[1], D. Modest[2], C. Cremolini[3], E. Smyth[4], [1]Hospital Universitario Marqués de Valdecilla, Santander, ES, [2]Charité - Universitaetsmedizin Berlin, Berlin, DE, [3]AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, [4]Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Gilead Sciences Europe Ltd - MILLIONS OF LIVES. ONE MISSION. Exploring the potential of ADCs in multiple solid tumours** Chair(s): Peter Schmid, GB	**León Auditorium - Hall 7**

13:00 - 13:15 **Welcome and introduction: ADCs – A journey across time**

P. Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

13:15 - 13:35 **Improving the lives of patients with triple-negative and HR+/HER2- metastatic breast cancer**

S. Tolaney, Dana Farber Cancer Institute, Boston, US

13:35 - 13:55 **Unlocking the potential for the treatment of metastatic urothelial cancer**

T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

13:55 - 14:10 **Expanding opportunities in patients with metastatic NSCLC**

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

14:10 - 14:30 **Q&A and closing remarks**

P. Schmid[1], S. Tolaney[2], T. Powles[3], E. Felip[4], [1]Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, [2]Dana Farber Cancer Institute, Boston, US, [3]St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, [4]Vall d'Hebron University Hospital, Barcelona, ES

13:00 - 14:30	**Type: Patient Advocacy session** **Title: New approaches for technologies, therapies, and surgery** Chair(s): Tanja Spanic, SI; Anne-Marie Baird, IE	**Cádiz Auditorium - NCC**

13:00 - 13:15 **How to decide which mutation to investigate and invest in**

M.F. Mosele, Gustave Roussy - Cancer Campus, Villejuif, FR

13:15 - 13:30 **Surgical therapies: What are the new robotic models and how do they support efficient processes in clinical settings?**

S. Sandrucci, AOU Città della Salute e della Scienza Torino, Torino, IT

13:30 - 13:45 **Radiation therapies: How do proton beam therapy, stereotactic radiosurgery and gamma knife surgery treat cancer?**

P. Poortmans, AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, BE

13:45 - 14:00 **Identification of new biomarkers in lung cancer**

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

14:00 - 14:25 **Discussion**

14:25 - 14:30 **Conclusion**

14:15 - 15:45 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Supportive care
Chair(s): Eva Pape, BE

14:15 - 14:30 **eHealth and digital innovations in supportive care: IBM Watson at your service**
A. Charalambous, Cyprus University of Technology - Nursing Science, Limassol, CY

14:30 - 14:45 **Psychosocial aspects of living long term with advanced cancer and ongoing systemic treatment**
E. Kolsteren, Radboud University Medical Center, Nijmegen, NL

14:45 - 15:00 **Cancer nurses roles in a late effect clinic**
K. Dieperink, Odense University Hospital, Odense C, DK

15:00 - 15:15 **The European Cancer Nursing Index 2020 and 2022**
L. Sharp, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE

15:15 - 15:25 **CN36 - Current care for patients on oral anticancer therapy through a different lens: Assessment from a patient and healthcare professional perspective**
A. Van Hecke[1], L.-M. Kinnaer[2], V. Foulon[3], I. Kenis[4], [1]Ghent University - University Centre for Nursing and Midwifery, GENT, BE, [2]Ghent University - University Centre for Nursing and Midwifery, Ghent, BE, [3]KU Leuven, Leuven, BE, [4]Ghent University, Gent, BE

15:25 - 15:45 **Q&A and discussion**

14:45 - 16:10 **Type: Proffered Paper session** **Barcelona Auditorium - Hall 9**
Title: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Chair(s): Manuela Schmidinger, AT; Cristina Suarez Rodriguez, ES

14:45 - 14:55 **LBA87 - Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)**
T. Choueiri[1], T. Bauer[2], J. Merchan[3], D. Mcdermott[4], R. Figlin[5], E. Arrowsmith[6], M.D. Michaelson[7], E. Heath[8], A. D'Souza[9], S. Zhao[10], L. Mhamdi[11], R. Perini[11], D. Vickery[11], S. Tykodi[12], [1]Dana-Farber Cancer Institute, Boston, US, [2]Sarah Cannon Research Institute and Tennessee Oncology, Nashville, US, [3]University of Miami Health System, Miami, US, [4]Beth Israel Deaconess Medical Center, Boston, US, [5]Cedars-Sinai Medical Center, Los Angeles, US, [6]Tennessee Oncology, Chattanooga, US, [7]Massachusetts General Hospital, Boston, US, [8]Karmanos Cancer Institute, Detroit, US, [9]University of Southern California, Los Angeles, US, [10]Swedish Medical Center, Seattle, US, [11]Merck & Co., Inc., Rahway, US, [12]University of Washington and Fred Hutchinson Cancer Center, Seattle, US

14:55 - 15:05 **LBA88 - Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-**

label phase III LITESPARK-005 study

L. Albiges[1], B. Rini[2], K. Peltola[3], G.A. De Velasco Oria[4], M. Burotto[5], C. Suarez Rodriguez[6], P. Ghatalia[7], R. Iacovelli[8], E. Lam[9], E. Verzoni[10], M. Gumus[11], W. Stadler[12], C. Kollmannsberger[13], B. Melichar[14], B. Venugopal[15], A. Wang[16], R. Perini[17], D. Vickery[18], T. Powles[19], T. Choueiri[20], [1]Institut Gustave Roussy, Villejuif, Cedex, FR, [2]Vanderbilt Ingram Cancer Center, Nashville, US, [3]Comprehensive Cancer Center - Helsinki University Central Hospital, Helsinki, FI, [4]Hospital Universitario 12 de Octubre, Madrid, ES, [5]Bradford Hill-Clinical Center, Santiago, CL, [6]Vall d'Hebron University Hospital, Barcelona, ES, [7]Fox Chase Cancer Center - Main Campus, Philadelphia, US, [8]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, [9]UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, [10]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [11]Istanbul Medeniyet University, Prof.Dr. Suleyman Yalcin City Hospital, Istanbul, TR, [12]The University of Chicago Medical Center, Chicago, US, [13]BC Cancer Agency - Vancouver, Vancouver, CA, [14]FN Olomouc/ University Hospital Olomouc, Olomouc, CZ, [15]BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, [16]Merck & Co., Inc., Rahway, US, [17]Merck & Co., Inc. - Corporate Headquarters, Whitehouse Station, US, [18]Merck & Co., Inc. - Rahway, Rahway, US, [19]St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, [20]Dana Farber Cancer Institute, Boston, US

15:05 - 15:15

1881O - Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study

N. Agarwal[1], J. Brugarolas[2], P. Ghatalia[3], S. George[4], J. Haanen[5], H. Gurney[6], R. Ravilla[7], A. Van Der Veldt[8], B. Beuselinck[9], I. Pokataev[10], B. Suelmann[11], M. Tuthill[12], D. Vaena[13], F. Zagouri[14], J. Wu[15], Y. Liu[15], R. Perini[15], J. Merchan[16], M. Atkins[17], [1]Huntsman Cancer Institute, Salt Lake City, US, [2]University of Texas Southwestern Medical Center, Dallas, US, [3]Fox Chase Cancer Center, Philadelphia, US, [4]Roswell Park Cancer Institute, Buffalo, US, [5]Netherlands Cancer Institute, Amsterdam, NL, [6]Macquarie University, Sydney, AU, [7]New York Oncology Hematology - Albany Cancer Center, Albany, US, [8]Erasmus MC, Rotterdam, NL, [9]UZ Leuven, Leuven, BE, [10]City Clinical Oncology Hospital No. 1, Moscow, RU, [11]Universitair Medisch Centrum Utrecht, Utrecht, NL, [12]Oxford University Hospitals NHS Foundation Trust, London, GB, [13]West Cancer Center and Research Institute, Germantown, US, [14]Alexandra Regional General Hospital, Athens, GR, [15]Merck & Co., Inc., Rahway, US, [16]University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services, Miami, US, [17]Georgetown University Medical Center, Washington, US

15:15 - 15:30

Invited Discussant LBA87, LBA88 and 1881O

L. Pickering, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

15:30 - 15:40

Q&A

15:40 - 15:50

1882O - RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase III study

X. Sheng[1], M. Ye[2], Q. Zou[3], P. Chen[4], Z. He[5], B. Wu[6], D. He[7], C. He[8], X. Xue[9], Z. Ji[10], H. Chen[11], S. Zhang[12], Y. Liu[13], W. Zhai[14], X. Zhang[15], C. Fu[16], D. Xu[17], M. Qiu[18], Y.

Huang[14], J. Guo[1], [1]Peking University Cancer Hospital and Institute, Beijing, CN, [2]Hunan Cancer Hospital, Changsha, CN, [3]Jiangsu Cancer Hospital, Nanjing, CN, [4]Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, CN, [5]Peking University First Hospital, Beijing, CN, [6]Shengjing Hospital of China Medical University - Nanhu Campus, Shenyang, CN, [7]First Affiliated of Xian Communication University, Xian, CN, [8]Henan Cacer Hospital, Zhengzhou, CN, [9]The First Affiliated Hospital of Fujian Medical University, Fuzhou, CN, [10]Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, [11]Harbin Medical University Cancer Hospital, Harbin, CN, [12]West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, [13]The First Hospital of China Medical University, Shenyang, CN, [14]Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CN, [15]Beijing Chaoyang Hospital - Capital Medical University, Beijing, CN, [16]Liaoning Cancer Hospital & Institute, Shenyang, CN, [17]Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, [18]Sichuan Academy of Medical Sciences/Sichuan Provincial People's Hospital, Chengdu, CN

15:50 - 16:00 **Invited Discussant 1882O**

A. Van Der Veldt, Erasmus MC - University Medical Center, Rotterdam, NL

16:00 - 16:10 **Q&A**

14:45 - 16:15 **Type: Proffered Paper session** **Sevilla Auditorium - Hall 9**
Title: Proffered Paper session 1 - Gastrointestinal tumours, lower digestive
Chair(s): Chiara Cremolini, IT; Rodrigo Dienstmann, BR

14:45 - 14:55 **LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION)**

T. Zhang[1], K. Tao[1], Z. Lin[1], P. Zhang[1], Y. Yin[1], P. Chi[2], Y. Huang[2], Y. Xiao[3], Z. Sun[3], X. Xu[4], A. Zhang[5], X. Qiu[6], W. Junxin[7], Y. Yuan[8], Z. Wang[9], X.J. Qu[9], F. Zhao[10], C. Ma[10], F. Cheng[10], Z. Hou[10], [1]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, [2]Fujian Medical University Union Hospital, Fuzhou, CN, [3]Peking Union Medical College Hospital, Beijing, CN, [4]Renmin Hospital of Wuhan University, Wuhan, CN, [5]Affiliated Hospital of Hebei University, Baoding, CN, [6]Zhongshan Hospital Xiamen University, Xiamen, CN, [7]Fujian Cancer Hospital, Fuzhou, CN, [8]The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, [9]The First Affiliated Hospital of China Medical University, Shenyang, CN, [10]Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai, CN

14:55 - 15:05 **LBA26 - Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Final results of a phase III trial**

P.-R. Ding[1], X.-Z. Wang[2], Y.-F. Li[3], Y.-M. Sun[4], C.-K. Yang[5], Z.-G. Wu[6], R. Zhang[7], W. Wang[8], Y. Li[9], Y.-Z. Zhuang[10], J. Lei[11], Y. Ren[12], X. Wan[13], Y. Cheng[14], W.-L. Li[15], Z.-Q. Wang[16], Z. Pan[1], Y.H. Gao[1], Z.-F. Zeng[17], D.-S. Wan[17], [1]Sun Yat-sen University Cancer

Center, Guangzhou, CN, [2]Shantou Central Hospital, Shantou, CN, [3]Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, CN, [4]Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, [5]Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, [6]Meizhou People's Hospital, Meizhou, CN, [7]Liaoning Cancer Hospital & Institute, Shenyang, CN, [8]the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, [9]Guangdong Provincial People's Hospital, Guangzhou, CN, [10]Cancer Hospital of Shantou University Medical College, Shantou, CN, [11]The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, [12]Henan Cancer Hospital, Zhengzhou, CN, [13]Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, [14]The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN, [15]The First Affiliated Hospital of Kunming Medical University, Kunming, CN, [16]West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, [17]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN

15:05 - 15:15 **Invited Discussant LBA25 and LBA26**

K. Haustermans, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:15 - 15:25 **Q&A**

15:25 - 15:35 **549O - Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations**

M. Pelster[1], R. Yaeger[2], S. Klempner[3], S.-H. Ou[4], A. Spira[5], P. Jänne[6], N. Uboha[7], Y. Gaffar[8], G. Newman[9], C. Paweletz[6], G. Heavey[6], L. Alejandro[10], T. Kheoh[10], K. Anderes[10], H. Der Torossian[10], J. Christensen[10], J. Weiss[11], [1]Sarah Cannon Research Institute, Nashville, US, [2]Memorial Sloan Kettering Cancer Center, New York, US, [3]Massachusetts General Cancer Center, Boston, US, [4]UCI Health Chao Family Comprehensive Cancer Center, Orange, US, [5]Virginia Cancer Specialist, Fairfax, VA; US Oncology Research, The Woodlands, US, [6]Dana Farber Cancer Institute, Boston, US, [7]University of Wisconsin, Madison, US, [8]Maryland Oncology Hematology, Columbia, US, [9]Ridley-Tree Cancer Center, Santa Barbara, US, [10]Mirati Therapeutics, Inc., San Diego, US, [11]University of North Carolina-Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, US

15:35 - 15:45 **550O - Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study**

R.-H. Xu[1], Y. Xu[2], D. Yan[3], P. Munster[4], D. Ruan[1], Y. Deng[5], H. Pan[6], C. Underhill[7], G. Richardson[8], I. Nordman[9], K.-W. Lee[10], S. Wei[11], X.-Y. Li[12], J. Shan[13], G. Han[14], S. Henderson[4], X. Xie[15], Z. Xiang[15], Z. Shi[15], L. Zhang[15], [1]Sun Yat-sen University Cancer Center, Guangzhou, CN, [2]Fudan University Shanghai Cancer Center, Shanghai, CN, [3]Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, CN, [4]UCSF, San Francisco, US, [5]The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, [6]Sir Run Run Shaw Hospital School of Medcine Zhejiang University, Hangzhou, CN, [7]Border Medical Oncology, Albury, AU, [8]Cabrini Hospital - Malvern, Malvern, AU, [9]Calvary Mater Newcastle, Waratah, AU, [10]Seoul National University College of

Medicine, Seoul National University Bundang Hospital, Seongnam-si, KR, [11]Hubei Cancer Hospital, Wuhan, CN, [12]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, [13]The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, [14]Xi'an International Medical Center Hospital, Xi'an, CN, [15]InventisBio Co., Ltd, Shanghai, CN

15:45 - 15:55 **551O - Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER**

J. Strickler[1], A. Cercek[2], K. Ng[3], S. Siena[4], T. André[5], E. Van Cutsem[6], C. Wu[7], A. Paulson[8], J. Hubbard[9], A. Coveler[10], C. Fountzilas[11], A. Kardosh[12], P. Kasi[13], H.J. Lenz[14], K. Ciombor[15], M.E. Elez Fernandez[16], M. Stecher[17], P. Cronin[17], M. Bieda[17], T. Bekaii-Saab[7], [1]Duke Cancer Center, Durham, US, [2]Memorial Sloan Kettering Cancer Center, New York, US, [3]Dana Farber Cancer Institute, Boston, US, [4]Università degli Studi di Milano, Milan, IT, [5]Hopital Saint-Antoine, Paris, FR, [6]UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, [7]Mayo Clinic Cancer Center, Phoenix, US, [8]Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, [9]Mayo Clinic, Rochester, US, [10]Fred Hutchinson Cancer Research Center, Seattle, US, [11]Roswell Park Comprehensive Cancer Center, Buffalo, US, [12]OHSU - Oregon Health Science University, Portland, US, [13]Weill Cornell Medicine, New York, US, [14]USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, [15]Vanderbilt University Medical Center, Nashville, US, [16]Vall d'Hebron University Hospital, Barcelona, ES, [17]Seagen Inc., Bothell, US

15:55 - 16:05 **Invited Discussant 549O, 550O and 551O**

R. Dienstmann, Grupo Oncoclinicas, Sao Paulo, BR

16:05 - 16:15 **Q&A**

14:45 - 16:15	**Type: Educational session** **Title: Optimal treatment sequence in metastatic breast cancer (mBC) in 2023** Chair(s): Hervé Bonnefoi, FR; Christoph Thomssen, DE	**Bilbao Auditorium - NCC**

14:45 - 14:50 **Introduction**

C. Thomssen, MLU - Martin-Luther-University Halle-Wittenberg, Halle, DE

14:50 - 15:10 **Luminal-like breast cancer**

S. Delaloge, Institut Gustave Roussy, Villejuif, Cedex, FR

15:10 - 15:30 **HER2+ breast cancer**

I. Krop, Yale University School of Medicine - Yale Cancer Center, New Haven, US

15:30 - 15:50 **Triple-negative breast cancer**

A. Schneeweiss, German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE

15:50 - 16:15 **Discussion**

14:45 - 16:15	**Type: Educational session** **Title: Managing disease progression in oncogene-driven lung cancer** Chair(s): Noemi Reguart Aransay, ES; Ross Soo, SG	**Granada Auditorium - Hall 3**

14:45 - 15:00 **Detection: From technology to clinical practice**

C. Rolfo, Icahn School of Medicine at Mount Sinai, New York, US

15:00 - 15:15 **Mechanisms of resistance**

A.-M. Baird, St. James's Hospital, Dublin, IE

15:15 - 15:35 **Managing progression after EGFR TKIs in EGFR-mutant lung cancer**

M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

15:35 - 15:55 **Managing progression after TKIs in oncogenic fusion-driven lung cancer**

J. Lin, MGH - Massachusetts General Hospital, Boston, US

15:55 - 16:15 **Discussion**

14:45 - 16:15 **Type: Educational session** **Valencia Auditorium - Hall 10**
Title: Is neoadjuvant immunotherapy a therapeutic platform for all tumour types?

Chair(s): Myriam Chalabi, NL; Jessica Hassel, DE

14:45 - 15:10 **Is chemotherapy plus immunotherapy equal to immunotherapy alone at the neoadjuvant stage?**

T. Cascone, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

15:10 - 15:35 **Novel neoadjuvant combination immunotherapies**

A. Menzies, Melanoma Institute Australia, Wollstonecraft, AU

15:35 - 16:00 **How to personalise neoadjuvant immunotherapy**

C. Blank, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:00 - 16:15 **Q&A and Discussion**

14:45 - 16:15 **Type: Mini Oral session** **Salamanca Auditorium - Hall 3**
Title: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies

Chair(s): Andrea Ardizzoni, IT; Joachim Aerts, NL; Kersti Oselin, EE

14:45 - 14:50 **1988MO - Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data**

F. Bozorgmehr[1], F. Weykamp[2], T. Overbeck[3], N. Maguire[4], E. Buchmeier[5], M. Hammer-Hellmig[5], T. Gauler[6], M. Wermke[7], E.G.C. Troost[8], M. Ulmer[9], A.-C. Mueller[10], K. Kokowski[11], B. Röper[12], T. Wehler[13], S. Hey-Koch[14], N.-S. Consdorf[15], R. Behnisch[16], P. Christopoulos[1], M. Thomas[1], S. Rieken[17], [1]Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, DE, [2]University Hospital Heidelberg, Heidelberg University, Heidelberg, DE, [3]University Medical Center Göttingen, Göttingen University, Goettingen, DE, [4]Barmherzige Brueder Krankenhaus Regensburg, Regensburg, DE, [5]Klinikum Köln-Merheim, Köln, DE, [6]WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, [7]University Hospital Dresden, TU Dresden, Dresden, DE, [8]Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, DE, [9]Klinikum Ludwigsburg Medizinische Klinik I, Ludwigsburg, DE, [10]Klinikum Ludwigsburg, Ludwigsburg, DE, [11]Krankenhaus München Bogenhausen II Med. Abteilung, Munich, DE, [12]Strahlentherapie Klinikum Bogenhausen, München, DE, [13]Sana Klinikum Offenbach GmbH, Offenbach am Main, DE, [14]Sana Klinikum Offenbach, Offenbach am Main, DE, [15]Lungenklinik Hemer des Deutschen Gemeinschafts-Diakonieverbandes GmbH, Hemer, DE, [16]Heidelberg University Hospital, Heidelberg, DE, [17]Universitätsmedizin Göttingen, Goettingen, DE

14:50 - 14:55

1989MO - Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study

A. Calles Blanco[1], A. Navarro Mendivil[2], B. Doger De Spéville[3], E. Álvarez Colomé[4], M.J. De Miguel Luken[5], R. Alvarez[1], V. Moreno Garcia[3], J. Ramon[6], M. Arregui Valles[7], E. Corral De La Fuente[6], D. Alcalá[8], M. Fernández[8], J. Rodríguez Morató[8], E. Calvo[6], R. Palmero Sanchez[9], M. Jové[10], E. Felip[11], [1]Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, ES, [2]Vall d´Hebron Hospital Universitari and Vall d´Hebron Institute of Oncology (VHIO); MEDSIR - Medica Scientia Innovation Research, Barcelona, ES, [3]Hospital Universitario Fundación Jiménez Díaz, Madrid, ES, [4]Vall d´Hebron Hospital Universitari and Vall d´Hebron Institute of Oncology (VHIO), Barcelona, ES, [5]Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, ES, [6]START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, ES, [7]Hospital General Universitario Gregorio Maranon, Madrid, ES, [8]MEDSIR - Medica Scientia Innovation Research, Barcelona, ES, [9]ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, L'Hospitalet de Llobregat, ES, [10]ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES, [11]Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

14:55 - 15:00

1990MO - Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial

A. Dowlati[1], A. Cervantes[2], S. Babu[3], E. Hamilton[4], S.F. Wong[5], A. Tazbirkova[6], I.G. Sullivan[7], C. Van Marcke De Lummen[8], A. Italiano[9], J. Patel[10], S. Mekan[10], T. Wu[10], A. Chiang[11], [1]University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, US, [2]INCLIVA Instituto de Investigación Sanitaria, University of Valencia, Valencia, ES, [3]Fort Wayne Medical Oncology and Hematology, Fort Wayne, Fort Wayne, US, [4]Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, [5]Andrew Love Cancer Centre, Geelong, Geelong, AU, [6]Pindara Private Hospital, Southport, AU, [7]Hospital de la Santa Creu i Sant Pau, Barcelona, ES, [8]Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BE, [9]Institute Bergonié, Bordeaux, FR, [10]Gilead Sciences, Inc., Foster City, US, [11]Yale University School of Medicine, New Heaven, US

15:00 - 15:15

Invited Discussant 1988MO, 1989MO and 1990MO

A. Ardizzoni, University of Bologna - Alma Mater Studiorum, Bologna, IT

15:15 - 15:20

LBA99 - First survival data from the NIPU trial: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma

A. Helland[1], V. Haakensen[2], A. Ojlert[3], S. Thunold[4], A. Nowak[5], W.L. Chin[5], O. Grundberg[6], S. Farooqi[7], M. Lund-Iversen[8], W. Szejniuk[9], S. Cedres Perez[10], J. Sørensen[11], M. Bjaanaes[12], [1]University of Oslo, Institute of Clinical medicine, Oslo, NO, [2]Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, [3]Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, NO, [4]Oslo University Hospital - Radiumhospitalet, Oslo, NO, [5]University of Western Australia, Perth, AU, [6]Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE, [7]Oslo University Hospital - Ulleval Hospital, Oslo, NO, [8]Oslo University Hospital, Oslo,

NO, [9]Aalborg University Hospital, Aalborg, DK, [10]Vall d'Hebron University Hospital, Barcelona, ES, [11]Rigshospitalet, Copenhagen, DK, [12]Oslo University Hospital - Ulleval Hospital, Oslo, NO

15:20 - 15:25

LBA93 - EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)

Y. Cheng[1], Y. Liu[2], W. Zhang[3], L. Wu[4], C. Zhou[5], D. Wang[6], B. Xia[7], M. Bi[8], X. Fu[9], C. Li[10], G. Chen[11], D. Lv[12], Y. Zhao[13], J. Huang[14], M. Li[15], T. Yi[16], X. Huang[17], R. Yang[18], Z. Chen[19], Y. Wang[20], [1]Jilin Cancer Hospital, Changchun, CN, [2]Jilin Cancer Hospital, ChangChun, CN, [3]The First Affiliated Hospital of Nanchang University, Nanchang, CN, [4]Hunan Cancer Hospital, Changsha, CN, [5]Shanghai Pulmonary Hospital, Shanghai, CN, [6]Chongqing Cancer Hospital, Chongqing, CN, [7]Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, CN, [8]The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, [9]The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, CN, [10]The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, CN, [11]Cancer Hospital Affiliated to Harbin Medical University,, Harbin, CN, [12]Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou, CN, [13]Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, [14]The First Affiliated Hospital Of Soochow University, Suzhou, CN, [15]Xiangya Hospital of Central South University, Changsha, CN, [16]Xiangyang Central Hospital, Xiangyang, CN, [17]Chongqing University Three Gorges Hospital, Chongqing, CN, [18]Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, CN, [19]The Second Affiliated Hospital of Anhui Medical University, Hefei, CN, [20]West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN

15:25 - 15:35

Invited Discussant LBA99 and LBA93

J. Aerts, Erasmus MC - University Medical Center, Rotterdam, NL

15:35 - 15:40

1262MO - Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial

G. Eberst[1], J. Henriques[2], M. Monchatre[3], E. Giroux-Leprieur[4], E. Kelkel[5], A. Bizieux Thaminy[6], P. Ravier[7], P. Thomas[8], S. Bayle[9], C. Audigier Valette[10], H. Berard[11], F. Desliers[12], A. Lagrange[13], P. Bonnefoy[14], A. Langlais[15], D. Vernerey[2], A. Anota[2], F. Morin[15], V. Westeel[1], [1]CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, [2]CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, [3]Clinique Claude Bernard, Ermont, FR, [4]University Paris-Saclay, UVSQ, APHP – Ambroise Paré Hospital, Boulogne-Billancourt, FR, [5]Centre Hospitalier Metropole Savoie - Chambery, Chambéry, FR, [6]CHD Vendée, La Roche-sur-Yon, FR, [7]Cabinet de Pneumologie, DIJON, FR, [8]CHU Alpes du Sud - Site de Gap, Gap, FR, [9]CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, [10]Hopital Sainte Musse, Toulon, FR, [11]Hôpital d'Instruction des Armées Sainte Anne Toulon, Toulon, Cedex, FR, [12]Cabinet de Pneumologie, Lens, FR, [13]Centre Hospitalier Louis Pasteur, Dôle, FR, [14]Hôpital de Jonzac, Jonzac, FR, [15]French Cooperative Thoracic Intergroup, Paris, FR

15:40 - 15:45

1263MO - The impact of PET-CT and brain MRI for metastasis detection among

patients with T1-stage lung cancer: Findings from a large cohort study

W. Liang, Y. Feng, B. Cheng, J. Li, J. He, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN

15:45 - 15:55 **Invited Discussant 1262MO and 1263MO**

K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE

14:45 - 16:15 **Type: Educational session** **Málaga Auditorium - Hall 10**
Title: Integrating immunotherapy into the standard of care for cervical cancer

Chair(s): Nicoletta Colombo, IT; Alexandra Leary, FR

14:45 - 15:10 **IO in combination with chemoradiation therapy in locally advanced cervical cancer**

S. De Boer, LUMC - Universitair Medisch Centrum, Leiden, NL

15:10 - 15:35 **In metastatic and recurrence**

N. Colombo, IEO - Istituto Europeo di Oncologia, Milan, IT

15:35 - 16:00 **Treatment after progression on immunotherapy**

A. Leary, Institut Gustave Roussy, Villejuif, FR

16:00 - 16:15 **Discussion**

14:45 - 16:15 **Type: Proffered Paper session** **Santander Auditorium - Hall 9**
Title: Proffered Paper session 2 - Basic Science and Translational research

Chair(s): Göran Jönsson, SE; Elin Gray, AU

14:45 - 14:55 **131O - A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort**

M. Rübsam[1], M. Rheinnecker[1], B. Hutter[1], M. Fröhlich[1], C. Heilig[1], N. Paramasivam[1], M. Oleś[1], C. Ball[2], H. Glimm[2], M. Hlevnjak[1], M. Zapatka[1], P. Lichter[1], S. Fröhling[1], R. Schlenk[3], D. Hübschmann[1], [1]German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE, [2]National Center for Tumor Diseases (NCT/UCC) Dresden, German Cancer Research Center (DKFZ) Heidelberg, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, DE, [3]National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), and Heidelberg University Hospital, Heidelberg, DE

14:55 - 15:05 **1O - CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via promoting PARP1 binding to DNA damage sites**

L. Ruilin[1], Q. Li[2], H. Yao[3], [1]2nd Affiliated Hospital/Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, CN, [2]The Second Affiliated Hospital of Sun Yat-Sen

University, Guangzhou, CN, [3]2nd Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN

15:05 - 15:15 **Invited Discussant 131O and 1O**

E. Gray, Edith Cowan University, Perth, AU

15:15 - 15:25 **Q&A**

15:25 - 15:35 **2232O - Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031**

N. Harbeck[1], C. Duan[2], K. Dupree[3], C.-W. Chang[3], C. Barrios[4], H. Zhang[5], S. Saji[6], K. Jung[7], M. Telli[8], M. Liste Hermoso[9], S. Chui[3], M. Dieterich[9], E. Mittendorf[10], L. Molinero[3], [1]LMU Klinikum München, Munich, DE, [2]Roche (China) Holding Ltd, Shanghai, CN, [3]Genentech, Inc., South San Francisco, US, [4]Hospital São Lucas, Porto Alegre, BR, [5]Memorial Sloan Kettering Cancer Center, New York, US, [6]Fukushima Medical University, Fukushima, JP, [7]Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, [8]Stanford University School of Medicine, Stanford, US, [9]F. Hoffmann-La Roche AG, Basel, CH, [10]Brigham and Women's Hospital, Boston, US

15:35 - 15:45 **2O - PD-1 defines a distinct, functional, tissue-adapted state in V-delta-1+ T cells with implications for cancer immunotherapy**

Y. Wu[1], D. Davies[1], S. Kamdar[1], R. Woolf[1], I. Zlatareva[1], M.L. Iannito[1], C. Morton[2], Y. Haque[1], H. Martin[3], O. O'Neill[3], O. Nussbaumer[1], A. Hayday[1], [1]King's College London, London, GB, [2]Guy’s and St Thomas’ NHS Foundation Trust, London, GB, [3]The Francis Crick Institute, London, GB

15:45 - 15:55 **3O - IGSF8 is an innate immune checkpoint and cancer immunotherapy target**

K. Benhadji[1], Y. Li[2], X. Wu[2], H. Liu[2], X. Xiao[2], H. Liu[2], Q. Ding[2], B. Xie[2], C. Sheng[2], R. Zheng[2], Q. Yu[2], X. Hu[1], X.S. Liu[1], T. Xiao[2], [1]GV20 Therapeutics, Cambridge, US, [2]GV20 Therapeutics, Shanghai, CN

15:55 - 16:05 **Invited Discussant 2232O, 2O and 3O**

G. Jönsson, Lund University, Lund, SE

16:05 - 16:15 **Q&A**

14:45 - 16:15 **Type: Mini Oral session** **Toledo Auditorium - Hall 3**
Title: Mini oral session - Supportive and palliative care

Chair(s): Christina Ruhlmann, DK; Karin Jordan, DE; Camilla Zimmermann, CA

14:45 - 14:50 **2032MO - Correlation of safety and efficacy in atezolizumab therapy across indications**

J. Naidoo[1], G. Durán-Pacheco[2], V. Maiya[3], M. Socinski[4], G. Sonpavde[4], J. Puente[5], L. Essioux[6], C. Carter[3], J. Cardona[2], R. Mohindra[7], S. Chandler[6], [1]Beaumont Hospital, Dublin, IE, [2]F. Hoffmann-La Roche Ltd, Basel, CH, [3]Genentech, Inc. - Member of the Roche Group, South San Francisco, US, [4]AdventHealth Medical Group - Internal Medicine at Orlando, Orlando, US, [5]Hospital Clinico Universitario San Carlos, Madrid, ES, [6]F. Hoffmann-La Roche AG, Basel, CH, [7]F. Hoffmann-La Roche AG - Elsaessertor II, Basel, CH

14:50 - 14:55

1843MO - The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial)

F. Wu[1], Y. Zeng[1], Y. Li[1], J. Liu[1], C. Xiao[1], M. Liu[2], Z. Qiu[1], C. Deng[1], F. Ma[1], C. Xia[1], B. Zhang[3], Z. Xiao[4], C. Xu[5], Z. Sheng[6], P. Liu[7], X. Zeng[8], Y. Zhao[8], J. Zhou[1], X. Liu[1], C. Hu[1], [1]The Second Xiangya Hospital of Central South University, Changsha, CN, [2]University of Washington, Seattle, US, [3]Hunan Yiyang Central Hospital, Yiyang, CN, [4]CHANGDE City First People's Hoapital, Changsha, CN, [5]Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital, Jishou, CN, [6]The Third Hospital of Changsha, Changsha, CN, [7]The First Hospital of Changsha, Changsha, CN, [8]Changsha Central Hospital, Changsha, CN

14:55 - 15:00

2033MO - The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based study

L. Eng[1], S. Saibil[2], R. Sutradhar[3], V. Aghanya[3], Y. Kaliwal[3], Y. Niu[3], N. Liu[3], Y. Liu[3], M. Powis[4], G. Liu[1], J. Peppercorn[5], P. Bedard[1], M. Krzyzanowska[1], [1]UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, [2]UHN - University Health Network - Princess Margaret Cancer Centre, Toronto, CA, [3]ICES - Institute for Clinical Evaluative Sciences, Toronto, CA, [4]Princess Margaret Cancer Centre, Toronto, CA, [5]Massachusetts General Hospital, Boston, US

15:00 - 15:15

Invited Discussant 2032MO, 1843MO, 2033MO

C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

15:15 - 15:20

LBA96 - Roxadustat for chemotherapy-induced anemia in patients with non-myeloid malignancies: A randomized, open-label, active-controlled, phase III study

S. Lu[1], J. Wu[2], J. Jiang[3], Q. Guo[4], Y. Yu[5], Y. Liu[6], H. Zhang[7], L. Qian[8], X. Dai[9], Y. Xie[10], T. Fu[11], T. Lee[12], Y.(. Lu[13], R. Ma[13], M. Eisner[12], [1]Shanghai Chest Hospital, Shanghai, CN, [2]Fudan University, Shanghai, CN, [3]The First Hospital of Jiaxing, Jiaxing, CN, [4]Shandong First Medical University Cancer Hospital, Jinan, CN, [5]Harbin Medical University Cancer Hospital, Harbin, CN, [6]Neijiang Second People's Hospital, Neijiang, CN, [7]The First People's Hospital of Foshan, Foshan, CN, [8]Shanghai Fifth People's Hospital, Shanghai, CN, [9]Xuzhou Central Hospital, Xuzhou, CN, [10]The People's Hospital of Guangxi Zhuang Autononous Region, Nanning, CN, [11]Zhuzhou Central Hospital, Zhuzhou, CN, [12]FibroGen, Inc., San Francisco, US, [13]FibroGen (China) Medical Technology Development Co., Ltd., Shanghai, CN

15:20 - 15:25

LBA97 - Olanzapine for the prevention of chemotherapy induced nausea vomiting in patients receiving moderately emetogenic chemotherapeutic (MEC) regimens: Results of a prospective triple blinded phase III multicentric study (OMEC)

V. Ostwal[1], S. Mandavkar[1], M. Parulekar[1], A. Ramaswamy[1], P. Bhargava[2], S. Srinivas[1], D. Chaugule[1], D. Naughane[1], A. Kapoor[3], A. Gupta[4], B. Sansar[4], A. Sharma[3], R. Rai[5], P. Gupta[5], B. Mishra[3], V.K. Muddu[6], I. Olver[7], [1]Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, [2]Tata Memorial Hospital Centre, Mumbai, IN, [3]Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, IN, [4]Homi Bhabha Cancer Hospital, Varanasi, IN, [5]Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, IN, [6]AIG Hospitals, Hyderabad, IN, [7]University of Adelaide, Adelaide, AU

15:25 - 15:30

1844MO - Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive symptoms in lung cancer patients undergoing systemic therapy

A. Starzer, J. Fuerst, E. Tomasich, L. Gottmann, J. Berger, M. Korpan, C. Englisch, M. Kleinberger, F. Moik, G. Heller, L. Carlberg, M. Preusser, A.S. Berghoff, Medical University of Vienna, Vienna, AT

15:30 - 15:45

Invited Discussant LBA96, LBA97 and 1844MO

K. Jordan, Ernst von Bergmann Klinikum Potsdam, Potsdam, DE

15:45 - 15:50

1592MO - Anticancer therapy at the end-of-life: A cluster-randomized trial

M. Hjermstad[1], A. Pirnat[2], N. Aass[3], S. Andersen[4], G. Astrup[2], O. Dajani[1], H. Garresori[5], K.V. Guldhav[6], H.M. Hamre[7], E. Haukland[8], F. Jordal[9], E.T. Lohre[10], T. Lundeby[3], S. Mjaaland[11], Ø. Paulsen[12], K.A. Semb[13], E.S. Staff[14], T.E. Wester[2], S. Kaasa[3], [1]Oslo University Hospital - Ulleval Hospital, Oslo, NO, [2]Oslo University Hospital, Oslo, NO, [3]Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, [4]University Hospital of North Norway, Tromso, NO, [5]Helse Stavanger HF, Stavanger, NO, [6]Health Forde - Forde Central Hospital, Forde, NO, [7]Akershus University Hospital HF, Lorenskog, NO, [8]Nordlandsykehuset Bodoe, Bodoe, NO, [9]Sykehuset Ostfold, Fredrikstad, NO, [10]St. Olavs Hospital, Trondheim University Hospital, Trondheim, NO, [11]Sorlandet Hospital, Kristiansand, NO, [12]Sykehuset Telemark HF, Skien, NO, [13]Sykehuset i Vestfold HF, Tonsberg, NO, [14]Helse More og Romsdal HF, Alesund, NO

15:50 - 15:55

1593MO - Combined early palliative care in patients with non small cell lung cancer: A randomised controlled trial in Chongqing, China

M. Chen, H. Yu, Chongqing Cancer Hospital, Chongqing, CN

15:55 - 16:00

2034MO - EAGER: A randomized, controlled, multicenter trial of electro-acupuncture in gastric cancer patients undergoing adjuvant chemotherapy

H.-B. Zhang[1], Y. Zhu[1], J. Mao[2], X.-S. Chang[1], J.-J. Peng[3], X.-Y. Wu[4], W. Wang[5], D.-C. Diao[1], Y. Li[6], H.-Y. Zhang[7], X.-H. Zhai[8], J.-L. Yu[9], W. Wang[10], J.-X. Zhou[11], Z.-L. Huang[12], T. Zhang[13], Y.-H. Liu[1], R. Zhou[1], H.-C. Ma[1], Y.-D. Chen[1], [1]Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, CN, [2]MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, [3]The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, [4]Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, CN, [5]the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, [6]Guangdong Provincial People’s Hospital, Guangzhou, CN, [7]The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, CN, [8]The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, [9]Zhujiang Hospital of Southern

Medical University, Guangzhou, CN, [10]Foshan First People's Hospital, Foshan, CN, [11]The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, [12]Affiliated Cancer Hospital and Insitute of Guangzhou Medical University, Guangzhou, CN, [13]Yuebei People's Hosptial, Shaoguan, CN

16:00 - 16:15 **Invited Discussant 1592MO, 1593MO and 2034MO**

C. Zimmermann, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

14:45 - 16:15 **Type: Special session** **Oviedo Auditorium - Hall 7**
Title: Management of novel treatments' toxicities

Chair(s): Lazar Popovic, RS; Alice Indini, IT

14:45 - 15:00 **Toxicities of novel therapies: Why is that important?**

L. Popovic, Oncology Institute of Vojvodina, Sremska Kamenica, RS

15:00 - 15:20 **Toxicity of IO + targeted agents**

E. Grande Pulido, MD Anderson Cancer Center Madrid, Madrid, ES

15:20 - 15:40 **Management of antibody-drug conjugates toxicities**

J. Gligorov, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR

15:40 - 16:00 **Toxicities of TILs, CAR-Ts and bispecific antibodies**

A. Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

16:00 - 16:15 **Discussion and Q&A**

A. Indini, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

14:45 - 16:10 **Type: Mini Oral session** **León Auditorium - Hall 7**
Title: Mini oral session - Melanoma and other skin tumours

Chair(s): Georgina Long, AU; Omid Hamid, US; Caroline Robert, FR

14:45 - 14:50 **1083MO - Brain metastases and survival evaluation in the SECOMBIT trial**

P. Ascierto[1], M. Mandalà[2], P.F. Ferrucci[3], M. Guidoboni[4], P. Rutkowski[5], V. Ferraresi[6], A.M. Arance Fernandez[7], M. Guida[8], E. Maiello[9], H. Gogas[10], E. Richtig[11], M.T. Fierro[12], C. Lebbe[13], H. Helgadottir[14], I. Melero[15], G. Palmieri[16], D. Giannarelli[17], A. Grimaldi[18], R. Dummer[19], V. Chiarion Sileni[20], [1]Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, [2]Università degli Studi di Perugia, Perugia, IT, [3]IEO - Istituto Europeo di Oncologia, Milan, IT, [4]IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, IT, [5]Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, [6]IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT, [7]Hospital Clinic y Provincial de Barcelona, Barcelona, ES, [8]Istituto Tumori Giovanni Paolo II, Bari, IT, [9]IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni

Rotondo, IT, [10]National and Kapodistrian University of Athens - School of Medicine, Athens, GR, [11]Universitätsklinik für Dermatologie und Venerologie, Graz, AT, [12]University of Turin, Torino, IT, [13]Hopital Saint Louis AP-HP, Paris, FR, [14]Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE, [15]Clinica Universitaria de Navarra, Pamplona, ES, [16]University of Sassari, Sassari, IT, [17]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, [18]AORN "San Pio", Napoli, IT, [19]Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, [20]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

14:50 - 14:55

1084MO - Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

A. Di Giacomo[1], V. Chiarion Sileni[2], M. Del Vecchio[3], P.F. Ferrucci[4], M. Guida[5], P. Quaglino[6], M. Guidoboni[7], P. Marchetti[8], E. Simonetti[9], G. Amato[10], A. Covre[9], R. Camerini[11], L. Calabro[12], M. Valente[10], M. Mandalà[13], D. Giannarelli[14], M. Maio[1], [1]University of Siena, Center for Immuno-Oncology, University Hospital of Siena, Siena, IT, [2]Veneto Institute of Oncology IOV-IRCCS, Padova, IT, [3]Istituto Nazionale dei Tumori, Milan, IT, [4]European Institute of Oncology, IRCCS, Milan, IT, [5]IRCCS Istituto Tumori "Giovanni Paolo II", Bari, IT, [6]University of Turin, Torino, IT, [7]Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, [8]Sapienza University of Rome, Rome, IT, [9]University of Siena, Siena, IT, [10]Center for Immuno-Oncology, University Hospital of Siena, Siena, IT, [11]NIBIT Foundation Onlus, Genova, IT, [12]University of Ferrara, Ferrara, IT, [13]University of Perugia, Santa Maria della Misericordia, University Hospital of Perugia, Perugia, IT, [14]Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, IT

14:55 - 15:10

Invited Discussant 1083MO and 1084MO

G. Long, University of Sydney, Sydney, AU

15:10 - 15:15

LBA50 - Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial

S. Piperno-Neumann[1], J. Hassel[2], P. Rutkowski[3], J.-F. Baurain[4], M. Schlaak[5], M. Butler[6], R. Sullivan[7], R. Dummer[8], J. Kirkwood[9], M. Orloff[10], J. Sacco[11], S. Ochsenreither[12], A. Joshua[13], L. Gastaud[14], B. Curti[15], R. Carvajal[16], O. Hamid[17], L. Collins[18], C. Holland[19], P. Nathan[20], [1]Institut Curie, Paris, FR, [2]NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, [3]Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, [4]Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, [5]Charité - Universitaetsmedizin Berlin, Berlin, DE, [6]UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, [7]MGH - Massachusetts General Hospital, Boston, US, [8]Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, [9]UPMC Hillman Cancer Center, Pittsburgh, US, [10]Thomas Jefferson Univ Hospital, Philadelphia, US, [11]Clatterbridge Cancer Center - NHS Foundation Trust, Wirral, GB, [12]Charité - Universitätsmedizin Berlin, Berlin, DE, [13]The Kinghorn Cancer Centre, Sydney, AU, [14]Centre Anticancer Antoine Lacassagne, Nice, FR, [15]Portland Providence Medical Center, Portland, US, [16]Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, [17]The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US, [18]Immunocore Limited, Abingdon-on-Thames, GB, [19]Immunocore LLC, Conshohocken, US, [20]Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB

15:15 - 15:20

1086MO - Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study

G.-U. Grigoleit[1], H. Kluger[2], S. Thomas[3], J. Chesney[4], E. Domingo-Musibay[5], M.F. Sanmamed[6], T. Medina[7], M. Ziemer[8], E. Whitman[9], F. Graf Finckenstein[10], J. Chou[10], X. Wu[10], G. Sulur[10], W. Shi[10], A. Sarnaik[11], [1]Helios Klinikum Duisburg, Duisburg, DE, [2]Yale Cancer Center, New Haven, US, [3]Orlando Health Cancer Institute, Orlando, US, [4]Brown Cancer Center University of Louisville, Louisville, US, [5]University of Minnesota, Minneapolis, US, [6]Clinica Universidad de Navarra, Pamplona, ES, [7]University of Colorado Cancer Center, Aurora, US, [8]Universitätsklinikum Leipzig - Klinik und Poliklinik für Frauenheilkunde, Leipzig, DE, [9]Atlantic Health System, Morristown, US, [10]Iovance Biotherapeutics, Inc., San Carlos, US, [11]H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US

15:20 - 15:25

LBA51 - Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047

E. Lipson[1], S. Dolfi[2], H. Tang[2], H. Gogas[3], H. Tawbi[4], F.S. Hodi[5], P. Ascierto[6], E. Gutierrez[7], D. Schadendorf[8], F. Medina Soto[9], P. Rutkowski[10], E. Murillo Ramirez[11], M. Maio[12], Y. Xu[2], K. Desai[2], A. Yu[2], K. Demers[2], K. Miller-Moslin[2], G. Long[13], C. Garnett-Benson[2], [1]The Sidney Kimmel Comprehensive Cancer Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, US, [2]Bristol Myers Squibb, Princeton, US, [3]National and Kapodistrian University of Athens - School of Medicine, Athens, GR, [4]The University of Texas MD Anderson Cancer Center, Houston, US, [5]Dana Farber Cancer Institute, Boston, US, [6]Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, IT, [7]FAICIC Clinical Research, Veracruz, MX, [8]University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, [9]Axis Heilsa S. de R.L. de C.V, Monterrey, Nuevo León, MX, [10]Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, [11]iBiomed Clinical Research, Guadalajara, MX, [12]Center for Immuno-Oncology, University Hospital of Sienadelle Scotte, Siena, IT, [13]Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals, Wollstonecraft, AU

15:25 - 15:40

Invited Discussant LBA50, 1086MO and LBA51

O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US

15:40 - 15:45

1087MO - A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study

J. Becker[1], B. Schilling[2], U. Leiter-Stoppke[3], L. Zimmer[4], J. Hassel[5], I. Von Wasielewski[6], M. Ziemer[7], M. Fluck[8], F. Meier[9], A. Spillner[10], A. Gesierich[2], T. Eigentler[11], E. Livingstone[12], M. Albers[10], Y. Angela[13], R. Gutzmer[14], [1]German Cancer Consortium (DKTK), Essen, DE, [2]UKW - University Hospital Würzburg, Würzburg, DE, [3]Universitaetsklinik Tuebingen, Tuebingen, DE, [4]Universitätsklinikum Essen, Essen, DE, [5]NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, [6]MHH - Medizinische Hochschule Hannover, Hannover, DE, [7]Universitätsklinikum Leipzig - Klinik und Poliklinik für Frauenheilkunde, Leipzig, DE, [8]Fachklinik Hornheide, Münster, DE, [9]Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, [10]Alcedis GmbH,

Giessen, DE, [11]Charité - Universitätsmedizin Berlin, Berlin, DE, [12]University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, [13]Johannes Weseling Klinikum, Minden, DE, [14]Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE

15:45 - 15:50

1088MO - A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up

N. Gross[1], D.M. Miller[2], N. Khushalani[3], V. Divi[4], E. Ruiz[5], E. Lipson[6], F. Meier[7], Y.B. Su[8], P.L. Swiecicki[9], J.L. Atlas[10], J.L. Geiger[11], A. Hauschild[12], J.H. Choe[13], B. Hughes[14], S.-Y. Yoo[15], M. Mathias[15], H. Han[15], M. Fury[15], D. Rischin[16], [1]The University of Texas M. D. Anderson Cancer Center, Houston, US, [2]Beth Israel Deaconess Medical Center, Boston, US, [3]Moffitt Cancer Centre, Tampa, US, [4]Stanford University School of Medicine, Stanford, US, [5]Brigham and Women's Hospital, Harvard Medical School, Boston, US, [6]Johns Hopkins, Baltimore, US, [7]Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, [8]Nebraska Cancer Specialists - Midwest Cancer Center-Legacy, Omaha, US, [9]University of Michigan, Ann Arbor, US, [10]Carolinas HealthCare System/Atrium Health, Charlotte, US, [11]Cleveland Clinic, Cleveland, US, [12]Schleswig-Holstein University Hospital, Kiel, DE, [13]Duke Cancer Institute, Durham, US, [14]Royal Brisbane and Women's Hospital and University of Queensland, Herston, AU, [15]Regeneron Pharmaceuticals, Inc., Tarrytown, US, [16]Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, AU

15:50 - 15:55

LBA52 - A randomized phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

O. Straume[1], C. Schuster[1], S. Aziz[2], K. Davidsen[1], J. Karlsen[3], A.J. Rayford[4], M.I. Siraji[4], H. Løvendahl Svendsen[2], L. Reisæter[2], B.T. Gjertsen[4], L. Akslen[4], J. Lorens[4], [1]Haukeland Universitetssykehus, Bergen, NO, [2]Helse Bergen - Haukeland University Hospital, Bergen, NO, [3]NTNU - Norwegian University of Science and Technology, Trondheim, NO, [4]University of Bergen, Bergen, NO

15:55 - 16:10

Invited Discussant 1087MO, 1088MO and LBA52

C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR

14:45 - 16:15 **Type: Proffered Paper session** **Cádiz Auditorium - NCC**
Title: Proffered paper session: Policy and preventive strategie

Chair(s): Jose Martin-Moreno, ES; Mary Gospodarowicz, CA

14:45 - 14:55

1687O - PRIMCAT: A novel approach to informing health technology assessment decision making in Australia

F. Franchini[1], K. Trapani[1], J. Soon[1], B. Daniels[2], P. Gillett[1], K. Degeling[1], M. Alexander[3], Y.H. To[4], S. O'Haire[5], O. Yang[3], S. Fox[6], J. Desai[5], Y. Zhang[3], B. Solomon[5], P. Gibbs[4], G. Mcarthur[7], S. Pearson[2], M. Ijzerman[8], [1]University of Melbourne, Parkville, AU, [2]University of New South Wales, Kensington, AU, [3]The University of Melbourne, Parkville, AU, [4]WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU, [5]Peter MacCallum Cancer Center, Melbourne, AU, [6]Peter MacCallum Cancer Centre, Melbourne, AU, [7]University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, AU, [8]Erasmus University, Rotterdam, NL

14:55 - 15:05 **1688O - Informative censoring of surrogate end-point data in FDA-approved cancer drugs**

T. Meirson[1], J. Ofer[2], G. Markel[1], Y. Pras[3], S. Gilboa[4], [1]Rabin Medical Center, Petah Tikva, IL, [2]Davidoff Cancer Center - Rabin Medical Center, Petah Tikva, IL, [3]Tel Aviv University, Tel Aviv, IL, [4]Tel Aviv University-Sackler Faculty of Medicine, Tel Aviv, IL

15:05 - 15:15 **1689O - Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group**

A. Pellat[1], T. Grinda[2], A. Prelaj[3], P. Cresta[4], A. Valachis[5], I. Zerdes[6], D. Martins Branco[7], L. Provenzano[3], A. Spagnoletti[3], G. Nader Marta[7], B. Wilson[8], F. Montemurro[9], L. Castelo-Branco[10], G. Pentheroudakis[10], S. Delaloge[11], M. Koopman[12], [1]Hôpital Cochin, Paris, FR, [2]Institut Gustave Roussy, Villejuif, Cedex, FR, [3]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [4]VHIO - Vall d'Hebron Institute of Oncology, Barcelona, ES, [5]Faculty of Medicine & Health, Örebro University, Örebro, SE, [6]Karolinska Institutet - Bioclinicum, Solna, SE, [7]Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, BE, [8]Queen's University, Kingston, CA, [9]IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, [10]ESMO - European Society for Medical Oncology, Lugano, CH, [11]Institut Gustave Roussy, Villejuif, FR, [12]UMC - University Medical Center Utrecht, Utrecht, NL

15:15 - 15:25 **Invited Discussant 1687O, 1688O and 1689O**

A. Cortellini, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT

15:25 - 15:35 **Q&A**

15:35 - 15:45 **1690O - Impact of the SARS-CoV-2 outbreak on the initial clinical presentation of new solid cancer diagnoses: A systematic review and meta-analysis**

S. Marty[1], G. Lamé[2], E. Guével[3], S. Priou[2], G. Chatellier[4], C. Tournigand[1], E. Kempf[1], [1]Centre Hospitalier Universitaire Henri-Mondor AP-HP, Creteil, FR, [2]CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR, [3]Assistance Publique - Hopitaux De Paris AP-HP, Paris, FR, [4]Assistance Publique - Hopitaux De Paris, Paris, FR

15:45 - 15:55 **1691O - Trends in new patient consultations during the COVID-19 pandemic at a comprehensive cancer centre in a public healthcare system**

C. Barron[1], T. Pittman[2], W. Xu[2], M. Madunic[1], J. Brierley[1], M. Krzyzanowska[1], [1]UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, [2]Princess Margaret Cancer Centre, Toronto, CA

15:55 - 16:05 **Invited Discussant 1690O and 1691O**

L. Castelo-Branco, ESMO - European Society for Medical Oncology, Lugano, CH

16:05 - 16:15 **Q&A**

15:00 - 16:00	**Type: Controversy session** **Title: Pregnancy after breast cancer: Is it safe?** Chair(s): Ann H. Partridge, US	**Burgos Auditorium - Hall 3**

15:00 - 15:05 **Welcome and "set the scene"**
A.H. Partridge, Dana Farber Cancer Institute, Boston, US

15:05 - 15:20 **Yes**
P. Neven, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:20 - 15:35 **No**
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

15:35 - 15:40 **First voting**
A.H. Partridge, Dana Farber Cancer Institute, Boston, US

15:40 - 15:55 **Perspective from the Chair**
A.H. Partridge, Dana Farber Cancer Institute, Boston, US

15:55 - 16:00 **Second voting**
A.H. Partridge, Dana Farber Cancer Institute, Boston, US

15:00 - 16:00	**Type: Young Oncologists session** **Title: ESMO for medical students and young physicians** Chair(s): Andres Cervantes, ES; Kok Haw Jonathan Lim, GB	**Pamplona Auditorium - Hall 9**

15:00 - 15:15 **ESMO-ESO Medical Students Course**
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

15:15 - 15:30 **Developing a successful career in medical oncology**
P. Grivas[1], M. Lambertini[2], [1]University of Washington, Seattle, US, [2]IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

15:30 - 16:00 **Guided poster walk**

16:15 - 17:45 **Type: EONS Industry Satellite Symposium** **Alicante Auditorium - Hall 10**
Title: AstraZeneca - Wellbeing in cancer nursing workforce
Chair(s): Virpi Sulosaari, FI

16:15 - 16:20 **Opening remarks**
V. Sulosaari, Turku University of Applied Sciences, Turku, FI

16:20 - 16:45 **Healthy work environment – what does it stand for in cancer care setting and how to apply the principles into practice**
V. Sulosaari, Turku University of Applied Sciences, Turku, FI

16:45 - 17:10 **The role of cancer nursing leadership in support of well-being at work**
H. Ullgren, Karolinska University Hospital-Solna, Solna, SE

17:10 - 17:35 **Factors contributing to well-being at work – cancer nurse's experience**
M. Cable, University Hospital Coventry - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB

17:35 - 17:45 **Q&A and Conclusion remarks**
V. Sulosaari[1], H. Ullgren[2], M. Cable[3], [1]Turku University of Applied Sciences, Turku, FI, [2]Karolinska University Hospital-Solna, Solna, SE, [3]University Hospital Coventry - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB

16:30 - 18:10 **Type: Mini Oral session** **Bilbao Auditorium - NCC**
Title: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Chair(s): Lorenza Rimassa, IT; Hanneke van Laarhoven, NL; Tania Fleitas, ES

16:30 - 16:35 **945MO - AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)**
Z. Ren[1], Y. Huang[2], Y. Guo[3], M.M. Hou[4], W. Wang[5], M. Kuang[6], C. Hao[7], W. Wang[8], Y. Zhang[9], T. Song[10], C. Dai[11], K. Hsing-Tao[12], V. Li[13], R. Abdrashitov[14], L. Wang[13], J. Fan[15], [1]Zhongshan Hospital Fudan University, Shanghai, CN, [2]Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, CN, [3]Nanfang Hospital, Southern Medical University, Guangzhou, CN, [4]Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, [5]Hunan Cancer Hospital, Changsha, CN, [6]The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, [7]Beijing Cancer Hospital, Beijing, CN, [8]West China Hospital Sichuan University, Sichuan, CN, [9]Harbin Medical University Cancer Hospital, Harbin, CN, [10]HCC Research Center for Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, [11]Shengjing Hospital of China Medical University - Huaxiang Campus, Shenyang, CN, [12]Chi Mei Medical Center - Chiali, Tainan City, TW, [13]BeiGene (Beijing) Co. Ltd, Beijing, CN, [14]BeiGene USA, Inc., Fulton, US, [15]Liver Cancer Institute, Zhongshan Hospital - Fudan University, Shanghai, CN

16:35 - 16:40 **94MO - Advanced extrahepatic cholangiocarcinoma: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials**

A. Lamarca[1], P. Ross[2], H. Wasan[3], R. Hubner[4], M. Mcnamara[4], A. Lopes[5], D. Palmer[6], J. Valle[4], J. Bridgewater[7], [1]Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, [2]Guy's Hospital, London, GB, [3]Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, GB, [4]The Christie NHS Foundation Trust, Manchester, GB, [5]CRUK & UCL Cancer Trials Centre, London, GB, [6]University of Liverpool - Imaging Centre at Liverpool, ICaL (formerly NiCaL), Liverpool, GB, [7]UCL Cancer Institute - Paul O'Gorman Building, London, GB

16:40 - 16:45 **95MO - Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma**

M. Javle[1], L. Kankeu Fonkoua[2], A. Mahipal[3], C.-Y. Liao[4], C. Fountzilas[5], D. Li[6], M. Pelster[7], S. Goel[8], P. Peng[9], C. Sun[9], H. Wang[9], K. Hennessy[10], X. Fu[11], L. Neo[9], Y. Shan[9], P. Huang[9], D. Wu[9], F. Wu[9], J. Fan[12], S.A. Piha-Paul[13], [1]MD Anderson Cancer Center, Houston, US, [2]Mayo Clinic, Rochester, US, [3]University Hospitals Cleveland Medical Center, Cleveland, US, [4]University of Chicago – Department of Medicine, Chicago, US, [5]Roswell Park Comprehensive Cancer Center, Buffalo, US, [6]City of Hope Comprehensive Cancer Center, Duarte, US, [7]Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, [8]Rutgers Cancer Institute of New Jersey, New Brunswick, US, [9]TransThera Sciences (Nanjing), Inc., Nanjing, CN, [10]TransThera Sciences (US), Inc., Gaithersburg, US, [11]TransThera Sciences (Nanjing), Inc., nanjing, CN, [12]TransThera Sciences (US), Inc, Gaithersburg, US, [13]The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

16:45 - 17:00 **Invited Discussant 945MO, 94MO and 95MO**

L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT

17:00 - 17:05 **LBA78 - Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial**

X. Zhang[1], Z. Li[1], H. Liang[2], Y. Xue[3], Y. Wang[4], Z. Zhou[5], J. Yu[6], L. Chen[7], Y. Du[8], G. Li[9], G. Xiao[10], D. Wu[11], Y. Zhou[12], C. Dang[13], Y. He[14], Z. Zhang[15], Y. Sun[16], Y. Li[17], L. Shen[1], J. Ji[1], [1]Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, [2]Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, [3]Harbin Medical University Cancer Hospital, Harbin, CN, [4]Fudan University Shanghai Cancer Center, Shanghai, CN, [5]Sun Yat-sen University Cancer Center, Guangzhou, CN, [6]The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, CN, [7]Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, [8]Zhejiang Cancer Hospital, Hangzhou, CN, [9]East theater General Hospital of PLA, Nanjing, CN, [10]Beijing Hospital, Beijing, CN, [11]The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, [12]The Affiliated Hospital of Qingdao University, Qingdao, CN, [13]The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, [14]The First Affiliated Hospital, Sun Yat-sen University, Guangdong, CN, [15]Beijing Friendship Hospital, Capital Medical University, Beijing, CN, [16]Zhongshan Hospital Fudan University, Shanghai, CN, [17]The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN

17:05 - 17:10

1512MO - Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)

C. Li[1], Y. Zheng[1], Z. Shi[2], L. Yang[3], B. Zhang[1], Z. Wang[1], H. Chen[4], X. Wang[5], P. Zhao[6], J. Dong[7], C. Lian[8], Q. Zhao[9], Z. Zheng[10], A. Zhang[11], S. Xu[12], K. Wang[13], F. Yuan[1], Y. Tian[3], K. Yin[2], Z. Zhu[1], [1]Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, [2]Changhai Hospital of Shanghai, Shanghai, CN, [3]Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, [4]Lanzhou University Second Hospital, Lanzhou, CN, [5]Yantai Yuhuangding Hospital, Yantai, CN, [6]Sichuan Provincial Cancer Hospital, Chengdu, CN, [7]Shanxi Provincial Cancer Hospital, Taiyuan, CN, [8]Heping Hospital Affiliated to Changzhi Medical College, Changzhi, CN, [9]The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, [10]Liaoning Cancer Hospital & Institute, Shenyang, CN, [11]Affiliated Hospital of Hebei University, Baoding, CN, [12]Affiliated Hospital of Jiangsu University, Zhenjiang, CN, [13]Sichuan Provincial People's Hospital, Chengdu, CN

17:10 - 17:20

Invited Discussant LBA78 and 1512MO

H. Van Laarhoven, Academic Medical Center, University of Amsterdam, Amsterdam, NL

17:20 - 17:25

LBA79 - GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

X. Zhang[1], J. Wang[2], G. Wang[3], Y. Zhang[4], Q. Fan[5], L. Chuangxin[6], C. Hu[7], M.L. Sun[8], Y. Wan[9], S. Sun[10], J. Wang[11], L. Zhang[12], Y. Shu[13], J. Luo[14], D. Zhu[14], H. Wang[14], Y. Xu[14], Q. Shi[14], J. Yang[14], L. Shen[1], [1]Beijing Cancer Hospital, Beijing, CN, [2]Henan Cancer Hospital, Zhengzhou, CN, [3]Anhui Provincial Hospital, Hefei, CN, [4]Harbin Medical University Cancer Hospital, Harbin, CN, [5]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, [6]Henan Provincial People's Hospital, Zhengzhou, CN, [7]Anhui Provincial Cancer Hospital, Hefei, CN, [8]Jinan Central Hospital, Jinan, CN, [9]Jiangxi Cancer Hospital, Nanchang, CN, [10]Xuzhou Central Hospital, Xuzhou, CN, [11]Affiliated Hospital of Jining Medical University, Jining, CN, [12]Chongqing University Three Gorges Hospital, Chongqing, CN, [13]Jiangsu Province Hospital, Nanjing, CN, [14]CStone Pharmaceuticals Co. Ltd., Shanghai, CN

17:25 - 17:30

LBA80 - Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

R.-H. Xu[1], D.-Y. Oh[2], K. Kato[3], T. Arkenau[4], J. Tabernero[5], M. Cruz-Correa[6], A. Zimina[7], Y. Bai[8], J. Shi[9], K.-W. Lee[10], H. Hirano[3], D.R. Spigel[11], L. Wyrwicz[12], R. Pazo Cid[13], L. Li[14], Y. Xu[15], M.B. Mchenry[16], S. Yang[14], M. Moehler[17], [1]Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, CN, [2]Seoul National University Hospital Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, [3]National Cancer Center Hospital, Tokyo, JP, [4]Sarah Cannon Research Institute, London, GB, [5]Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, ES, [6]University of Puerto Rico, San Juan, PR, [7]BIH Of Omsk Region, Omsk Oblast, RU, [8]Harbin Medical University Cancer Hospital, Harbin, CN, [9]Linyi Cancer Hospital, Linyi, CN, [10]Seoul

National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, [11]Tennessee Oncology, Nashville, US, [12]Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, [13]Hospital Universitario Miguel Servet, Zaragoza, ES, [14]BeiGene (Beijing) Co., Ltd., Beijing, CN, [15]BeiGene (Shanghai) Co., Ltd., Shanghai, CN, [16]BeiGene USA, Inc., Cambridge, US, [17]Johannes Gutenberg-University Clinic, Mainz, DE

17:30 - 17:35

1513MO - A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)

K. Muro[1], H. Kawakami[2], S. Kadowaki[1], A. Makiyama[3], M. Tsuda[4], K. Hirata[5], N. Sugimoto[6], N. Machida[7], H. Hara[8], H. Hirano[9], T. Esaki[10], Y. Komatsu[11], S. Hironaka[12], [1]Aichi Cancer Center Hospital, Nagoya, JP, [2]Kindai University Faculty of Medicine, Osakasayama, JP, [3]Gifu University Hospital, Gifu, JP, [4]Hyogo Cancer Center, Akashi, JP, [5]Keio University School of Medicine, Shinjuku-ku, JP, [6]Osaka International Cancer Institute, Osaka, JP, [7]Kanagawa Cancer Center, Yokohama, JP, [8]Saitama Cancer Center, Ina, JP, [9]National Cancer Center Hospital, Chuo-ku, JP, [10]National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, [11]Hokkaido University Hospital, Sapporo, JP, [12]Kyorin University Faculty of Medicine, Mitaka, JP

17:35 - 17:50

Invited Discussant LBA79, LBA80 and 1513MO

T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES

17:50 - 17:55

LBA81 - Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

F. Lordick[1], M. Shah[2], K. Shitara[3], J. Ajani[4], Y.-J. Bang[5], P. Enzinger[6], D. Ilson[7], E. Van Cutsem[8], J. Gallego Plazas[9], J. Huang[10], L. Shen[11], S.C. Oh[12], P. Sunpaweravong[13], H.H.F. Soo[14], H. Türk[15], J.W. Park[16], D. Moran[16], P. Bhattacharya[16], Y. Cao[17], R.-H. Xu[18], [1]University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, DE, [2]Weill Cornell Medical College, New York, US, [3]National Cancer Center Hospital East, Kashiwa, JP, [4]The University of Texas MD Anderson Cancer Center, Houston, US, [5]Seoul National University College of Medicine, Seoul, KR, [6]Dana Farber Cancer Institute, Boston, US, [7]Memorial Sloan Kettering Cancer Center, New York, US, [8]University Hospitals Gasthuisberg, Leuven, and KULeuven, Leuven, BE, [9]Hospital General Universitario de Elche, Elche, ES, [10]National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, [11]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, CN, [12]Korea University Guro Hospital, Seoul, KR, [13]Prince of Songkla University, Amphoe Hat Yai, TH, [14]Penang Hospital, Penang, MY, [15]BezmialemVakif University, Istanbul, TR, [16]Astellas Pharma Global Development, Inc., Northbrook, US, [17]Astellas Pharma USA, Northbrook, US, [18]Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, CN

17:55 - 18:00

LBA82 - Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for

patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

J. Ajani[1], F. Lordick[2], Y.-J. Bang[3], P. Enzinger[4], D. Ilson[5], M. Shah[6], E. Van Cutsem[7], R.-H. Xu[8], G. Aprile[9], J. Xu[10], R. Pazo Cid[11], Y.-K. Kang[12], J. Yang[13], D. Moran[13], P. Bhattacharya[13], M. Matsangou[14], A. Arozullah[13], J.W. Park[13], K. Shitara[15], [1]The University of Texas MD Anderson Cancer Center, Houston, US, [2]University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, DE, [3]Seoul National University College of Medicine, Seoul, KR, [4]Dana-Farber Cancer Institute, Boston, US, [5]Memorial Sloan Kettering Cancer Center, New York, US, [6]Weill Cornell Medical College, New York, US, [7]University Hospitals Gasthuisberg, Leuven, and KULeuven, Leuven, BE, [8]Sun Yat-sen University Cancer Center, Guangzhou, CN, [9]Azienda ULSS 8 Berica, Vicenza, IT, [10]The Fifth Medical Center of the PLA General Hospital, Beijing, CN, [11]Hospital Universitario Miguel Servet, Zaragoza, ES, [12]Asan Medical Center, University of Ulsan, Seoul, KR, [13]Astellas Pharma Global Development, Inc., Northbrook, US, [14]Astellas Pharma Inc., Northbrook, US, [15]National Cancer Center Hospital East, Kashiwa, JP

18:00 - 18:10 **Invited Discussant LBA81 and LBA82**

S. Lorenzen, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

16:30 - 18:00 **Type: Educational session** **Granada Auditorium - Hall 3**
Title: Biomarkers in metastatic colorectal cancer: What has changed in the last few years?
Chair(s): Myriam Chalabi, NL; Hans Prenen, BE

16:30 - 16:55 **Clinical data of genomic subtypes of mCRC (MSI, BRAF V600, HER2, KRAS G12C, NTRK)**

M. Chalabi, Netherlands Cancer Institute, Amsterdam, NL

16:55 - 17:20 **Biomarkers in 2023: What, how and when to test?**

H. Prenen, UZA - University Hospital Antwerp, Edegem, BE

17:20 - 17:45 **Biomarkers in the near future: What to expect?**

F. Pietrantonio, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

17:45 - 18:00 **Q&A and Discussion**

16:30 - 17:45 **Type: Multidisciplinary session** **Burgos Auditorium - Hall 3**
Title: Bladder preservation strategies
Chair(s): Elizabeth Plimack, US; Andrea Necchi, IT

16:30 - 16:35 **Presentation of case/condition: Non-muscle invasive bladder cancer (NMIBC) progressing to MIBC**
A. Necchi, IRCCS Ospedale San Raffaele, Milan, IT

16:35 - 16:55 **Organ preservation for refractory NMIBC: A surgeon's perspective**
J. Boormans, Erasmus MC, Rotterdam, NL

16:55 - 17:15 **Radiotherapy in bladder preservation**
R. Huddart, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB

17:15 - 17:35 **The role of systemic therapy in bladder preservation**
E. Plimack, Fox Chase Cancer Center - Main Campus, Philadelphia, US

17:35 - 17:45 **Discussion**

16:30 - 18:15 **Type: Proffered Paper session** **Madrid Auditorium - Hall 6**
Title: Presidential 1
Chair(s): Solange Peters, CH; Jean-Yves Blay, FR

16:30 - 16:42 **LBA1 - CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC**

T. Cascone[1], M. Awad[2], J. Spicer[3], J. He[4], S. Lu[5], B. Sepesi[1], F. Tanaka[6], J. Taube[7], R. Cornelissen[8], L. Havel[9], J. Kuzdzal[10], L. Petruzelka[11], L. Wu[12], J.-L. Pujol[13], H. Ito[14], C. Coronado Erdmann[15], P. Sathyanarayana[15], S. Meadows-Shropshire[15], M. Provencio Pulla[16], [1]The University of Texas MD Anderson Cancer Center, Houston, US, [2]Dana-Farber Cancer Institute, Boston, US, [3]McGill University Health Center, Montreal, CA, [4]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijng, CN, [5]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, [6]University of Occupational and Environmental Health, Kitakyushu, JP, [7]The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, US, [8]Erasmus MC Cancer Institute, Rotterdam, NL, [9]Thomayer Hospital, Prague, CZ, [10]John Paul II Hospital, Krakow, PL, [11]Charles University, Prague, CZ, [12]Hunan Cancer Hospital, Changsha, CN, [13]Montpellier Regional University Hospital, Montpellier, FR, [14]Kanagawa Cancer Center, Yokohama, JP, [15]Bristol Myers Squibb, Princeton, US, [16]Hospital Universitario Puerta de Hierro, Madrid, ES

16:42 - 16:54 **LBA2 - ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)**

B. Solomon[1], J.S. Ahn[2], R. Dziadziuszko[3], F. Barlesi[4], M. Nishio[5], D.H. Lee[6], J.-S. Lee[7], W.-

Z. Zhong[8], H. Horinouchi[9], W. Mao[10], M. Hochmair[11], F. De Marinis[12], M.R. Migliorino[13], I. Bondarenko[14], T. Lohmann[15], T. Xu[16], A. Cardona Gavaldon[15], W. Bordogna[15], T. Ruf[15], Y.-L. Wu[8], [1]Peter MacCallum Cancer Center, Melbourne, AU, [2]Samsung Medical Center, Seoul, KR, [3]Medical University of Gdansk, Gdańsk, PL, [4]International Center for Thoracic Cancers (CICT), Villejuif, FR, [5]Japanese Foundation for Cancer Research, Tokyo, JP, [6]Asan Medical Center, Seoul, KR, [7]Seoul National University Bundang Hospital, Seongnam, KR, [8]Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CN, [9]National Cancer Center Hospital, Tokyo, JP, [10]Chinese Academy of Sciences, Zhejiang, CN, [11]Klinik Floridsdorf, Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Vienna, AT, [12]European Institute of Oncology (IRCSS), Milan, IT, [13]San Camillo Forlanini Hospital, Roma, IT, [14]Dnipropetrovsk Medical Academy, Dnipro, UA, [15]F. Hoffmann-La Roche Ltd, Basel, CH, [16]Roche (China) Holding Ltd, Shanghai, CN

16:54 - 17:04 **Invited Discussant LBA1 and LBA2**

M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

17:04 - 17:10 **Q&A**

17:10 - 17:22 **LBA3 - Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer**

J. Hadoux[1], R. Elisei[2], M. Brose[3], A. Hoff[4], B. Robinson[5], M. Gao[6], B. Jarzab[7], P. Isaev[8], K. Kopeckova[9], J. Wadsley[10], D. Führer[11], B. Keam[12], E. Sherman[13], M. Tahara[14], M. Hu[15], Y. Lin[16], P. Maeda[16], L. Wirth[17], J. Capdevila Castillon[18], [1]Gustave Roussy, Villejuif, Cedex, FR, [2]University of Pisa - DAM, Pisa, IT, [3]Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, US, [4]Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, BR, [5]University of Sydney, Sydney, AU, [6]Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, [7]Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, PL, [8]A. Tsyb MRRC, Obninsk, RU, [9]Motol University Hospital, Prague, CZ, [10]Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, [11]University Hospital, Essen, University of Duisburg-Essen, Endocrine Tumour Center at West German Cancer Center, Essen, DE, [12]Seoul National University Hospital, Seoul, KR, [13]MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, [14]National Cancer Center Hospital East, Kashiwa, JP, [15]The University of Texas M. D. Anderson Cancer Center, Houston, US, [16]Eli Lilly and Company, Indianapolis, US, [17]MGH - Massachusetts General Hospital, Boston, US, [18]Vall Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

17:22 - 17:30 **Invited Discussant LBA3**

L. Locati, ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano, Milan, IT

17:30 - 17:35 **Q&A**

17:35 - 17:47

LBA4 - Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC

H.H.F. Loong[1], K. Goto[2], B. Solomon[3], K. Park[4], M. Pérol[5], E. Arriola[6], S. Novello[7], Y. Cheng[8], A. Ardizzoni[9], M. Mak[10], F. Santini[11], Y. Elamin[12], A. Drilon[13], J. Wolf[14], B. Han[15], H. Han[16], M. Uh[16], T. Puri[16], V. Ilaria[17], C. Zhou[18], [1]The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, [2]National Cancer Center Hospital East, Kashiwa, JP, [3]Peter MacCallum Cancer Center, Melbourne, AU, [4]Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, [5]Centre Léon Bérard, Lyon, FR, [6]HOSPITAL DEL MAR, BARCELONA, ES, [7]Università Degli Studi Di Torino - Orbassano, Orbassano, IT, [8]Jilin Cancer Hospital, Changchun, CN, [9]University of Bologna - Alma Mater Studiorum, Bologna, IT, [10]ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, [11]Hospital Sirio Libanes - Complexo Hospitalar Bela Vista, Sao Paulo, BR, [12]The University of Texas M. D. Anderson Cancer Center, Houston, US, [13]Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, [14]University Hospital of Cologne, Cologne, DE, [15]Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, [16]Eli Lilly and Company, Indianapolis, US, [17]Eli Lilly and Company - Global Headquarters, Indianapolis, US, [18]Shanghai Pulmonary Hospital, Shanghai, CN

17:47 - 17:59

LBA5 - Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study

N. Girard[1], K. Park[2], K. Tang[3], B.C. Cho[4], L. Paz-Ares[5], S. Cheng[6], S. Kitazono[7], M. Thiagarajan[8], J. Goldman[9], J. Sabari[10], R. Sanborn[11], A. Mansfield[12], J.-Y. Hung[13], S. Popat[14], J. Dias[15], A. Bhattacharya[16], T. Agrawal[17], M. Shreeve[18], R. Knoblauch[17], C. Zhou[19], [1]Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, FR, [2]Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, (current affiliation: MD Anderson Cancer Center), Houston, US, [3]The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, [4]Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, [5]Hospital Universitario 12 de Octubre, Madrid, ES, [6]Sunnybrook Odette Cancer Centre, Toronto, CA, [7]Japanese Foundation for Cancer Research, Tokyo, JP, [8]General Hospital Kuala Lumpur, Kuala Lumpur, MY, [9]University of California Los Angeles, Los Angeles, US, [10]NYU Langone Health, New York, US, [11]Providence Cancer Institute, Portland, US, [12]Mayo Clinic, Rochester, US, [13]Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TW, [14]The Institute of Cancer Research, London, GB, [15]Barretos Cancer Hospital, Barretos, BR, [16]Janssen R&D, High Wycombe, GB, [17]Janssen R&D, Spring House, US, [18]Janssen R&D, San Diego, US, [19]Tongji University School of Medicine, Shanghai, CN

17:59 - 18:09

Invited Discussant LBA4 and LBA5

B. Besse, Institut Gustave Roussy, Villejuif, FR

18:09 - 18:15

Q&A

16:30 - 18:00 **Type: Special symposium** **Salamanca Auditorium - Hall 3**
Title: New mechanisms and drugs for the treatment of patients with sarcomas

Chair(s): Kjetil Boye, NO; Marta Sbaraglia, IT

16:30 - 16:35 **Introduction and scientific background**

16:35 - 16:50 **Targeting fusion driven sarcomas**

C. Kadoch, Dana Farber Cancer Institute, Boston, US

16:50 - 17:05 **Targeting proapoptotic pathways: MDM2 and beyond**

S. Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

17:05 - 17:20 **Multi-facets of antiangiogenic agents**

T.W.-W. Chen, NTU - National Taiwan University - College of Medicine, Taipei City, TW

17:20 - 17:35 **Novel combinations**

R. Jones, The Royal Marsden Hospital - Chelsea, London, GB

17:35 - 17:55 **Discussion**

17:55 - 18:00 **Conclusions and perspectives**

16:30 - 17:50 **Type: Mini Oral session** **Málaga Auditorium - Hall 10**
Title: Mini oral session - Investigational immunotherapy

Chair(s): Alessandra Curioni-Fontecedro, CH; María José De Miguel, ES

16:30 - 16:35 **1020MO - AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity**

F. Wang[1], C.-Y. Lin[2], J.-M. Sun[3], C.-H. Lu[4], X. Zhu[5], Z. Chen[6], I.-H. Kim[7], Y. Pan[8], J. Zhang[9], Z. Chen[10], D. Tougeron[11], S.-B. Kim[12], E. Van Cutsem[13], R. Abdrashitov[14], R. Ge[15], J. Sun[15], J. Zhou[15], R.-H. Xu[1], [1]Sun Yat-Sen University Cancer Center, Guangzhou, CN, [2]China Medical University Hospital, Taiwan, CN, [3]Samsung Medical Center, Seoul, KR, [4]Chiayi Chang Gung Memorial Hospital, Taiwan, CN, [5]Sichuan Provincial People’s Hospital, Chengdu, CN, [6]The Second Affiliated Hospital of Anhui Medical University, Hefei, CN, [7]Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, KR, [8]Anhui Provincial Hospital, Hefei, CN, [9]Liaoning Cancer Hospital & Institute, Shenyang, CN, [10]People's Hospital of Deyang City, Deyang, CN, [11]Poitiers University Hospital, Poitiers, FR, [12]Asan Medical Center, Seoul, KR, [13]University Hospitals Gasthuisberg Leuven and University of Leuven (KUL), Leuven, BE, [14]BeiGene USA, Inc., Fulton, US,

[15]BeiGene (Beijing) Co., Ltd., Beijing, CN

16:35 - 16:40

1021MO - Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors

M. Mckean[1], E. Dumbrava[2], O. Hamid[3], P. Merriam[4], J. Call[5], W. Feely[6], A. Green[7], U. Vaishampayan[8], K. Moore[9], S. Weroha[10], S. Krishnan[6], A. George[11], [1]Sarah Cannon Research Institute, Nashville, US, [2]M. D. Anderson Cancer Center, Houston, US, [3]The Angeles Clinic and Research Institute, Los Angeles, US, [4]Dana Farber Cancer Institute, Boston, US, [5]START Mountain Region, West Valley City, US, [6]OncoMed Pharmaceuticals, Inc. - Mereo BioPharma Group plc, Redwood City, US, [7]Memorial Sloan Kettering Cancer Center, New York, US, [8]Michigan Medicine University of Michigan, Ann Arbor, US, [9]Oklahoma University, Oklahoma City, US, [10]Mayo Clinic, Rochester, US, [11]The Royal Marsden Foundation Trust, London, GB

16:40 - 16:55

Invited Discussant 1020MO and 1021MO

A. Curioni-Fontecedro, Cantonal Hospital Fribourg, Villar sur Glane, CH

16:55 - 17:00

1022MO - Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy using AI combining total tumor volume and tumor heterogeneity on CT-Scans

L. Dawi[1], S. Ammari[2], Y. Belkouchi[3], J. Hadchiti[4], L. Lawrance[2], F. Wirth[4], A. Bertin[4], S. Morer[4], N. Billet[4], C. Balleyguier[5], P.-H. Cournede[2], H. Talbot[3], N. Lassau[2], [1]Gustave Roussy, Bourg-la-reine, FR, [2]Gustave Roussy - Cancer Campus, Villejuif, FR, [3]CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR, [4]Gustave Roussy, Paris, FR, [5]Institut Gustave Roussy, Villejuif, Cedex, FR

17:00 - 17:05

1023MO - Decoding immunotherapy resistance: A novel multiparametric magnetic resonance imaging approach to stratify cancer patient outcomes

K. Bernatowicz[1], F. Grussu[1], C. Tozzi[1], A. Voronova[1], M. Sanz[2], M. Vieito Villar[2], G. Alonso Casal[2], V. Galvao[2], A. Oberoi[2], I. Braña[2], O. Saavedra Santa Gadea[2], E. Muñoz Couselo[2], G. Serna[1], A.B. Moreno[1], M. Rotxes[2], J. Tabernero[2], R. Toledo[1], P. Nuciforo[1], E. Garralda[2], R. Perez Lopez[1], [1]Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, [2]Vall d'Hebron University Hospital, Barcelona, ES

17:05 - 17:10

1024MO - Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in patients with melanoma treated with anti-PD-1-based therapy

D. Jimenez-Sanchez[1], E.M. Will[1], J. Lai[1], G. Warrier[2], E. Lipson[2], J. Deutsch[1], A.S. Szalay[1], J. Taube[3], [1]Johns Hopkins Hospital, Baltimore, US, [2]Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, [3]Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US

17:10 - 17:25

Invited Discussant 1022MO, 1023MO and 1024MO

M. Donia, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK

17:25 - 17:30

1025MO - Preliminary safety, pharmacokinetics and immunomodulatory activity

of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

T. Marron[1], J. Misleh[2], C. Chen[3], Z. Wainberg[4], J. Powderly[5], R. Boccia[6], M. Gordon[7], J. Segar[8], I. Csiki[9], J. Schanzer[9], L. O'Toole[9], N. Huang[9], J. Seppa[9], J. Glenn[10], K. Klumpp[11], A. Spira[12], [1]The Mount Sinai Hospital - Icahn School of Medicine, New York, US, [2]Christiana Care Health System - Helen F. Graham Cancer Center and Research Institute, Newark, US, [3]Stanford Cancer Center Palo Alto, Palo Alto, US, [4]UCLA - David Geffen School of Medicine, Los Angeles, US, [5]Carolina BioOncology Institute, Huntersville, US, [6]AOP, Bethesda, US, [7]HonorHealth Research Institute, Scottsdale, US, [8]The University of Arizona, Tucson, US, [9]Riboscience LLC, Sunnyvale, US, [10]Stanford Health Care, Stanford, US, [11]Riboscience, Sunnyvale, US, [12]Virginia Cancer Specialist, Fairfax, US

17:30 - 17:35

1026MO - A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors

R.-H. Xu[1], L. Huiyan[1], H. Zhao[1], W. Wei[1], D. Ma[2], X. Yin[3], Y. Ni[4], Y. Wang[5], Y. Zhang[6], J. Zhou[7], H. Pan[8], Z. Niu[9], J. Zhang[10], H. Ren[11], M. Kang[12], W. Jia[13], S. Gu[14], P. Liu[15], Z. Zhang[15], S. Wang[16], [1]Sun Yat-sen University Cancer Center, Guangzhou, CN, [2]Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, [3]Hunan Cancer Hospital, Changsha, CN, [4]Shanxi Provincial Hospital of Traditional Chinese Medicine, Taiyuan, CN, [5]Shanxi Provincial Cancer Hospital, Taiyuan, CN, [6]Harbin Medical University Cancer Hospital, Harbin, CN, [7]Sichuan Cancer Hospital, Chengdu, CN, [8]Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, [9]Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, [10]Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, [11]The Second Affiliated Hospital of Chongqing Medical University, Chongqing, CN, [12]Affiliated Hospital of Guilin Medical University, Guilin, CN, [13]The First Affiliated Hospital of USTC/Anhui Provincial Hospital, Hefei, CN, [14]Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, [15]Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN, [16]Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shenyang, CN

17:35 - 17:50

Invited Discussant 1025MO and 1026MO

M.J. De Miguel Luken, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

16:30 - 18:00	**Type: Patient Advocacy session** **Title: The importance of secondary prevention: Early detection and screening programmes** Chair(s): Eva-Maria Strömsholm, FI; Barbara Moss, GB	**Cádiz Auditorium - NCC**

16:30 - 16:45 **Improving early diagnosis through screening programme guidelines: The case of lung cancer**

J. Van Meerbeeck, UZA - University Hospital Antwerp, Edegem, BE

16:45 - 17:00 **The importance of harmonizing screening programmes across different levels of healthcare systems: Europe, national, regional**

R. Giuliani, Guy's and St Thomas' NHS Foundation Trust, Liverpool, GB

17:00 - 17:15 **Cancer screening, another ground of health equity**

G. Gorgoni, Agenzia Strategica Regionale per la Salute e il Sociale, Bari, IT

17:15 - 17:30 **The case of colon cancer**

B. Moss, DiCE - Digestive Cancers Europe - EuropaColon LTD, Salisbury, GB

17:30 - 17:45 **The case of dental screening programmes**

M. Heffernan, Dr. Heffs, London, GB

17:45 - 17:55 **Discussion**

17:55 - 18:00 **Conclusion**

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: GSK - Convergence of evidence and experience in first-line advanced ovarian cancer Experts debate considerations and options for optimized clinical management** Chair(s): Antonio Gonzalez Martin, ES	**Burgos Auditorium - Hall 3**

18:30 - 18:40 **The evidence nexus: Treatment evolution in first-line advanced ovarian cancer**

A. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES

18:40 - 19:25 **Not too little, not too much: What is the best 1L maintenance treatment approach for patients with HRd tumors?**

A. Leary[1], J. Ledermann[2], [1]Institut Gustave Roussy, Villejuif, FR, [2]UCL Cancer Institute - UCL - London's Global University, London, GB

19:25 - 19:50 **What's next: Novel strategies to address unmet needs in advanced ovarian cancer**

A. Leary[1], J. Ledermann[2], [1]Institut Gustave Roussy, Villejuif, FR, [2]UCL Cancer Institute - UCL - London's Global University, London, GB

19:50 - 19:55 **Conclusions and thoughts**

A. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: Pfizer Oncology - Understanding novel PARPi combination mechanisms in mCRPC** Chair(s): Josep M. Piulats, ES	**Valencia Auditorium - Hall 10**

18:30 - 18:35 **Introduction**

J.M. Piulats, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

18:35 - 19:00 **Molecular rationale behind PARPi and ARPi combinations in mCRPC**

J.M. Piulats, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

19:00 - 19:20 **Novel PARPi + ARPi therapeutic combinations in 1L mCRPC: Findings from Clinical Trials**

A. Azad, Peter MacCallum Cancer Centre, Melbourne, AU

19:20 - 19:40 **Role of novel PARPi + ARPi therapeutic combinations in evolving clinical practice**

P. Barthélémy, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR

19:40 - 19:55 **Q&A**

J.M. Piulats, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

19:55 - 20:00 **Conclusion**

J.M. Piulats, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

18:30 - 20:00	**Type: ESMO Colloquium** **Title: ESMO Colloquium supported by Eisai Europe Ltd.: Optimising outcomes for patients with advanced renal cancer** Chair(s): Toni Choueiri, US; Thomas Powles, GB	**Salamanca Auditorium - Hall 3**

18:30 - 18:40 **Welcome and introduction**

T. Choueiri, Dana Farber Cancer Institute, Boston, US

18:40 - 18:55 **Current and emerging clinicopathologic and molecular prognostic schemes for patients with advanced renal cell carcinoma**

V. Gruenwald, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

18:55 - 19:10 **State-of-the-art combination therapies for patients with advanced RCC**

L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR

19:10 - 19:25 **Do all patients need combination therapy? De-escalation and patient selection**

T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

19:25 - 19:40 **Research insights in enhancing treatment efficacy: Escalation, sequencing and prediction**

T. Choueiri, Dana Farber Cancer Institute, Boston, US

19:40 - 19:55 **Q&A and discussion**

19:55 - 20:00 **Concluding remarks**

T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

18:30 - 20:00 **Type: Industry Satellite Symposium** **Málaga Auditorium - Hall 10**
Title: AstraZeneca - Keeping abreast of a dynamic disease: Considerations in HR+ mBC
Chair(s): Rebecca Dent, SG

18:30 - 18:35 **Welcome and brief introduction to a dynamic disease**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

18:35 - 19:00 **Adapting to a dynamic disease: Optimising endocrine therapy and the role for genomic medicine**
F.C. Bidard, Institut Curie, Paris, FR

19:00 - 19:25 **Responding to a dynamic disease: Utilising ADCs**
I. Krop, Yale University School of Medicine - Yale Cancer Center, New Haven, US

19:25 - 19:50 **Managing a dynamic disease: Tailoring treatment strategies**
K. Jhaveri, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

19:50 - 19:58 **The future of a dynamic disease: What's on the horizon for HR+ mBC?**
R. Dent[1], F.C. Bidard[2], I. Krop[3], K. Jhaveri[4], [1]NCCS - National Cancer Centre Singapore, Singapore, SG, [2]Institut Curie, Paris, FR, [3]Yale University School of Medicine - Yale Cancer Center, New Haven, US, [4]Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

19:58 - 20:00 **Meeting summary and close**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: MSD - Oncologists at the Helm of Translating Biomarker Insights into Actionable Patient Care** Chair(s): Maria Alsina Maqueda, ES	**Santander Auditorium - Hall 9**

18:30 - 18:35 **Welcome and Introductions**

M. Alsina Maqueda, Hospital Universitario de Navarra, Pamplona, ES

18:35 - 18:55 **How have clinical Biomarkers changed the treatment of cancer patients and what may the future look like?**

M. Alsina Maqueda, Hospital Universitario de Navarra, Pamplona, ES

18:55 - 19:05 **Q&A**

M. Alsina Maqueda[1], K. Pantel[2], C. Eloy[3], [1]Hospital Universitario de Navarra, Pamplona, ES, [2]UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, [3]IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT

19:05 - 19:30 **Emerging role of NGS and ctDNA in transforming the clinical utility of biomarkers**

K. Pantel, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

19:30 - 19:45 **How will the use of Digital pathology and AI tools lead to better patient care (Panel discussion)**

C. Eloy, IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT

19:45 - 19:55 **Q&A**

M. Alsina Maqueda[1], K. Pantel[2], C. Eloy[3], [1]Hospital Universitario de Navarra, Pamplona, ES, [2]UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, [3]IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT

19:55 - 20:00 **Closing Remarks**

M. Alsina Maqueda, Hospital Universitario de Navarra, Pamplona, ES

18:30 - 20:00 **Type: Industry Satellite Symposium** **Toledo Auditorium - Hall 3**

Title: Ipsen - aRCC and mCRPC: is your decision-making up-to-date?

Chair(s): Joaquim Bellmunt, US

18:30 - 18:37 **Welcome & introduction**

J. Bellmunt, Harvard Medical School, Boston, US

18:37 - 18:49 **Keeping pace in aRCC Description: A presentation highlighting the rapid advances in treatment landscape as well as biological understanding of aRCC, and what this means for patients in the real world.**

D. Heng, Tom Baker Cancer Centre, Calgary, CA

18:49 - 19:01 **Spoilt for choice in 1L aRCC? Or not Really? Description: A presentation discussing the clinical endpoints that are considered when selecting first-line treatment for patients with aRCC.**

S. Pal, City of Hope Comprehensive Cancer Center, Duarte, US

19:01 - 19:10 **Panel Discussion**

J. Bellmunt[1], S. Pal[2], D. Heng[3], C. Suarez Rodriguez[4], A. Merseburger[5], [1]Harvard Medical School, Boston, US, [2]City of Hope Comprehensive Cancer Center, Duarte, US, [3]Tom Baker Cancer Centre, Calgary, CA, [4]Vall d'Hebron University Hospital, Barcelona, ES, [5]UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE

19:10 - 19:35 **Putting theory into practice Description: A simulated multi-disciplinary tumour board considering the first- and second-line treatment choices for a patient with aRCC.**

C. Suarez Rodriguez[1], D. Heng[2], [1]Vall d'Hebron University Hospital, Barcelona, ES, [2]Tom Baker Cancer Centre, Calgary, CA

19:35 - 19:55 **Direction of travel in mCRPC Description: A presentation reflecting on the similar rapid changes that are occurring in mCRPC and changes anticipated in the near-term, and considering the data available to help clinicians select and sequence treatments.**

A. Merseburger, UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE

19:55 - 20:00 **Closing Remarks**

J. Bellmunt, Harvard Medical School, Boston, US

18:30 - 19:58 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 7**
Title: Merck - Exploring SCCHN: insight into an evolving treatment landscape

Chair(s): Hisham Mehanna, GB

18:30 - 18:35 **Welcome and Introduction**

H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham, GB

18:35 - 18:47 **Treatment of LA SCCHN: challenges and unmet needs**

S. Rieken, Universitätsmedizin Göttingen, Goettingen, DE

18:47 - 18:59 **A matter of life and cell death: resistance to apoptosis in SCCHN**

J. Schoenfeld, Dana-Farber Cancer Institute, Boston, US

18:59 - 19:11 **Looking ahead: ongoing developments in LA SCCHN**

C. Le Tourneau, Institut Curie, Paris, FR

19:11 - 19:26 **Panel discussion**

H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham, GB

19:26 - 19:38 **Reviewing the evidence: treatment sequencing in R/M SCCHN**

N. Baste Rotllan, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

19:38 - 19:53 **Panel discussion**

H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham, GB

19:53 - 19:58 **Closing remarks**

H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham, GB

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: Gilead Sciences Europe Ltd - Lines of progress: Continuing to improve outcomes in metastatic breast cancer** Chair(s): Eva Ciruelos, ES	**León Auditorium - Hall 7**

18:30 - 18:45 **Metastatic Breast Cancer: A journey of progress through innovations**

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

18:45 - 19:10 **Expanding possibilities in HR+/HER2- mBC**

H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

19:10 - 19:35 **Improving outcomes for patients with metastatic TNBC**

A. Schneeweiss, German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE

19:35 - 19:55 **Audience Q&A**

A. Schneeweiss[1], H. Rugo[2], S. Tolaney[3], [1]German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE, [2]UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, [3]Dana Farber Cancer Institute, Boston, US

19:55 - 20:00 **Closing Remarks**

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

22.10.2023

08:30 - 10:00 **Type: Special symposium** **Barcelona Auditorium - Hall 9**
Title: Circulating tumour DNA: A perfect fit?
Chair(s): Clara Montagut Viladot, ES; Julien Taieb, FR

08:30 - 08:35 **Introduction and scientific background**
J. Taieb, Hopital European George Pompidou, Paris, FR

08:35 - 08:50 **ctDNA assessment: How and when?**
K. Pantel, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

08:50 - 09:05 **ctDNA in mCRC: Monitoring response and guiding treatment**
C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

09:05 - 09:20 **ctDNA in early-stage CRC: Tailoring the adjuvant therapy**
J. Taieb, Hopital European George Pompidou, Paris, FR

09:20 - 09:35 **ctDNA clearance: Surrogacy for cure and organ-sparing approaches**
J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**
C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

08:30 - 10:00 **Type: Mini Oral session** **Sevilla Auditorium - Hall 9**
Title: Mini oral session 2 - NSCLC, metastatic
Chair(s): Martin Reck, DE; Jessica Lin, US; Tetsuya Mitsudomi, JP

08:30 - 08:35 **1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)**
Y. Ma[1], H. Zhao[1], Y. Zhao[2], Y. Cheng[3], J. Cui[4], G. Liu[5], D. Xiong[5], J. Zhang[5], L. Xu[5], J. Yu[5], L. Men[5], E. Liang[6], D. Yang[5], L. Zhang[1], Y. Zhai[6], [1]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, CN, [2]Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, [3]Jilin Cancer Hospital, Changchun, CN, [4]The First Hospital of Jilin University, Changchun, CN, [5]Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, CN, [6]Ascentage Pharma Group, Inc., Rockville, US

08:35 - 08:40 **1318MO - First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)**
J. Rotow[1], S.N. Waqar[2], K. Papadopoulos[3], J.-Y. Hung[4], A. Spira[5], H. Gan[6], T. Yoshida[7], C.-

H.S. Kuo[8], B. Doger De Spéville[9], E. Felip[10], K. Yoh[11], G. Morrison-Thiele[12], R. Robinson[13], N. Rudraganguly[13], R. Saab[13], B.C. Cho[14], [1]The Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Boston, US, [2]Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, [3]South Texas Accelerated Research Therapeutics (START), San Antonio, US, [4]Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung City, TW, [5]Virginia Cancer Specialists, US Oncology Research, Fairfax, US, [6]Austin Health - Austin Hospital, Heidelberg, AU, [7]National Cancer Center Hospital, Tokyo, JP, [8]Chang Gung Memorial Hospital, Chang Gung University, Taipei, TW, [9]START Madrid Hospital Universitario, Madrid, ES, [10]Vall d'Hebron University Hospital, Barcelona, ES, [11]National Cancer Center Hospital East, Kashiwa, JP, [12]Abbvie Inc. - Headquarters, North Chicago, US, [13]AbbVie, Inc., San Francisco, US, [14]Yonsei University, Seoul, KR

08:40 - 08:45

1320MO - Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088

H.H.F. Loong[1], G. Daniele[2], T.-Y. Yang[3], T. Leal[4], K. Goto[5], Y. Shinno[6], K. Nishino[7], T. Sakamoto[8], E. Felip[9], J.C. Ruffinelli[10], N. Gallot[11], Z. Wang[12], C. Chen[13], B. Brennan[14], S.-F. Pu[14], M. Kornacker[15], P. Grassi[16], X. Le[17], D.S.W. Tan[18], B.-C. Goh[19], [1]The Chinese University of Hong Kong, Hong Kong, CN, [2]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, [3]Taichung Veterans General Hospital, Taichung City, TW, [4]Emory University, Atlanta, US, [5]National Cancer Center Hospital East, Kashiwa, JP, [6]National Cancer Center Hospital, Tokyo, JP, [7]Osaka International Cancer Institute, Osaka, JP, [8]Tottori University, Yonago, JP, [9]Vall d'Hebron University Hospital, Barcelona, ES, [10]ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, [11]ClinBAY Ltd., Limassol, CY, [12]Bayer HealthCare Pharmaceuticals, Inc., Cambridge, US, [13]Bayer HealthCare Pharmaceuticals Inc., Whippany, US, [14]Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, [15]Bayer Consumer Care, Basel, CH, [16]Bayer S.p.A., Milan, IT, [17]MD Anderson Cancer Center, Houston, US, [18]National Cancer Centre Singapore, Singapore, SG, [19]National University Cancer Institute, Singapore, SG

08:45 - 09:00

Invited Discussant 1317MO, 1318MO and 1320MO

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

09:00 - 09:05

1319MO - Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01

M. Johnson[1], P. Jänne[2], Y. Goto[3], K. Yoh[4], S.-H. Lee[5], L. Paz-Ares[6], B. Besse[7], S. Novello[8], H. Hayashi[9], D.-W. Kim[10], T. John[11], S. Kao[12], E. Felip[13], J.C.-H. Yang[14], M. Reck[15], Q. Dong[16], A. Sporchia[16], D. Sternberg[16], H.A. Yu[17], [1]Sarah Cannon Research Institute, Nashville, US, [2]Dana-Farber Cancer Institute, Boston, US, [3]National Cancer Center Hospital, Chuo-ku, JP, [4]National Cancer Center Hospital East, Kashiwa, JP, [5]Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, KR, [6]Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid, ES, [7]Gustave Roussy, Villejuif, FR, [8]University of Turin, Orbassano, IT, [9]Kindai University, Osaka, JP, [10]Seoul National University College of Medicine and Seoul National University Hospital, Seoul, KR, [11]Peter MacCallum Cancer Centre, Melbourne, AU, [12]Sydney Medical School,

The University of Sydney, Sydney, AU, [13]Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, [14]National Taiwan University Hospital, Taipei City, TW, [15]Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, [16]Daiichi Sankyo, Inc, Basking Ridge, US, [17]Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, US

09:05 - 09:10 **1321MO - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02**

B. Li[1], D. Planchard[2], K. Goto[3], E. Smit[4], J. De Langen[5], Y. Goto[6], K. Ninomiya[7], T. Kubo[7], M. Pérol[8], E. Felip[9], H. Hayashi[10], K. Nakagawa[10], J. Shimizu[11], M. Nagasaka[12], K. Pereira[13], A. Taguchi[14], A. Ali[15], M. Karnoub[13], R. Yonemochi[13], P. Jänne[16], [1]Memorial Sloan Kettering Cancer Center, New York, US, [2]Gustave Roussy, Villejuif, Cedex, FR, [3]National Cancer Center Hospital East, Kashiwa, JP, [4]LUMC-Leiden University Medical Center, Leiden, NL, [5]Netherlands Cancer Institute, Amsterdam, NL, [6]National Cancer Center Hospital, Tokyo, JP, [7]Okayama University Hospital, Okayama, JP, [8]Léon Bérard Cancer Center, Lyon, FR, [9]Vall d'Hebron University Hospital, Barcelona, ES, [10]Kindai University Hospital, Osakasayama, JP, [11]Aichi Cancer Center Hospital, Nagoya, JP, [12]University of California Irvine School of Medicine, Orange, US, [13]Daiichi Sankyo, Inc., Basking Ridge, US, [14]Daiichi Sankyo Co., Ltd., Chuo-ku, JP, [15]Daiichi Sankyo Europe GmbH, Munich, DE, [16]Dana-Farber Cancer Institute, Boston, US

09:10 - 09:15 **1324MO - CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis**

R. Soo[1], B.C. Cho[2], J.-H. Kim[3], M.-J. Ahn[4], K.H. Lee[5], A. Zimina[6], S. Orlov[7], I. Bondarenko[8], Y.-G. Lee[9], L. Yueh Ni[10], S.S. Lee[11], K.H. Lee[12], Y.K. Pang[13], C.H. Fong[14], J.H. Kang[15], C.S. Lim[16], P. Danchaivijitr[17], H. Lee[18], S. Park[18], I. Cicin[19], [1]National University Cancer Institute Singapore, Singapore, SG, [2]Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, [3]CHA Bundang Medical Center, Seongnam, KR, [4]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [5]Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, KR, [6]State Budgetary Healthcare Institution of Omsk Region, Omsk, RU, [7]Pavlov State Medical University, Saint-Petersburg, RU, [8]Dnipropetrovsk Medical Academy, Dnipro, UA, [9]Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KR, [10]Hospital Umum Sarawak, Sarawak, MY, [11]IInje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, KR, [12]Yeungnam Univeristy Medical Center, Daegu, KR, [13]University Malaya Medical Centre, Kuala Lumpur, MY, [14]Hospital Pulau Pinang, Georgetown, MY, [15]Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KR, [16]Hospital Sultan Ismail, Johor Bahru, MY, [17]Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH, [18]Yuhan Corporation, Seoul, KR, [19]Trakya University Medical Faculty, Edirne, TR

09:15 - 09:30 **Invited Discussant 1319MO, 1321MO and 1324MO**

J. Lin, MGH - Massachusetts General Hospital, Boston, US

09:30 - 09:35 **1322MO - Insights into tumour dissemination and progression using**

longitudinal Imaging and ctDNA in the TRACERx lung cancer study

W.K. Liu[1], B. Ding[2], S. Hessey[1], C. Martinez Ruiz[3], J. Kittel[1], C. Lombardelli[1], H. Lee[2], C. Veiga[2], C. Richard[1], A. Huebner[3], A. Hackshaw[4], C. Abbosh[5], G. Royle[2], A. Frankell[6], C. Swanton[6], M. Jamal-Hanjani[1], [1]University College London Cancer Institute, London, GB, [2]UCL - University College London, London, GB, [3]UCL Cancer Institute - Paul O'Gorman Building, London, GB, [4]Cancer Research UK & University College London Cancer Trials Centre, London, GB, [5]Cancer Research UK, London, GB, [6]Francis Crick Institute, London, GB

09:35 - 09:40 **LBA72 - DARWIN II: Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC**

C. Hiley[1], S. Saghafinia[1], T. Ahmad[2], M. Krebs[3], D. Fennell[4], S. Baijal[5], N. Steele[6], G. Price[7], C. Lombardelli[8], W.K. Liu[9], C. Castignani[10], K. Enfield[10], B. Chain[8], S. Quezada[11], G. Kassiotis[12], K. Litchfield[13], N. Mcgranahan[9], A. Hackshaw[14], M. Jamal-Hanjani[1], C. Swanton[10], [1]UCL Cancer Institute - Paul O'Gorman Building, London, GB, [2]University College London Hospitals NHS Foundation Trust, London, GB, [3]The Christie NHS Foundation Trust, Manchester, GB, [4]Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, [5]Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, [6]BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, [7]Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB, [8]UCL - University College London, London, GB, [9]University College London Cancer Institute, London, GB, [10]Francis Crick Institute, London, GB, [11]UCL Cancer Institute, London, GB, [12]The Francis Crick Institute, London, GB, [13]UCL Cancer Institute - UCL - London's Global University, London, GB, [14]Cancer Research UK & University College London Cancer Trials Centre, London, GB

09:40 - 09:45 **1323MO - Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study**

S. Hessey[1], W.K. Liu[1], O. Pich[2], A. Huebner[1], A. Bunkum[1], C. Richard[1], C. Puttick[2], C. Lombardelli[1], D. Moore[1], N. Mcgranahan[1], S. Zaccaria[1], C. Hiley[2], C. Swanton[2], M. Jamal-Hanjani[1], [1]University College London Cancer Institute, London, GB, [2]Francis Crick Institute, London, GB

09:45 - 10:00 **Invited Discussant 1322MO, LBA72 and 1323MO**

T. Mitsudomi, Kindai University - Faculty of Medicine, Osaka, JP

08:30 - 09:55 **Type: Mini Oral session** **Bilbao Auditorium - NCC**
Title: Mini oral session - Breast cancer, metastatic

Chair(s): Barbara Pistilli, FR; Christoph Thomssen, DE; Hervé Bonnefoi, FR

08:30 - 08:35 **379MO - Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study**

P. Schmid[1], P. Wysocki[2], C. Ma[3], Y.H. Park[4], R. Fernandes[5], S. Lord[6], R. Baird[7], C. Prady[8], K. Jung[9], J. Asselah[10], R. Huisden[11], R. Stewart[11], K. Heider[11], P. Vukovic[11], N. Denduluri[12], Z. Nowecki[13], [1]Barts Cancer Institute, Queen Mary University of London, London, GB, [2]Jagiellonian University Medical College, Krakow, PL, [3]Washington

University School of Medicine, St. Louis, US, [4]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [5]Schulich School of Medicine & Dentistry, Western University, London Health Sciences Centre, London, CA, [6]University of Oxford, Oxford, GB, [7]Cancer Research UK Cambridge Centre, Cambridge, GB, [8]Sherbrooke University, Centre intégré de Cancérologie de la Montérégie, CISSS Montérégie Centre, Greenfield Park, Quebec, CA, [9]Asan Medical Center, University of Ulsan, College of Medicine, Seoul, KR, [10]McGill University Health Centre, Montreal, CA, [11]AstraZeneca, Cambridge, GB, [12]AstraZeneca, Gaithersburg, US, [13]Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

08:35 - 08:40

380MO - SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial

Q. Ouyang[1], Y. Yin[2], L. Song[3], M. Yan[4], X. Wu[5], Z. Tong[6], Y. Liu[7], X. Wang[8], X. Jin[9], Y. Diao[9], G. Liu[9], J. Ge[9], J. Li[10], [1]Hunan Cancer Hospital, Changsha, CN, [2]Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, [3]Shandong Cancer Hospital and Institute, Jinan, CN, [4]Henan Cancer Hospital, Zhengzhou, CN, [5]Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology and Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan, CN, [6]TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, [7]The First Hospital of China Medical University, Shenyang, CN, [8]Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, [9]Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, CN, [10]Shanghai East Hospital, Shanghai, CN

08:40 - 08:55

Invited Discussant 379MO and 380MO

B. Pistilli, Institut Gustave Roussy, Villejuif, Cedex, FR

08:55 - 09:00

382MO - Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer

N. Lin[1], V. Borges[2], M.R. Patel[3], M. Okera[4], J. Meisel[5], R. Wesolowski[6], T. Pluard[7], K. Miller[8], N. Mccarthy[9], A. Conlin[10], R. Mahtani[11], D. Sabanathan[12], K. Mccann[13], E. Roesch[14], G. Mathauda-Sahota[15], J. Schroeder[15], E. Hamilton[16], [1]Dana Farber Cancer Institute, Boston, US, [2]UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, [3]Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers, US, [4]Cancer Research SA, Adelaide, AU, [5]Winship Cancer Institute, Emory University, Atlanta, US, [6]The Ohio State University Comprehensive Cancer Center, Columbus, US, [7]Saint Luke's Hospital of Kansas City - Saint Luke's Health System, Kansas City, US, [8]Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, US, [9]ICON Cancer Center - Wesley Medical Centre, Auchenflower, AU, [10]Providence Cancer Institute, Portland, US, [11]Miami Cancer Institute - Baptist Health South Florida, Miami, US, [12]Macquarie University, Macquarie Park, AU, [13]Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, US, [14]Cleveland Clinic, Taussig Cancer Center, Cleveland, US, [15]Olema Pharmaceuticals, Inc., San Francisco, US, [16]Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US

09:00 - 09:05

383MO - Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study

K. Jhaveri[1], R. Jeselsohn[2], C. Ma[3], E. Lim[4], K. Yonemori[5], E. Hamilton[6], K. Harnden[7], S.-A. Im[8], T. Beck[9], S. Sammons[10], M. Bhave[11], P. Kaufman[12], C. Saura Manich[13], T. Meniawy[14], F. Bacchion[15], R. Ismail-Khan[15], Y. Li[16], S. Estrem[15], B. Nguyen[15], M. Beeram[17], [1]Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, [2]Dana Farber Cancer Institute, Boston, US, [3]Washington University School of Medicine, St. Louis, US, [4]Garvan Institute of Medical Research, Darlinghurst, AU, [5]National Cancer Center Hospital, Tokyo, JP, [6]Sarah Cannon Research Institute, Nashville, US, [7]Inova Schar Cancer Institute, Fairfax, US, [8]Seoul National University Hospital, Seoul, KR, [9]Highlands Oncology Group - Rogers, Fayetteville, US, [10]Duke Cancer Institute, Boston, US, [11]Winship Cancer Institute of Emory University, Atlanta, US, [12]University of Vermont - Larner College of Medicine, Burlington, US, [13]Vall d'Hebron University Hospital, Barcelona, ES, [14]Sir Charles Gairdner Hospital and Linear Research Institute, Subiaco, AU, [15]Loxo@Lilly, Lilly Corporate Center, Indianapolis, US, [16]Eli Lilly and Company, New York, US, [17]South Texas Accelerated Research Therapeutics (START), San Antonio, US

09:05 - 09:10

384MO - Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)

J. Robertson[1], Z. Shao[2], S. Noguchi[3], S. Singh[4], S. Subramaniam[5], M. Ellis[6], [1]University of Nottingham, School of Medicine, Nottingham, GB, [2]University Shanghai Cancer Center, Shanghai, CN, [3]Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, JP, [4]AstraZeneca Netherlands, Zoetermeer, NL, [5]AstraZeneca India, Bangalore, IN, [6]AstraZeneca Pharmaceuticals LP, Gaithersburg, US

09:10 - 09:25

Invited Discussant 382MO, 383MO and 384MO

C. Thomssen, MLU - Martin-Luther-University Halle-Wittenberg, Halle, DE

09:25 - 09:30

385MO - A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors

J. Zhang[1], X. Hu[1], Y. Du[1], Y. Meng[1], Y. Liu[2], Y. Shi[3], J. Wang[4], A. Zang[5], S. Gu[6], T. Liu[7], H. Zhou[8], H. Guo[9], S. Xiang[10], X. Zhang[11], S. Wu[10], M. Li[12], [1]Fudan University Shanghai Cancer Center, Shanghai, CN, [2]The First Hospital of China Medical University, Shenyang, CN, [3]Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, [4]Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, [5]Affiliated Hospital of Hebei University, Baoding, CN, [6]Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, [7]Zhongshan Hospital Fudan University, Shanghai, CN, [8]The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, [9]Nanjing Drum Tower Hospital, Nanjing, CN, [10]CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Beijing, CN, [11]CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Shijiazhuang, CN, [12]CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Shanghai, CN

09:30 - 09:35

386MO - Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

P. Aftimos[1], N. Turner[2], J. O'Shaughnessy[3], E. Van Den Tweel[4], M. Oesterholt[4], S. Escrivá-De-Romaní[5], N. Quenel Tueux[6], T. Tan[7], J. Lim[8], S. Ladoire[9], A. Armstronh[10], A. Stradella[11], G. Bianchi[12], M. Colleoni[13], E. Kaczmarek[14], K. Punie[15], X. Song[16], N.

Koper[4], C. Saura Manich[5], [1]Institute Jules Bordet, Anderlecht, BE, [2]The Royal Marsden Hospital - Chelsea, London, GB, [3]Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, [4]Byondis B.V., Nijmegen, NL, [5]Vall d'Hebron University Hospital, Barcelona, ES, [6]Institute Bergonié, Bordeaux, FR, [7]NCCS - National Cancer Centre Singapore, Singapore, SG, [8]NUHS - National University Health System, Singapore, SG, [9]Centre Georges-François Leclerc (Dijon), Dijon, FR, [10]The Christie NHS Foundation Trust, Manchester, GB, [11]ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, [12]SC Oncologia Medica 1 Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, IT, [13]IEO - Istituto Europeo di Oncologia, Milan, IT, [14]Centre Oscar Lambret, Lille, FR, [15]Leuven Cancer Institute, University Hospitals Leuven, Leuven, BE, [16]The Ottawa Hospital Regional Cancer Centre, Ottawa, CA

09:35 - 09:40

387MO - First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer

T. Pascual[1], E. Segui Solis[2], R. Olivera-Salguero[3], J.M. Cejalvo[4], M. Oliveira[5], P. Tolosa Ortega[6], M.J. Vidal Losada[7], M. Malumbres[8], J. Gavilá-Gregori[9], C. Saura Manich[5], S. Pernas Simon[10], M. Margeli Vila[11], E. Ciruelos[6], E. Galve-Calvo[12], P. Galván[13], E. Sanfeliu Torres[7], R. Olmos[14], M. Forns[15], A. Casas Fernandez Tejerina[16], A. Prat[17], [1]SOLTI/Hospital Clinic y Provincial de Barcelona/IDIBAPS, Barcelona, ES, [2]Hospital Clinic y Provincial de Barcelona/SOLTI/IDIBAPS, Barcelona, ES, [3]SOLTI Cancer Research Group, Barcelona, ES, [4]Hospital Clinico Universitario de Valencia/INCLIVA/SOLTI, Valencia, ES, [5]Vall d'Hebron University Hospital, Barcelona, ES, [6]Hospital Universitario 12 de Octubre, Madrid, ES, [7]Hospital Clinic of Barcelona, Barcelona, ES, [8]Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, [9]IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, [10]ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, [11]ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, [12]Hospital Universitario de Basurto, Bilbao, ES, [13]IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES, [14]Asociación Española de Cáncer de Mama Metastásico (CMM), Oviedo, ES, [15]Asociación Española de Cáncer de Mama Metastásico, Oviedo, ES, [16]Fundación Actitud Frente al Cáncer, Seville, ES, [17]Hospital Clinic y Provincial de Barcelona, Barcelona, ES

09:40 - 09:55

Invited Discussant 385MO, 386MO and 387MO

H. Bonnefoi, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR

08:30 - 09:35 **Type: Mini Oral session** **Granada Auditorium - Hall 3**
Title: Mini oral session - Genitourinary tumours, prostate

Chair(s): Boris Hadaschik, DE; Himisha Beltran, US

08:30 - 08:35

1766MO - Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study

S. Freedland[1], M. Gleave[2], U. De Giorgi[3], A. Rannikko[4], C. Pieczonka[5], R. Tutrone[6], B. Venugopal[7], H. Woo[8], M. Ramirez Backhaus[9], S. Supiot[10], A. Lantz[11], A. Ganguli[12], J. Ivanova[13], P. Kral[14], S.-P. Huang[15], F. Saad[16], N. Shore[17], [1]Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, US,

[2]University of British Columbia Faculty of Medicine, Vancouver, CA, [3]IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, IT, [4]Helsingin yliopistollinen keskussairaala, Helsinki, FI, [5]PLLC, Syracuse, US, [6]Chesapeake Urology Research Associates, Towson, US, [7]BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, [8]Australian National University, Canberra, AU, [9]Instituto Valenciano de Oncologia IVO, Valencia, ES, [10]ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, [11]Karolinska University Hospital, Solna, SE, [12]Astellas Pharma USA, Northbrook, US, [13]Pfizer, New York, US, [14]IQVIA, Bratislava, SK, [15]Kaohsiung Medical University Hospital, Kaohsiung City, TW, [16]Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Montreal, CA, [17]Carolina Urologic Research Center/GenesisCare US, Myrtle Beach, US

08:35 - 08:40

1767MO - External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials

C. Parker[1], L. Mendes[1], E. Grist[1], V. Liu[2], D. Van Der Wal[2], J. Griffin[2], E. Chen[2], P. Tran[3], D. Spratt[4], L. Murphy[5], A. Sachdeva[6], S. Lall[1], M. Parmar[5], M. Sydes[7], L. Brown[5], A. Esteva[2], F. Feng[8], N. Clarke[6], N. James[9], G. Attard[10], [1]UCL Cancer Institute - Paul O'Gorman Building, London, GB, [2]ArteraAI, Los Altos, US, [3]Maryland Proton Treatment Center, Baltimore, US, [4]Case Western Reserve University / University Hospitals, Cleveland, US, [5]MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB, [6]The Christie & Salford NHS Foundation Trust, Manchester, GB, [7]Medical Research Council Clinical Trials Unit, London, GB, [8]UCSF Medical Center at Mission Bay, San Francisco, US, [9]Institute of Cancer Research and Royal Marsden Hospital, London, GB, [10]University College London, London, GB

08:40 - 08:45

1768MO - Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons

C. Jones[1], P. Dutey-Magni[2], L. Murphy[2], M. Murray[2], J. Brown[3], E. Mccloskey[3], M. Parmar[4], N. James[5], M. Sydes[6], L. Brown[2], N. Clarke[7], A. Sachdeva[1], [1]The Christie NHS Foundation Trust, Manchester, GB, [2]MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB, [3]University of Sheffield Medical School, Sheffield, GB, [4]Institute of Clinical Trials and Methodology-UCL, London, GB, [5]ICR - Institute of Cancer Research, London, GB, [6]Medical Research Council Clinical Trials Unit, London, GB, [7]The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB

08:45 - 09:00

Invited Discussant 1766MO, 1767MO and 1768MO

B. Hadaschik, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

09:00 - 09:05

1771MO - Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

J. Graff[1], M. Burotto[2], P. Fong[3], D. Pook[4], B. Zurawski[5], R. Manneh Kopp[6], J. Salinas[7], K. Bylow[8], G. Kramer[9], R. Ratta[10], M. Kwiatkowski[11], M. Retz[12], C. Kwak[13], J. Arranz Arija[14], H. Gurney[15], N. Matsubara[16], L.W. Liang[17], J. Todoric[17], K. Imai[17], A. Stenzl[18],

[1]OHSU - Oregon Health Science University, Portland, US, [2]Bradford Hill-Clinical Center, Recoleta, CL, [3]Auckland City Hospital, Auckland, NZ, [4]Monash Health - Monash Medical Centre, Clayton, AU, [5]Prof. Franciszek Łukaszczyk Oncology Centre, Bydgoszcz, PL, [6]Sociedad de Oncologia y Hematologia Del Cesar, Valledupar, CO, [7]Hospital Provincial de Córdoba, Cordoba, ES, [8]Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US, [9]Medical University of Vienna, Vienna, AT, [10]Hopital Foch, Suresnes, FR, [11]Szpital Wojewódzki im. Mikolaja Kopernika w Koszalinie, Koszalin, PL, [12]Rechts der Isar Medical Center, Technical University Munich, Munich, DE, [13]Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR, [14]Hospital General Universitario Gregorio Maranon, Madrid, ES, [15]Macquarie University - Faculty of Medicine, Health and Human Sciences, Sydney, AU, [16]National Cancer Center Hospital East, Kashiwa, JP, [17]Merck & Co., Inc., Rahway, US, [18]Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE

09:05 - 09:10

1772MO - Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study

C. Gratzke[1], M. Ozguroglu[2], A. Peer[3], M.A.N. Sendur[4], M. Retz[5], J. Goh[6], W.C. Loidl[7], G. Jayram[8], S.-S. Byun[9], C. Kwak[10], M. Kwiatkowski[11], R. Manneh Kopp[12], J.C. Vazquez Limon[13], J.F. Escobar Penagos[14], U. De Giorgi[15], K.M.D. Trindade[16], C. Niu[17], Y. Liu[18], C. Poehlein[19], J.M. Piulats[20], [1]University Medical Center Freiburg, Freiburg im Breisgau, DE, [2]Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, TR, [3]Rambam Health Care Center, Haifa, IL, [4]Ankara Yıldırım Beyazıt University Faculty of Medicine and Ankara Bilkent City Hospital, Ankara, TR, [5]Rechts der Isar Medical Center, Technical University Munich, Munich, DE, [6]Fiona Stanley Hospital, Murdoch, AU, [7]Ordensklinikum Linz Barmherzige Schwestern, Linz, AT, [8]Urology Associates, P.C, Nashville, US, [9]Seoul National University Bundang Hospital, Seongnam, KR, [10]Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR, [11]Szpital Wojewódzki im. Mikolaja Kopernika w Koszalinie, Koszalin, PL, [12]Sociedad de Oncologia y Hematologia Del Cesar, Valledupar, CO, [13]Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, MX, [14]Hospital San Lucas Cardiologica del Sureste, Tuxtla Gutierrez, MX, [15]IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, [16]Oncocentro Ceara, Fortaleza, BR, [17]MSD China - One Merck Campus Beijing, Beijing, CN, [18]Merck & Co. Inc., Rahway, US, [19]Merck & Co., Inc., Rahway, US, [20]ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

09:10 - 09:15

LBA85 - Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

K.N. Chi[1], E. Castro[2], G. Attard[3], M.R. Smith[4], S. Sandhu[5], E. Efstathiou[6], G. Roubaud[7], E.J. Small[8], A.J. Gomes[9], D. Rathkopf[10], M. Saad[11], H. Gurney[12], W. Jung[13], G. Mason[14], S. Dibaj[14], D. Wu[14], B. Diorio[14], A. Lopez-Gitlitz[14], W. Kim[14], D. Olmos[2], [1]University of British Columbia, Vancouver, CA, [2]Hospital Universitario 12 de Octubre, Madrid, ES, [3]UCL Cancer Institute, London, GB, [4]Harvard Medical School, Boston, US, [5]Peter MacCallum Cancer Centre, Melbourne, AU, [6]Houston Methodist Cancer Center, Houston, US, [7]Institute Bergonié, Bordeaux, FR, [8]University of California San Francisco Medical

Center, San Francisco, US, [9]Liga Norte Riograndense Contra o Câncer, Natal, BR, [10]Memorial Sloan Kettering Cancer Center, New York, US, [11]University of Malaya Medical Centre, Kuala Lumpur, MY, [12]Macquarie University, Sydney, AU, [13]Keimyung University Dongsan Hospital, Daegu, KR, [14]Research & Development, Raritan, US

09:15 - 09:20

LBA86 - Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial

H. Grönberg[1], J. Lindberg[1], B. De Laere[1], A. Crippa[1], A. Discacciati[1], C. Karlsson[2], A. Ullén[3], E. Jänes[4], A. Mortezavi[5], P. Ost[6], G. Enblad[7], J. Oldenburg[8], J. Sandzén[9], L. Pettersson[10], M. Vigmostad[11], M. Hjälm-Eriksson[12], M. Olsson[13], P. Schatteman[14], C. Ghysel[15], M. Eklund[1], [1]Karolinska Institutet, Stockholm, SE, [2]Umea University, Umea, SE, [3]Karolinska University Hospital-Solna, Solna, SE, [4]Sundsvall Hospital, Sundsvall, SE, [5]University Hospital Basel, Basel, CH, [6]UZ Gent - University Hospital Ghent, Gent, BE, [7]Akademiska Sjukhuset Uppsala, Uppsala, SE, [8]Akershus University Hospital (Ahus), Lorenskog, NO, [9]Centralsjukhuset i Karlstad, Karlstad, SE, [10]Ryhov County Hospital, Jonkoping, SE, [11]Stavanger University Hospital - Helse Stavanger HF, Stavanger, NO, [12]Capio St. Görans Hospital, Stockholm, SE, [13]Växjö lasarett, xx, SE, [14]Onze-Lieve-Vrouw Clinic - Campus Aalst, Aalst, BE, [15]AZ Sint-Jan Brugge-Oostende AV, Brugge, BE

09:20 - 09:35

Invited Discussant 1771MO, 1772MO, LBA85 and LBA86

H. Beltran, Dana Farber Cancer Institute, Boston, US

08:30 - 10:00 **Type: Proffered Paper session** **Valencia Auditorium - Hall 10**
Title: Proffered Paper session - Sarcoma
Chair(s): Silvia Stacchiotti, IT; Sebastian Bauer, DE

08:30 - 08:40

1913O - A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study

P. Pautier[1], A. Italiano[2], S. Piperno-Neumann[3], C. Chevreau[4], N. Penel[5], N. Firmin[6], P. Boudou Rouquette[7], F. Bertucci[8], V. Le Brun-Ly[9], I. Ray-Coquard[10], E. Kalbacher[11], E. Bompas[12], O. Collard[13], N. Isambert[14], C. Guillemet[15], M. Rios[16], A. Le Cesne[17], B. Archambaud[17], F. Duffaud[18], [1]Gustave Roussy Cancer Campus, VILLEJUIF, FR, [2]Institute Bergonié, Bordeaux, FR, [3]Institut Curie, Paris, FR, [4]Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, [5]Centre Oscar Lambret, Lille, FR, [6]Icm Val D Aurelle, Montpellier, FR, [7]Hopital Cochin - Site Port-Royal AP-HP, Paris, FR, [8]IPC - Institut Paoli-Calmettes, Marseille, FR, [9]CHU Limoges - Hopital Dupuytren, Limoges, FR, [10]Centre Léon Bérard, Lyon, FR, [11]CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, [12]ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, [13]Institute de Cancerologie de la Loire, Saint-Priest-en-Jarez, FR, [14]CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, [15]Centre Henri Becquerel, Rouen, FR, [16]Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, [17]Gustave Roussy - Cancer Campus, Villejuif, FR, [18]CHU La Timone Adultes, Marseille, FR

08:40 - 08:50

Invited Discussant 1913O

D. Callegaro, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

08:50 - 08:55 **Q&A**

08:55 - 09:05 **LBA89 - Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas**

R. Jones[1], R. Sanfilippo[2], S. Schuetze[3], A. Sebio[4], R. Alvarez[5], N. Bui[6], A. Wagner[7], S. Chawla[8], T.W.-W. Chen[9], D. Pink[10], A. Le Cesne[11], A. Italiano[12], B. Vincenzi[13], I. Kiladze[14], S. Patel[15], R. Bryce[16], F. Xu[17], R. Doebele[17], G. Schwartz[18], M. Gounder[19], [1]The Royal Marsden Hospital and Institute of Cancer Research, London, GB, [2]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [3]University Hospital - Michigan Medicine, Ann Arbor, US, [4]Hospital de la Santa Creu i Sant Pau, Barcelona, ES, [5]Hospital General Universitario Gregorio Maranon, Madrid, ES, [6]Stanford Cancer Center Palo Alto, Palo Alto, US, [7]Dana-Farber Cancer Institute, Boston, US, [8]Keck Medical Center of USC, Santa Monica, US, [9]NTU - National Taiwan University - College of Medicine, Taipei City, TW, [10]HELIOS Klinikum Bad Saarow, Bad Saarow, DE, [11]Gustave Roussy - Cancer Campus, Villejuif, FR, [12]Institute Bergonié, Bordeaux, FR, [13]Policlinico Universitario Campus Bio-Medico, Rome, IT, [14]CMC - Caucasus Medical Centre, Tbilisi, GE, [15]The University of Texas M. D. Anderson Cancer Center, Houston, US, [16]Rain Oncology, Inc., Newark, US, [17]Rain Oncology Inc, Newark, US, [18]Case Comprehensive Cancer Center, Cleveland, US, [19]Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

09:05 - 09:15 **Invited Discussant LBA89**

S. Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

09:15 - 09:20 **Q&A**

09:20 - 09:30 **LBA90 - A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS-0415)**

V. Gruenwald, University Hospital Essen, Essen, DE

09:30 - 09:40 **LBA91 - TOMAS2: A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS) after failure of standard treatments**

L. D'Ambrosio[1], A. Merlini[1], A. Brunello[2], V. Ferraresi[3], A. Paioli[4], B. Vincenzi[5], M. Pantaleo[6], T. De Pas[7], L. Gurrieri[8], R. Sanfilippo[9], A. Buonadonna[10], G.G. Baldi[11], G. Badalamenti[12], C. Marchiò[13], Y. Pignochino[1], G. Manessi[1], S. Aliberti[14], A.P. Dei Tos[15], S. Stacchiotti[9], G. Grignani[16], [1]University of Turin, Torino, IT, [2]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [3]IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT, [4]IOR - Istituto Ortopedico Rizzoli - IRCCS, Bologna, IT, [5]Policlinico Universitario Campus Bio-Medico, Rome, IT, [6]University of Bologna - Alma Mater Studiorum, Bologna, IT, [7]IEO - Istituto Europeo di Oncologia, Milan, IT, [8]IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, [9]Fondazione IRCCS - Istituto

Nazionale dei Tumori, Milan, IT, [10]CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, [11]Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT, [12]University of Palermo, Palermo, IT, [13]IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, [14]Istituto di Candiolo - FPO, Candiolo, IT, [15]University of Padua - School of Medicine, Padua, IT, [16]Istituto di Candiolo - FPO, IRCCS, Candiolo, IT

09:40 - 09:50 **Invited Discussant LBA90 and LBA91**

B. Wilky, UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US

09:50 - 10:00 **Q&A**

08:30 - 10:00 **Type: Special symposium** **Salamanca Auditorium - Hall 3**
Title: Immunotherapy for head and neck cancer: What, when and how long?

Chair(s): Sjoukje Oosting, NL; Melvin Lee Kiang Chua, SG

08:30 - 08:35 **Introduction and scientific background**

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL

08:35 - 08:50 **Perioperative immunotherapy for head and neck squamous cell carcinoma (HNSCC)**

A. Argiris, Hygeia Hospital, Marousi, GR

08:50 - 09:05 **Incorporating immunotherapy into the approach to locally advanced HNSCC**

K. Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

09:05 - 09:20 **Novel combinations in the non-curative HNSCC setting**

B. Ma, The Chinese University of Hong Kong, Sha Tin, HK

09:20 - 09:35 **Patient selection is crucial to improve immunotherapy effectiveness**

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**

M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

08:30 - 10:00 **Type: Proffered Paper session** **Málaga Auditorium - Hall 10**
Title: Proffered Paper session - Developmental therapeutics

Chair(s): Lillian Siu, CA; Elena Garralda, ES

08:30 - 08:40

652O - Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

K. Arbour[1], S. Punekar[2], I. Garrido-Laguna[3], D. Hong[4], B. Wolpin[5], M. Pelster[6], M. Barve[7], A. Starodub[8], D. Sommerhalder[9], S. Chang[10], Y. Zhang[10], Z. Salman[10], X. Wang[10], C. Gustafson[10], A. Spira[11], [1]Memorial Sloan Kettering Cancer Center, New York, US, [2]New York University Medical Center, New York, US, [3]University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, [4]The University of Texas MD Anderson Cancer Center, Houston, US, [5]Dana Farber Cancer Institute, Boston, US, [6]Sarah Cannon Research Institute, Nashville, US, [7]Mary Crowley Cancer Research Center, Dallas, US, [8]The Christ Hospital - Hematology & Oncology, Cincinnati, US, [9]NEXT OncologyTM, San Antonio, US, [10]Revolution Medicines, Inc., Redwood City, US, [11]Virginia Cancer Specialists, Fairfax, US

08:40 - 08:50

653O - Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors

J. Wang[1], J. Zhao[2], J. Zhong[1], X. Li[3], J. Fang[2], Y. Yu[4], X. Li[5], X. Fang[6], J. Chang[7], Z. Liu[8], Y. Zhao[9], Q. Song[10], C. Bai[11], A. Wang-Gillam[12], Y. Ding[13], Z. Rao[13], C. Bi[13], [1]Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, [2]Beijing Cancer Hospital, Beijing, CN, [3]Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, [4]Harbin Medical University Cancer Hospital, Harbin, CN, [5]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, [6]The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, [7]Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, CN, [8]Beijing Chest Hospital, Capital Medical University, Beijing, CN, [9]Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, [10]Renmin Hospital of Wuhan University/ Hubei General Hospital, Wuhan, CN, [11]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, [12]Jacobio (US) Pharmaceuticals, Inc, Boston, US, [13]Jacobio Pharmaceuticals Co., Ltd., Beijing, CN

08:50 - 09:00

LBA33 - A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation

C. Zhou[1], W. Li[1], Z. Song[2], Y. Zhang[2], Y. Zhang[3], D. Huang[4], Z. Yang[5], M. Zhou[6], R. Mao[7], C. Huang[7], X. Li[7], J. Wang[7], [1]Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN, [2]Zhejiang Cancer Hospital, Hangzhou, CN, [3]West China Hospital, Sichuan University, Chengdu, CN, [4]Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, [5]The Second Affiliated Hospital of Chongqing Medical University, Chongqing, CN, [6]Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, [7]Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN

09:00 - 09:10

Invited Discussant 652O, 653O and LBA33

E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES

09:10 - 09:20

Q&A

09:20 - 09:30

654O - Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study

B. Li[1], F. Meric-Bernstam[2], A. Bardia[3], Y. Naito[4], S. Siena[5], P. Aftimos[6], I. Anderson[7], G. Curigliano[8], M.J. De Miguel Luken[9], M. Kalra[10], D.-Y. Oh[11], J.O. Park[12], S. Postel-Vinay[13], S.Y. Rha[14], T. Satoh[15], I. Spanggaard[16], F. Michelini[17], A. Smith[18], K. Kalil Machado[19], C. Saura Manich[20], [1]Memorial Sloan Kettering Cancer Center, New York, US, [2]MD Anderson Cancer Center, University of Texas, Houston, US, [3]Massachusetts General Hospital Cancer Center, Boston, US, [4]National Cancer Center Hospital East, Kashiwa, JP, [5]Università degli Studi di Milano, Milan, IT, [6]Institute Jules Bordet, Anderlecht, BE, [7]Providence Medical Group, Santa Rosa, US, [8]European Institute of Oncology IRCCS, Division of New Drugs and Early Drug Development for Innovative Therapies., Milan, IT, [9]Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, ES, [10]LifeBridge Health, Baltimore, US, [11]Seoul National University Hospital, Seoul, KR, [12]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [13]Institut Gustave Roussy, Villejuif, FR, [14]Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, [15]Osaka University, Suita, JP, [16]Rigshospitalet, Copenhagen, DK, [17]AstraZeneca, Waltham, US, [18]AstraZeneca UK, Royston, GB, [19]AstraZeneca, Gaithersburg, US, [20]SOLTI/Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, ES

09:30 - 09:40

655O - Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)

B.C. Cho[1], M. Johnson[2], J. Bar[3], E. Schaefer[4], K. Yoh[5], A. Zer[6], M. Moskovitz[7], S.-H. Lee[8], V. Moreno Garcia[9], M.J. De Miguel Luken[10], Y. Okuma[11], J.-H. Kim[12], C.-H. Lee[13], P. Ansell[14], C. Biesdorf De Almeida[15], R. Saab[15], K. Freise[15], D. Ramies[16], E. Jeng[17], D. Camidge[18], [1]Yonsei University, Seoul, KR, [2]Sarah Cannon Research Institute-Cancer Centre, Nashville, US, [3]Chaim Sheba Medical Center, Ramat Gan, IL, [4]HOG - Highlands Oncology Group, Rogers, US, [5]National Cancer Center Hospital East, Kashiwa, JP, [6]Rambam Health Care Campus, Haifa, IL, [7]Rambam Health Care Campus, Haifa, IL, [8]Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, KR, [9]Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, [10]Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, [11]NCCH - National Cancer Center Hospital, Chuo-ku, JP, [12]CHA Bundang Medical Center, Seongnam, KR, [13]NCKUH - National Cheng Kung University Hospital, Tainan City, TW, [14]AbbVie Inc USA, North Chicago, US, [15]Abbvie Inc. - Headquarters, North Chicago, US, [16]AbbVie, Inc., North Chicago, US, [17]Abbvie, Mettawa, US, [18]University of Colorado Denver - Anschutz Medical Campus, Aurora, US

09:40 - 09:50

Invited Discussant 654O and 655O

A.A. Adjei, Cleveland Clinic Main Campus, Cleveland, US

09:50 - 10:00

Q&A

08:30 - 10:00

Type: Mini Oral session **Santander Auditorium - Hall 9**
Title: Mini oral session - Basic science & translational research

Chair(s): Caterina Marchiò, IT; Sanjay Aneja, US; Luis Montuenga, ES

08:30 - 08:35

132MO - Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study

M. Morfouace[1], J. Oliveira[2], N. Penel[3], J. Peron[4], M. Pracht[5], B. Brasiuniene[6], A. Capela Marques[7], C. Gennigens[8], L. Greillier[9], M.-S. Robert[1], H.J. Klumpen[10], R. Peeters[11], L. Licitra[12], N. Girard[13], J. Gietema[14], W. De Herder[15], E. Kapiteijn[16], A. Idbaih[17], I. Ray-Coquard[18], J.-Y. Blay[18], [1]EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE, [2]Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Porto, PT, [3]Centre Oscar Lambret, Lille, FR, [4]Ch Lyon Sud, Pierre Benite, FR, [5]Centre Eugene - Marquis, Rennes, FR, [6]National Cancer Institute, Vilnius, LT, [7]CHVNG/E - Centro Hospitalar de Vila Nova de Gaia/Espinho - Unidade 1 - EPE-SNS, Vila Nova de Gaia, PT, [8]Centre Hospitalier Universitaire Sart Tilman, Liège, BE, [9]Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, [10]Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, [11]Erasmus MC - University Medical Center, Rotterdam, NL, [12]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [13]Institut Curie, Paris, FR, [14]UMCG - University Medical Center Groningen, Groningen, NL, [15]Erasmus MC - Erasmus University Rotterdam, Rotterdam, NL, [16]Leiden University Medical Center (LUMC), Leiden, NL, [17]Hopital Pitié Salpetrière AP-HP, Paris, FR, [18]Centre Léon Bérard, Lyon, FR

08:35 - 08:40

LBA100 - CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes

H. Wasan[1], J. Wang[2], E.M. Elaine Mccartney[3], H. Soifer[4], K. Treuner[4], Y. Zhang[4], C. Schnabel[4], K. Carty[3], L. Mcmahon[3], T.R.J. Evans[3], M. Nicolson[5], H. Thygesen[3], J.R. Roche[3], K. Oien[3], [1]Hammersmith Hospital - Imperial College Healthcare, London, GB, [2]UCLH - University College London Hospital, London, GB, [3]University of Glasgow, Glasgow, GB, [4]Biotheranostics, A Hologic Company, San Diego, US, [5]NHS Highland, Inverness, GB

08:40 - 08:45

1208MO - A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary

Z. Luo[1], X. Liu[1], X. Zhang[1], S. Jiang[1], M. Mo[1], Q. Wang[1], Y. Wang[1], L. Zhou[1], S. Hu[1], H. Yang[1], Y. Hou[1], Y. Chen[1], X. Lu[1], X. Zhou[1], W. Li[1], X. Yang[1], K. Chen[1], J. Cao[1], Q. Xu[2], X. Hu[1], [1]Fudan University Shanghai Cancer Center, Shanghai, CN, [2]The Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd., Hangzhou, China, 311000, Shanghai, CN

08:45 - 08:50

LBA101 - BRCA-DIRECT: A randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer

B. Torr[1], S. Choi[1], S. Allen[1], M. Hamill[1], G. Kavanaugh[1], S. Macmahon[2], E. Poyastro-Pearson[2], L. Yuan[2], M. Valganon-Petrizan[2], A. George[3], V. Jenkins[4], L. Fallowfield[4], R. Manchanda[5], A. Gandhi[6], G. Evans[6], Z. Kemp[7], M. Hubank[1], C. Turnbull[1], [1]ICR - The Institute of Cancer Research - North Site, Sutton, GB, [2]The Royal Marsden Hospital

(Sutton), Sutton, GB, [3]The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, [4]Brighton and Sussex Medical School - University of Sussex, Brighton, GB, [5]Wolfson Institute of Population Health, London, GB, [6]Manchester University NHS Foundation Trust, Manchester, GB, [7]The Royal Marsden Hospital - NHS Foundation Trust, London, GB

08:50 - 09:05 **Invited Discussant 132MO, LBA100, 1208MO and LBA101**

C. Marchiò, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT

09:05 - 09:10 **1209MO - Computer-aided HCC lesion detection based on deep learning and CT images**

O. Lucidarme[1], T. Broussaud[1], S. Bodard[2], V. Paradis[3], I. Brocheriou[1], C. Guettier[4], L. Ayache[5], C. Bougharka[1], A. O'Keane[2], S. Poullot[6], J. Shen[6], V.K. Le[6], E. Geremia[6], V. Groza[6], Q. Renault[6], M. Macrez[6], T. Foriel[6], Y. Liu[6], M. Lewin-Zeitoun[4], V. Vilgrain[7], [1]Sorbonne Université, Paris, FR, [2]GH Necker - Enfants Malades, Paris, FR, [3]Campus hospitalo-universitaire Grand Paris-Nord, Paris, FR, [4]CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR, [5]Institut Necker Enfant Malades, Paris, FR, [6]Median Technologies, Valbonne, FR, [7]Beaujon Hospital APHP, Clichy, FR

09:10 - 09:15 **1210MO - Comparison of clinical and radiological features-based and radiomics features-based models for pulmonary nodule malignancy prediction on CT images**

F. Zeng[1], B. Wang[2], M. Peng[2], J. Tao[2], X. Tu[2], H. Lu[3], X. Qiu[2], Y. Yang[2], Q. Zeng[1], J.-B. Fan[4], Q. Liu[1], [1]The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, [2]Anchordx Medical Co., Ltd, Guangzhou, CN, [3]AnchorDX Medical Co., Ltd, Guangzhou, CN, [4]Southern Medical University, Guangzhou, CN

09:15 - 09:25 **Invited Discussant 1209MO and 1210MO**

S. Aneja, Yale University School of Medicine, New Heaven, US

09:25 - 09:30 **2233MO - CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate**

Á. Quintanal-Villalonga[1], S. Zaidi[1], W.R. Karthaus[1], Y.A. Zhan[1], M. Shafer[1], J. Qiu[1], E. De Stanchina[1], M.C. Haffner[2], C.L. Sawyers[1], C. Rudin[1], [1]MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, [2]Fred Hutchinson Cancer Research Center, Seattle, US

09:30 - 09:35 **133MO - Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma**

P.-H. Chen[1], T.-M. Tsai[2], D. Pamart[3], T. Bygott[3], M. Herzog[3], J. Micallef[3], J.-S. Chen[2], [1]National Taiwan University Hospital Hsin - Chu Branch, Hsinchu City, TW, [2]NTUCC - National Taiwan University Cancer Center, Taipei City, TW, [3]Belgian Volition SRL, Isnes, BE

09:35 - 09:45 **Invited Discussant 2233MO and 133MO**

L. Montuenga, FIMA-UNAV-CUN, PAMPLONA, ES

08:30 - 10:00 **Type: Proffered Paper session** **Toledo Auditorium - Hall 3**
Title: Proffered Paper session - NETs and endocrine tumours

Chair(s): Marianne Pavel, DE; Jaume Capdevila Castillon, ES

08:30 - 08:40

723O - Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multi-cohort basket phase II trial (CABATEN/GETNE-T1914)

J. Capdevila Castillon[1], J. Molina-Cerrillo[2], M. Benavent Viñuales[3], R. Garcia-Carbonero[4], A. Teule[5], A. Custodio[6], P. Jimenez-Fonseca[7], C. López[8], C. Hierro[9], A. Carmona-Bayonas[10], J. Martínez-Trufero[11], M. Llanos[12], I. Sevilla[13], J. Hernando[1], T. Alonso-Gordoa[2], I. Gallego Jimenez[3], J. Gallego[14], B. Antón Pascual[4], E. Grande Pulido[15], [1]Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, [2]Hospital Universitario Ramón y Cajal, Madrid, ES, [3]University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, ES, [4]Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, ES, [5]Institut Català d´Oncologia (ICO) - IDIBELL, L´Hospitalet de Llobregat, ES, [6]Hospital Universitario La Paz, IdiPAZ, Madrid, ES, [7]Hospital Universitario Central de Asturias, ISPA, Oviedo, ES, [8]Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, ES, [9]Catalan Institute of Oncology (ICO-Badalona) Germans Trias i Pujol University Hospital, Badalona, ES, [10]Hospital Universitario Morales Meseguer. UMI. IMIB., Murcia, ES, [11]Instituto Aragonés de Investigación Sanitaria, Hospital Universitario Miguel Servet, Zaragoza, ES, [12]Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, [13]Investigación Clínica y Traslacional en Cáncer / Instituto de Investigaciones Biomédicas de Málaga (IBIMA) / Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, ES, [14]General Universitario de Elche Hospital, Alicante, ES, [15]MD Anderson Cancer Center Madrid, Madrid, ES

08:40 - 08:50

LBA53 - Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

J. Chan[1], S. Geyer[2], F.-S. Ou[2], M. Knopp[3], S. Behr[4], T. Zemla[2], J. Acoba[5], A. Shergill[6], E. Wolin[7], T. Halfdanarson[8], N. Trikalinos[9], B. Konda[10], N. Vijayvergia[11], N.A. Dasari[12], J. Strosberg[13], E. Kohn[14], M. Kulke[15], E. O'Reilly[16], J. Meyerhardt[1], [1]Dana-Farber Cancer Institute, Boston, US, [2]Mayo Clinic, Rochester, US, [3]University of Cincinnati, Cincinnati, US, [4]UCSF - University of California San Francisco, San Francisco, US, [5]University of Hawaii Cancer Center, Honolulu, US, [6]University of Chicago, Chicago, US, [7]Icahn School of Medicine at Mount Sinai, New York, US, [8]Mayo Clinic - Rochester, Rochester, US, [9]Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, [10]The Ohio State University Comprehensive Cancer Center, Columbus, US, [11]Fox Chase Cancer Center - Main Campus, Philadelphia, US, [12]MD Anderson Cancer Center, Houston, US, [13]H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, [14]National Cancer Institute, Bethesda, US, [15]Boston University and Boston Medical Center, Boston, US, [16]Memorial Sloan Kettering Cancer Center, New York, US

08:50 - 09:00

Invited Discussant 723O and LBA53

M. Pavel, Universitätsklinik Erlangen - Medizinische Klinik 1, Erlangen, DE

09:00 - 09:10 **Q&A**

09:10 - 09:20 **LBA54 - Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network**

T. Walter[1], T. Lecomte[2], J. Hadoux[3], P. Niccoli[4], L. Saban-Roche[5], E. Gaye[6], R. Guimbaud[7], M. Baconnier[8], V. Hautefeuille[9], C. Do Cao[10], C. Petorin[11], O. Hentic Dhome[12], M. Perrier[13], T. Aparicio[14], J.-Y. Scoazec[15], C. Lombard Bohas[16], S. Bin[1], V. Hervieu[1], M. Barritault[1], L. Gerard[17], [1]Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, Lyon, FR, [2]CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, [3]Institut Gustave Roussy, Villejuif, Cedex, FR, [4]IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, [5]Institut cancerologie de la loire, Saint etienne, FR, [6]Centre Oscar Lambret, Lille, FR, [7]Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, FR, [8]CH Annecy Genevois, Annecy, FR, [9]CHU Amiens-Picardie - Site Nord, Amiens, FR, [10]Centre Hospitalier Régional Universitaire de Lille, Lille, FR, [11]CHU Estaing, Clermont-Ferrand, FR, [12]Beaujon Hospital APHP, Clichy, FR, [13]Reims University Hospital, Reims, FR, [14]Hopital Saint Louis AP-HP, Paris, FR, [15]Institut Gustave Roussy, Villejuif, FR, [16]Hopital Edouard Herriot Pav. E bis, Lyon, FR, [17]Hospices Civils de Lyon, Bron, FR

09:20 - 09:30 **1182O - Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors**

L. De Mestier Du Bourg[1], D. Cohen[2], J. Masliah-Planchon[3], S. Sivakumar[4], O. De Rycke[5], O. Hentic Dhome[1], Z. Fleischmann[6], E. Sokol[6], B. Decker[7], A. Couvelard[1], P. Ruszniewski[1], I. Bieche[3], J. Cros[8], [1]Beaujon Hospital APHP, Clichy, FR, [2]INSERM, Paris, FR, [3]Institut Curie, Paris, FR, [4]Foundation Medicine, Inc., Morrisville, US, [5]Assistance Publique - Hopitaux De Paris AP-HP, Paris, FR, [6]Foundation Medicine, Inc., Cambridge, US, [7]Foundation Medicine, Boston, US, [8]Beaujon Hospital APHP, Saint Maur des Fosses, FR

09:30 - 09:40 **724O - EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER**

E. Baudin[1], S. Grisanti[2], C. Menke-Van Der Houven Van Oordt[3], H. Haak[4], J. Capdevila Castillon[5], M. Fassnacht[6], V. Subbiah[7], C. Jimenez[7], C. De La Fouchardiere[8], J. Yachnin[9], D. Granberg[9], M. Kroiss[10], K.G. Daugaard[11], D. Cosentini[2], L. Lamartina[1], J.-M. Paillarse[12], L. Aubergeon[12], J. Fagerberg[12], L. Chêne[12], A. Berruti[2], [1]Gustave Roussy, Villejuif, FR, [2]Università degli Studi di Brescia, Azienda Ospedaliera Spedali Civili, Brescia, IT, [3]Amsterdam UMC, Amsterdam, NL, [4]Maxima Medish Centrum, Eindhoven, NL, [5]Hospital Universitari Vall d'Hebron, Barcelona, ES, [6]University Hospital Würzburg, Würzburg, DE, [7]The University of Texas MD Anderson Cancer Center (MDACC), Houston, US, [8]Centre Léon Bérard, Lyon, FR, [9]Karolinska Institutet, Karolinska University Hospital, Stockholm, SE, [10]LMU - Ludwig Maximilians University of Munich, Munich, DE, [11]Rigshospitalet, Copenhagen, DK, [12]Enterome, Paris, FR

09:40 - 09:50 **Invited Discussant LBA54, 1182O and 724O**

N. Fazio, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

09:50 - 10:00 **Q&A**

08:30 - 10:00 **Type: Educational session** **Cádiz Auditorium - NCC**
Title: Current issues in primary prevention and screening to block the onset or development of cancer
Chair(s): Wendy Tse Yared, BE; Mary Gospodarowicz, CA

08:30 - 08:50 **Processed meat, sugar, exercise: Prevention opportunities for oncologists**
E. Weiderpass, International Agency for Research on Cancer, Lyon, FR

08:50 - 09:10 **Structural and behavioural interventions: Applying the latest insights from implementation science to cancer prevention**
J. Martin-Moreno, Hospital Clinico Universitario de Valencia, Valencia, ES

09:10 - 09:30 **Commercial drivers of cancer medicines and non-pharmaceutical technologies in cancer care**
R. Sullivan, Institute of cancer policy, London, GB

09:30 - 09:50 **False dichotomies and going beyond screening**
M. Gospodarowicz, University of Toronto - St. George Campus, Toronto, CA

09:50 - 10:00 **Q&A and Discussion**

08:30 - 10:00	**Type: Young Oncologists session** **Title: YO Fellowship Session: Fellowships in Europe: Educational opportunities for young oncologists** Chair(s): Teresa Amaral, DE; Alexios Matikas, SE	**Ávila Auditorium - NCC**

08:30 - 08:45 **Introduction to the ESMO Fellowship Programme**

T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

08:45 - 09:00 **Practical tips from a former fellow**

A. Matikas, Karolinska Institutet, Huddinge, SE

09:00 - 09:15 **Best Fellowship Project**

F. Papaccio, University of Salerno, Salerno, IT

09:15 - 09:30 **Best Publication from a Fellowship**

M.-J. Devlin, QMUL - Queen Mary University of London - Charterhouse Square, London, GB

09:30 - 09:40 **Conclusions**

T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

09:40 - 10:00 **Awards: Presentation of the 2023 Fellows and Best Exam**

G. Awada[1], P. Baxevanos[2], M. Chalabi[3], P. Lombardi[4], M. Mair[5], N. Ngoi[6], N. Saoudi Gonzalez[7], [1]UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, [2]NNA - Naval and Veterans Hospital of Athens, Athens, GR, [3]Netherlands Cancer Institute, Amsterdam, NL, [4]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, [5]MedUni Wien - Medical University of Vienna, Vienna, AT, [6]The University of Texas M. D. Anderson Cancer Center, Houston, US, [7]Vall d'Hebron University Hospital, Barcelona, ES

08:30 - 10:00	**Type: EONS Industry Satellite Symposium** **Title: Pfizer - Perspectives on adverse events and healthcare needs management in kidney cancer** Chair(s): Daniel Kelly, GB	**Alicante Auditorium - Hall 10**

08:30 - 08:35 **Opening remarks**

D. Kelly, Cardiff University - School of Healthcare Sciences, Cardiff, GB

08:35 - 08:55 **Anticancer therapies and adverse events profile in kidney cancer – A medic's perspective**

F. Schlürmann, CHRU Brest - Hopital Augustin Morvan, Brest, FR

08:55 - 09:15 **Adverse events management in kidney cancer: Seeing the whole person – A nurse's perspective**

S. Smith, East & North Hertfordshire NHS Trust, Stevenage, GB

09:15 - 09:35 **Living with and being treated for kidney cancer – A patient's perspective**

S. Pointon, Action Kidney Cancer, Manchester, GB

09:35 - 09:50 **RCC4Nurses – interactive education program**

G. Kotronoulas, University of Glasgow, Glasgow, GB

09:50 - 10:00 **Q&A and Conclusion remarks**

D. Kelly, Cardiff University - School of Healthcare Sciences, Cardiff, GB

09:00 - 10:00	**Type: Controversy session** **Title: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy** Chair(s): Georgina Long, AU	**Burgos Auditorium - Hall 3**

09:00 - 09:05 **Welcome and “set the scene”**

G. Long, University of Sydney, Sydney, AU

09:05 - 09:20 **Yes**

D. Schadendorf, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

09:20 - 09:35 **No**

R. Lee, The University of Manchester, Manchester, GB

09:35 - 09:40 **First voting**

G. Long, University of Sydney, Sydney, AU

09:40 - 09:55 **Perspective from the Chair**

G. Long, University of Sydney, Sydney, AU

09:55 - 10:00 **Second voting**

G. Long, University of Sydney, Sydney, AU

09:00 - 09:45	**Type: Challenge your Expert** **Title: Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC)** Chair(s): Laurence Albiges, FR	**Oviedo Auditorium - Hall 7**

09:00 - 09:20 **Presentation by Expert**

M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

09:20 - 09:45 **Discussion led by Chair**

L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR

09:00 - 10:00 **Type: Special session** **León Auditorium - Hall 7**
Title: Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases
Chair(s): Andrea Ferrari, IT; Ivana Bozovic Spasojevic, RS

09:00 - 09:02 **Introduction**
I. Bozovic Spasojevic, Institute for Oncology and Radiology of Serbia, Belgrade, RS

09:02 - 09:17 **Setting priorities for AYA patients with sarcoma**
A. Ferrari, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

09:17 - 09:32 **Short- and long-term side effects in AYA patients, with a focus on patients with breast cancer**
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

09:32 - 09:47 **AYA oncology: The importance of research, with a focus on patients with melanoma**
K. Young, The Royal Marsden Hospital - Chelsea, London, GB

09:47 - 10:00 **Discussion**

10:00 - 11:00 **Type: Special session** **Pamplona Auditorium - Hall 9**
Title: Resilience Task Force - Caring for caregivers: How to build a sustainable oncology workforce
Chair(s): Kok Haw Jonathan Lim, GB

10:00 - 10:10 **Introduction**
K.H.J. Lim, The Francis Crick Institute, London, GB

10:10 - 11:00 **Moderated discussion and Q&A**
K. Punie[1], M. O'Connor[2], M.E. Elez Fernandez[3], C. Hardy[4], I. Vaz Luis[5], J.-Y. Blay[6], [1]UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, [2]University Hospital Waterford, Waterford, IE, [3]Vall d'Hebron University Hospital, Barcelona, ES, [4]Lancaster University Division of Health Research, Lancaster, GB, [5]Institut Gustave Roussy, Villejuif, Cedex, FR, [6]Centre Léon Bérard, Lyon, FR

10:15 - 11:45 **Type: Proffered Paper session** **Barcelona Auditorium - Hall 9**
Title: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive
Chair(s): Radka Obermannova, CZ; Andrew Ko, US

10:15 - 10:25 **1616O - Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial**

A. Ohba[1], M. Ozaka[2], G. Ogawa[1], T. Okusaka[1], S. Kobayashi[3], T. Yamashita[4], M. Ikeda[5], I. Yasuda[6], K. Sugimori[7], N. Sasahira[2], K. Ikezawa[8], I. Miki[9], N. Okano[10], N. Mizuno[11], M. Furukawa[12], H. Shirakawa[13], Y. Sano[1], H. Katayama[1], J. Furuse[3], M. Ueno[3], [1]National Cancer Center Hospital, Tokyo, JP, [2]Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, [3]Kanagawa Cancer Center, Yokohama, JP, [4]Kanazawa University, Kanazawa, JP, [5]National Cancer Center Hospital East, Kashiwa, JP, [6]University of Toyama, Toyama, JP, [7]Yokohama City University Medical Center, Yokohama, JP, [8]Osaka International Cancer Institute, Osaka, JP, [9]Hyogo Cancer Center, Hyogo, JP, [10]Kyorin University Faculty of Medicine, Tokyo, JP, [11]Aichi Cancer Center Hospital, Nagoya, JP, [12]National Hospital Organization, Kyushu Cancer Center, Fukuoka, JP, [13]Tochigi Cancer Center, Utsunomiya, JP

10:25 - 10:35 **LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial**

B. Groot Koerkamp[1], Q. Janssen[1], J. Van Dam[1], B. Bonsing[2], H. Bos[3], K. Bosscha[4], B. Haberkorn[5], I. De Hingh[6], T. Karsten[7], M. Van Der Kolk[8], M. Liem[9], O. Loosveld[10], G. Patijn[11], H.C. Van Santvoort[12], J. De Vos-Geelen[13], B. Van Der Holt[14], M. Homs[1], G. Van Tienhoven[15], M.G. Besselink[15], H. Wilmink[15], [1]Erasmus MC Cancer Institute, Rotterdam, NL, [2]LUMC-Leiden University Medical Center, Leiden, NL, [3]Ziekenhuis De Tjongerschans, Heerenveen, NL, [4]Jeroen Bosch Hospital, 's-Hertogenbosch, NL, [5]Maasstad Ziekenhuis, Rotterdam, NL, [6]Catharina Hospital Eindhoven, Eindhoven, NL, [7]OLVG Hospital, Amsterdam, NL, [8]Radboud University Medical Center, Nijmegen, Nijmegen, NL, [9]Medisch Spectrum Twente, Enschede, NL, [10]Amphia Ziekenhuis-location Molengracht, Breda, NL, [11]Isala Hospital, Zwolle, NL, [12]UMC - University Medical Center Utrecht, Utrecht, NL, [13]Maastricht University Medical Center (MUMC), Maastricht, NL, [14]Erasmus MC Cancer Institue, Rotterdam, NL, [15]Amsterdam UMC - University of Amsterdam, Amsterdam, NL

10:35 - 10:50 **Invited Discussant 1616O and LBA83**

A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

10:50 - 11:05 **Q&A**

11:05 - 11:15 **LBA76 - The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)**

S. Kadowaki[1], D. Sakai[2], R. Kawabata[3], H. Hara[4], H. Yasui[5], M. Takahashi[6], M. Hirao[7], H. Imai[8], K. Minashi[9], T. Kawakami[10], H. Satake[11], J. Matsuyama[12], Y. Sakamoto[13], K. Sawada[14], M. Kataoka[15], H. Kawakami[16], T. Shimokawa[17], N. Boku[18], T. Satoh[19], [1]Aichi Cancer Center Hospital, Nagoya, JP, [2]Osaka International Cancer Institute, Osaka, JP, [3]Osaka Rosai Hospital, Sakai, JP, [4]Saitama Cancer Center, Saitama, JP, [5]Kobe City Medical Center General Hospital, Kobe, JP, [6]Yokohama Municipal Citizen's Hospital, Yokohama, JP, [7]National Hospital Organization Osaka National Hospital, Osaka, JP, [8]Tohoku University Hospital, Sendai, JP, [9]Chiba Cancer Center Hospital, Chiba, JP, [10]Shizuoka Cancer Center, Shizuoka, JP, [11]Kansai Medical University Hospital, Hirakata, JP, [12]Higashiosaka City Medical Center, Higashiosaka, JP, [13]Osaki Citizen Hospital, Osaki,

JP, [14]Kushiro Rosai Hospital, Kushiro, JP, [15]National Hospital Organization, Nagoya Medical Center, Nagoya, JP, [16]Kindai University Faculty of Medicine, Osakasayama, JP, [17]Wakayama Medical University, Faculty of Medicine, Wakayama, JP, [18]IMS Hospital, Institute of Medical Science, University of Tokyo, Tokyo, JP, [19]Osaka University Hospital, Suita, JP

11:15 - 11:25 **LBA77 - 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD**

A. Zaanan[1], O. Bouche[2], C. De La Fouchardiere[3], E. Samalin-Scalzi[4], K. Le Malicot[5], S. Pernot[6], P. Artru[7], V. Ly Lebrun[8], K. Aldabbagh[9], F. Khemissa Akouz[10], H. Castanie[11], M. Laly[12], D. Botsen[13], M. Muller[14], G. Roth[15], T. Lecomte[16], J.M. Phelip[17], C. Lepage[18], C. Louvet[19], [1]Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, [2]CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR, [3]Centre Léon Bérard, Lyon, FR, [4]ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, [5]Fédération Francophone de Cancérologie Digestive, Dijon, FR, [6]Institut Bergonié, Bordeaux, FR, [7]Hôpital privé Jean Mermoz, Lyon, FR, [8]CHU Limoges - Hopital Dupuytren, Limoges, FR, [9]Polyclinique Saint Côme, Compiegne, FR, [10]Centre Hospitalier de Perpignan - Hôpital Saint Jean, Perpignan, Cedex, FR, [11]Centre Catherine de Sienne, Nantes, FR, [12]CHD Vendee - Hopital Les Oudairies, La Roche-sur-Yon, FR, [13]Institut Jean Godinot, Reims, FR, [14]CHRU Nancy, Nancy, FR, [15]CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, [16]CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, [17]CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, [18]CHU Dijon, Dijon, FR, [19]IMM - Institut Mutualiste Montsouris, Paris, FR

11:25 - 11:40 **Invited Discussant LBA76 and LBA77**

R. Obermannova, Masaryk Memorial Cancer Institute, Brno, CZ

11:40 - 11:55 **Q&A**

10:15 - 11:45 **Type: Mini Oral session** **Sevilla Auditorium - Hall 9**
Title: Mini oral session - Genitourinary tumours, non-prostate

Chair(s): Patrizia Giannatempo, IT; Ursula Vogl, CH; Deborah Mukherji, AE

10:15 - 10:20 **2361MO - Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC) [PET-MUSE]**

S. Sridhar[1], S. Mukherjee[2], N. Power[3], R. Breau[4], S. Cheng[5], P. Chung[6], G. Pond[7], U. Metser[6], M. Levine[8], [1]Princess Margaret Cancer Center, Toronto, CA, [2]JCC - Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, CA, [3]London Health Sciences Centre (LHSC) - London Regional Cancer Program (LRCP), London, CA, [4]University of Ottawa Faculty of Medicine, Ottawa, CA, [5]Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, [6]Princess Margaret Cancer Centre, Toronto, CA, [7]McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, CA, [8]McMaster University, Hamilton, CA

10:20 - 10:25

2362MO - Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study

Y. Loriot[1], N. Matsubara[2], R. Huddart[3], N. Houede[4], B. Laguerre[5], V. Guadalupi[6], J.H. Ku[7], S. Triantos[8], S. Akapame[8], K. Deprince[9], S. Mukhopadhyay[10], A. Siefker-Radtke[11], [1]INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, Cedex, FR, [2]National Cancer Center Hospital East, Chiba, JP, [3]Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, GB, [4]Institut de Cancérologie du Gard - CHU Caremeau, Nîmes, France and Montpellier University, Nimes, FR, [5]Centre Eugene Marquis, Rennes, FR, [6]Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, IT, [7]Seoul National University Hospital, Seoul, KR, [8]Janssen Research & Development, Spring House, US, [9]Janssen Research & Development, Beerse, BE, [10]Janssen Research & Development, Lexington, US, [11]The University of Texas MD Anderson Cancer Center, Houston, US

10:25 - 10:35

Invited Discussant 2361MO and 2362MO

P. Giannatempo, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

10:35 - 10:40

2363MO - A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)

B. Szabados[1], E. Nogueron Martinez[2], F.J. Alvarez Marquez[3], D. Castellano Gauna[4], A. Rodriguez-Vida[5], M.C. Garcias De Espana[6], S. Hussain[7], C. Alvarez Fernandez[8], M. Linch[9], T. Bonfill Abella[10], M. Gross Goupil[11], J. Kelly[12], R. Jones[13], S. Crabb[14], L. Beltran[15], R. Garonce-Hediger[16], N.J. Rakebrandt[17], R. Georgescu 18,[18], C. Ackerman[18], T. Powles[19], [1]Barts Cancer Institute, London, GB, [2]Complejo Hospitalario Universitario de Albacete, Albacete, ES, [3]Hospital General Juan Ramon Jimenez, Huelva, ES, [4]Hospital Universitario 12 de Octubre, Madrid, ES, [5]Hospital del Mar IMIM Research Institute, Barcelona, ES, [6]Hospital Universitario Son Espases, Palma de Mallorca, ES, [7]8. Sheffield Teaching Hospitals NHS Trust, Sheffield, GB, [8]Hospital Universitario Central de Asturias, Oviedo, ES, [9]UCL Cancer Institute - Paul O'Gorman Building, London, GB, [10]Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES, [11]CHU Bordeaux - Hopital St. André, Bordeaux, FR, [12]UCLH - University College London Hospitals NHS Foundation Trust, London, GB, [13]MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB, [14]Southampton General Hospital, Southampton, GB, [15]Barts Hospital NHS Trust, London, GB, [16]F. Hoffmann-La Roche AG, Basel, CH, [17]Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, CH, [18]Barts ECMC, London, GB, [19]St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

10:40 - 10:45

2364MO - Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial

C. Thibault[1], M. Bennamoun[2], A. Flechon[3], G. Gravis[4], D. Pouessel[5], P.-F. Combe[6], D. Borchiellini[7], Y. Loriot[8], B. Laguerre[9], P. Barthélémy[10], M. Gross Goupil[11], C. Helissey[12], O. Huillard[13], M. Cancel[14], L. Campedel[15], F. Audenet[1], H. Belhouari[16], S. Kotti[16], Y. Tran[16], S. Oudard[1], [1]HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, [2]Institute Mutualiste Montsouris, Paris, FR, [3]Centre Leon Berard, Lyon, FR, [4]IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, [5]Oncopole Claudius Regaud - Institut Universitaire du Cancer Toulouse, Toulouse, FR, [6]Pôle Santé Léonard de Vinci,

Chambray-lès-Tours, FR, [7]Centre Anticancer Antoine Lacassagne, Nice, FR, [8]Institut Gustave Roussy, Paris Saclayrsité ar, Villejuif, Cedex, FR, [9]Centre Eugene - Marquis, Rennes, FR, [10]ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, [11]CHU Bordeaux - Hopital St. André, Bordeaux, FR, [12]Military Hospital Begin, Saint-Mandé, FR, [13]Hopital Cochin AP-HP, Paris, FR, [14]University hospital of Tours, Tours, cedex, FR, [15]Hôpital Pitié Salpêtrière, Paris, FR, [16]ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, cedex, FR

10:45 - 10:50

2365MO - Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

S. Sridhar[1], P. O'Donnell[2], T. Flaig[3], J. Rosenberg[4], C. Hoimes[5], M. Milowsky[6], S. Srinivas[7], S. George[8], R. Mckay[9], D. Petrylak[10], P.M. Coelho Barata[11], C. Hwang[12], M. Cruz-Correa[13], M. Iafolla[14], M. Mckean[15], R. Dreicer[16], S. Brancato[17], J. Lukas[18], Y. Yu[18], H. Moon[19], [1]Princess Margaret Cancer Center, Toronto, CA, [2]The University of Chicago, Chicago, US, [3]UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, [4]MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, [5]Duke Cancer Institute, Durham, US, [6]University of North Carolina - Chapel Hill, Chapel Hill, US, [7]Stanford Comprehensive Cancer Institute, Stanford, US, [8]Roswell Park Comprehensive Cancer Center, Buffalo, US, [9]University of California San Diego - UCSD, La Jolla, US, [10]Yale University School of Medicine, New Heaven, US, [11]Case Western Reserve University / University Hospitals, Cleveland, US, [12]Henry Ford Cancer Institute-Henry Ford Health, Detroit, US, [13]Hospital Oncologico Isaac Gonzalez Martinez, San Juan, PR, [14]University Health Network - Princess Margaret Cancer Center, Toronto, CA, [15]Sarah Cannon Research Institute, Nashville, US, [16]University of Virginia Cancer Center, Charlottesville, US, [17]Astellas Pharma USA, Northbrook, US, [18]Seagen Inc., Bothell, US, [19]Kaiser Permanente - Riverside Medical Center, Riverside, US

10:50 - 11:05

Invited Discussant 2363MO, 2364MO and 2365MO

U. Vogl, IOSI - Istituto Oncologico della Svizzera Italiana, Bellinzona, CH

11:05 - 11:10

LBA104 - First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)

A. Vilaseca[1], G. Jayram[2], C. Raventos[3], N. Shore[4], D. Zainfeld[5], T.W. Kang[6], J.H. Ku[7], J. Meeks[8], Ó. Rodríguez Faba[9], F. Roghmann[10], S. Daneshmand[11], N. Beeharry[12], C. Cost[12], A. Kalota[12], J. Lauring[12], M. Peterson[13], M. Quiroz[12], N. Stone[12], W. Zhu[13], F. Guerrero-Ramos[14], [1]Hospital Clínic de Barcelona, Barcelona, ES, [2]Urology Associates, Nashville, US, [3]Vall d'Hebron, Barcelona, ES, [4]Carolina Urologic Research Center, Myrtle Beach, US, [5]Urology San Antonio, San Antonio, US, [6]Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, KR, [7]Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR, [8]Northwestern University, Feinberg School of Medicine, Chicago, US, [9]Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, ES, [10]Ruhr-University Bochum, Marien Hospital, Herne, DE, [11]University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, [12]Janssen Research & Development, Spring House, US, [13]Janssen Research & Development, Raritan, US, [14]University Hospital 12 de Octubre, Madrid, ES

11:10 - 11:15

LBA105 - Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy

A. Necchi[1], J. Jacob[2], S. Daneshmand[3], G. Simone[4], E. Xylinas[5], D. Morris[6], P. Spiegelhalder[7], D. Zainfeld[8], T.W. Kang[9], J. Matulay[10], L. Belkoff[11], K. Decaestecker[12], H. Arentsen[13], S. Hampras[14], C. Cutie[15], H. Sweiti[16], K. Stromberg[14], J. Martin[17], A. Shukla[15], M. Van Der Heijden[18], [1]Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital and Scientific Institute, Milan, IT, [2]Upstate Medical University, Syracuse, US, [3]University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, [4]'Regina Elena' National Cancer Institute, Rome, IT, [5]Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris, FR, [6]Urology Associates, Nashville, US, [7]Urologie Neandertal, Gemeinschaftspraxis für Urologie, Mettmann, DE, [8]Urology San Antonio, San Antonio, US, [9]Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, KR, [10]Atrium Health Levine Cancer Institute, Charlotte, US, [11]MidLantic Urology/Solaris Health, Bala Cynwyd, US, [12]Ghent University Hospital; AZ Maria Middelares, Ghent, BE, [13]AZ Sint-Jan Hospital Brugge-Oostende, Oostende, BE, [14]Janssen Research & Development, Raritan, US, [15]Janssen Research & Development, Lexington, US, [16]Janssen Research & Development, Spring House, US, [17]Janssen Research & Development, High Wycombe, GB, [18]Netherlands Cancer Institute, Amsterdam, NL

11:15 - 11:25

Invited Discussant LBA104 and LBA105

J. Boormans, Erasmus MC, Rotterdam, NL

11:25 - 11:30

1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)

M. Voss[1], B. Garmezy[2], S.H. Kim[3], J.P. Maroto Rey[4], A. Mansinho[5], A. Rodriguez-Vida[6], J. Oliveira[7], M. Van Dongen[8], L. Medina Rodríguez[9], S. Negrier[10], B. Tran[11], B. Carneiro[12], E. Castanon Alvarez[13], S.Y. Rha[14], Y. Wang[15], S. Gainer[15], Z. Tang[15], I. Achour[15], J. Asare[15], L. Albiges[16], [1]Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, US, [2]Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US, [3]Seoul National University Bundang Hospital, Seongnam, KR, [4]Santa Creu i Sant Pau Hospital, Barcelona, ES, [5]Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, PT, [6]Hospital del Mar, IMIM Research Institute, Barcelona, ES, [7]Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), Porto, PT, [8]The Netherlands Cancer Institute, Amsterdam, NL, [9]Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, ES, [10]Centre Léon Bérard, Lyon I University, Lyon, FR, [11]Peter MacCallum Cancer Centre, Melbourne, AU, [12]Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Lifespan Cancer Institute, Providence, US, [13]Clínica Universidad de Navarra, Madrid, ES, [14]Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, [15]AstraZeneca, Gaithersburg, US, [16]Institut Gustave Roussy, Villejuif, Cedex, FR

11:30 - 11:35

1884MO - Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC):

The TIDE-A study

R. Iacovelli[1], C. Ciccarese[1], M. Bersanelli[2], P. Zucali[3], E. Fantinel[4], D. Bimbatti[5], E. Verzoni[6], C. Accettura[7], L. Bonomi[8], C. Buttigliero[9], G. Fornarini[10], S. Pipitone[11], F. Atzori[12], C. Masini[13], F. Massari[14], F. Primi[15], S. Buti[16], M. Perrino[17], S. Pafumi[18], G. Tortora[1], [1]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, [2]University Hospital of Parma, Parma, IT, [3]Humanitas University, Pieve Emanuele, IT, [4]AOU Integrata di Verona - Ospedale Borgo Trento, Verona, IT, [5]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [6]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [7]Ospedale Vito Fazzi - ASL Lecce, Lecce, IT, [8]ASST Papa Giovanni XXIII, Bergamo, IT, [9]Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, [10]IRCCS Ospedale Policlinico San Martino, Genova, IT, [11]Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, [12]Azienda Ospedaliero Universitaria di Cagliari, Monserrato, IT, [13]Azienda Ospedaliera - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, [14]AOU Policlinico S. Orsola-Malpighi, Bologna, IT, [15]Ospedale Belcolle - ASL Viterbo, Viterbo, IT, [16]University of Parma, Parma, IT, [17]IRCCS Humanitas Research Hospital, Rozzano, IT, [18]AOU Integrata di Verona - University of Verona, Verona, IT

11:35 - 11:45 **Invited Discussant 1883MO and 1884MO**

D. Mukherji, Clemenceau Medical Center, Dubai, AE

10:15 - 11:45 **Type: Special session** **Bilbao Auditorium - NCC**
Title: ESMO Clinical Practice Guidelines 1
Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR

10:15 - 10:25 **Early breast cancer case presentation**
F. Giugliano, IEO - Istituto Europeo di Oncologia, Milan, IT

10:25 - 10:35 **Early breast cancer case discussion**
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

10:35 - 10:45 **Q&A**

10:45 - 10:55 **Oncogene-addicted metastatic NSCLC case presentation**
M. Brandão, Institute Jules Bordet, Brussels, BE

10:55 - 11:05 **Oncogene-addicted metastatic NSCLC discussion**
L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

11:05 - 11:15 **Q&A**

11:15 - 11:25 **Advanced pancreatic cancer case presentation**
E. Mariamidze, Todua Clinic, Tbilisi, GE

11:25 - 11:35 **Advanced pancreatic cancer discussion**
T. Conroy, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR

11:35 - 11:45 **Q&A and Discussion**

10:15 - 11:45 **Type: Educational session** **Granada Auditorium - Hall 3**
Title: Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit
Chair(s): Karim Fizazi, FR; Dana Rathkopf, US

10:15 - 10:35 **Evidence from trials: Summary of a fantastic decade**
D. Rathkopf, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

10:35 - 10:55 **Next generation imaging: How does it change the evidence seen in trials?**
B. Tombal, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE

10:55 - 11:15 **How to best integrate biology**

G. Attard, University College London, London, GB

11:15 - 11:35 **Tolerance and long-term side-effects**
A. Morgans, Dana Farber Cancer Institute, Boston, US

11:35 - 11:45 **Discussion**

10:15 - 11:45 **Type: Educational session** **Burgos Auditorium - Hall 3**
Title: Liquid biopsies development and application: Where do we stand?
Chair(s): Scott Bratman, CA; Naureen Starling, GB

10:15 - 10:32 **Detection of HPV circulating tumour DNA**
S. Bratman, Princess Margaret Cancer Centre, Toronto, CA

10:32 - 10:49 **Incorporating liquid biopsies into clinical trials**
S. Marsoni, IFOM-IEO Campus, Milan, IT

10:49 - 11:06 **Standardisation of liquid biopsy approaches**
E. Heitzer, Medical University of Graz, Graz, AT

11:06 - 11:23 **Genome-wide cell-free DNA fragmentation in cancer**
V. Velculescu, Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US

11:23 - 11:45 **Q&A and Discussion**

10:15 **Type: Mini Oral session** **Valencia Auditoriu**

- 11:55 **Title: Mini oral session - Gynaecological cancers**

Chair(s): Christian Marth, AT; Alexandra Leary, FR; Kosei Hasegawa, JP

10:15 - 10:20 **LBA43 - Updated response data and analysis of progression free survival by mechanism of m repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial**

R. Eskander[1], M. Sill[2], A. Miller[2], L. Beffa[3], R. Moore[4], J. Hope[5], F. Musa[6], R. Mannel[7], M. Shahin[8], C Canturia[9], E. Girda[10], C. Mathews[11], J. Kavecansky[12], C. Leath Iii[13], L. Gien[14], E. Hinchcliff[15], S. Lel Powell[17], C. Aghajanian[18], [1]University of California San Diego - UCSD, La Jolla, US, [2]NRG Oncology and Data Management Center, Philadelphia, US, [3]Case Western Reserve University / University Hosp Cleveland, US, [4]URMC - University of Rochester Medical Center, Rochester, US, [5]Alaska Women's Ca Anchorage, US, [6]Pacific Cancer Care, Monterey, US, [7]Stephenson Cancer Center, Oklahoma Universi Science Center, Oklahoma City, US, [8]Sidney Kimmel Cancer Center - Thomas Jefferson University, Ph US, [9]Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute, Atlanta, US, [10]Ru Cancer Institute of New Jersey, New Brunswick, US, [11]Women & Infants Hospital - Warren Alpert Me of Brown Univ, Providence, US, [12]The Permanente Medical Group, San Jose, US, [13]University of Alab Birmingham, Birmingham, US, [14]Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toront [15]Northwestern Medical Group, Chicago, US, [16]Roswell Park Comprehensive Cancer Center, Buffalo, [17]National Cancer Institute Sponsored NRG Oncology, Washington University School of Medicine, Ph US, [18]Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

10:20 - 10:25 **740MO - Dostarlimab + chemotherapy for the treatment of primary advanced or recur endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall surviva outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial**

M.R. Mirza[1], S. Sharma[2], J. Herrstedt[3], M. Shahin[4], D. Cibula[5], E. Fleming[6], F. Raspagliesi[7], J. Busce Hanker[9], R. Coleman[10], I. Boere[11], K. Schneider[12], L. Gilbert[13], B. Slomovitz[14], M.G. Teneriello[15], M Powell[16], S. Ghosh[17], S. Stevens[18], K. Ring[19], A. Stuckey[20], [1]Rigshospitalet, Copenhagen University Copenhagen, and Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, DK, [2]AM Adventist Hinsdale Hospital, Hinsdale, US, [3]Zealand University Hospital Roskilde, Roskilde, DK, [4]Ha Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Si Kimmel Medical College of Thomas Jefferson University, Willow Grove, US, [5]General University Hosp Prague, First Faculty of Medicine, Charles University, Prague, CZ, [6]Norris Cotton Cancer Center, Dar Hitchcock Medical Center, Lebanon, US, [7]Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT, [8]A Oncology, Tucson, US, [9]University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, and AGO S Wiesbaden, DE, [10]Sarah Cannon Research Institute, Nashville, US, [11]Erasmus MC Cancer Centre, Ro NL, [12]Norvant Health Cancer Institute – Elizabeth, Charlotte, US, [13]McGill University Health Centre CA, [14]Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida Interna University, Miami Beach, US, [15]US Oncology Research, The Woodlands, US, [16]National Cancer Instit Sponsored NRG Oncology, Washington University School of Medicine, St. Louis, US, [17]GSK, Waltham [18]GSK, London, GB, [19]University of Virginia, Charlottesville, US, [20]Women and Infants Hospital, Prov

10:25 - 10:30 **742MO - Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometri**

M. De Bruyn[1], A. Eerkens[1], K. Brummel[1], A. Vledder[1], S. Paijens[2], M. Requesens[1], D. Loiero[3], N. Van Plat[1], P. Klok[1], F.-J. Haan[1], D. Church[4], R. Wardenaar[1], F. Foijer[1], V. Koelzer[3], T. Bosse[5], J. Bart[1], M. J Reyners[1], H. Nijman[1], [1]UMCG - University Medical Center Groningen, Groningen, NL, [2]Erasmus MC Rotterdam, NL, [3]USZ - Universitätsspital Zürich, Zurich, CH, [4]University of Oxford, Oxford, GB, [5]Lei University Medical Center, Leiden, NL

10:30 - 10:35 **741MO - Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) a drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial end cancer (EEC): STRO-002-GM1 phase I dose expansion**

B. Pothuri[1], R. Naumann[2], L. Martin[3], D. O'Malley[4], D. Uyar[5], J. Moroney[6], J. Diaz[7], J. Garcia-Donas[8], Redondo[9], A. Gonzalez Martin[10], D. Illescas[11], L. Liu[12], C. Berman[13], A. Oaknin[11], [1]NYU Langone La Isaac Perlmutter Cancer Center, New York, US, [2]Levine Cancer Institute, Charlotte, US, [3]Fox Chase (Center - Main Campus, Philadelphia, US, [4]OSUCCC - The Ohio State University Comprehensive Canc James, Columbus, US, [5]Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US, [6]Univers Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, [7]Miami Cancer Ins Baptist Health South Florida, Miami, US, [8]Hospital Madrid Norte San Chinarro - Centro Integral Onc Clara Campal, Madrid, ES, [9]Hospital Universitario La Paz, Madrid, ES, [10]Clinica Universidad de Nav Madrid, ES, [11]Vall d'Hebron University Hospital, Barcelona, ES, [12]Sutro Biopharma - Headquarters, Francisco, US, [13]Sutro Biopharma, Inc., South San Francisco, US

10:35 - 10:50 **Invited Discussant LBA43, 740MO, 742MO and 741MO**

C. Marth, Innsbruck Medical University, Innsbruck, AT

10:50 - 10:55 **743MO - Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- be (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): A single-arm, mu phase II study**

N. Liu[1], Z. Yang[2], D. Tang[3], H. Lou[4], K. Zhang[3], H. Cao[5], D. Zou[6], X. Zhang[7], S. Xue[7], X. Kang[7], D. W [1]Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, [2]Cancer Hospital of China M University,Liaoning Cancer Hospital & Institute, Shenyang, CN, [3]The Affiliated Tumor Hospital of Xia Medical School of Central South University, Changsha, CN, [4]Cancer Hospital of the University of Chi Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, [5]Guizhou Provincial People's Hospit College of Guizhou University, Guiyang, CN, [6]Chongqing University Cancer Hospital, Chongqing, CN, Pharmaceutical Co., Ltd., Jinan, CN

10:55 - 11:00 **744MO - AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic cervical cancer (CC)**

J.-Y. Lee[1], L. Wu[2], S. Boonyapipat[3], H.S. Kim[4], J.-W. Lee[5], L. Wang[6], T. Wang[7], D. Wang[8], D. Yao[9], H. L Andabekov[11], X. Zhang[12], W. Wang[13], Y.M. Kim[14], K. Wang[15], Y. Gao[15], X. Mu[16], I. Volodymyrovych Sinielnikov[17], [1]Severance Hospital Yonsei University Health System, Seoul, KR, [2]Cancer Hospital Ch Academy of Medical Sciences, Beijing, CN, [3]Songklanagarind Hospital (Prince of Songkhla University Songkhla, TH, [4]Seoul National University Hospital, Seoul, KR, [5]Samsung Medical Center, Seoul, KR, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, [7]The Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, [8]Liaoning Cancer Hospital & Institute, Xi'a Tumor Hospital Affiliated to Guangxi Medical University, Nanning, CN, [10]Anhui Provincial Cancer Ho West Branch of Anhui Province Hospital, Hefei City, CN, [11]Oncological Scientific Center LLC, Moscov [12]Zhejiang Cancer Hospital, Hangzhou, CN, [13]Second Hospital of Shanxi Medical University, Taiyuan [14]Asan Medical Center, Seoul, KR, [15]BeiGene (Beijing) Co. Ltd, Beijing, CN, [16]BeiGene (Shanghai) C Shanghai, CN, [17]Volyn Regional Medical Center of Oncology, Lutsk, UA

11:00 - **LBA44 - Camrelizumab plus famitinib versus camrelizumab alone and investigator&#x2019 of chemotherapy in women with recurrent or metastatic cervical cancer**

11:05

X. Wu[1], L. Xia[1], K. Zhang[2], Y. Tang[3], G.N. Zhang[4], D. Wang[5], H. Lou[6], N. Liu[7], H. Zhang[8], H. Chen[9], I
S. Wei[11], L. Wang[12], K. Gao[13], G. Li[14], H. Zhang[15], Y. Hu[16], X. Zhou[17], Y. Wang[17], Q. Wang[17], [1]Fudar
Shanghai Cancer Center, Shanghai, CN,
[2]Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central Sout
Changsha, CN, [3]Chongqing University Cancer Hospital, Chongqing, CN, [4]Sichuan Cancer Hospital &
Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China,
CN, [5]Liaoning Cancer Hospital & Institute, Shenyang, CN, [6]Zhejiang Cancer Hospital, Hangzhou, CN
[7]Shandong Cancer Hospital & Institute, Jinan, CN, [8]Yunnan Cancer Hospital & The Third Affliated H
Kunming Medical University, Kunming, CN, [9]The First Affiliated Hospital of Xi'an Jiaotong University,
[10]Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, [11]Shanxi Cancer Hospital, Ta
[12]The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN,
Medical University Cancer Hospital, Nanning, CN, [14]Cancer Center Union Hospital Tongji Medical C
Huazhong University of Science and Technology, Wuhan, CN, [15]Hubei Cancer Hospital, Wuhan, CN, [1
Central Hospital of Gynecology Obstetrics, Tianjin, CN, [17]Jiangsu Hengrui Pharmaceuticals Co., Ltd.,
CN

11:05 - 11:15 **Invited Discussant 743MO, 744MO and LBA44**

A. Leary, Institut Gustave Roussy, Villejuif, FR

11:15 - 11:20 **LBA45 - Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing sing olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in r plat sensitive ovarian cancer (OvCa)**

J. Liu[1], M. Brady[2], U. Matulonis[1], A. Miller[2], E. Kohn[3], E. Swisher[4], W. Tew[5], N. Cloven[6], C. Muller[7], I
R. Moore[9], D. Michelin[10], S. Waggoner[11], M. Geller[12], K. Fujiwara[13], S. D'Andre[14], M. Carney[15], A. S
Walker[17], M. Bookman[18], [1]Dana Farber Cancer Institute, Boston, US, [2]Roswell Park Comprehensive
Center, Buffalo, US, [3]National Cancer Institute, Bethesda, US, [4]University of Washington, Seattle, US
Sloan Kettering Cancer Center, New York, US, [6]Texas Oncology, Fort Worth, US, [7]University of New I
Albuquerque, US, [8]University of Iowa Hospitals and Clinics, Iowa City, US, [9]URMC - University of Ro
Medical Center, Rochester, US, [10]Cancer Research Consortium of West Michigan, Grand Rapids, US,
Western Reserve University / University Hospitals, Cleveland, US, [12]University of Minnesota, Minnea
[13]Saitama Medical University International Medical Center, Saitama, JP, [14]Sutter Institute for Medica
Sacramento, US, [15]University of Hawaii Cancer Center, Honolulu, US, [16]Duke University, Durham, U
[17]University of Oklahoma Health Sciences Center, Oklahoma City, US, [18]Kaiser Permanente Medical
Francisco, US

11:20 - 11:25 **746MO - Randomized phase II trial of durvalumab in combination with olaparib and cedira compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY**

J.-M. Lee[1], A. Miller[2], P. Rose[3], M. Alhilli[3], C. Washington[4], V. John[5], C. Shah[6], K. Matsuo[7], J. Siedel[8],
J. Chan[10], E. Hopp[11], E. Kohn[1], K. Moore[4], J. Liu[12], [1]National Cancer Institute, Bethesda, US, [2]NRG
Buffalo, US, [3]Case Western Reserve University / University Hospitals, Cleveland, US, [4]Stephenson Ca
Center/University of Oklahoma, Oklahoma City, US, [5]Northwell Health Cancer Institute, Lake Succes
[6]Swedish Cancer Institute - Medical Oncology - First Hill, Seattle, US, [7]Keck School of Medicine - Un
Southern California USC, Los Angeles, US, [8]University of Michigan Hospital, Ann Arbor, US, [9]UTSW
of Texas Southwestern Medical Center, Dallas, US, [10]Sutter Cancer Center, Sacramento, US, [11]Froed
Hospital & Medical College of Wisconsin, Milwaukee, US, [12]Dana Farber Cancer Institute, Boston, U

11:25 - 11:35 **Invited Discussant LBA45 and 746MO**

K. Hasegawa, Saitama Medical University International Medical Center, Saitama, JP

11:35 - 11:40 **745MO - Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previous ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study**

K. Moore[1], A. Philipovskiy[2], K. Harano[3], B. Rini[4], K. Sudo[5], S. Kitano[6], D.R. Spigel[7], J. Lin[8], M. Kundu Bensmaine[9], Y. Myobatake[8], E. Hamilton[10], [1]Oklahoma University, Oklahoma City, US, [2]Florida Canc Specialists, Lake Mary, US, [3]National Cancer Center Hospital East, Kashiwa, JP, [4]Vanderbilt-Ingram (Center, Nashville, US, [5]National Cancer Center Hospital, Tokyo, JP, [6]Japanese Foundation for Cancer Tokyo, JP, [7]Tennessee Oncology, PLLC, Nashville, US, [8]Daiichi Sankyo, Inc., Basking Ridge, US, [9]Daii France SAS, Rueil-Malmaison, FR, [10]Sarah Cannon Research Institute, Nashville, US

11:40 - 11:45 **747MO - First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-dire platform study: Cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)**

I. Ray-Coquard[1], S. Pignata[2], J.-Y. Lee[3], R. Coleman[4], J. Brown[5], J.-W. Kim[6], F. Selle[7], D. Lorusso[8], M.J Pérez[9], P. Pautier[10], C. Gourley[11], A. Ayhan[12], G. Richardson[13], D. Cibula[14], L. Yauch[15], M. Dieterich Krishnan[15], O. Calas-Zeroug[17], P. Harter[18], D. Gershenson[19], [1]Centre Léon Bérard and University of FR, [2]Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, [3]Yonsei University College Medicine, Seoul, KR, [4]The US Oncology Network, The Woodlands, US, [5]Levine Cancer Institute at At Health, Charlotte, US, [6]Seoul National University College of Medicine, Seoul, KR, [7]Groupe Hospitalie Diaconesses Croix Saint-Simon, Paris, FR, [8]Fondazione Policlinico Universitario Agostino Gemelli, IR Catholic University of Sacred Heart, Rome, IT, [9]Hospitales Universitarios Regional y Virgen Victoria, Málaga, ES, [10]Gustave Roussy, Villejuif, FR, [11]Cancer Research UK Edinburgh Centre, Western Gene Hospital, Edinburgh, GB, [12]Baskent University Hospital, Ankara, TR, [13]Cabrini Hospital, Malvern, AU Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, CZ, [15]Ge South San Francisco, US, [16]F. Hoffmann-La Roche Ltd, Basel, CH, [17]Cytel Inc - Clinical Research Ser Geneva, CH, [18]Evang. Kliniken Essen-Mitte, Essen, DE, [19]The University of Texas MD Anderson Canc Houston, US

11:45 - 11:55 **Invited Discussant 745MO and 747MO**

M.R. Mirza, Rigshospitalet, Copenhagen, DK

10:15 - 11:45 **Type: Special symposium** **Salamanca**
Title: Cutting edge diagnostics and innovation in the treatment of brain tumours **Auditorium - Hall 3**

Chair(s): Roger Stupp, US; Slavka Lukacova, DK

10:15 - 10:20 **Introduction and scientific background**

S. Lukacova, Aarhus University Hospital, Aarhus, DK

10:20 - 10:35 **New treatment targets: From bench to bedside**

M. Sanson, Hopital Pitié Salpetrière AP-HP, Paris, FR

10:35 - 10:50 **Immunotherapy**

M. Platten, Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE

10:50 - 11:05 **Opening the blood-brain barrier (BBB)**

A. Sonabend, Northwestern University Feinberg School of Medicine, Chicago, US

11:05 - 11:20 **Methylation profiling: Hype or progress?**

H.-K. Ng, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

11:20 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**

R. Stupp, Northwestern University Feinberg School of Medicine, Chicago, US

10:15 - 11:45	**Type: Multidisciplinary session** **Title: A young female with limited stage classic Hodgkin's lymphoma and large mediastinal mass** Chair(s): Olivier Casasnovas, FR; Ramon Garcia-Sanz, ES	**Toledo Auditorium - Hall 3**

10:15 - 10:20 **Presentation of case/condition**

O. Casasnovas, CHU Dijon, Dijon, FR

10:20 - 10:40 **How to select the chemotherapy**

P. Borchmann, University Hospital Cologne, Köln, DE

10:40 - 11:00 **How to guide treatment with PET**

O. Casasnovas, CHU Dijon, Dijon, FR

11:00 - 11:20 **When or when not to irradiate**

U. Ricardi, Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, IT

11:20 - 11:40 **Preserving fertility in female patients**

R. Garcia-Sanz, University Hospital of Salamanca, Salamanca, ES

11:40 - 11:45 **Discussion**

10:15 - 11:45 **Type: Special session** **León Auditorium - Hall 7**
Title: More intelligent trial design
Chair(s): Mahesh Parmar, GB; Ian Tannock, CA

10:15 - 10:20 **Introduction and scientific background**
I. Tannock, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

10:20 - 10:35 **Multi-arm multi-stage (MAMS) trials**
M. Parmar, Institute of Clinical Trials and Methodology-UCL, London, GB

10:35 - 10:50 **Pragmatic trials**
J. Bogaerts, EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE

10:50 - 11:05 **De-escalation trials**
L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US

11:05 - 11:20 **Trials in low-and middle-income countries (LMIC)**
C. Pramesh, Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN

11:20 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**
M. Parmar, Institute of Clinical Trials and Methodology-UCL, London, GB

10:15 - 11:45	**Type: Educational session** **Title: Transnational cancer policies: EU and WHO projects driving improvements in national cancer plans** Chair(s): Bente Mikkelsen, CH; Tit Albreht, SI	**Cádiz Auditorium - NCC**

10:15 - 10:35 **EBCP and implementation plans at the EU level**

P. Roux, European Commission - Directorate General Health and Food Safety, Luxembourg City, LU

10:35 - 10:55 **The joint development of policies through Joint Actions as policy projects, and the arising EU guide for National Cancer Control Programmes**

T. Albreht, National Institute of Public Health of Slovenia - Nacionalni institut za javno zdravje, Ljubljana, SI

10:55 - 11:15 **The Youth Cancer Europe's perspective**

S. Narbutas, Lithuanian Cancer Patient Coalition, Kaunas, LT

11:15 - 11:35 **WHO/IARC national cancer control plan tool and case studies**

B. Mikkelsen, WHO - World Health Organization, Geneva, CH

11:35 - 11:45 **Q&A and Discussion**

10:15 - 11:45 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Symptom management
Chair(s): Tugba Pehlivan Sarıbudak, TR

10:15 - 10:30 **Prevalence and predictors of unmet needs among lymphoma cancer survivors**
V. Boland, Trinity College Dublin, Dublin, IE

10:30 - 10:45 **PROMS in patients with advanced RCC and advanced hepatocellular carcinoma**
G. Kotronoulas, University of Glasgow, Glasgow, GB

10:45 - 11:00 **Digital innovation in cancer care: Symptom assessment and management**
E. Furlong, National University of Ireland - University College Dublin, Dublin, IE

11:00 - 11:15 **Evaluation of the ABC4Nurses education programme**
A. Drury, DCU - Dublin City University, Dublin, IE

11:15 - 11:25 **CN3 - Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies**
J. Lijnsvelt[1], S.G. Aanes[2], S. Iivanainen[3], M.G. Vitale[4], S. Mentu[5], R. Arokoski[5], P. Mohr[6], A. Addeo[7], P. Ascierto[4], J. Koivunen[3], E. Haukland[8], C. Blank[1], [1]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [2]Nordlandsykehuset HF, Bodoe, NO, [3]OYS - Oulu University Hospital, Oulu, FI, [4]Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, [5]Kaiku Health, Helsinki, FI, [6]Elbe-Kliniken, Buxtehude, DE, [7]HUG - Hopitaux Universitaires de Geneve, Geneva, CH, [8]University of Stavanger, Stavanger, NO

11:25 - 11:35 **CN59 - The comparison between two types of educational information in reducing nausea and vomiting in patients undergoing chemotherapy: Randomized controlled trial**
C. Mazzega Fabbro[1], J. Polesel[1], M. Manicone[1], L. Brusutti[1], E. Malnis[1], F. Puglisi[2], [1]CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, [2]Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, IT

11:35 - 11:45 **Q&A and discussion**

10:30 - 11:45	**Type: Multidisciplinary session** **Title: Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC?** Chair(s): Matthias Guckenberger, CH; Gaetano Rocco, US	**Málaga Auditorium - Hall 10**

10:30 - 10:45 **Characteristics and treatment outcomes of screening-detected early NSCLC**
W. Rzyman, Medical University of Gdansk, Gdansk, PL

10:45 - 11:00 **A radiation oncologist’s perspective**
M. Guckenberger, USZ - University Hospital Zürich, Zurich, CH

11:00 - 11:15 **A surgeon's perspective**
G. Rocco, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

11:15 - 11:30 **Opportunities for immunotherapy in stage I NSCLC**
S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

11:30 - 11:45 **Discussion**

10:30 - 11:15	**Type: Challenge your Expert** **Title: How do we manage patients with complicated toxicity to immunotherapy?** Chair(s): John Haanen, NL	**Santander Auditorium - Hall 9**

10:30 - 10:50 **Presentation by Expert**
M. Postow, Memorial Sloan Kettering 60th Street Outpatient Center, New York, US

10:50 - 11:15 **Discussion led by Chair**
J. Haanen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

10:30 - 11:45 **Type: Multidisciplinary session** **Oviedo Auditorium - Hall 7**
Title: Management of retroperitoneal sarcoma
Chair(s): Winan Van Houdt, NL; Claudia María Valverde Morales, ES

10:30 - 10:35 **Presentation of case/condition**
H. Kosela Paterczyk, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL

10:35 - 10:50 **A pathologist's perspective**
M. Sbaraglia, Ospedale Regionale di Treviso S.Maria di Cà Foncello - ULSS2, Treviso, IT

10:50 - 11:05 **A surgeon's perspective**
D. Callegaro, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

11:05 - 11:20 **A radiation oncologist's perspective**
A. Miah, The Royal Marsden Hospital - Chelsea, London, GB

11:20 - 11:35 **A medical oncologist's perspective**
C.M. Valverde Morales, Vall d'Hebron University Hospital, Barcelona, ES

11:35 - 11:45 **Discussion**

11:00 - 11:45 **Type: Young Oncologists session** **Ávila Auditorium - NCC**
Title: YO Brunch 2: How to tell a compelling story in scientific articles and presentations
Chair(s): Rille Pihlak, GB

11:00 - 11:15 **How to tell a compelling story in scientific articles and presentations**
P. Sobczuk, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

11:15 - 11:45 **Discussion led by Chair**
R. Pihlak, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

12:00 - 12:30 **Type: Keynote lecture** **Barcelona Auditorium - Hall 9**
Title: Healthcare in times of crises
Chair(s): Jose Martin-Moreno, ES

12:00 - 12:05 **Introduction by the Chair**
J. Martin-Moreno, Hospital Clinico Universitario de Valencia, Valencia, ES

12:05 - 12:30 **Healthcare in times of crises**
B. Mikkelsen, WHO - World Health Organization, Geneva, CH

12:00 - 13:30 **Type: EONS Industry Satellite Symposium** **Alicante Auditorium - Hall 10**
Title: MSD - The Role of Cancer Nurses in the Management of gBRCAm HER2- Breast Cancer
Chair(s): Julio de la Torre-Montero, ES

12:00 - 12:05 **Welcome and Introduction**
J. De La Torre-Montero, Universidad Pontificia Comillas, Madrid, ES

12:05 - 12:20 **Genetic risk/surgical management**
S. González-Santiago, Hospital San Pedro De Alcantara, Caceres, ES

12:20 - 12:25 **Q&A**
J. De La Torre-Montero[1], S. González-Santiago[2], Y. Hanhauser[3], E. Schumacher-Wulf[4], [1]Universidad Pontificia Comillas, Madrid, ES, [2]Hospital San Pedro De Alcantara, Caceres, ES, [3]St James's Hospital, Dublin, IE, [4]Mamma MIA - The Breast Cancer Magazine, Köln, DE

12:25 - 12:40 **Decision-making in BRCA+ risk management**
Y. Hanhauser, St James's Hospital, Dublin, IE

12:40 - 12:45 **Q&A**
J. De La Torre-Montero[1], S. González-Santiago[2], Y. Hanhauser[3], E. Schumacher-Wulf[4], [1]Universidad Pontificia Comillas, Madrid, ES, [2]Hospital San Pedro De Alcantara, Caceres, ES, [3]St James's Hospital, Dublin, IE, [4]Mamma MIA - The Breast Cancer Magazine, Köln, DE

12:45 - 13:00 **Nursing considerations related to PARP inhibitors**
S. González-Santiago, Hospital San Pedro De Alcantara, Caceres, ES

13:00 - 13:05 **Q&A**
J. De La Torre-Montero[1], S. González-Santiago[2], E. Schumacher-Wulf[3], Y. Hanhauser[4], [1]Universidad Pontificia Comillas, Madrid, ES, [2]Hospital San Pedro De Alcantara, Caceres, ES, [3]Mamma MIA - The Breast Cancer Magazine, Köln, DE, [4]St James's Hospital, Dublin, IE

13:05 - 13:20 **Patient experience of care**

E. Schumacher-Wulf, Mamma MIA - The Breast Cancer Magazine, Köln, DE

13:20 - 13:25 **Q&A**

J. De La Torre-Montero[1], S. González-Santiago[2], Y. Hanhauser[3], E. Schumacher-Wulf[4], [1]Universidad Pontificia Comillas, Madrid, ES, [2]Hospital San Pedro De Alcantara, Caceres, ES, [3]St James's Hospital, Dublin, IE, [4]Mamma MIA - The Breast Cancer Magazine, Köln, DE

13:25 - 13:30 **Conclusions**

J. De La Torre-Montero, Universidad Pontificia Comillas, Madrid, ES

13:00 - 14:30 **Type: Industry Satellite Symposium** **Burgos Auditorium - Hall 3**
Title: AstraZeneca - Transforming care in Early stage Lung cancer

Chair(s): Sanjay Popat, GB

13:00 - 13:05 **Welcome and introduction**

S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

13:05 - 13:20 **Optimising resectable NSCLC outcomes in patients with actionable mutations**

R.S. Herbst, Yale University School of Medicine, New heaven, US

13:20 - 13:35 **Improving outcomes in unresectable NSCLC: from clinical trial to clinical practice**

S. Formenti, Weill Cornell Medicine - Gastrointestinal (GI) Oncology, New York, US

13:35 - 13:50 **Leveraging the MDT to navigate early-stage disease**

J. Naidoo, Beaumont Hospital, Dublin, IE

13:50 - 14:25 **Panel discussion and audience Q&A**

S. Popat[1], R.S. Herbst[2], S. Formenti[3], J. Naidoo[4], [1]The Royal Marsden Hospital - NHS Foundation Trust, London, GB, [2]Yale University School of Medicine, New heaven, US, [3]Weill Cornell Medicine - Gastrointestinal (GI) Oncology, New York, US, [4]Beaumont Hospital, Dublin, IE

14:25 - 14:30 **Summary and Close**

S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Novartis - Expanding Horizons: Clinical and Patient Perspectives on CDK4/6 Inhibitors in HR+/HER2- Early Breast Cancer** Chair(s): Michael Gnant, AT	**Valencia Auditorium - Hall 10**

13:00 - 13:10 **Unmet Need in HR+/HER2- Early Breast Cancer**

M. Gnant, MedUni Wien - Medical University of Vienna, Vienna, AT

13:10 - 13:20 **Efficacy of CDK4/6i in HR+/HER2- Early Breast Cancer**

M. Piccart, Institute Jules Bordet, Brussels, BE

13:20 - 13:30 **Discussion**

M. Gnant[1], M. Piccart[2], [1]MedUni Wien - Medical University of Vienna, Vienna, AT, [2]Institute Jules Bordet, Brussels, BE

13:30 - 13:40 **Safety and QoL with CDK4/6i in HR+/HER2- Early Breast Cancer**

M. Gnant, MedUni Wien - Medical University of Vienna, Vienna, AT

13:40 - 13:50 **Discussion**

M. Gnant[1], M. Piccart[2], [1]MedUni Wien - Medical University of Vienna, Vienna, AT, [2]Institute Jules Bordet, Brussels, BE

13:50 - 14:00 **Key Takeaways and Live Q&A**

M. Gnant[1], M. Piccart[2], [1]MedUni Wien - Medical University of Vienna, Vienna, AT, [2]Institute Jules Bordet, Brussels, BE

14:00 - 14:10 **QOL and Treatment Adherence in Early Breast Cancer: The Patient Perspective**

R. Haidinger, Brustkrebs Deutschland e.V., Hohenbrunn, DE

14:10 - 14:20 **Discussion**

M. Gnant[1], M. Piccart[2], [1]MedUni Wien - Medical University of Vienna, Vienna, AT, [2]Institute Jules Bordet, Brussels, BE

14:20 - 14:30 **Live Q&A and Closing**

M. Gnant[1], M. Piccart[2], R. Haidinger[3], [1]MedUni Wien - Medical University of Vienna, Vienna, AT, [2]Institute Jules Bordet, Brussels, BE, [3]Brustkrebs Deutschland e.V., Hohenbrunn, DE

13:00 - 14:30 **Type: Industry Satellite Symposium** **Salamanca Auditorium - Hall 3**

Title: MSD - Treatment Modalities in Early-Stage Resectable NSCLC

Chair(s): Delvys Rodriguez Abreu, ES

13:00 - 13:05 **Welcome & opening comments**

D. Rodriguez Abreu, Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES

13:05 - 13:25 **Current early-stage resectable disease data**

H. Wakelee, Standford University, Stanford, US

13:25 - 13:45 **Surgical considerations in early-stage disease**

J. Spicer, McGill University, Montreal, CA

13:45 - 14:05 **Integrating treatment strategies into practice**

B. Besse, Institut Gustave Roussy, Villejuif, FR

14:05 - 14:25 **Panel Q&A**

D. Rodriguez Abreu[1], H. Wakelee[2], J. Spicer[3], B. Besse[4], [1]Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES, [2]Standford University, Stanford, US, [3]McGill University, Montreal, CA, [4]Institut Gustave Roussy, Villejuif, FR

14:25 - 14:30 **Closing Remarks**

D. Rodriguez Abreu, Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Janssen Pharmaceutica N.V. - Transforming treatment approaches for patients with EGFR-mutant NSCLC** Chair(s): Luis Paz-Ares, ES; Natasha Leighl, CA	**Málaga Auditorium - Hall 10**

13:00 - 13:05 **Welcome and introductions**

L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

13:05 - 13:20 **Strategies for overcoming EGFR resistance in NSCLC patient management**

A. Passaro, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

13:20 - 13:32 **Discussion**

L. Paz-Ares[1], N. Leighl[2], N. Girard[3], J. Sabari[4], A. Passaro[5], [1]Hospital Universitario 12 de Octubre, Madrid, ES, [2]UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, [3]Institut Curie, Paris, FR, [4]NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, [5]IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

13:32 - 13:47 **Expanding our horizons: Novel frontline approaches in EGFR-mutant NSCLC**

N. Girard, Institut Curie, Paris, FR

13:47 - 13:59 **Discussion**

L. Paz-Ares[1], N. Leighl[2], N. Girard[3], J. Sabari[4], A. Passaro[5], [1]Hospital Universitario 12 de Octubre, Madrid, ES, [2]UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, [3]Institut Curie, Paris, FR, [4]NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, [5]IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

13:59 - 14:14 **Current and future directions for EGFR exon 20 insertion mutations in NSCLC**

J. Sabari, NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US

14:14 - 14:26 **Discussion**

L. Paz-Ares[1], N. Leighl[2], N. Girard[3], J. Sabari[4], A. Passaro[5], [1]Hospital Universitario 12 de Octubre, Madrid, ES, [2]UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, [3]Institut Curie, Paris, FR, [4]NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, [5]IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

14:26 - 14:30 **Key learnings/closing remarks**

N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

13:00 - 14:00 **Type: Industry Satellite Symposium** **Santander Auditorium - Hall 9**

Title: Astellas Pharma Europe Ltd - Putting the patient first: Considering treatment choice and maximising quality of life in mHSPC

Chair(s): Christopher Sweeney, AU

13:00 - 13:05 **Welcome and introduction**

C. Sweeney, The University of Adelaide, Adelaide, AU

13:05 - 13:20 **Reinforcing standard of care: The benefits of early treatment intensification in patients with mHSPC**

H. Payne[1], C. Sweeney[2], J. Puente[3], [1]University College London Hospitals NHS Foundation Trust, London, GB, [2]The University of Adelaide, Adelaide, AU, [3]Hospital Clinico Universitario San Carlos, Madrid, ES

13:20 - 13:35 **The importance of first-line treatment choice in patients with mHSPC**

H. Payne[1], C. Sweeney[2], J. Puente[3], [1]University College London Hospitals NHS Foundation Trust, London, GB, [2]The University of Adelaide, Adelaide, AU, [3]Hospital Clinico Universitario San Carlos, Madrid, ES

13:35 - 13:50 **Maintaining quality of life: Holistic approaches in the management of patients with mHSPC**

H. Payne[1], C. Sweeney[2], J. Puente[3], [1]University College London Hospitals NHS Foundation Trust, London, GB, [2]The University of Adelaide, Adelaide, AU, [3]Hospital Clinico Universitario San Carlos, Madrid, ES

13:50 - 13:55 **Q&A**

H. Payne[1], C. Sweeney[2], J. Puente[3], [1]University College London Hospitals NHS Foundation Trust, London, GB, [2]The University of Adelaide, Adelaide, AU, [3]Hospital Clinico Universitario San Carlos, Madrid, ES

13:55 - 14:00 **Closing remarks**

C. Sweeney, The University of Adelaide, Adelaide, AU

13:00 - 14:30 **Type: ESMO Colloquium** **Toledo Auditorium - Hall 3**

Title: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC

Chair(s): Enriqueta Felip, ES; Pasi Jänne, US

13:00 - 13:10 **Welcome and introduction**

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

13:10 - 13:30 **Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients**

P. Jänne, Dana Farber Cancer Institute, Boston, US

13:30 - 13:50 **Improving the safety profiles of ADCs: Early detection and optimal management of toxicities**

M. Pérol, Centre Léon Bérard, Lyon, FR

13:50 - 14:10 **Antibody-drug conjugates: Novel combinations with precision therapeutics and the quest for biomarkers**

A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

14:10 - 14:25 **Q&A and discussion**

14:25 - 14:30 **Concluding remarks**

P. Jänne, Dana Farber Cancer Institute, Boston, US

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: F. Hoffmann-La Roche LTD - Redefining Lung Cancer Together: A New Era for Patients** Chair(s): Stephen Liu, US	**Oviedo Auditorium - Hall 7**

13:00 - 13:05 **Welcome and introduction**

S. Liu, Lombardi Cancer Center Georgetown University, Washington, US

13:05 - 13:25 **Optimising the patient journey: from lung cancer detection to biomarker testing**

S. Liu[1], L. Pijuan[2], [1]Lombardi Cancer Center Georgetown University, Washington, US, [2]Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES

13:25 - 13:45 **Evolving treatment decisions in resectable NSCLC**

M. Reck[1], N. Altorki[2], [1]Krankenhaus Grosshansdorf, Grosshansdorf, DE, [2]NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US

13:45 - 13:55 **A look at the patient journey through the lens of the nurse**

A. Silverio Pons, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, ES

13:55 - 14:25 **Panel discussion and Q&A**

S. Liu[1], M. Reck[2], N. Altorki[3], L. Pijuan[4], A. Silverio Pons[5], [1]Lombardi Cancer Center Georgetown University, Washington, US, [2]Krankenhaus Grosshansdorf, Grosshansdorf, DE, [3]NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, [4]Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES, [5]Vall d'Hebron Institut de Recerca (VHIR), Barcelona, ES

14:25 - 14:30 **Conclusion**

S. Liu, Lombardi Cancer Center Georgetown University, Washington, US

13:00 - 14:30 **Type: Industry Satellite Symposium** **León Auditorium - Hall 7**
Title: GSK - The breakthrough era in endometrial cancer treatment

Chair(s): Ana Oaknin, ES

13:00 - 13:10 **Three ways EC management is changing**

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

13:10 - 13:35 **Anti–PD-(L)1s plus chemotherapies continue to evolve: Updates from 2023 congresses**

I. Colombo, EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH

13:35 - 13:55 **Synergy: Is it more than a buzzword for IO plus PARPi or TKI?**

K. Moore, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US

13:55 - 14:15 **Surge in molecular-based targets brings new hope for EC treatment**

A. Oaknin[1], I. Colombo[2], K. Moore[3], [1]Vall d'Hebron University Hospital, Barcelona, ES, [2]EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH, [3]Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US

14:15 - 14:30 **Full discussion/Q&A**

A. Oaknin[1], K. Moore[2], I. Colombo[3], [1]Vall d'Hebron University Hospital, Barcelona, ES, [2]Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, [3]EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH

13:00 - 14:30 **Type: Patient Advocacy session** **Cádiz Auditorium - NCC**
Title: Living with and after cancer
Chair(s): André Deschamps, BE; Natacha Bolanos Fernandez, ES

13:00 - 13:15 **Resilience is key after diagnosis, during treatment, and after treatment**
N. Bolanos Fernandez, Lymphoma Coalition, Madrid, ES

13:15 - 13:30 **Behavioural changes in daily life: A cross-cutting approach for daily wellbeing**
J. Kufel-Grabowska, Wielkopolskie Centrum Onkologii, Poznan, PL

13:30 - 13:45 **Quality of life and survivorship**
M. Die-Trill, Atrium: Psycho-Oncology & Clinical Psychology, Madrid, ES

13:45 - 14:00 **Palliative and supportive care**
C. Ostgathe, Universität Erlangen-Nürnberg, Nürnberg, DE

14:00 - 14:15 **Reducing inequalities in Europe through robust national cancer control plans that include palliative care**
T. Albreht, National Institute of Public Health of Slovenia - Nacionalni institut za javno zdravje, Ljubljana, SI

14:15 - 14:25 **Discussion**

14:25 - 14:30 **Conclusion**

14:45 - 16:15	**Type: Special symposium** **Title: Finding the positive in triple negative breast cancer** Chair(s): Andrew Tutt, GB; Eva Ciruelos, ES	**Barcelona Auditorium - Hall 9**

14:45 - 14:50 **Introduction and scientific background**

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

14:50 - 15:05 **Integrative multiomics analysis to dissect TNBC**

S.J. Sammut, CRUK - Cancer Research UK Cambridge Institute - University of Cambridge, Cambridge, GB

15:05 - 15:20 **Targeting DNA damage response**

A. Tutt, ICR - Institute of Cancer Research, London, GB

15:20 - 15:35 **Predicting response or resistance to IO**

G. Bianchini, IRCCS Ospedale San Raffaele, Milan, IT

15:35 - 15:50 **Emerging targets in TNBC**

M. Arnedos, Institute Bergonié, Bordeaux, FR

15:50 - 16:10 **Discussion**

16:10 - 16:15 **Conclusions and perspectives**

A. Tutt, ICR - Institute of Cancer Research, London, GB

14:45 - 16:15 **Type: Special symposium** **Sevilla Auditorium - Hall 9**

Title: Molecular profiling of gynaecological cancers for therapeutic stratification

Chair(s): David SP Tan, SG; Clare Scott, AU

14:45 - 14:50 **Introduction and scientific background**

D.S. Tan, NUHS - National University Health System, Singapore, SG

14:50 - 15:05 **Molecular profiling of gynaecological cancers: A pathologist's view**

G. Mccluggage, Royal Victoria Hospital - Belfast Health and Social Care Trust HSC, Belfast, GB

15:05 - 15:20 **Endometrial cancer**

V. Makker, Memorial Sloan-Kettering Cancer Center, New York City, US

15:20 - 15:35 **Ovarian and rare gynaecological cancers**

C. Scott, Walter and Eliza Hall Institute WEHI, Parkville, AU

15:35 - 15:50 **Cervical cancer**

D.S. Tan, NUHS - National University Health System, Singapore, SG

15:50 - 16:10 **Discussion**

16:10 - 16:15 **Conclusions and perspectives**

D.S. Tan, NUHS - National University Health System, Singapore, SG

14:45 - 16:15 **Type: Special session** **Bilbao Auditorium - NCC**
Title: ESMO Clinical Practice Guidelines 2
Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR

14:45 - 14:55 **Non-oncogene-addicted metastatic NSCLC case presentation**
M. Tagliamento, Gustave Roussy - Cancer Campus, Villejuif, FR

14:55 - 15:05 **Non-oncogene-addicted metastatic NSCLC discussion**
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

15:05 - 15:15 **Q&A**

15:15 - 15:25 **Recurrent/metastatic squamous cell carcinoma of the head and neck case presentation**
C. Gurizzan, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

15:25 - 15:35 **Recurrent/metastatic squamous cell carcinoma of the head and neck discussion**

C. Even, Institut Gustave Roussy, Villejuif, Cedex, FR

15:35 - 15:45 **Q&A**

15:45 - 15:55 **Prostate cancer case presentation**
P. Rescigno, The University of Newcastle, Callaghan, AU

15:55 - 16:05 **Prostate cancer discussion**
K. Fizazi, Institut Gustave Roussy, Villejuif, Cedex, FR

16:05 - 16:15 **Q&A and Discussion**

14:45 - 16:15 **Type: Educational session** **Granada Auditorium - Hall 3**
Title: Managing stage III NSCLC in the era of IO
Chair(s): Kersti Oselin, EE; Rafal Dziadziuszko, PL

14:45 - 14:50 **Presentation of case/condition**
J. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

14:50 - 15:15 **Who should and shouldn't get surgery?**
J. Spicer, McGill University, Montreal, CA

15:15 - 15:40 **IO and chemotherapy before or after surgery?**
L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

15:40 - 16:05 **IO after or with chemoradiotherapy? For how long?**
J. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

16:05 - 16:15 **Q&A and Discussion**

14:45 - 16:20 **Type: Mini Oral session** **Burgos Auditorium - Hall 3**
Title: Mini oral session - Gastrointestinal tumours, lower digestive
Chair(s): Gunnar Folprecht, DE; Raghav Sundar, SG; Jeanne Tie, AU

14:45 - 14:50 **LBA30 - Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study**

T. Mazard[1], F. Ghiringhelli[2], A. Winter[1], C. De La Fouchardiere[3], D. Botsen[4], T. André[5], J. Vanbockstael[6], M. Dos Santos[7], J. Martin-Babau[8], Y. Rinaldi[9], L. Evesque[10], S. Ellis[11], C. Gavoille[12], D. Smith[13], M. Fonck[14], D. Sefrioui[15], V. Pezzella[16], S. Nougaret[1], A.R. Thierry[1], O. Bouche[17], [1]ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, [2]Centre Georges-François Leclerc (Dijon), Dijon, FR, [3]IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, [4]Institut Jean Godinot, Reims, FR, [5]Hopital Saint-Antoine, Paris, FR, [6]ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, [7]Centre Francois Baclesse, Caen, FR, [8]Hôpital Privé des Côtes d'Armor, Plérin, FR, [9]Marseille European Hospital, Marseille, FR, [10]Centre Anticancer Antoine Lacassagne, Nice, FR, [11]Centre Catalan d'Oncologie Clinique St. Pierre, Perpignan, FR, [12]Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, [13]Hopital Haut Leveque, Pessac, FR, [14]Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, [15]Hopital Charles-Nicolle - CHU de Rouen, Rouen, FR, [16]Unicancer, Paris, Cedex, FR, [17]CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR

14:50 - 14:55 **554MO - Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial**

Y. Li[1], D. Wang[1], C. Ren[1], S.-S. Li[2], W. Pat Fong[1], X. Wu[1], J. Xiao[2], Y. Yuan[1], B.-K. Li[1], P.-R. Ding[1], Z. Wang[1], F. Wang[1], Z. Pan[1], G. Chen[1], X.-Z. Wang[3], L.-Y. Wang[4], T. Chen[4], T. Liu[5], Y. Yuan[6], R.-H. Xu[1], [1]Sun Yat-sen University Cancer Center, Guangzhou, CN, [2]The 6th Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN, [3]Shantou Central Hospital, Shantou, CN, [4]Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CN, [5]Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, [6]The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN

14:55 - 15:00

555MO - Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13)

Y. Sunakawa[1], M. Shiozawa[2], T. Watanabe[3], H. Ota[4], H. Yasui[5], M. Kochi[6], D. Manaka[7], H. Ohori[8], T. Yamaguchi[9], M. Matsuura[10], Y. Shinohara[11], T. Miyake[12], T. Sagawa[13], C. Tanaka[14], S. Okamura[15], M. Takeuchi[16], W. Ichikawa[17], M. Fujii[18], A. Tsuji[19], [1]St. Marianna University School of Medicine, Kawasaki, JP, [2]Kanagawa Cancer Center, Yokohama, JP, [3]Japanese Red Cross Society Himeji Hospital, Himeji, JP, [4]Ikeda City Hospital, Ikeda, JP, [5]Kobe City Medical Center General Hospital, Kobe, JP, [6]Nihon University School of Medicine, Tokyo, JP, [7]Kyoto-Katsura Hospital, Kyoto, JP, [8]Japanese Red Cross Ishinomaki Hospital, Miyagi, Miyagi, JP, [9]Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP, [10]Kobe City Nishi-Kobe Medical Center, Kobe, JP, [11]JCHO - Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, JP, [12]Shiga University of Medical Science, Otsu, JP, [13]Hokkaido Cancer Center, Sapporo, JP, [14]Gifu Prefectural General Medical Center, Gifu, JP, [15]Suita Municipal Hospital, Suita, JP, [16]The University of Tokyo, Tokyo, JP, [17]Showa University Fujigaoka Hospital, Yokohama, JP, [18]Japan Clinical Cancer Research Organization, TOKYO, JP, [19]Kagawa University Faculty of Medicine/Graduate School of Medicine, Miki, JP

15:00 - 15:15

Invited Discussant LBA30, 554MO and 555MO

G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE

15:15 - 15:20

LBA31 - Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study

Y. Verschoor[1], J. Van Den Berg[1], S. Balduzzi[1], J. Van Blijderveen[1], S. Oosterling[2], P. Burger[3], T. Aukema[4], T. Vogten[5], S. Dokter[1], R. Beets-Tan[6], A. Lent[7], G. Beets[1], M. Van Leerdam[1], J. Haanen[1], M. Chalabi[1], [1]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [2]Spaarne Hospital Hoofddorp, Hoofddorp, NL, [3]Catharina Hospital Eindhoven, Eindhoven, NL, [4]Hagaziekenhuis, Den Haag, NL, [5]Tergooi Ziekenhuizen, Blaricum, NL, [6]Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, [7]OLVG Hospital, Amsterdam, NL

15:20 - 15:25

556MO - A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer

F. Wang[1], Y. Jin[1], H.-Y. Luo[1], W.-L. Guan[1], Y. Li[1], F. Wang[1], M. Qiu[1], L.-L. Liu[2], X. Hu[3], Y. Zhang[4], W. Fang[2], Z.-X. Wang[1], C. Ren[1], D. Wang[1], R.-H. Xu[1], [1]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, CN, [2]The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, CN, [3]The First Affiliated Hospital of

Guangxi Medical University, Nanning, CN, [4]Cancer Hospital Affiliated to Harbin Medical University, Harbin, CN

15:25 - 15:30

LBA32 - Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study

K.-K. Shiu[1], T. André[2], T.W. Kim[3], B. Vittrup Jensen[4], L.H. Jensen[5], C. Punt[6], D. Smith[7], R. Garcia-Carbonero[8], J. Alcaide-Garcia[9], P. Gibbs[10], C. De La Fouchardiere[11], F. Rivera[12], M.E. Elez Fernandez[13], D. Le[14], T. Yoshino[15], Y. Zuo[16], D. Fogelman[17], D. Adelberg[17], L. Diaz[18], [1]University College Hospital, NHS Foundation Trust, London, GB, [2]Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM 938, SIRIC CURAMUS, Paris, FR, [3]Asan Medical Center, University of Ulsan, Seoul, KR, [4]Herlev and Gentofte Hospital, Herlev, DK, [5]University Hospital of Southern Denmark, Vejle, DK, [6]Amsterdam University Medical Center, University of Amsterdam, Amsterdam Netherlands, and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, NL, [7]Bordeaux University Hospital, Bordeaux, FR, [8]Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, ES, [9]Hospitales Universitarios Regional y Virgen de la Victoria IBIMA, Malaga, ES, [10]Western Health, St. Albans, AU, [11]Centre Léon Bérard, Lyon, FR, [12]Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, ES, [13]Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology, Barcelona, ES, [14]Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, US, [15]National Cancer Center Hospital East, Kashiwa, JP, [16]MSD China, Beijing, CN, [17]Merck & Co., Inc., Rahway, US, [18]Memorial Sloan Kettering Cancer Center, New York, US

15:30 - 15:35

557MO - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial

C. Coutzac[1], F. Bigot[2], D. Vansteene[3], M. Dos Santos[4], F. Ghiringhelli[5], B. You[6], A. Lambert[7], C. Gomez-Roca[8], C. Abdeddaim[9], C. Neuzillet[10], E. Jeannot[10], E. Guerini Rocco[11], G. Frige[12], L. Mazzarella[12], C. Dupain[10], M. Kamal[10], F. Legrand[13], M. Jimenez[14], T. Filleron[15], C. Le Tourneau[2], [1]Centre Léon Bérard, Lyon, FR, [2]ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, [3]ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, [4]Centre Francois Baclesse, Caen, FR, [5]Centre Georges-François Leclerc (Dijon), Dijon, FR, [6]Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, [7]Capsule Corp, Nancy, FR, [8]Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, [9]Centre Oscar Lambret, Lille, FR, [10]Institut Curie, Paris, FR, [11]IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, [12]IEO - Istituto Europeo di Oncologia, Milan, IT, [13]Unicancer, Paris, Cedex, FR, [14]Unicancer, Paris, FR, [15]Institut Claudius Regaud - IUCT Oncopole, Toulouse, Cedex, FR

15:35 - 15:50

Invited Discussant LBA31, 556MO, LBA32 and 557MO

R. Sundar, NUHS - National University Health System, Singapore, SG

15:50 - 15:55

558MO - Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): An updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)

Y. Nakamura[1], D. Kotani[2], M. Saori[2], H. Yukami[3], J. Watanabe[4], N. Akazawa[5], K.

Kataoka[6], K. Hirata[7], K. Yamazaki[8], K.-H. Yeh[9], G. Laliotis[10], V. Aushev[10], A. Jurdi[10], M. Kotaka[11], H. Bando[2], H. Taniguchi[12], I. Takemasa[13], T. Kato[14], T. Yoshino[1], E. Oki[15], [1]National Cancer Center Hospital East, 柏市柏の葉--, JP, [2]National Cancer Center Hospital East, Kashiwa, JP, [3]Osaka Medical and Pharmaceutical University Hospital, Takatsuki, JP, [4]Yokohama City University Medical Center, Yokohama, JP, [5]Sendai City Medical Center Sendai Open Hospital, Sendai, JP, [6]Hyogo College of Medicine, Nishinomiya, JP, [7]University of Occupational and Environmental Health, Kitakyushu, JP, [8]Shizuoka Cancer Center, Shizuoka, JP, [9]NTUH - National Taiwan University Hospital, Taipei City, TW, [10]Natera, Inc., San Carlos, US, [11]Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, [12]Aichi Cancer Center Hospital, Nagoya, JP, [13]Sapporo Medical University School of Medicine, Sapporo, JP, [14]National Hospital Organization Osaka National Hospital, Osaka, JP, [15]Kyushu University - Graduate School of Medical Sciences - Faculty of Medical Sciences, Fukuoka, JP

15:55 - 16:00

559MO - Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: Individual patients’ data pooled analysis from 4 phase II trials

D. Ciardiello[1], G. Mauri[2], D. Rossini[3], V. Famiglietti[4], G. Martini[5], S. Napolitano[5], S. Del Tufo[4], M.G. Zampino[6], A. Avallone[7], F. Pietrantonio[8], S. Lonardi[9], D. Santini[10], G. Masi[11], S. Siena[12], A. Bardelli[13], F. Ciardiello[5], C. Cremolini[11], A. Sartore Bianchi[14], T. Troiani[5], E. Martinelli[5], [1]IEO, Milan, IT, [2]IFOM, Milan, IT, [3]Università di Pisa, Pisa, IT, [4]Università degli Studi della Campania Luigi Vanvitelli, Caserta, IT, [5]Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, [6]IEO - Istituto Europeo di Oncologia, Milan, IT, [7]Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, [8]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [9]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [10]Università degli Studi di Roma la Sapienza - Facoltà di Medicina, Latina, IT, [11]AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, [12]UNIMI - Università degli Studi di Milano Statale, Milan, IT, [13]IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, [14]Università degli Studi di Milano, Milan, IT

16:00 - 16:05

560MO - Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial

P. García Alfonso[1], M.E. Elez Fernandez[2], J. Soto Alsar[1], D. Paez[3], A. Fernandez Montes[4], B. Grana Suarez[5], A. Salud[6], A. Yubero Esteban[7], M.A. Gomez España[8], I. Macias Declara[9], G.A. Quintero Aldana[10], C. Lopez Lopez[11], T. Fernandez Rodriguez[12], M.C. Gravalos Castro[13], E. González-Flores[14], M. Guix Arnau[15], B. García Paredes[16], J.J. Reina Zoilo[17], J. Sastre Varela[16], E. Aranda Aguilar[8], [1]Gregorio Marañon General University Hospital, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, ES, [2]Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, ES, [3]Hospital de la Santa Creu i Sant Pau, Barcelona, ES, [4]Complexo Hospitalario Universitario de Ourense, Ourense, ES, [5]Hospital Universitario de A Coruña. Instituto Investigación Biomédica INIBIC, A Coruña, ES, [6]Hospital de Lleida Arnau de Vilanova, Lleida, ES, [7]Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, [8]Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III. Hospital Universitario Reina Sofía, Cordoba, ES, [9]Hospital Parc Taulí de Sabadell, Barcelona, ES, [10]Hospital Universitario Lucus Augusti (HULA), Lugo, ES, [11]Hospital Marqués de Valdecilla, IDIVAL, UNICAN, Santander, ES, [12]Hospital Son Llatzer, Palma de Mallorca, ES, [13]Hospital Universitario 12 de Octubre, Madrid, ES, [14]Hospital Universitario Virgen

de las Nieves, Granada, ES, [15]Hospital del Mar, Barcelona, ES, [16]Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, ES, [17]Complejo Hospitalario Virgen de la Macarena, Seville, ES

16:05 - 16:20 **Invited Discussant 558MO, 559MO and 560MO**

J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU

14:45 - 16:15 **Type: Multidisciplinary session** **Valencia Auditorium - Hall 10**
Title: Pancreatic cancer: Evidence based options to improve quality of life and extend survival
Chair(s): Stephen Chan, HK; Radka Obermannova, CZ

14:45 - 14:50 **Case/Condition presentation**

S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

14:50 - 15:05 **Endoscopic management of obstructive jaundice: What clinicians should know?**

R. Tang, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

15:05 - 15:20 **Pain management and palliative care**

A. Epstein, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

15:20 - 15:35 **Malignant ascites**

J. Herre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB

15:35 - 15:50 **Nutrition and exercise**

R. Obermannova, Masaryk Memorial Cancer Institute, Brno, CZ

15:50 - 16:05 **Radiotherapy**

L. Dawson, Princess Margaret Cancer Centre, Toronto, CA

16:05 - 16:15 **Discussion**

14:45 - 16:15	**Type: Educational session** **Title: Neoadjuvant and adjuvant therapy in genitourinary cancers** Chair(s): Srikala Sridhar, CA; Axel Bex, GB	**Salamanca Auditorium - Hall 3**

14:45 - 15:05 **State-of-the-art in adjuvant treatment of renal cell carcinoma**

G.A. De Velasco Oria, Hospital Universitario 12 de Octubre, Madrid, ES

15:05 - 15:25 **State-of-the-art in adjuvant treatment of urothelial cancer**

M. De Santis, Charité - Universitätsmedizin Berlin, Berlin, DE

15:25 - 15:45 **Interpretation of current peri-operative trial designs and endpoints**

S. Sridhar, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

15:45 - 16:05 **Global access considerations in systemic treatment of genitourinary cancers**

F.A. Barros Schutz, Beneficencia Portuguesa de Sao Paulo - BP Mirante, Sao Paulo, BR

16:05 - 16:15 **Discussion**

14:45 - 16:15 **Type: Multidisciplinary session** **Málaga Auditorium - Hall 10**
Title: Early-stage (II/III) melanoma: Risk stratification and treatment decisions
Chair(s): Mathilde Jalving, NL; Dirk Schadendorf, DE

14:45 - 14:50 **Presentation of case/condition**
P. Sobczuk, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

14:50 - 15:05 **A pathologist's perspective: What to look for and how to report it**
B. Bastian, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

15:05 - 15:20 **A dermatologist's perspective: Secondary prevention and risk stratifications strategies**
D. Schadendorf, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

15:20 - 15:35 **Further development of the clinical case: A surgeon's perspective – Do we still need surgery in the era of risk scores stratification and systemic therapy?**
A. Van Akkooi, Melanoma Institute Australia, Wollstonecraft, AU

15:35 - 15:50 **Further development of the clinical case: A medical oncologist's perspective – Do all patients need adjuvant systemic therapy and how does this influences therapy in advanced setting?**
M. Jalving, UMCG - University Medical Center Groningen, Groningen, NL

15:50 - 16:15 **Discussion**

14:45 - 16:15 **Type: Educational session** **Santander Auditorium - Hall 9**
Title: Intensification vs descalation of therapy in H&N cancer: When and for whom?
Chair(s): Amanda Psyrri, GR; Jens Peter Klussmann, DE

14:45 - 15:10 **Novel strategies to de-escalate surgery**
R. Ferris, University of Pittsburgh Cancer Institute, Pittsburgh, US

15:10 - 15:35 **De-escalation in radiation and systemic therapy**
A. Psyrri, Attikon University Hospital, Haidari, GR

15:35 - 16:00 **Which patients need more intensive treatment?**
J. Bourhis, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

16:00 - 16:15 **Q&A and Discussion**

14:45 - 16:15 **Type: Special symposium** **Oviedo Auditorium - Hall 7**
Title: Advances in our understanding of paraganglioma / pheochromocytoma

Chair(s): Margot Tesselaar, NL; Patricia Dahia, US

14:45 - 14:50 **Introduction and scientific background**

M. Tesselaar, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:50 - 15:05 **The genetics of paraganglioma (PPGL) and implications for testing and screening**

M. Robledo, CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES

15:05 - 15:20 **Perioperative considerations and management of localised disease**

M. Tesselaar, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:20 - 15:35 **Targeted radionuclide therapy for advanced disease/theranostics**

J. Kunikowska, University of Warsaw, Warsaw, PL

15:35 - 15:50 **The treatment landscape for metastatic PPGL: Are we making progress?**

P. Dahia, UTHSCSA - University of Texas Health Science Center at San Antonio, San Antonio, US

15:50 - 16:10 **Discussion**

16:10 - 16:15 **Conclusions and perspectives**

P. Dahia, UTHSCSA - University of Texas Health Science Center at San Antonio, San Antonio, US

14:45 - 16:15	**Type: Special session** **Title: In collaboration with the MASCC - The multiple faces of fatigue in the cancer ecosystem** Chair(s): Christina Ruhlmann, DK; Florian Scotté, FR	**León Auditorium - Hall 7**

14:45 - 15:05 **The epidemiology, biology and aetiology of cancer-related fatigue**
F. Scotté, Institut Gustave Roussy, Villejuif, FR

15:05 - 15:25 **Fatigue in health care professionals: Another term for burnout?**
K. Punie, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:25 - 15:45 **Systemic anticancer therapy-related fatigue: Causes and management**
C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

15:45 - 16:05 **Fatigue related to emerging targeted anticancer therapeutics**
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

16:05 - 16:15 **Panel discussion / Q&A**

14:45 - 16:15	**Type: Educational session** **Title: Oncology drug trials: How can we bring true value for patients?** Chair(s): Ian Tannock, CA; E.G. Elisabeth de Vries, NL	**Cádiz Auditorium - NCC**

14:45 - 15:05 **Challenges, pitfalls and the way forward: Investigator's perspective**
I. Tannock, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

15:05 - 15:25 **Walking the tightrope without losing sight of the patient**
K. Yonemori, National Cancer Center - Tsukiji Campus, Chuo-ku, JP

15:25 - 15:40 **Clinical trials in oncology: What really matters to patients?**
T. Lang, Myeloma Patients Europe AISBL, Brussels, BE

15:40 - 16:00 **"Value" and what it really means for new cancer drugs**
A. Fojo, Columbia University, New York, US

16:00 - 16:15 **Q&A and Discussion**

14:45 - 17:45 **Type: Young Oncologists session** **Ávila Auditorium - NCC**
Title: YO Masterclass: Tackling new challenges facing young investigators

Chair(s): Kok Haw Jonathan Lim, GB; Elizabeth Connolly, AU

14:45 - 15:10 **Bridging the gap between basic science and clinical research**
C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

15:10 - 15:25 **Discussion**

15:25 - 15:50 **Investigator-initiated trials: From design to activation**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

15:50 - 16:05 **Discussion**

16:05 - 16:25 **Coffee break**

16:25 - 16:50 **Preprints from medRxiv and bioRxiv: Should I trust them?**
L. Rowett, ESMO - European Society for Medical Oncology, Lugano, CH

16:50 - 17:05 **Discussion**

17:05 - 17:30 **Interpreting clinical trial data: How to understand subgroup analyses**
S. Brown, University of Leeds - Leeds Institute of Molecular Medicine (LIMM), Leeds, GB

17:30 - 17:45 **Discussion**

15:00 - 15:45	**Type: Challenge your Expert** **Title: Tertiary lymphoid structures: The control centre of immune responses against tumors** Chair(s): Daniela Thommen, NL	**Toledo Auditorium - Hall 3**

15:00 - 15:20 **Presentation by Expert**

C. Sautes-Fridman, Centre de Recherche des Cordeliers, Paris, FR

15:20 - 15:45 **Discussion led by Chair**

D. Thommen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:00 - 16:30 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Palliative and end-of-life care
Chair(s): Tugba Pehlivan Sarıbudak, TR

15:00 - 15:15 **Co-design of a web-based resource for head and neck cancer patients using the person-based approach**
C. Semple, Ulster Hospital - South Eastern Health and Social Care Trust, Dundonald, GB

15:15 - 15:30 **Managing Cancer and Living Meaningfully (CALM) for oncology nurses**
M. Van Klinken, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

15:30 - 15:45 **The journey of persons with genitourinary malignancies: Nurses' perspective on supportive and palliative care**
S. Terzoni, Ospedale San Paolo - ASST Santi Paolo e Carlo, Milan, IT

15:45 - 15:55 **CN25 - Psycho-education and telephone counselling on the quality of life of advanced cancer patients undergoing chemotherapy in Indonesia**
N. Huda, W.N. Dewi, H. Deli, Universitas Riau, Pekanbaru, ID

15:55 - 16:05 **CN26 - Healthcare professionals’ perceptions on palliative care in onco-haematological area: Validation of the palliative care perception instrument**
T. Buttiron Webber[1], G. Pegoraro[2], I. Lima[2], G. Catania[2], M. Calzolari[2], M. Zanini[2], L. Sasso[2], A. Bagnasco[2], [1]Ente Ospedaliero Ospedali Galliera, Genova, IT, [2]University of Genoa, Genova, IT

16:05 - 16:15 **CN27 - Pain in men with metastatic castration-resistant prostate cancer (mCRPC) starting their first-line of life prolonging treatment: A cross sectional study in Sweden**
U. Rönningås[1], M. Holm[2], P. Fransson[3], L. Beckman[4], A. Wennman-Larsen[1], [1]Karolinska Institutet, Stockholm, SE, [2]Sophiahemmet Universty, Stockholm, SE, [3]Umea University, Umea, SE, [4]Sundsvalls sjukhus, Sundsvall, SE

16:15 - 16:30 **Q&A and discussion**

16:30 - 18:00 **Type: Mini Oral session** **Burgos Auditorium - Hall 3**
Title: Mini oral session - NETs and endocrine tumours
Chair(s): Mauro Cives, IT; Sara De Dosso, CH; Jaydira Del Rivero, US

16:30 - 16:35 **2211MO - Uncovering the mechanisms of persistent disease in RET-altered thyroid cancers: Insights from patient-derived xenograft models treated with selective RET inhibitors**
A. Garcia Alvarez[1], J. Hernando[2], I. Chicote[2], J. Martínez-Quintanilla[3], A. Carmona[3], C. Iglesias[1], X. Serres Créixams[1], J. Jimenez[4], P. Nuciforo[4], S. Aguilar Izquierdo[1], J. Gonzalo[4], A. Vivancos[1], H.G. Palmer[3], J. Capdevila Castillon[1], [1]Vall d'Hebron University

Hospital, Barcelona, ES, [2]Hospital Universitario Vall d'Hebron, Vall d´Hebron Institut of Oncology (VHIO), Barcelona, ES, [3]VHIO - Vall d'Hebron Institute of Oncology, Barcelona, ES, [4]Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

16:35 - 16:40

1183MO - Molecular characterization of rectal neuroendocrine tumors (NETs) with unfavorable prognosis by multiomics analysis: A multicenter retrospective cohort study (GARNET)

T. Shibuki[1], N. Mizuno[2], N. Kobayashi[3], H. Hirano[4], T. Tsuchikawa[5], S. Matsumoto[6], H. Okuyama[7], E. Sasaki[8], K. Shinjo[9], R. Yamaguchi[10], T. Kawata[11], W. Hosoda[2], [1]National Cancer Center Hospital East, Chiba, JP, [2]Aichi Cancer Center Hospital, Aichi, JP, [3]Yokohama City University Hospital, Kanagawa, JP, [4]National Cancer Center Hospital, Tokyo, JP, [5]Hokkaido University Hospital, Hokkaido, JP, [6]Kyoto University Hospital, Kyoto, JP, [7]Kagawa University Hospital, Kagawa, JP, [8]Fukushima Medical University Hospital, Fukushima, JP, [9]Nagoya University Graduate School of Medicine, Aichi, JP, [10]Aichi Cancer Center Research Institute, Aichi, JP, [11]Novartis Pharma K.K., Tokyo, JP

16:40 - 16:55

Invited Discussant 2211MO and 1183MO

M. Cives, Università degli Studi di Bari Aldo Moro, Bari, IT

16:55 - 17:00

1184MO - Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)

M. Pavel[1], L. Fischer Von Weikersthal[2], G. Klöppel[3], K. Krause[4], L. Apostolidis[5], [1]Universitätsklinik Erlangen, Erlangen, DE, [2]Klinikum St. Marien Amberg, Amberg, DE, [3]Technical University Munich, München, DE, [4]AIO-Studien-gGmbH, Berlin, DE, [5]National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE

17:00 - 17:05

1185MO - Activity and safety of avelumab alone or in combination with cabozantinib in patients with advanced high grade neuroendocrine neoplasias (NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter AVENEC and CABOAVENEC trials

M.M. Weber[1], L. Apostolidis[2], S. Krug[3], A. Rinke[4], B. Gruen[2], P. Michl[5], T. Gress[4], D. Wagner[1], W. Roth[1], E. Mettler[1], C. Ruckes[1], P. Galle[1], C. Fottner[6], [1]Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, [2]National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE, [3]UKH - Universitätsklinikum Halle (Saale), Halle (Saale), DE, [4]UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, [5]UKHD - Universitätsklinikum Heidelberg, Heidelberg, DE, [6]Universitätsmedizin Mainz, Mainz, DE

17:05 - 17:10

725MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas

V. Gambardella[1], J. Capdevila Castillon[2], Y. Kuboki[3], O. Alese[4], D. Morgensztern[5], C.M. Sayehli[6], M.F. Sanmamed[7], E. Arriola[8], Z. Oum'Hamed[9], E. Song[10], M. Studeny[11], M. Wermke[12], [1]Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, ES, [2]Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncologyology, Barcelona, ES, [3]National Cancer Center Hospital East, Kashiwa, JP, [4]Winship Cancer Institute of Emory University, Atlanta, US, [5]Washington University School of Medicine, St. Louis, US, [6]Medical Clinic and Polyclinic II of the

University Hospital, Würzburg, DE, [7]Clínica Universidad de Navarra, Pamplona, ES, [8]Hospital del Mar - CIBERONC (Centro de Investigación Biomédica en Red de Oncología), Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, ES, [9]Boehringer Ingelheim France SAS, Paris, FR, [10]Boehringer Ingelheim (China) Investment Co., Shanghai, CN, [11]Boehringer Ingelheim International GmbH, Ingelheim, DE, [12]NCT/UCC Early Clinical Trial Unit, Dresden, DE

17:10 - 17:25 **Invited Discussant 1184MO, 1185MO and 725MO**

S. De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

17:25 - 17:30 **1186MO - A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE followed by surgery for pancreatic neuroendocrine tumors (NeoLuPaNET)**

S. Partelli[1], L. Landoni[2], M. Bartolomei[3], A. Zerbi[4], C. Grana[5], U. Boggi[6], G. Butturini[7], R. Casadei[8], C. Bassi[2], M. Falconi[9], [1]UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT, [2]AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT, [3]Arcispedale Sant'Anna - AOU di Ferrara, Ferrara, IT, [4]Department of Biomedical Sciences, Humanitas University, Milan, IT, [5]IEO - Istituto Europeo di Oncologia, Milan, IT, [6]Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, [7]Ospedale P. Pederzoli Casa di Cura Privata Spa, Peschiera Del Garda, IT, [8]University of Bologna - Alma Mater Studiorum, Bologna, IT, [9]IRCCS Ospedale San Raffaele, Milan, IT

17:30 - 17:35 **2212MO - Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radioiodine necessary for low-risk differentiated thyroid cancer patients?**

A. Hackshaw[1], K. Newbold[2], M. Beasley[3], K. Garcez[4], J. Wadsley[5], S. Johnson[6], T. Stephenson[7], M. Gaze[8], A. Goodman[9], S. Jeffries[10], D. Wilkinson[11], E. Macias[12], D. Power[13], T. Roques[14], L. Speed[15], G. Gerrard[16], S. Forsyth[1], E. Chang[1], K. Farnell[17], U. Mallick[18], [1]Cancer Research UK & University College London Cancer Trials Centre, London, GB, [2]The Royal Marsden Hospital (Sutton), Sutton, GB, [3]BHOC - Bristol Haematology and Oncology Centre, Bristol, GB, [4]The Christie NHS Foundation Trust, Manchester, GB, [5]Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, [6]Newcastle General Hospital Northern Centre for Cancer Treatment, Newcastle-upon-Tyne, GB, [7]Northern General Hospital-Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, [8]University College London Hospitals NHS Foundation Trust, London, GB, [9]RD&E - Royal Devon and Exeter Hospital (Wonford), Exeter, GB, [10]Addenbrooke's Hospital, Cambridge, GB, [11]The James Cook University Hospital, Middlesbrough, GB, [12]Kent and Canterbury Hospital, Canterbury, GB, [13]St. Mary's Hospital Imperial College Healthcare NHS Trust, London, GB, [14]Norfolk and Norwich University Hopsital NHS Foundation Trust, Norwich, GB, [15]Leicester Royal Infirmary, Leicester, GB, [16]Leeds Cancer Centre, Leeds, GB, [17]Butterfly Thyroid Cancer Trust, Newcastle, GB, [18]Newcastle Freeman Hospital - Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, GB

17:35 - 17:40 **1187MO - Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France?**

R. Libe[1], G. Coureau[2], A.-S. Foucan[2], M. Haissaguerre[3], D. Drui[4], S. Grunenwald[5], F.

Castinetti[6], S. Laboureau[7], C. Docao[8], F. Borson-Chazot[9], B. Goichot[10], L. Lamartina[11], O. Chabre[12], S. Moog[11], J. Bertherat[13], A. Tabarin[14], M. Faron[15], E. Baudin[11], [1]Hopital Cochin - Site Port-Royal AP-HP, Paris, FR, [2]CHU - Centre Universitaire Hospitalier de Bordeaux, Bordeaux, FR, [3]CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, FR, [4]CHU de Nantes, Hôtel Dieu, Nantes, FR, [5]Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, [6]Aix-Marseille University - Faculté de Médecine - Timone, Marseille, FR, [7]CHU Angers, Angers, Cedex, FR, [8]CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, [9]Hospices Civils de Lyon, Bron, FR, [10]Hopital de Hautepierre - Hopitaux Universitaires de Strasbourg, Strasbourg, FR, [11]Gustave Roussy - Cancer Campus, Villejuif, FR, [12]CHU Grenoble Alpes - Site Nord (La Tronche), La Tronche, FR, [13]Institut Cochin, Paris, FR, [14]University of Bordeaux, Bordeaux, FR, [15]Institut Gustave Roussy, Villejuif, FR

17:40 - 17:55 **Invited Discussant 1186MO, 2212MO and 1187MO**

J. Del Rivero, NIH - National Institutes of Health, Bethesda, US

16:30 - 18:15 **Type: Proffered Paper session** **Madrid Auditorium - Hall 6**
Title: Presidential 2

Chair(s): Andres Cervantes, ES; Silke Gillessen, CH

16:30 - 16:42 **LBA6 - EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)**

T. Powles[1], B. Perez Valderrama[2], S. Gupta[3], J. Bedke[4], E. Kikuchi[5], J. Hoffman-Censits[6], G. Iyer[7], C. Vulsteke[8], S.H. Park[9], S.J. Shin[10], D. Castellano Gauna[11], G. Fornarini[12], J.-R. Li[13], M. Gumus[14], N. Mar[15], S. Narayanan[16], X. Yu[16], S. Gorla[17], B. Homet Moreno[18], M. Van Der Heijden[19], [1]Saint Barts Cancer Institute, Queen Mary University of London,, London, GB, [2]Hospital Universitario Virgen del Rocio, Seville, ES, [3]Taussig Cancer Center-Cleveland Clinic, Cleveland, US, [4]Klinikum Stuttgart Katharinenhospital (KH), Stuttgart, DE, [5]St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, JP, [6]Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, [7]Memorial Sloan Kettering Cancer Center, New York, US, [8]AZ Maria Middelares AZMMSJ, Gent, BE, [9]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [10]Yonsei University College of Medicine, Seoul, KR, [11]Hospital Universitario 12 de Octubre, Madrid, ES, [12]Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, IT, [13]Taichung Veterans General Hospital, Taichung City, TW, [14]Istanbul Medeniyet University, Yalcin City Hospital, Istanbul, TR, [15]UCI Health - University of California Irvine, Orange, US, [16]Seagen Inc., Bothell, US, [17]Astellas Pharma USA, Northbrook, US, [18]Merck, Rahway, US, [19]Netherlands Cancer Institute, Amsterdam, NL

16:42 - 16:54 **LBA7 - Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial**

M. Van Der Heijden[1], G. Sonpavde[2], T. Powles[3], A. Necchi[4], M. Burotto[5], M. Schenker[6], J.P. Sade[7], A. Bamias[8], P. Beuzeboc[9], J. Bedke[10], J. Oldenburg[11], Y. Urun[12], D. Ye[13], Z. He[14], B. Perez Valderrama[15], Y. Tomita[16], J. Filian[17], D. Purcea[18], F. Nasroulah[17], M. Galsky[19], [1]Netherlands Cancer Institute, Amsterdam, NL, [2]Dana-Farber Cancer Institute,

Harvard Medical School, Boston, US, [3]Barts Cancer Institute, Queen Mary University of London, London, GB, [4]Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, [5]Bradford Hill-Clinical Center, Santiago, CL, [6]Sf. Nectarie Oncology Center Craiova, Craiova, RO, [7]Alexander Fleming Institute, Buenos Aires, AR, [8]National & Kapodistrian University of Athens, ATTIKON University Hospital, Athens, GR, [9]Hopital Foch, Suresnes, FR, [10]Eberhard Karls University Tübingen, Tübingen, DE, [11]Akershus University Hospital (Ahus), Lorenskog, NO, [12]Ankara University, Ankara, TR, [13]Fudan University Shanghai Cancer Center, Shanghai, CN, [14]Peking University First Hospital, Beijing, CN, [15]Hospital Universitario Virgen del Rocio, Seville, ES, [16]Niigata University Graduate School of Medical and Dental Sciences, Niigata, JP, [17]Bristol Myers Squibb, Princeton, US, [18]Bristol Myers Squibb, Boudry, CH, [19]Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US

16:54 - 17:04 **Invited Discussant LBA6 and LBA7**

A. Apolo, National Cancer Institute, Bethesda, US

17:04 - 17:10 **Q&A**

17:10 - 17:22 **LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial**

M. Mccormack[1], D. Gallardo Rincón[2], G. Eminowicz[3], P. Diez[4], L. Farrelly[5], C. Kent[6], E. Hudson[7], M. Panades[8], T. Mathews[9], A. Anand[10], M. Persic[11], J. Forrest[12], R. Bhana[13], N. Reed[14], A. Drake[15], H. Stobart[16], A. Mukhopadhyay[17], A.M. Hacker[18], A. Hackshaw[5], J. Ledermann[19], [1]University College London Hospital, London, GB, [2]The National Cancer Institute, Ciudad de Mexico, MX, [3]UCH - University College Hospital, London, GB, [4]Mount Vernon Cancer Centre, Northwood, GB, [5]Cancer Research UK & University College London Cancer Trials Centre, London, GB, [6]Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, [7]Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, [8]United Lincolnshire Hospitals - Lincoln County Hospital, Lincoln, GB, [9]Northern General Hospital-Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, [10]Nottingham City Hospital, Nottingham, GB, [11]Royal Derby Hospital - University Hospitals of Derby and Burton NHS Foundation Trust, Derby, GB, [12]Royal Devon and Exeter NHS Hospital (Wonford) - Royal Devon and Exeter Foundation Trust, Exeter, GB, [13]Royal Stoke University Hospital, Stoke-on-Trent, GB, [14]BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, [15]Belfast City Hospital - Belfast Health & Social Care Trust, Belfast, GB, [16]Independent Cancer Patients Voice, London, GB, [17]CNCI - Chittaranja National Cancer Institute, Kolkata, IN, [18]UCL - University College London, London, GB, [19]UCL Cancer Institute - UCL - London's Global University, London, GB

17:22 - 17:34 **LBA9 - innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer**

I. Vergote[1], A. Gonzalez Martin[2], K. Fujiwara[3], E. Kalbacher[4], A. Bagameri[5], S. Ghamande[6], J.-Y. Lee[7], S. Banerjee[8], F. Maluf[9], D. Lorusso[10], K. Yonemori[11], E. Van

Nieuwenhuysen[1], L. Manso[12], L. Woelber[13], A. Westermann[14], A. Covens[15], E. Whalley[16], M.S.L. Teng[16], I. Soumaoro[17], B. Slomovitz[18], [1]Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and Belgium and Luxembourg Gynaecological Oncology Group, Belgium, European Union, Leuven, BE, [2]Cancer Center Clinica Universidad de Navarra, Madrid, Spain and GEICO, Madrid, ES, [3]Saitama Medical University International Medical Center, Saitama, JP, [4]Centre Hospitalier Universitaire de Besançon, Besancon, FR, [5]Országos Onkológiai Intézet, Budapest, HU, [6]Georgia Cancer Center, August University, Augusta, US, [7]Yonsei University College of Medicine, Seoul, KR, [8]The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, [9]Hospital Beneficencia Portuguesa of Sao Paulo, Sao Paulo, BR, [10]Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome and Catholic University of Sacred Heart, Rome, IT, [11]National Cancer Center - Tsukiji Campus, Chuo-ku, JP, [12]Hospital Universitario 12 de Octubre, Madrid, ES, [13]Arbeitsgemeinschaft Gynäkologische Onkologie Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, DE, [14]Amsterdam University Medical Centres, Amsterdam, NL, [15]Sunnybrook Research Institue, Toronto, CA, [16]Seagen Inc., Bothell, US, [17]Genmab, Princeton, US, [18]Mount Sinai Medical Center, Miami Beach, US

17:34 - 17:44 **Invited Discussant LBA8 and LBA9**

K. Tewari, UC Irvine Medical Center, Orange, US

17:44 - 17:50 **Q&A**

17:50 - 18:02 **LBA10 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study**

F. Pietrantonio[1], L. Salvatore[2], T. Esaki[3], D. Modest[4], D. Paez[5], J. Taieb[6], M. Karamouzis[7], E. Ruiz[8], T.W. Kim[9], Y. Kuboki[10], F. Meriggi[11], D. Cunningham[12], K.-H. Yeh[13], E. Chan[14], J. Chao[15], N. Strydom[16], Y. Saportas[17], Q. Tran[17], C. Cremolini[18], M. Fakih[19], [1]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [2]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, [3]National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, [4]Charité - Universitaetsmedizin Berlin, Berlin, DE, [5]Hospital de la Santa Creu i Sant Pau, Barcelona, ES, [6]Hopital European George Pompidou, Paris, FR, [7]National and Kapodistrian University of Athens - School of Medicine, Athens, GR, [8]INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, MX, [9]Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, [10]National Cancer Center Hospital East, Kashiwa, JP, [11]Fondazione Poliambulanza Istituto Ospedaliero, Brescia, IT, [12]The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, [13]NTUH - National Taiwan University Hospital, Taipei City, TW, [14]Amgen, Thousand Oaks, US, [15]AMGEN - USA, Seattle, US, [16]Amgen Inc - SSF, South San Francisco, US, [17]AMGEN (Headquarters) - USA, Thousand Oaks, US, [18]AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, [19]City of Hope Comprehensive Cancer Center, Duarte, US

18:02 - 18:10 **Invited Discussant LBA10**

M. Koopman, UMC - University Medical Center Utrecht, Utrecht, NL

18:10 - 18:15 **Q&A**

16:30 - 18:00 **Type: Educational session** **Valencia Auditorium - Hall 10**
Title: ESMO Guideline updates on supportive and palliative care
Chair(s): Florian Scotté, FR; Christina Ruhlmann, DK

16:30 - 16:55 **Antiemetics**
J. Herrstedt, ZUH - Zealand University Hospital Roskilde - Region Sjaelland, Roskilde, DK

16:55 - 17:20 **Anxiety, depression and insomnia**
R. Ródenas, Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES

17:20 - 17:45 **Prognostication in advanced cancer: Navigating the uncertainty**
P. Stone, University College London, London, GB

17:45 - 18:00 **Q&A and Discussion**

16:30 - 18:00 **Type: Proffered Paper session** **Toledo Auditorium - Hall 3**
Title: Proffered paper session - Haematological malignancies
Chair(s): Davide Rossi, CH; Alessandra Tedeschi, IT

16:30 - 16:40 **822O - Activation of γ9δ2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed/refractory hematologic cancers (EVICTION trial)**
S. Garciaz[1], S. Champiat[2], P. Peterlin[3], K. Lemmens[4], A. De Gassart[4], P. Brune[4], E. Valentin[4], C. Leparquier[5], M. Iche[5], D. Olive[6], N. Vey[7], P. Frohna[4], [1]Institut Paoli-Calmettes, Aix-Marseille University, Marseille, FR, [2]Gustave Roussy - Cancer Campus, Villejuif, FR, [3]University Hospital of Nantes (Hôtel-Dieu - CHU de Nantes), Nantes, FR, [4]ImCheck Therapeutics SAS, Marseille, Cedex, FR, [5]Ilife Consulting, Argenteuil, FR, [6]Centre de Recherche en Cancérologie de Marseille, Marseille, FR, [7]IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR

16:40 - 16:50 **823O - Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)**
M. Jongen-Lavrencic[1], A. Bajel[2], S. Garciaz[3], A. Maiti[4], S. Fleming[5], S. De Button[6], G. A Huls[7], K. Jensen[8], S. Ziti-Ljajic[9], D. Draganov[8], F. Rotolo[10], C. Palu[11], J. Courta[9], W. Passe-Coutrin[9], K. Traudtner[12], T. Wagenaar[8], G. Abbadessa[8], A. Selwyn Stein[13], [1]Erasmus University Medical Center, Rotterdam, NL, [2]Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, AU, [3]Institut Paoli-Calmettes, Aix-Marseille University, Marseille, FR, [4]MD Anderson Cancer Center, Houston, US, [5]Alfred Health, Melbourne, AU, [6]Institut Gustave Roussy, Paris, FR, [7]University Medical Center

Groningen, Groningen, NL, [8]Sanofi, Cambridge, US, [9]Sanofi, Chilly-Mazarin, FR, [10]Sanofi, Montpellier, FR, [11]Sanofi, Cambridge, GB, [12]Sanofi, Amsterdam, NL, [13]City of Hope National Medical Center, Duarte, US

16:50 - 17:00 **Invited Discussant 822O and 823O**

D. Rossi, EOC - Amministrazione IOSI, Bellinzona, CH

17:00 - 17:10 **Q&A**

17:10 - 17:20 **824O - Treatment and survival in patients with localized primary ocular adnexal MALT lymphoma: A large bicentric cohort study**

L.-R. Gao[1], X. Li[2], X. Wang[1], Y. Wu[1], L. Wang[2], S. Qi[1], Y. Li[1], [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, [2]Beijing TongRen Hospital, Capital Medical University, Beijing, CN

17:20 - 17:30 **825O - Genomic traits of therapeutic response to anti-PD-1 therapy in peripheral T cell lymphoma**

N. Lou[1], M. Yang[1], X. Han[2], [1]Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, [2]CAMS-PUMC - Chinese Academy of Medical Sciences and Peking Union Medical College - Dongdan Campus, Dongcheng-qu, CN

17:30 - 17:40 **826O - A single-arm, multicenter clinical study of radiotherapy combined with toripalimab in stage I/II extranodal NK/T cell lymphoma**

M. Jiang, L. Liang, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN

17:40 - 17:50 **Invited Discussant 824O, 825O and 824O**

O. Casasnovas, CHU Dijon, Dijon, FR

17:50 - 18:00 **Q&A**

16:30 - 18:00	**Type: Patient Advocacy session** **Title: How does digitalisation help personalised care throughout the patient journey?** Chair(s): Tanja Spanic, SI; Gregor Cuzak, SI	**Cádiz Auditorium - NCC**

16:30 - 16:45 **Patients at the centre of the new digital solutions: HealthDay and personalised care**

T. Spanic, Europa Donna Slovenia, Ljubljana, SI

16:45 - 17:00 **New solutions for cancer patients**

G. Cuzak, Trokot d.o.o., Ljubljana, SI

17:00 - 17:15 **Saving life trough tracking symptoms and early detection of cancer recurrence: The importance of collecting data in registries**

R. Cordoba Mascunano, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

17:15 - 17:30 **Virtual nursing services: Data for healthier patient lives**

H. Ullgren, Karolinska University Hospital-Solna, Solna, SE

17:30 - 17:45 **New technologies in hospitals, improving patient experience**

L. Kornowska, Polish Federation of Hospitals, Warsaw, PL

17:45 - 17:55 **Discussion**

17:55 - 18:00 **Conclusion**

16:45 - 17:45	**Type: EONS session** **Title: ECL/EONS collaborative session – Let's break the taboo around cancer and sexuality: Improving communication and care** Chair(s): Johan De Munter, BE	**Alicante Auditorium - Hall 10**

16:45 - 17:00 **How to improve communication and care for sexual wellbeing? Recommendations and tools for oncology professionals**

H. Neefs, Kom op tegen Kanker, Brussels, BE

17:00 - 17:15 **Cancer and sexuality in adolescents and young adults (AYAs)**

S. Sleeman, Association of European Cancer Leagues, Brussels, BE

17:15 - 17:25 **CN37 - Perceptions and attitudes of healthcare providers towards discussing sexuality and sexual problems in cancer patients (from LGBTQ+ backgrounds)**

C. Beyts[1], J. Verhelle[1], E. Pape[2], G. Van Ramshorst[2], [1]Ghent University - Campus Ufo, Gent, BE, [2]UZ Gent - Universitair Ziekenhuis Gent, Gent, BE

17:25 - 17:45 **Q&A and discussion**

17:00 - 18:00	**Type: Controversy session** **Title: PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor: One approach for all** Chair(s): Elena Castro, ES	**Málaga Auditorium - Hall 10**

17:00 - 17:05 **Welcome and "set the scene"**

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

17:05 - 17:20 **Pro**

N. Clarke, The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB

17:20 - 17:35 **Contra**

J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

17:35 - 17:40 **First voting**

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

17:40 - 17:55 **Perspective from the Chair**

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

17:55 - 18:00 **Second voting**

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

18:30 - 20:00 **Type: Industry Satellite Symposium** **Burgos Auditorium - Hall 3**

Title: Sanofi Regeneron - Overcoming Therapeutic Challenges in Non-melanoma Skin Cancer: A Multidisciplinary Approach

Chair(s): Paolo Ascierto, IT

18:30 - 18:35 **Welcome and Introduction**

P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

18:35 - 18:55 **Multidisciplinary management of non-melanoma skin cancer: Dermatological Standpoint**

C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR

18:55 - 19:15 **Multidisciplinary management of non-melanoma skin cancer: Oncological Approach**

P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

19:15 - 19:35 **Multidisciplinary management of non-melanoma skin cancer: Surgical Perspective**

W. Van Houdt, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

19:35 - 19:55 **Multidisciplinary management of non-melanoma skin cancer: Radiological Viewpoint**

S. Billan, Rambam Health Care Campus, Haifa, IL

19:55 - 20:00 **Summary and Close**

P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

18:30 - 20:00 **Type: Industry Satellite Symposium** **Valencia Auditorium - Hall 10**
Title: Seagen - ADCs' Potential Across Tumors
Chair(s): Josep Tabernero, ES

18:30 - 18:33 **Welcome and Introduction**
J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

18:33 - 18:43 **ADC Technologies in Oncology**
J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

18:43 - 19:13 **Emerging ADCs in Non-Small Cell Lung Cancer**
D. Planchard, Institut Gustave Roussy, Villejuif, Cedex, FR

19:13 - 19:28 **Advances in ADCs for Head and Neck Cancer**
L. Locati, ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano, Milan, IT

19:28 - 19:48 **Future Directions for ADCs in Urothelial Cancer**
T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

19:48 - 19:58 **Panel Discussion and Audience Q&A**
J. Tabernero[1], D. Planchard[2], L. Locati[3], T. Powles[4], [1]Vall d'Hebron University Hospital, Barcelona, ES, [2]Institut Gustave Roussy, Villejuif, Cedex, FR, [3]ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano, Milan, IT, [4]St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

19:58 - 20:00 **Closing Remarks**
J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: AstraZeneca - Assessing therapeutic options for patients with hepatobiliary cancers: the role of immunotherapy-based regimens** Chair(s): Stephen Chan, HK	**Salamanca Auditorium - Hall 3**

18:30 - 18:35 **Welcome and introductions**

S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

18:35 - 18:55 **Plenary: Integration of immunotherapy-based approaches in HCC and BTC**

B. Sangro, Clinica Universidad de Navarra, Pamplona, ES

18:55 - 19:10 **Panel discussion 1: Assessing long-term survivorship and prognostic factors in patients with hepatobiliary cancers**

S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

19:10 - 19:25 **Case study discussion 1: Assessing patient outcomes in unresectable / advanced HCC**

S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

19:25 - 19:40 **Case study discussion 2: Navigating clinical decision-making in advanced BTC**

A. Casadei Gardini, IRCCS Ospedale San Raffaele, Milan, IT

19:40 - 19:55 **Panel discussion 2: Current management of immune-mediated adverse events in patients with hepatobiliary cancers**

S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG

19:55 - 20:00 **Audience Q&A**

S. Chan[1], S.P. Choo[2], B. Sangro[3], A. Casadei Gardini[4], [1]The Chinese University of Hong Kong - Sino Building, Sha Tin, HK, [2]NCCS - National Cancer Centre Singapore, Singapore, SG, [3]Clinica Universidad de Navarra, Pamplona, ES, [4]IRCCS Ospedale San Raffaele, Milan, IT

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: Illumina - Detection of homologous recombination deficiency (HRD): Role of HRD testing and impact on patient management** Chair(s): Frederique Penault-Llorca, FR	**Málaga Auditorium - Hall 10**

18:30 - 18:35 **Introduction & Welcome**

F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

18:35 - 18:55 **The clinical value of HRD testing in ovarian cancer**

D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT

18:55 - 19:15 **The value of biomarker testing for homologous recombination deficiency in prostate cancer**

D. Olmos, Hospital Universitario 12 de Octubre, Madrid, ES

19:15 - 19:35 **The role of HRD and related tests in cancer care**

F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

19:35 - 19:55 **The utility of HRD testing – current status and future trends**

F. Barve[1], F. Penault-Llorca[2], D. Lorusso[3], D. Olmos[4], [1]CRUK - Cancer Research UK Cambridge Institute - University of Cambridge, Cambridge, GB, [2]Jean Perrin Center, Clermont-Ferrand, FR, [3]Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, [4]Hospital Universitario 12 de Octubre, Madrid, ES

19:55 - 20:00 **Closing remarks**

F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: PeerVoice - The Science and the Art of Modern Prostate Cancer Care: Improving Patient Outcomes Through Intensification and Individualisation of Treatment** Chair(s): Karim Fizazi, FR	**Santander Auditorium - Hall 9**

18:30 - 18:33 **Welcome and Introduction**

K. Fizazi, Institut Gustave Roussy, Villejuif, Cedex, FR

18:33 - 19:03 **State of the Science, State of the Art: Are We Implementing Individualised and Evidence-Based Treatment Plans for mHSPC?**

C. Gratzke[1], A. Morgans[2], K. Fizazi[3], [1]University Medical Center Freiburg, Freiburg im Breisgau, DE, [2]Dana Farber Cancer Institute, Boston, US, [3]Institut Gustave Roussy, Villejuif, Cedex, FR

19:03 - 19:15 **Audience Q&A: What's on Your Mind in mHSPC?**

K. Fizazi[1], A. Morgans[2], C. Gratzke[3], [1]Institut Gustave Roussy, Villejuif, Cedex, FR, [2]Dana Farber Cancer Institute, Boston, US, [3]University Medical Center Freiburg, Freiburg im Breisgau, DE

19:15 - 19:45 **Mastering the Science and the Art: Are We Taking Advantage of Opportunities to Optimise Care and Outcomes in nmCRPC?**

A. Morgans[1], K. Fizazi[2], C. Gratzke[3], [1]Dana Farber Cancer Institute, Boston, US, [2]Institut Gustave Roussy, Villejuif, Cedex, FR, [3]University Medical Center Freiburg, Freiburg im Breisgau, DE

19:45 - 19:57 **Audience Q&A: Sharing Challenges and Solutions in nmCRPC**

K. Fizazi[1], A. Morgans[2], C. Gratzke[3], [1]Institut Gustave Roussy, Villejuif, Cedex, FR, [2]Dana Farber Cancer Institute, Boston, US, [3]University Medical Center Freiburg, Freiburg im Breisgau, DE

19:57 - 20:00 **Final Remarks and Closing**

K. Fizazi, Institut Gustave Roussy, Villejuif, Cedex, FR

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: Takeda - Navigating Treatment Choices In ALK+ mNSCLC: A Focus on Patient-Centered Decision Making** Chair(s): Stephen Liu, US	**Toledo Auditorium - Hall 3**

18:30 - 18:35 **Chair Introduction**

S. Liu, Lombardi Cancer Center Georgetown University, Washington, US

18:35 - 18:55 **Optimizing Molecular Testing and Diagnosis of NSCLC**

R. Califano, The Christie NHS Foundation Trust, Manchester, GB

18:55 - 19:15 **Quality of Life and Impact on Individuals Living With ALK+ mNSCLC**

L. Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

19:15 - 19:35 **Current and Emerging Treatment Landscape in ALK+ mNSCLC**

S. Liu, Lombardi Cancer Center Georgetown University, Washington, US

19:35 - 19:45 **Panel Q&A**

S. Liu[1], R. Califano[2], L. Mezquita[3], [1]Lombardi Cancer Center Georgetown University, Washington, US, [2]The Christie NHS Foundation Trust, Manchester, GB, [3]Hospital Clinic y Provincial de Barcelona, Barcelona, ES

19:45 - 20:00 **A Conversation With an Individual Living With Lung Cancer: Perspectives on Testing and Quality of Life**

S. Liu[1], Y. Diaz[2], [1]Lombardi Cancer Center Georgetown University, Washington, US, [2]ALK+ International, London, GB

18:30 - 20:00	**Type: ESMO Colloquium** **Title: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer** Chair(s): Noemi Reguart Aransay, ES; Jürgen Wolf, DE	**Oviedo Auditorium - Hall 7**

18:30 - 18:40 **Welcome and introduction**

N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

18:40 - 19:00 **The importance of next-generation sequencing (NGS) testing in non-small cell lung cancer: Science, implementation and timing**

A. Stenzinger, University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE

19:00 - 19:20 **The availability of molecular testing in Europe and its implications for state-of-the-art care for patients with lung cancer**

A. Bayle, Institut Gustave Roussy, Villejuif, Cedex, FR

19:20 - 19:40 **Targeting molecular aberrations beyond EGFR, ALK: Clinical evidence for efficacy and ongoing research**

J. Wolf, University Hospital of Cologne, Cologne, DE

19:40 - 19:55 **Q&A and discussion**

19:55 - 20:00 **Concluding remarks**

J. Wolf, University Hospital of Cologne, Cologne, DE

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: Daiichi Sankyo - The Multi-Tumor Toolkit: ADCs in Cancer Therapy** Chair(s): Benjamin Levy, US	**León Auditorium - Hall 7**

18:30 - 18:40 **ADC technology in cancer therapy**

B. Levy, Johns Hopkins University, Baltimore, US

18:40 - 19:05 **The role of ADCs in the lung treatment landscape**

M. Thomas, Thoraxklinik Heidelberg gGmbH, Heidelberg, DE

19:05 - 19:25 **The impact of ADCs on the breast cancer treatment landscape**

C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES

19:25 - 19:40 **The current state and future potential of ADCs in other tumor types**

K. Shitara, National Cancer Center Hospital East, Kashiwa, JP

19:40 - 20:00 **Multi-tumor panel roundtable discussion and Q&A**

B. Levy[1], M. Thomas[2], C. Saura Manich[3], K. Shitara[4], [1]Johns Hopkins University, Baltimore, US, [2]Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, [3]Vall d'Hebron University Hospital, Barcelona, ES, [4]National Cancer Center Hospital East, Kashiwa, JP

23.10.2023

08:30 - 10:00 **Type: Proffered Paper session** **Barcelona Auditorium - Hall 9**
Title: Proffered Paper session 2 - Gastrointestinal tumours, lower digestive

Chair(s): Dominik Modest, DE; Clara Montagut Viladot, ES

08:30 - 08:40 **552O - FOxTROT: Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended biomarker panel**

J. Seligmann[1], D. Morton[2], M. Seymour[3], F. Elliott[3], K. Handley[4], B. Glimelius[5], C. Williams[3], G. Hemmings[6], D. Bottomley[7], R. Gray[8], P. Quirke[3], L. Magill[4], A. Beggs[2], N. West[9], [1]University of Leeds, leeds, GB, [2]The University of Birmingham - Medical School, leeds, GB, [3]UL - University of Leeds, leeds, GB, [4]The University of Birmingham - Institute for Cancer Studies, leeds, GB, [5]Akademiska Sjukhuset Uppsala, leeds, GB, [6]University of Leeds - Institute of Cancer and Pathology (LICAP), Leeds, GB, [7]UL - University of Leeds, Leeds, GB, [8]University of Oxford, leeds, GB, [9]St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, leeds, GB

08:40 - 08:50 **LBA27 - First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group**

C. Punt[1], M. Bond[1], K. Bolhuis[2], O. Loosveld[3], J.W. De Groot[4], H. Droogendijk[5], H. Helgason[6], M. Hendriks[7], J. Klaase[8], G. Kazemier[9], M. Liem[10], A. Rijken[3], C. Verhoef[11], J. De Wilt[12], K. De Jong[8], M. Van Amerongen[13], B. De Valk[14], E. Kerver[15], A. Komurcu[16], R.-J. Swijnenburg[9], [1]University Medical Center Utrecht, Utrecht, NL, [2]The Netherlands Cancer Institute, Amsterdam, NL, [3]Amphia Ziekenhuis, Breda, NL, [4]Isala, Zwolle, NL, [5]Bravis Ziekenhuis, Roosendaal, NL, [6]Haaglanden Medisch Centrum, Den Haag, NL, [7]Noordwest Ziekenhuisgroep, Alkmaar, NL, [8]University Medical Center Groningen, Groningen, NL, [9]Amsterdam UMC, Amsterdam, NL, [10]Medisch Spectrum Twente, Enschede, NL, [11]Erasmus MC, Rotterdam, NL, [12]Radboud University Medical Center, Nijmegen, NL, [13]Sint Maartenskliniek, Woerden, NL, [14]Spaarne Gasthuis, Hoofddorp, NL, [15]OLVG Hospital, Amsterdam, NL, [16]IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL

08:50 - 09:00 **Invited Discussant 552O and LBA27**

D. Modest, Charité - Universitaetsmedizin Berlin, Berlin, DE

09:00 - 09:10 **Q&A**

09:10 - 09:20 **553O - Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of 7 trials**

J. Taieb[1], L. Pederson[2], F. Sinicrope[3], S. Lonardi[4], S. Alberts[2], T. George[5], L. Saltz[6], G. Yothers[7], R. Goldberg[8], R. Kerr[9], T. Yoshino[10], E. Van Cutsem[11], S. Ogino[12], T. André[13], P. Laurent-Puig[14], Q. Shi[3], [1]Hopital European George Pompidou, Paris, FR, [2]Mayo Clinic - Rochester, Rochester, US, [3]Mayo Clinic, Rochester, US, [4]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [5]UF - University of Florida Health, Gainesville, US, [6]Memorial Sloan

Kettering Cancer Center, New York, US, [7]University of Pittsburgh, Pittsburgh, US, [8]West Virginia University, Morgantown, US, [9]Churchill Hospital, Oxford, GB, [10]National Cancer Center Hospital East, Kashiwa, JP, [11]UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, [12]Harvard Medical School, Boston, US, [13]Hopital Saint-Antoine, Paris, FR, [14]Université Paris Cité, Paris, FR

09:20 - 09:30

LBA29 - Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial

J. Chia[1], E. Segelov[2], Y. Deng[3], W. Wang[4], G.F. Ho[5], A. Sharma[6], K. Ding[7], G. Chen[8], G.M. Jeffery[9], L. Nott[10], R. Zielinski[11], J.B. Ahn[12], T.-Y. Chao[13], T. Yau[14], S. Nabilah[15], M. Gandhi[15], P. Rothwell[16], J. Simes[17], R. Ali[18], H.C. Toh[19], [1]CURIE Oncology, Singapore, SG, [2]University of Bern, Bern, CH, [3]The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, [4]Foshan First People's Hospital, Foshan, CN, [5]Pusat Perubatan Universiti Malaya (PPUM), Kuala Lumpur, MY, [6]AIIMS - All India Institute of Medical Sciences, New Delhi, IN, [7]The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN, [8]Sun Yat-sen University Cancer Center, Guangzhou, CN, [9]Christchurch Hospital, Christchurch, NZ, [10]Department of Health - Australia, Canberra, AU, [11]Orange Health Service, Orange, AU, [12]Yonsei University, Seoul, KR, [13]Shuang Ho hospital, New Taipei City, CN, [14]The University of Hong Kong - Queen Mary Hospital, Hong Kong, HK, [15]CRIS - Consortium for Clinical Research and Innovation Singapore, Singapore, SG, [16]Wolfson Institute of Preventive Medicine - Barts and The London School of Medicine, London, GB, [17]University of Sydney, Sydney, AU, [18]Cambridge Clinical Trials Unit - Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, [19]NCCS - National Cancer Centre Singapore, Singapore, SG

09:30 - 09:40

LBA28 - The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

S. Lonardi[1], F. Pietrantonio[2], N. Tarazona Llavero[3], C. Montagut Viladot[4], A. Sartore Bianchi[5], M.G. Zampino[6], M.E. Elez Fernandez[7], C. Santos Vivas[8], M. Mandalà[9], S. Tamberi[10], M.S. Sciallero[11], S. Muñoz[12], L. Lazzari[13], P. Luraghi[13], V. Torri[14], A. Cervantes[3], A. Bardelli[13], J. Tabernero[7], S. Siena[5], S. Marsoni[13], [1]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [2]Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, [3]INCLIVA Biomedical Research Institute, University of Valencia, Valencia, ES, [4]Hospital del Mar - Parc de Salut Mar, Barcelona, ES, [5]Università degli Studi di Milano "La Statale", ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, [6]IEO - Istituto Europeo di Oncologia, Milan, IT, [7]Vall d'Hebron University Hospital, Barcelona, ES, [8]ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, [9]University of Perugia, Santa Maria della Misericordia, University Hospital of Perugia, Perugia, IT, [10]Ospedale degli Infermi - AUSL Romagna, Faenza, IT, [11]IRCCS Ospedale Policlinico San Martino, Genova, IT, [12]Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, [13]IFOM - the AIRC Institute of Molecular Oncology, Milan, IT, [14]Istituto Di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, IT

09:40 - 09:50

Invited Discussant 553O, LBA28 and LBA29

C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

09:50 - 10:00 **Q&A**

08:30 - 10:00 **Type: Multidisciplinary session** **Sevilla Auditorium - Hall 9**
Title: Management of oligometastatic disease in NSCLC
Chair(s): Anne-Marie Dingemans, NL; Giulia Veronesi, IT

08:30 - 08:45 **Introduction and definition of oligometastatic disease(s) + Case presentation**
A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

08:45 - 09:05 **The role of systemic therapy in patients with or without molecular alterations**
R. Soo, NCIS - National University Cancer Institute Singapore, Singapore, SG

09:05 - 09:25 **The role of surgery**
G. Veronesi, IRCCS Ospedale San Raffaele, Milan, IT

09:25 - 09:45 **The role of radiation therapy**
C. Le Pechoux, Institut Gustave Roussy, Villejuif, Cedex, FR

09:45 - 10:00 **Q&A and Discussion**

08:30 - 10:00 **Type: Educational session** **Bilbao Auditorium - NCC**
Title: How to navigate the different treatment options for hepatobiliary cancers
Chair(s): Angela Lamarca, ES; Jeroen Dekervel, BE

08:30 - 08:50 **Immunotherapy for liver cancer**
A. Vogel, University Health Network - Toronto General Hospital Research Institute (TGHRI), Toronto, CA

08:50 - 09:10 **Immunotherapy for biliary cancer**
A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

09:10 - 09:30 **Personalised medicine and targeted agents for biliary tract cancer**
L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT

09:30 - 09:50 **Personalised treatment for HCC: Where are we now?**
S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

09:50 - 10:00 **Q&A and Discussion**

08:30 - 10:00 **Type: Special symposium** **Granada Auditorium - Hall 3**
Title: Molecular targets and related treatments

Chair(s): Himisha Beltran, US; Daniel Heinrich, NO

08:30 - 08:45 **How to interpret a genomic testing report**
H. Beltran, Dana Farber Cancer Institute, Boston, US

08:45 - 09:00 **PSMA targeting**
D. Heinrich, Sykehuset Innlandet HF, Brumunddal, NO

09:00 - 09:15 **PARP inhibition**
E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

09:15 - 09:30 **Third generation AR targeting**
A. Bernard-Tessier, Institut Gustave Roussy, Villejuif, Cedex, FR

09:30 - 09:45 **Checkpoint inhibitors and Pi3K inhibitors**
N. Mehra, Radboud University Medical Center, Nijmegen, Nijmegen, NL

09:45 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**

08:30 - 09:55 **Type: Proffered Paper session** **Burgos Auditorium - Hall 3**
Title: Proffered Paper session - Head and neck cancer

Chair(s): Silke Tribius, DE; Paolo Bossi, IT

08:30 - 08:40 **853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase II trial**

J. Thariat[1], M. Bosset[2], A. Falcoz[3], D. Vernerey[4], Y. Pointreau[5], S. Racadot[6], J.C. Faivre[7], J. Castelli[8], S. Guihard[9], F. Huguet[10], S. Chapet[11], Y. Tao[12], J. Bourhis[13], X.S. Sun[14], [1]Centre Francois Baclesse, caen, FR, [2]Marie Curie Radiotherapy Center, valence, FR, [3]CHRU Besancon - Hopital Jean Minjoz, besancon, FR, [4]MSD, besancon, FR, [5]Jean Bernard Center, Le Mans, FR, [6]Centre Léon Bérard, Lyon, FR, [7]Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, [8]Centre Eugene - Marquis, Rennes, FR, [9]Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, [10]Hopital Tenon AP-HP, Paris, Cedex, FR, [11]CHRU Bretonneau, Tours, FR, [12]Institut Gustave Roussy, Villejuif, Cedex, FR, [13]CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, [14]Hôpital Nord Franche-Comté - HNFC, Belfort, FR

08:40 - 08:45 **857O - MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)**

P. Blanchard[1], M. Cheugoua-Zanetsie[2], I. Deneche[2], D. Rosenthal[3], M. Gillison[4], J. Eriksen[5], K. Prabhash[6], J. Giralt[7], J.A. Bonner[8], M.G. Ghi[9], H. Mehanna[10], L. Siu[11], M. Gebre Medhin[12], D. Rischin[13], A. Dietz[14], R. Mesia Nin[15], Y. Pointreau[16], T. Crombet[17], A. Auperin[18], [1]Institut Gustave Roussy, Villejuif, FR, [2]Gustave Roussy, Villejuif, FR, [3]The University of Texas MD Anderson Cancer Center, Houston, US, [4]University of Texas MD Anderson Cancer Center, Houston, US, [5]Aarhus University Hospital, Aarhus, DK, [6]Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, [7]Vall d'Hebron University Hospital, Barcelona, ES, [8]University of Alabama at Birmingham Hospital, Birmingham, US, [9]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [10]The University of Birmingham - Institute for Cancer Studies, Birmingham, GB, [11]Princess Margaret Cancer Centre, Toronto, CA, [12]Lund University, Lund, SE, [13]Peter MacCallum Cancer Centre, Melbourne, AU, [14]Universitätsklinikum Leipzig, Leipzig, DE, [15]ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES, [16]Centre Jean Bernard, Le Mans, FR, [17]Center of Molecular Immunology, Havana, CU, [18]Gustave Roussy - Cancer Campus, Villejuif, FR

08:45 - 08:55 **Invited Discussant 853O and 857O**

S. Tribius, Asklepios Klinik St. Georg, Hamburg, DE

08:55 - 09:05 **Q&A**

09:05 - 09:10 **858O - Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) assay after curative therapy in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) predicts disease relapse and survival**

N. Honoré[1], C. Van Marcke De Lummen[2], R. Galot[2], R. Helaers[3], A. Van Maanen[4], J. Ambroise[5], A. Mendola[1], H. Dahou[1], E. Marbaix[2], P. Van Eeckhout[2], E. Longton[2], M. Magremanne[2], S. Schmitz[2], N. Limaye[3], J.-P. Machiels[2], [1]UCLouvain -IREC/MIRO, Woluwe-Saint-Lambert, BE, [2]Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, [3]De Duve Institute UCLouvain, Woluwe-Saint-Lambert, BE, [4]Institut Roi Albert II - Cliniques universitaires St-Luc, Brussels, BE, [5]UCLouvain - Université Catholique de Louvain, Woluwe-Saint-Lambert, BE

09:10 - 09:25 **Invited Discussant 858O**

J.P. Klussmann, Universitätsklinikum Köln (AöR), Köln, DE

09:25 - 09:30 **Q&A**

09:30 - 09:40 **854O - INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)**

J. Fayette[1], L. Licitra[2], K. Harrington[3], R. Haddad[4], L. Siu[5], Y.C. Liu[6], M. Tahara[7], J.-P. Machiels[8], D. Rischin[9], T. Seiwert[10], R. Ferris[11], U. Keilholz[12], A. Psyrri[13], B. Keam[14], P. Bossi[15], R. Metcalf[16], O. Serrano[17], P. Kaur[18], D. Ruscica[19], R. Cohen[20], [1]Lyon-I University, Lyon, FR, [2]Milan and University of Milan, Milan, IT, [3]The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, London, GB, [4]Dana-Farber Cancer Institute, Boston, US, [5]Princess Margaret Cancer Centre, Toronto, CA, [6]Taichung Veterans General Hospital, Taichung City, TW, [7]Hospital East, Kashiwa, JP, [8]Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain, Brussels, BE, [9]Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, AU, [10]Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, US, [11]University of Pittsburgh Cancer Institute, Pittsburgh, US, [12]Charité Comprehensive Cancer Center, Berlin, DE, [13]Attikon University Hospital, National Kapodistrian University of Athens, Athens, GR, [14]Seoul National University Hospital, Seoul, KR, [15]Radiological Sciences and Public Health, University of Brescia, Brescia, IT, [16]The Christie NHS Foundation Trust, Manchester, GB, [17]AstraZeneca & Cytel Inc, Paris, FR, [18]Formerly AstraZeneca, Cambridge, GB, [19]AstraZeneca, Cambridge, GB, [20]University of Pennsylvania School of Medicine, Philadelphia, US

09:40 - 09:50 **Invited Discussant 854MO**

C. Le Tourneau, Institut Curie, Paris, FR

09:50 - 09:55 **Q&A**

08:30 - 10:00 **Type: Proffered Paper session** **Valencia Auditorium - Hall 10**

Title: Proffered Paper session - Melanoma and other skin tumours

Chair(s): Teresa Amaral, DE; Enrique Espinosa, ES

08:30 - 08:40 **LBA48 - Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801**

S. Patel[1], M. Othus[2], P. Wright[3], J. Hyngstrom[4], C. Lao[5], T.-G. Truong[6], S. Chandra[7], K. Kendra[8], C. Devoe[9], A. Hegde[10], A. Mangla[11], M. Lowe[12], E. Buchbinder[13], J. Kirkwood[14], E. Sharon[15], L. Korde[15], J. Moon[2], V. Sondak[16], A. Ribas[17], V. Prieto[1], [1]The University of Texas MD Anderson Cancer Center, Houston, US, [2]Fred Hutchinson Cancer Research Center, Seattle, US, [3]Spectrum Health, Grand Rapids, US, [4]University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, [5]University of Michigan Comprehensive Cancer Center, Ann Arbor, US, [6]Kaiser Permanente Vallejo Medical Center, Vallejo, US, [7]Robert. H. Lurie Cancer Center of Northwestern University, Chicago, US, [8]OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, [9]Northwell Health Cancer Institute, Lake Success, US, [10]The University of Alabama at Birmingham, Birmingham, US, [11]Case Western Reserve University / University Hospitals, Cleveland, US, [12]Emory University, Atlanta, US, [13]Dana Farber Cancer Institute, Boston, US, [14]UPMC Hillman Cancer Center, Pittsburgh, US, [15]National Cancer Institute, Bethesda, US, [16]H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, [17]Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

08:40 - 08:50 **LBA49 - mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response**

J. Weber[1], A. Khattak[2], M. Carlino[3], R. Sullivan[4], J. Luke[5], T. Meniawy[6], M. Taylor[7], G. Ansstas[8], K. Kim[9], M. Mckean[10], M. Faries[11], T. Tran[12], C.L. Cowey[13], A. Pecora[14], T. Medina[15], V. Atkinson[16], G. Gibney[17], E. Buchbinder[18], R. Meehan[19], G. Long[20], [1]Laura and Isaac Perlmutter Cancer Center, New York City, US, [2]Hollywood Private Hospital & Edith Cowan University, Perth, AU, [3]Crown Princess Mary Cancer Centre Westmead, Westmead, AU, [4]MGH - Massachusetts General Hospital, Boston, US, [5]University of Pittsburgh Cancer Institute, Pittsburgh, US, [6]Saint John of God Subiaco Hospital, Subiaco, AU, [7]Providence Cancer Institute, Southfield, US, [8]Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, [9]California Pacific Medical Center Research Institute, San Francisco, US, [10]Sarah Cannon Research Institute, Nashville, US, [11]The Angeles Clinic and Research Institute, Los Angeles, US, [12]Yale University School of Medicine - Yale Cancer Center, New Haven, US, [13]Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, [14]John Theurer Cancer Center - Hackensack University Medical Center, Hackensack, US, [15]University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, [16]Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU, [17]Georgetown Lombardi Comprehensive Cancer Center, Washington DC, US, [18]Dana Farber Cancer Institute, Boston, US, [19]Moderna, Inc. - Global Headquarters, Cambridge, US, [20]Melanoma Institute Australia, Wollstonecraft, AU

08:50 - 09:00 **1081O - ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM)**

M. Mckean[1], B. Chmielowski[2], M. Butler[3], R. Carvajal[4], J. Rodon[5], M. Carlino[6], K. Kim[7], T. Wise-Draper[8], S. Khan[9], A. Salama[10], J. Moser[11], J. Reeves[12], K. Wilner[13], M. Maurer[14], M. Abed[14], B. Mitchell[14], D. Beaupre[15], M. Orloff[16], [1]Sarah Cannon Research Institute, Nashville, US, [2]Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, US, [3]UHN - University Health Network - Princess Margaret Cancer Centre, Toronto, CA, [4]Northwell Health Cancer Institute, Lake Success, US, [5]The University of Texas MD Anderson Cancer Center, Houston, US, [6]Crown Princess Mary Cancer Centre Westmead, Westmead, AU, [7]California Pacific Medical Center Research Institute, San Francisco, US, [8]Vontz Center for Molecular Studies, Cincinnati, US, [9]HICCC - Herbert Irving Comprehensive Cancer Center - Columbia University, New York, US, [10]Duke University, Durham, US, [11]HonorHealth Research Institute, Scottsdale, US, [12]Sarah Cannon Research Institute at Florida Cancer Specialists, Cape Coral, US, [13]Pfizer Inc., San Diego, US, [14]IDEAYA Biosciences, South San Francisco, US, [15]Biosplice Therapeutics, Inc., San Diego, US, [16]Thomas Jefferson Univ Hospital, Philadelphia, US

09:00 - 09:10 **Invited Discussant LBA48, LBA49 and 1081O**

T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

09:10 - 09:20 **Q&A**

09:20 - 09:30 **1082O - Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)**

I. Glitza[1], S. Phillips[1], I. John[1], R. Bassett[2], R. Lin[2], M. Rohlfs[1], J. Richard[1], M. Iqbal[1], T. Hennegan[1], I. Mccutcheon[3], S. Ferguson[3], B. O'Brien[3], S. Tummala[3], N. Guha-Thakurta[1], M. Debnam[1], H. Tawbi[1], E. Burton[1], M. Davies[1], [1]The University of Texas M. D. Anderson Cancer Center, Houston, US, [2]MD Anderson Cancer Center, Houston, US, [3]The University of Texas MD Anderson Cancer Center, Houston, US

09:30 - 09:40 **1085O - Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM)**

E. Burton[1], V. Honaker[2], D. Milton[3], I. Glitza[1], R. Amaria[4], S. Patel[2], A. Diab[3], M. Wong[3], J. Mcquade[1], C. Chung[2], J. Wefel[3], J. Li[5], M. Davies[3], H. Tawbi[3], [1]The University of Texas M. D. Anderson Cancer Center, Houston, US, [2]MD Anderson Cancer Center, Houston, US, [3]The University of Texas MD Anderson Cancer Center, Houston, US, [4]The M.D. Anderson Cancer Center, Houston, US, [5]The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

09:40 - 09:50 **Invited Discussant 1082O and 1085O**

R. Dummer, USZ - University Hospital Zürich, Zurich, CH

09:50 - 10:00 **Q&A**

08:30 - 10:00 **Type: Special session** **Salamanca Auditorium - Hall 3**

Title: Women for Oncology - How is the progress towards gender equity? 10 years of ESMO W4O advocating for the cause

Chair(s): Pilar Garrido Lopez, ES; Duncan Hart, GB

08:30 - 08:35 **Welcome**

D. Hart, Cameron Communications, Glasgow, GB

08:35 - 08:50 **10 years of ESMO W4O advocating for gender equity**

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

08:50 - 10:00 **Live discussion, Q&A and wrap-up**

P. Garrido Lopez[1], S. Peters[2], G. Curigliano[3], H. Linardou[4], D. Mukherji[5], T. Powles[6], [1]Hospital Universitario Ramon y Cajal, Madrid, ES, [2]CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, [3]IEO - Istituto Europeo di Oncologia, Milan, IT, [4]Metropolitan Hospital, Athens, GR, [5]Clemenceau Medical Center, Dubai, AE, [6]St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

08:30 - 10:00 **Type: Educational session** **Santander Auditorium - Hall 9**
Title: Diffuse large B-cell lymphoma
Chair(s): Hervé Tilly, FR; Laurie Sehn, CA

08:30 - 08:55 **Molecular classification**
P. Johnson, University of Southampton, Southampton, GB

08:55 - 09:20 **First-line therapy**
H. Tilly, Centre Henri Becquerel, Rouen, FR

09:20 - 09:45 **Therapy at relapse**
L. Sehn, UBC - The University of British Columbia, Vancouver, CA

09:45 - 10:00 **Q&A and Discussion**

08:30 - 10:00 **Type: Special symposium** **León Auditorium - Hall 7**
Title: Cancer-related central and peripheral neuropathy
Chair(s): Maryam Lustberg, US; Jorn Herrstedt, DK

08:30 - 08:35 **Introduction and scientific background**
M. Lustberg, Yale University School of Medicine, New Heaven, US

08:35 - 08:50 **Antineoplastic drug-induced central neuropathy**
A. Argyriou, University Hospital Patras, Patras, GR

08:50 - 09:05 **Preventive strategies for chemotherapy-induced peripheral neuropathy (CIPN)**
S. Nielsen, Sjællands Universitets Hospital, Naestved, DK

09:05 - 09:20 **Treatment of established CIPN**
R. Geva, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL

09:20 - 09:35 **Unmet needs**
M. Lustberg, Yale University School of Medicine, New Heaven, US

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**
J. Herrstedt, ZUH - Zealand University Hospital Roskilde - Region Sjaelland, Roskilde, DK

08:30 - 10:00 **Type: Educational session** **Cádiz Auditorium - NCC**

Title: ESMO-WHO review of innovation in cancer therapeutics: Does the pipeline meet the need?

Chair(s): Rosa Giuliani, GB; André Ilbawi, CH

08:30 - 08:35 **Introduction**

A. Ilbawi, WHO - World Health Organization, Geneva, CH

08:35 - 08:50 **Evaluating innovative products in breast cancer: Characteristics, impact and market share**

R. Giuliani, Guy's and St Thomas' NHS Foundation Trust, Liverpool, GB

08:50 - 09:05 **Horizon scanning of emerging therapeutics in the next decade: What does the future hold?**

D. Trapani, Università degli Studi di Milano, Milan, IT

09:05 - 09:20 **Innovation in the EU Cancer Mission: Delivering solutions?**

C. Chomienne, Hopital Saint Louis AP-HP, Paris, FR

09:20 - 09:50 **Panel Discussion**

R. Giuliani[1], A. Ilbawi[2], W. Tse Yared[3], D. Trapani[4], C. Chomienne[5], [1]Guy's and St Thomas' NHS Foundation Trust, Liverpool, GB, [2]WHO - World Health Organization, Geneva, CH, [3]Association of European Cancer Leagues, Brussels, BE, [4]Università degli Studi di Milano, Milan, IT, [5]Hopital Saint Louis AP-HP, Paris, FR

09:50 - 10:00 **Q&A and closing remarks**

R. Giuliani, Guy's and St Thomas' NHS Foundation Trust, Liverpool, GB

08:30 - 10:00	**Type: Young Oncologists session** **Title: YO Forum: Preparing future-proof (young) oncologists** Chair(s): Maria Kfoury, FR; Rodrigo Sanchez Bayona, ES	**Ávila Auditorium - NCC**

08:30 - 08:50 **How to put together a great CV and make a standout application**

F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

08:50 - 09:10 **How to write a successful research grant/protocol**

R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB

09:10 - 09:30 **The dos and don’ts of research project management**

A.S. Berghoff, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

09:30 - 09:50 **Empowerment and resilience: A toolbox to foster your well-being and personal development**

C. Hardy, Lancaster University Division of Health Research, Lancaster, GB

09:50 - 10:00 **Discussion**

08:30 - 09:50 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Person centred care in cancer
Chair(s): Paz Fernández Ortega, ES

08:30 - 08:30 **Novice Research Dissemination Award**

A. Kolstrøm, Home nursing care, Kristiansund, NO

08:30 - 08:40 **CN28 - From difficulty to meaning: Palliative cancer patients experience on advance care planning conversation and having a palliative plan**

A. Kolstrøm, Kristiansund Municipality/ NTNU, Kristiansund, NO

08:40 - 09:00 **Person-centred care for older people with cancer**

N. Farrington, Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB

09:00 - 09:25 **Survivorship through the eyes of a cancer nurse**

V. Sulosaari[1], J. De Munter[2], [1]Turku University of Applied Sciences, Turku, FI, [2]UZ Gent - Universitair Ziekenhuis Gent, Gent, BE

09:25 - 09:35 **CN4 - Enabling patient empowerment through digital symptom monitoring**

E. Haukland[1], S.G. Aanes[1], V. Kataja[2], L. Lang[2], [1]Nordlandsykehuset HF, Bodoe, NO, [2]Kaiku Health, Helsinki, FI

09:35 - 09:50 **Q&A and discussion**

08:45 - 10:00	**Type: Multidisciplinary session** **Title: The positive sentinel lymph node: What does it mean for treatment?** Chair(s): Evandro de Azambuja, BE	**Málaga Auditorium - Hall 10**

08:45 - 08:50 **Case presentation: 50-year-old woman HR+ HER2+ EBC with 1/2 positive sentinel nodes**

S. Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, IL

08:50 - 09:10 **A surgeon's perspective**

P. Dubsky, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH

09:10 - 09:30 **A medical oncologist's perspective**

E. De Azambuja, Institute Jules Bordet, Brussels, BE

09:30 - 09:50 **A radiation oncologist's perspective**

P. Poortmans, AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, BE

09:50 - 10:00 **Discussion**

08:45 - 09:30	**Type: Challenge your Expert** **Title: Antibody drug conjugates: Current data and future role in drug development** Chair(s): Sarat Chandarlapaty, US	**Toledo Auditorium - Hall 3**

08:45 - 09:05 **Presentation by Expert**

I. Braña, Vall d'Hebron University Hospital, Barcelona, ES

09:05 - 09:30 **Discussion led by Chair**

S. Chandarlapaty, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

08:45 - 09:30	**Type: Challenge your Expert** **Title: Molecular evolution of brain metastases and therapeutic implications** Chair(s): Giuseppe Minniti, IT	**Oviedo Auditorium - Hall 7**

08:45 - 09:05 **Presentation by Expert**

S. Formenti, Weill Cornell Medicine - Gastrointestinal (GI) Oncology, New York, US

09:05 - 09:30 **Discussion led by Chair**

G. Minniti, Sapienza Università di Roma, Rome, IT

10:15 - 11:45 **Type: Special symposium** **Sevilla Auditorium - Hall 9**
Title: Novel targets, therapies and toxicities in genitourinary cancers

Chair(s): Yohann Loriot, FR; Debbie Robbrecht, NL

10:15 - 10:20 **Introduction and scientific background**

D. Robbrecht, Erasmus MC Cancer Institute, Rotterdam, NL

10:20 - 10:35 **Screening new agents in “window of opportunity” neoadjuvant trials**

A. Necchi, IRCCS Ospedale San Raffaele, Milan, IT

10:35 - 10:50 **Antibody drug conjugates and FGFR-directed therapies: New toxicities**

Y. Loriot, Institut Gustave Roussy, Villejuif, Cedex, FR

10:50 - 11:05 **Prediction of toxicity in current systemic treatment of genitourinary cancers**

S. Gusev, Dana Farber Cancer Institute, Boston, US

11:05 - 11:20 **Advances in the molecular understanding of GU cancers: The next generation of therapeutic targets**

S. Turajlic, The Royal Marsden Hospital - Chelsea, London, GB

11:20 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**

D. Robbrecht, Erasmus MC Cancer Institute, Rotterdam, NL

10:15 - 11:45 **Type: Mini Oral session** **Bilbao Auditorium - NCC**
Title: Mini oral session - Breast cancer, early stage

Chair(s): Ines Vaz Luis, FR; Carsten Denkert, DE; Ava Kwong, HK

10:15 - 10:20 **238MO - Long-term residential and workplace exposure to air pollution and breast cancer risk: A case-control study nested in the French E3N cohort from 1990 to 2011**

B. Fervers[1], M. Duboeuf[1], A. Amadou[1], T. Coudon[1], L. Grassot[1], E. Faure[2], G. Severi[2], F. Mancini[2], P. Salizzoni[3], J. Gulliver[4], D. Praud[1], [1]Centre Léon Bérard, Lyon, FR, [2]Gustave Roussy, Villejuif, FR, [3]Ecole Centrale, Ecully, FR, [4]University of Leicester, Leicester, GB

10:20 - 10:25 **LBA22 - Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: Results from the DISCO randomized trial**

B. Fervers[1], B. Fournier[1], T. Durand[1], D. Perol[1], C. Schiffler[1], A. Maire[1], L. Perrier[1], M. Préau[2], T. Bachelot[1], P.-E. Heudel[1], C. Faure[1], M. Heinemann[1], S. Kingler[1], D. Mouttet[1], L. Rossi[1], P. Toussaint[1], J. Grenier[3], O. Tredan[1], J.-Y. Blay[1], O. Pérol[1], [1]Centre Léon Bérard, Lyon, FR, [2]Université Lyon 2, Lyon, FR, [3]Institut Ste Catherine, Avignon, FR

10:25 - 10:30

239MO - Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials

H. Chen[1], X. Qian[2], Y. Tao[3], D. Wang[4], Y. Wang[1], Y. Yu[1], H. Yao[1], [1]Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, [2]Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, CN, [3]The Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN, [4]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN

10:30 - 10:45

Invited Discussant 238MO, LBA22 and 239MO

I. Vaz Luis, Institut Gustave Roussy, Villejuif, Cedex, FR

10:45 - 10:50

240MO - Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)

M. Goetz[1], N. Turner[2], H. Sasano[3], C. Arteaga[4], S. Chandarlapaty[5], S. Loi[6], J. Reis-Filho[5], H. Kreipe[7], N. Harbeck[8], P. Fasching[9], C. Rubenstein[10], S. Wijayawardana[10], M. Muñoz[10], L. Litchfield[10], S. Johnston[2], [1]Mayo Clinic, Rochester, US, [2]Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, GB, [3]Tohoku University Hospital, Sendai, JP, [4]University of Texas Southwestern Medical Center, Dallas, US, [5]Memorial Sloan Kettering Cancer Center, New York, US, [6]Peter MacCallum Cancer Centre, Melbourne, AU, [7]Hannover Medical School, Hannover, DE, [8]Ludwig Maximilians University Hospital, Munich, DE, [9]Universitätsklinikum Erlangen, Erlangen, DE, [10]Eli Lilly and Company, Indianapolis, US

10:50 - 10:55

LBA23 - Invasive disease–free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)

A. Bardia[1], G. Hortobagyi[2], O. Lipatov[3], N. Mcandrew[4], A. Lacko[5], J. Sohn[6], L. Hart[7], J. Crown[8], S.-A. Im[9], N. Harbeck[10], J. O'Shaughnessy[11], B. Xu[12], C. Barrios[13], R. Moroose[14], V. Gonzalez[15], R. Fresco[16], F. Ghaznawi[17], S. Waters[18], A. Chakravartty[19], D. Slamon[20], [1]Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, [2]The University of Texas M. D. Anderson Cancer Center, Houston, US, [3]Bashkirian Republican Oncology Center, Bashkortostan, RU, [4]UCLA Santa Monica Hematology / Oncology Regulatory-2, Santa Monica, US, [5]Dolnoslaskie Centrum Onkologii, Wrocław, PL, [6]Yonsei Cancer Center, Seoul, KR, [7]Florida Cancer Specialists, Fort Myers, US, [8]St Vincent's University Hospital, Dublin, IE, [9]SNUH - Seoul National University Hospital, Seoul, KR, [10]LMU University Hospital, Munich, DE, [11]Texas Oncology-Baylor University Medical Center and The US Oncology Research Network, Dallas, US, [12]Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, [13]Latin American Cooperative Oncology Group (LACOG), Porto Alegre, BR, [14]Orlando Health Cancer Institute, Orlando, US, [15]TRIO - Translational Research in Oncology, Montevideo, UY, [16]TRIO-Translational Research in Oncology, Montevideo, UY, [17]Novartis Pharmaceuticals Corporation, East Hanover, US, [18]Novartis Ireland Limited, Dublin, IE, [19]Novartis Pharmaceuticals Corp.,

East Hanover, US, [20]UCLA - David Geffen School of Medicine, Los Angeles, US

10:55 - 11:00

241MO - Patient characteristics and real-world outcomes in HER2 negative/ ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020

I. Fredriksson[1], B. Acs[1], J. Hartman[1], D. Sönmez[2], H. Lindman[3], [1]Karolinska Institutet & Karolinska University Hospital, Comprehensive Cancer Center, Stockholm, SE, [2]MSD - Merck Sharp & Dohme (Sweden) AB, Stockholm, SE, [3]University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE

11:00 - 11:05

242MO - Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studies

F. Miglietta[1], M.V. Dieci[2], T. Giarratano[3], V. Torri[4], M. Giuliano[5], F. Zustovich[6], M. Mion[7], C. Tondini[8], E. Bria[9], M. Franchi[10], L. Merlini[11], R. Giannatiempo[12], D. Russo[13], V. Fotia[8], P. Poletti[8], E. Rota Caremoli[8], G. Arpino[14], G. De Salvo[3], A. Zambelli[15], V. Guarneri[2], [1]IOV - Istituto Oncologico Veneto IRCCS; Unipd, Padova, IT, [2]University of Padua, Padova, IT, [3]IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, [4]Istituto Di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, IT, [5]AOU "Federico II", Napoli, IT, [6]Ospedale di Belluno, Belluno, IT, [7]Camposampiero-Cittadella, AULSS6,, Camposampiero, IT, [8]ASST Papa Giovanni XXIII, Bergamo, IT, [9]Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy, Rome, IT, [10]FROM Fondazione per la Ricerca Ospedale Maggiore, Bergamo, IT, [11]UOSD Montecchio Maggiore, Vicenza, IT, [12]Ospedale Evangelico Betania, Napoli, IT, [13]University of Naples Federico II, Napoli, IT, [14]Università degli Studi di Napoli Federico II - Dipartimento di Farmacia, Napoli, IT, [15]Humanitas University, Milan, IT

11:05 - 11:10

LBA24 - Multiparametric prognostic score in early HR+/HER2- breast cancer: Impact of recurrence score, clinical-pathological factors, gene mutations and histology

O. Gluz[1], M. Christgen[2], C. Zu Eulenburg[3], U. Nitz[3], S. Kummel[4], M. Braun[5], B. Aktas[6], K. Luedtke-Heckenkamp[7], H. Forstbauer[8], E.-M. Grischke[9], C. Schumacher[10], R. Baehner[11], R. Kates[3], M. Graeser[12], R. Würstlein[13], H. Kreipe[14], N. Harbeck[15], [1]Evang. Krankenhaus "Bethesda" Klinik, Mönchengladbach, DE, [2]MHH - Medizinische Hochschule Hannover, Hannover, DE, [3]Westdeutsche Studiengruppe GmbH, Mönchengladbach, DE, [4]Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE, [5]Rotkreuzklinikum München - Frauenklinik, Munich, DE, [6]Universitätsklinikum Leipzig - Klinik und Poliklinik für Frauenheilkunde, Leipzig, DE, [7]Franziskus-Hospital Harderberg - Niels-Stensen-KlinikenGmbH, Georgsmarienhütte, DE, [8]Praxisnetzwerk Onkologie, Troisdorf, DE, [9]Universitätsklinikum Tübingen, Tuebingen, DE, [10]St. Elisabeth Krankenhaus Köln-Hohenlind, Köln, DE, [11]Exact Sciences Corporation, Redwood City, US, [12]Evang. Krankenhaus Johanniter Bethesda, Mönchengladbach, DE, [13]LMU Klinikum der Universität München, Munich, DE, [14]Hannover Medical School, Hannover, DE, [15]Ludwig Maximilians University - Grosshadern, Munich, DE

11:10 - 11:25

Invited Discussant 240MO, LBA23, 241MO, 242MO and LBA24

C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE

11:25 - 11:30

243MO - Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial

H.M. Kuerer[1], G. Rauch[2], S. Krishnamurthy[1], E. Diego[3], W. Yang[1], Y. Shen[2], H. Lin[4], A. Lucci[4], T. Moseley[2], D. Ramirez[5], J. Mouabbi[2], J. Boughey[6], S. Shaitelman[1], R. White[7], K. Hunt[2], M. Mitchell[1], M. Teshome[1], H. Johnson[1], B. Smith[1], V. Valero[8], [1]The University of Texas MD Anderson Cancer Center, Houston, US, [2]MD Anderson Cancer Center, Houston, US, [3]University of Pittsburgh Medical Center Hillman Cancer Cente, Pittsburgh, US, [4]The University of Texas M. D. Anderson Cancer Center, Houston, US, [5]The University of Texas MD Anderson Cancer Center - Breast Medical Oncology, Houston, US, [6]Mayo Clinic, Rochester, US, [7]Levine Cancer Institute-Concord - Carolinas HealthCare System, Concord, US, [8]The M.D. Anderson Cancer Center, Houston, US

11:30 - 11:35

244MO - A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)

A. Demichele[1], A. Clark[1], L. Bayne[1], K. Rohn[1], I. Nivar[1], P. Wileyto[2], L. Berry[3], S. Deluca[1], J. Savage[1], I. Makhlin[1], T.C. Pan[2], J. Graves[2], G. Belka[2], J. Wang[2], N. Shih[1], D. Berry[3], A. Nayak[1], M. Feldman[4], L. Chodosh[2], [1]University of Pennsylvania, Philadelphia, US, [2]University Of Pennsylvania, Philadelphia, US, [3]Berry Consultants, Austin, US, [4]Indiana University, Indianapolis, US

11:35 - 11:45

Invited Discussant 243MO and 244MO

A. Kwong, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, HK

10:15 - 11:45 **Type: Special symposium** **Granada Auditorium - Hall 3**
Title: Challenging the status quo of early phase clinical trial design: Project Optimus
Chair(s): Emiliano Calvo, ES; Mirat Shah, US

10:15 - 10:20 **Introduction and scientific background**
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

10:20 - 10:35 **Project Optimus update**
M. Ratain, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

10:35 - 10:50 **Investigator perspective**
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

10:50 - 11:00 **Regulatory perspective: FDA**
M. Shah, U.S. Food and Drug Administration, Silver Spring, US

11:00 - 11:10 **Pharmaceutical industry perspective**

S. Arora, AstraZeneca Pharmaceuticals LP, Gaithersburg, US

11:10 - 11:25 **Patient advocacy perspective**
J. Feldman, EGFR Resisters, Deerfield, US

11:25 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**
M. Shah, U.S. Food and Drug Administration, Silver Spring, US

10:15 - 11:40 **Type: Proffered Paper session** **Burgos Auditorium - Hall 3**
Title: Proffered Paper session - Investigational immunotherapy
Chair(s): Gary Middleton, GB; Alessandra Curioni-Fontecedro, CH

10:15 - 10:25 **1016O - Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC**
L. Flatz[1], M. Frueh[2], V. Walter[3], A.-K. Jochum[2], S. Diem[4], E. Jaeger[5], C. Antonio[6], C. Schürch[3], C. Driessen[4], M. Brutsche[6], J. Walz[7], H.-G. Rammensee[3], B. Becher[8], A. Tufman[9], N. Nunez[10], M. Joerger[4], L. Zender[7], H. Läubli[11], F. Berner[4], N. Wyss[2], [1]Universitätsklinikum Tübingen, Tuebingen, DE, [2]Cantonal Hospital, St. Gallen, CH, [3]Universität Tübingen, Tübingen, DE, [4]Kantonsspital St. Gallen, St. Gallen, CH, [5]KHNW - Krankenhaus Nordwest GmbH, Frankfurt am Main, DE, [6]Cantonal Hospital, St.Gallen,

CH, [7]University Clinic Tübingen, Tuebingen, DE, [8]UZH - Universität Zürich, Zurich, CH, [9]LMU Klinikum der Universität München, Munich, DE, [10]Universidad Nacional de Cordoba, Cordoba, AR, [11]Universitatsspital Basel, Basel, CH

10:25 - 10:35 **Invited Discussant 1016O**

G. Middleton, Institute of Cancer and Genomic Sciences - University of Birmingham, Birmingham, GB

10:35 - 10:45 **Q&A**

10:45 - 10:55 **1017O - NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma**

J. Borgers[1], D. Lenkala[2], B. Mccarthy[2], V. Kohler[2], S. Hymson[2], K. Esaulova[2], O. Finney[2], K. Balogh[2], S. Klobuch[1], C. Nijenhuis[3], R. Gaynor[2], M. Demario[2], J. Haanen[1], M. Van Buuren[2], [1]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [2]BioNTech US, Cambridge, US, [3]Netherlands Cancer Institute, Amsterdam, NL

10:55 - 11:05 **1018O - Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer**

C. Qi[1], L. Chang[1], J. Li[1], J. Gong[1], X. Wang[1], Z. Wang[1], X. Lu[2], T. He[2], Y. Ding[2], F. Wu[2], D. Liu[2], L. Shen[1], [1]Peking University Cancer Hospital and Institute, Beijing, CN, [2]Beijing Imunopharm Technology Co., Ltd., Beijing, CN

11:05 - 11:15 **1019O - Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors**

V. Moreno Garcia[1], E. Calvo[2], A. Asch[3], M. Butler[4], J. Zugazagoitia[5], J. Charlson[6], A. Cervantes[7], B. Van Tine[8], D. Aggen[9], J. Clarke[10], M. Johnson[11], M. Wileman[12], A. Liddle[12], R. Naidoo[12], F. Brophy[13], M. Rosenberg[13], D. Jolliffe[14], D. Williams[15], E. Norry[13], D. Hong[16], [1]START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, ES, [2]Centro Integral Oncológico Clara Campal, Madrid, ES, [3]Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, US, [4]Department of Immunology, University of Toronto, Toronto, CA, [5]Hospital Universitario 12 de Octubre, Madrid, ES, [6]Medical College of Wisconsin, Milwaukee, US, [7]University of Valencia, Valencia, ES, [8]Washington University School of Medicine, St. Louis, US, [9]Memorial Sloan Kettering Cancer Center, New York, US, [10]Duke Cancer Center, Durham, US, [11]Sarah Cannon Research Institute, Nashville, US, [12]Adaptimmune Ltd, Abingdon-on-Thames, GB, [13]Adaptimmune, Philadelphia, US, [14]Adaptimmune, Abingdon, Oxfordshire, GB, [15]Adaptimmune Therapeutics plc, Philadelphia, US, [16]The University of Texas MD Anderson Cancer Center, Houston, US

11:15 - 11:30 **Invited Discussant 1017O, 1018O and 1019O**

I.-M. Svane, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK

11:30 - 11:40 **Q&A**

10:15 - 11:45 **Type: Multidisciplinary session** **Salamanca Auditorium - Hall 3**
Title: What is the optimal therapeutic approach following progression on front line PARP inhibitor maintenance therapy in ovarian cancer?
Chair(s): Antonio Gonzalez Martin, ES; Sven Mahner, DE

10:15 - 10:20 **Presentation of case/condition**
A. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES

10:20 - 10:35 **The role of surgery**
S. Mahner, University Hospital, LMU Munich, München, DE

10:35 - 10:50 **Systemic treatment options following progression on PARPi**
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

10:50 - 11:05 **Novel treatment options for PARPi resistant ovarian cancer**
C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB

11:05 - 11:20 **Understanding and overcoming resistance to PARP inhibitors: What is the way forward?**
J. Jonkers, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

11:20 - 11:45 **Discussion**

10:15 - 11:45 **Type: Special session** **León Auditorium - Hall 7**

Title: ESMO/ASCO Global Curriculum: Medical oncology Training: Challenges and opportunities

Chair(s): Tanja Cufer, SI; Kalijn Bol, NL

10:15 - 10:20 **Introduction**

K. Bol, Radboud University Medical Center, Nijmegen, Nijmegen, NL

10:20 - 10:35 **Development and update of the ESMO/ASCO Global Curriculum: Why and how**

T. Cufer, University of Ljubljana - Faculty of Medicine, Ljubljana, SI

10:35 - 10:50 **Using the ESMO/ASCO Global Curriculum and Log Book to improve educational content: The perspective of the mentor**

K. Bol, Radboud University Medical Center, Nijmegen, Nijmegen, NL

10:50 - 11:05 **Optimizing learning in a fast-paced training environment: The perspective of the trainee**

M. Fontes E Sousa, Hospital CUF Tejo, Lisbon, PT

11:05 - 11:20 **Integrating global standards in medical oncology training: The perspective of the trainee**

K. Sharma, AKUH - Aga Khan University Hospital - Nairobi, Nairobi, KE

11:20 - 11:35 **The role of the Global Curriculum in the era of digital health and artificial intelligence**

R. Dienstmann, Grupo Oncoclinicas, Sao Paulo, BR

11:35 - 11:45 **Discussion and Q&A**

10:15 - 11:45	**Type: Special session** **Title: In collaboration with the IARC - Cancer prevention: What every oncologist must know** Chair(s): Jean-Yves Blay, FR; Elisabete Weiderpass, FR	**Cádiz Auditorium - NCC**

10:15 - 10:20 **Introduction**

J.-Y. Blay, Centre Léon Bérard, Lyon, FR

10:20 - 10:35 **Presentation of the IARC-ESMO survey results on the educational needs of medical oncologists on cancer**

J.-Y. Blay, Centre Léon Bérard, Lyon, FR

10:35 - 10:50 **The IARC World Cancer Report Updates Learning Platform – Supported by ESMO**

E. Weiderpass, International Agency for Research on Cancer, Lyon, FR

10:50 - 11:05 **The present and future of lung cancer screening: What does the scientific evidence show?**

J. Aerts, Erasmus MC - University Medical Center, Rotterdam, NL

11:05 - 11:20 **IARC's European Code Against Cancer: The EONS-ESMO campaign**

L. Sharp, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE

11:20 - 11:35 **WHO's cancer prevention policy resolutions, best buys, and framework convention on tobacco control**

A. Ilbawi, WHO - World Health Organization, Geneva, CH

11:35 - 11:45 **Discussion**

10:15 - 11:30 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Professional and educational issues in cancer nursing
Chair(s): Julio de la Torre-Montero, ES

10:15 - 10:30 **Moral dilemmas of (cancer) nurses**
W. Oldenmenger, Erasmus MC Cancer Institute, Rotterdam, NL

10:30 - 10:45 **European College of Cancer Nursing: An evaluation of learning**
W. Mcinally, Open University, Edinburgh, GB

10:45 - 11:00 **Developing cancer nursing services in low- and middle-income countries**
M. Fowler, Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB

11:00 - 11:10 **CN5 - Shared decision making in rectal cancer surgery: The way to go?**
E. Pape[1], J. Dobbelaer[1], D. Van De Putte[2], K. Geboes[3], A. Van Hecke[4], I. Vlerick[4], G. Van Ramshorst[1], Y. Van Nieuwenhove[1], [1]UZ Gent - University Hospital Ghent, Gent, BE, [2]UZ Gent - University Hospital Ghent, Ghent, BE, [3]UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, [4]Ghent University - University Centre for Nursing and Midwifery, Ghent, BE

11:10 - 11:20 **CN77 - EONS advocacy toolkit: How to let your voice be heard as a cancer nurse**
D. Protogiros[1], M. Van Klinken[2], G. Suchodolska[3], T. Theologia[4], G. Catania[5], G. Knötgen[6], [1]Ministry of Health, Athens, GR, [2]Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, [3]Medical University of Gdańsk, Gdansk, PL, [4]Cyprus University of Technology - Nursing Science, Limassol, CY, [5]University of Genova, Genova, IT, [6]German Cancer Nursing Society, Munich, DE

11:20 - 11:30 **Q&A and discussion**

10:30 - 11:15 **Type: Challenge your Expert** **Valencia Auditorium - Hall 10**
Title: When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC)?
Chair(s): Karen Gelmon, CA

10:30 - 10:50 **Presentation by Expert**
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

10:50 - 11:15 **Discussion led by Chair**
K. Gelmon, BC Cancer Agency - Vancouver, Vancouver, CA

10:30 - 11:15 **Type: Challenge your Expert** **Málaga Auditorium - Hall 10**
Title: Looking ahead in SCLC: From biology to clinical practice
Chair(s): Maurice Pérol, FR

10:30 - 10:50 **Presentation by Expert**
T. Owonikoko, University of Pittsburgh, Pittsburgh, US

10:50 - 11:15 **Discussion led by Chair**
M. Pérol, Centre Léon Bérard, Lyon, FR

10:30 - 11:45 **Type: Multidisciplinary session** **Santander Auditorium - Hall 9**
Title: Rectal cancer with oligometastatic disease
Chair(s): Thomas Gruenberger, AT; Claudia Cardone, IT

10:30 - 10:35 **Case/condition presentation**
C. Cardone, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT

10:35 - 10:50 **How to perform an accurate staging?**
R. Beets-Tan, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

10:50 - 11:05 **Options for the choice of the systemic therapy**
G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE

11:05 - 11:20 **Radiotherapy and timing**
K. Haustermans, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

11:20 - 11:35 **Timing and modality of surgical intervention**
T. Gruenberger, Wiener Gesundheitsverbund - Klinik Favoriten, Vienna, AT

11:35 - 11:45 **Discussion**

10:30 - 11:15	**Type: Challenge your Expert** **Title: Adrenocortical carcinoma** Chair(s): Cristina Ronchi, GB	**Toledo Auditorium - Hall 3**

10:30 - 10:50 **Presentation by Expert**

A. Berruti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

10:50 - 11:15 **Discussion led by Chair**

C. Ronchi, The University of Birmingham - Medical School, Birmingham, GB

10:30 - 11:15	**Type: Challenge your Expert** **Title: When to stop systemic anticancer treatment in patients with advanced malignancy?** Chair(s): Gudrun Kreye, AT	**Oviedo Auditorium - Hall 7**

10:30 - 10:50 **Presentation by Expert**

S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

10:50 - 11:15 **Discussion led by Chair**

G. Kreye, Universitätsklinikum Krems, Krems an der Donau, AT

11:00 - 11:45	**Type: Young Oncologists session** **Title: YO Brunch 3: Establishing successful global research collaborations and network** Chair(s): Kevin Punie, BE	**Ávila Auditorium - NCC**

11:00 - 11:15 **Establishing successful global research collaborations and networks**

A. Awada, Institute Jules Bordet, Brussels, BE

11:15 - 11:45 **Discussion led by Chair**

K. Punie, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

12:00 - 12:30	**Type: Keynote lecture** **Title: Elucidating cancer biology, and transforming cancer care, through academic drug development** Chair(s): Lillian Siu, CA	**Barcelona Auditorium - Hall 9**

12:00 - 12:05 **Introduction by the Chair**

L. Siu, Princess Margaret Cancer Centre, Toronto, CA

12:05 - 12:30 **Elucidating cancer biology, and transforming cancer care, through academic drug development**

J. De Bono, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB

12:00 - 13:30	**Type: EONS Industry Satellite Symposium** **Title: MSD - Treatment and management of IO +/- TKi in advanced and recurrent endometrial cancer** Chair(s): Silvia Mazzanti, IT	**Alicante Auditorium - Hall 10**

12:00 - 12:05 **Introductions and Objectives**

S. Mazzanti, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

12:05 - 12:25 **Current landscape in the treatment and management of endometrial cancer patients**

V. Makker, Memorial Sloan-Kettering Cancer Center, New York City, US

12:25 - 12:50 **Understanding the AE management of patients receiving the IO +/- TKI treatments**

S. Mazzanti, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

12:50 - 13:15 **Challenges in endometrial cancer patient education and preparation prior to treatment**

J. Serra López, Hospital de la Santa Creu i Sant Pau, Barcelona, ES

13:15 - 13:25 **Q&A**

S. Mazzanti[1], V. Makker[2], J. Serra López[3], [1]IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, [2]Memorial Sloan-Kettering Cancer Center, New York City, US, [3]Hospital de la Santa Creu i Sant Pau, Barcelona, ES

13:25 - 13:30 **Conclusions**

S. Mazzanti, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

13:00 - 14:30 **Type: Industry Satellite Symposium**
Title: Exact Sciences - Shifting the Paradigm in Cancer Screening: Multi-cancer Early Detection (MCED) Testing
Burgos Auditorium - Hall 3

Chair(s): Elizabeth O'Donnell, US; Tomasz Beer, US

13:00 - 13:05 **Welcome and Introductions**

E. O'Donnell, Dana Farber Cancer Institute, Boston, US

13:05 - 13:15 **Meeting the Unmet Needs in Cancer Screening**

C. Marinac, Dana Farber Cancer Institute, Boston, US

13:15 - 13:30 **Advancements in Tumor Biology and Circulating Biomarkers: Application in Early Cancer Detection**

N. Papadopoulos, Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US

13:30 - 13:45 **A Multi-Biomarker Approach to MCED Test Design: Optimizing Performance to Help Enhance Future Clinical Impact**

F. Diehl, Exact Sciences Corporation, Madison, US

13:45 - 14:00 **Demonstrating the Potential Clinical Value of MCED Testing**

T. Beer, Exact Sciences Corporation, Madison, US

14:00 - 14:10 **The Future Paradigm of Cancer Screening**

E. O'Donnell, Dana Farber Cancer Institute, Boston, US

14:10 - 14:30 **Summary and Q&A**

C. Marinac, Dana Farber Cancer Institute, Boston, US

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Mirati Therapeutics, Inc. - New horizons in the treatment of KRAS-driven NSCLC and GI cancers** Chair(s): Luis Paz-Ares, ES	**Valencia Auditorium - Hall 10**

13:00 - 13:05 **Welcome & Introduction**

L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

13:05 - 13:30 **Recent advances in targeting KRASG12C-mutated NSCLC**

L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

13:30 - 13:55 **Targeting KRAS in GI cancers: where are we now?**

A. Parikh, MGH - Massachusetts General Hospital, Boston, US

13:55 - 14:15 **The key role of biomarker testing in precision medicine**

K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB

14:15 - 14:30 **Q&A**

L. Paz-Ares[1], A. Parikh[2], K. Kerr[3], [1]Hospital Universitario 12 de Octubre, Madrid, ES, [2]MGH - Massachusetts General Hospital, Boston, US, [3]Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Sanofi Regeneron - Considerations for Frontline Immunotherapy in NSCLC: A Case-Based Discussion** Chair(s): Martin Reck, DE	**Salamanca Auditorium - Hall 3**

13:00 - 13:05 **Welcome and Introduction**

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

13:05 - 13:30 **Mono vs combination therapy: identifying if less is more in complex patient cases**

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

13:30 - 13:55 **Tailoring the approach: selecting the optimal immunotherapy combination regimen**

D. Rodriguez Abreu, Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES

13:55 - 14:20 **Navigating difficult-to-treat populations: additional considerations for using immunotherapy**

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

14:20 - 14:30 **Group Discussion**

M. Reck[1], L. Hendriks[2], D. Rodriguez Abreu[3], [1]Krankenhaus Grosshansdorf, Grosshansdorf, DE, [2]Maastricht University Medical Center (MUMC), Maastricht, NL, [3]Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES

13:00 - 14:30 **Type: Industry Satellite Symposium**
Title: Bristol Myers Squibb - The Changing Paradigm of Melanoma Treatment: A Clinical Update for 2023
Málaga Auditorium - Hall 10

Chair(s): Eva Muñoz Couselo, ES

13:00 - 13:05 **Welcome and Introduction**

E. Muñoz Couselo, Vall d'Hebron University Hospital, Barcelona, ES

13:05 - 13:25 **Navigating the Adjuvant Setting: Who, When, and What?**

E. Muñoz Couselo, Vall d'Hebron University Hospital, Barcelona, ES

13:25 - 13:45 **Current and Emerging Neoadjuvant Treatment Options for Resectable Melanoma**

S. Patel, MD Anderson Cancer Center, Houston, US

13:45 - 14:05 **Panel Discussion: Factors Impacting Treatment Selection for Resectable Melanoma**

E. Muñoz Couselo[1], S. Patel[2], D. Schadendorf[3], [1]Vall d'Hebron University Hospital, Barcelona, ES, [2]MD Anderson Cancer Center, Houston, US, [3]WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

14:05 - 14:25 **Evidence-Based Considerations for the First-Line Treatment of Metastatic Melanoma**

D. Schadendorf, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

14:25 - 14:30 **Summary and Close**

E. Muñoz Couselo, Vall d'Hebron University Hospital, Barcelona, ES

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Seagen - Case by Case: Strategic Sequencing Considerations in 3L HER2+ Metastatic Breast Cancer (MBC)** Chair(s): Cristina Saura Manich, ES	**Santander Auditorium - Hall 9**

13:00 - 13:05 **Welcome and Introductions**

C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES

13:05 - 13:20 **Embracing Change: Uncovering Challenges and Opportunities in the Changing Treatment Landscape of HER2+ MBC**

C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES

13:20 - 13:40 **Decision-making in 3L Following T-DXd Progression (Case-based discussion)**

J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US

13:40 - 14:00 **Decision-making in 3L Progression With CNS Involvement (Case-based discussion)**

M. De Laurentiis, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT

14:00 - 14:15 **Charting the Course: Navigating the Landscape From Real-world Evidence to Future Studies**

J. Gligorov, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR

14:15 - 14:25 **Q&A**

C. Saura Manich[1], J. O'Shaughnessy[2], M. De Laurentiis[3], J. Gligorov[4], [1]Vall d'Hebron University Hospital, Barcelona, ES, [2]Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, [3]Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, [4]Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR

14:25 - 14:30 **Closing Remarks**

C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES

13:00 - 14:30	**Type: Industry Satellite Symposium** **Title: Myriad Genetics - Accessing cutting-edge precision oncology through local testing** Chair(s): Carsten Denkert, DE; Pascal Pujol, FR	**Toledo Auditorium - Hall 3**

13:00 - 13:05 **HRD round table**

P. Pujol, Hopital Arnaud de Villeneuve, Montpellier, FR

13:05 - 13:25 **Optimal HRD ovarian cancer treatment - Are genomic tests interchangeable?**

C. Denkert[1], B. You[2], F. Marmé[3], [1]UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, [2]Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, [3]UMM - Universitaetsklinikum Mannheim - Medizinische Fakultaet, Mannheim, DE

13:25 - 13:40 **How to implement local LoE1A HRD testing: experience of a center of excellence**

C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE

13:40 - 13:50 **Live Q&A**

P. Pujol[1], C. Denkert[2], B. You[3], F. Marmé[4], [1]Hopital Arnaud de Villeneuve, Montpellier, FR, [2]UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, [3]Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, [4]UMM - Universitaetsklinikum Mannheim - Medizinische Fakultaet, Mannheim, DE

13:50 - 14:10 **Real world prospective data support prognostic and predictive second-generation breast cancer signature performance**

M. Kiechle, E. Klein, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

14:10 - 14:20 **Live Q&A**

C. Denkert[1], M. Kiechle[2], E. Klein[2], [1]UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, [2]Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

14:20 - 14:30 **Conclusion**

C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE

13:00 - 14:30 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 7**
Title: Novocure GmbH - The evolving role of TTFields therapy in solid tumors

Chair(s): Jalid Sehouli, DE; Joachim Aerts, NL

13:00 - 13:05 **Welcome**

J. Sehouli[1], J. Aerts[2], [1]Charité - Universitaetsmedizin Berlin, Berlin, DE, [2]Erasmus MC - University Medical Center, Rotterdam, NL

13:05 - 13:20 **Practice changing experience of TTFields therapy in Glioblastoma**

S. Rieken, Universitätsmedizin Göttingen, Goettingen, DE

13:20 - 13:35 **Evolving role of TTFields therapy in NSCLC**

J. Aerts, Erasmus MC - University Medical Center, Rotterdam, NL

13:35 - 13:50 **Bringing change with TTFields therapy in ovarian cancer**

J. Sehouli, Charité - Universitaetsmedizin Berlin, Berlin, DE

13:50 - 14:30 **Fireside chat**

B. Monk[1], J. Aerts[2], J. Sehouli[3], S. Rieken[4], T. Macarulla[5], [1]The University of Arizona, Tucson, US, [2]Erasmus MC - University Medical Center, Rotterdam, NL, [3]Charité - Universitaetsmedizin Berlin, Berlin, DE, [4]Universitätsmedizin Göttingen, Goettingen, DE, [5]Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

13:00 - 14:30 **Type: Industry Satellite Symposium** **León Auditorium - Hall 7**
Title: Novartis - Navigating the evolving mCRPC landscape: Your questions, their answers

Chair(s): Alicia Morgans, US

13:00 - 13:10 **Welcome, introduction and educational objectives: Treatment landscape evolution in mCRPC**

A. Morgans, Dana Farber Cancer Institute, Boston, US

13:10 - 13:29 **Treatment of advanced prostate cancer: Frequently asked questions - How do I choose the right treatment for my patient with mCRPC?**

A. Morgans[1], E. Castro[2], B. Hadaschik[3], I. Burger[4], [1]Dana Farber Cancer Institute, Boston, US, [2]Hospital Universitario 12 de Octubre, Madrid, ES, [3]WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, [4]KSB - Kantonsspital Baden, Baden, CH

13:29 - 13:47 **Is there a right sequence in advanced prostate cancer?**

A. Morgans[1], E. Castro[2], B. Hadaschik[3], I. Burger[4], [1]Dana Farber Cancer Institute, Boston, US, [2]Hospital Universitario 12 de Octubre, Madrid, ES, [3]WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, [4]KSB - Kantonsspital Baden, Baden, CH

13:47 - 14:05 **What is the right approach to interdisciplinary/MDT collaborations?**

A. Morgans[1], E. Castro[2], B. Hadaschik[3], I. Burger[4], [1]Dana Farber Cancer Institute, Boston, US, [2]Hospital Universitario 12 de Octubre, Madrid, ES, [3]WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, [4]KSB - Kantonsspital Baden, Baden, CH

14:05 - 14:25 **Patient case discussion**

A. Morgans[1], E. Castro[2], B. Hadaschik[3], I. Burger[4], [1]Dana Farber Cancer Institute, Boston, US, [2]Hospital Universitario 12 de Octubre, Madrid, ES, [3]WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, [4]KSB - Kantonsspital Baden, Baden, CH

14:25 - 14:30 **Closing remarks**

A. Morgans, Dana Farber Cancer Institute, Boston, US

13:00 - 14:30 **Type: Patient Advocacy session** **Cádiz Auditorium - NCC**
Title: People at the centre of cancer care
Chair(s): Stefan Gijssels, BE

13:00 - 13:15 **People at the centre**
S. Gijssels, Patient Expert Center, Brussels, BE

13:15 - 13:30 **Patient satisfaction during treatment and after care**
J. Geissler, Leukemia Patient Advocates Foundation - LeukaNET e.V., Riemerling (Hohenbrunn), DE

13:30 - 13:45 **Personalised treatment: Reflections on CAR-T therapy**
J. Clark, Lymphoma Coalition, Motovun, HR

13:45 - 14:00 **A journalist's approach to advocacy for improved access to diagnosis and treatment**
I. Mantiñan Búa, ASARGA - La Asociación Sarcomas de Galicia, Carballo, ES

14:00 - 14:15 **Advocating for cancer care in Armenia**
H. Martirosyan, "HENARAN" charitable foundation, Yerevan, AM

14:15 - 14:30 **Discussion**

13:45 - 14:45 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: EONS-EBMT collaborative session
Chair(s): Johan De Munter, BE

13:45 - 14:00 **Developing a CAR-T service**
A. Tooley, Southampton General Hospital, Southampton, GB

14:00 - 14:15 **CAR-T therapy and impact to patient outcomes and experience of treatment**
M. Hellberg-Naegele, Kantonsspital St. Gallen, St. Gallen, CH

14:15 - 14:25 **CN7 - The effect of using mobile application on supportive care needs, distress and quality of life in hematopoietic stem cell transplant patients: Randomized controlled study**
D. Başcı[1], S. Kav[2], [1]University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TR, [2]Baskent University Faculty of Health Sciences, Ankara, TR

14:25 - 14:35 **CN78 - Chimeric antigen receptor T cell (CAR T) nursing educational pathway: Reporting on participant feedback**
A. O'Halloran[1], S. Impey[2], D. Byrne[1], M. Gillespie[1], K. Mc Tague[2], [1]St. James's Hospital, Dublin, IE, [2]Trinity College Dublin, Dublin, IE

14:35 - 14:45 **Q&A and discussion**

14:45 - 16:15 **Type: Special symposium** **Barcelona Auditorium - Hall 9**
Title: Controversies in early stage triple negative breast cancer
Chair(s): Valentina Guarneri, IT; Rebecca Dent, SG

14:45 - 14:50 **Introduction and scientific background**
V. Guarneri, University of Padua, Padova, IT

14:50 - 15:05 **Optimal neo-adjuvant therapy in TNBC: Does one size fit all?**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

15:05 - 15:20 **Individualisation of adjuvant therapy in TNBC: Who gets what?**
V. Guarneri, University of Padua, Padova, IT

15:20 - 15:35 **What to do with stage 1 TNBC: Can we deescalate systemic therapy?**
P. Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

15:35 - 15:50 **Role of biomarkers / ctDNA monitoring in therapy decisions**
A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

15:50 - 16:10 **Discussion**

16:10 - 16:15 **Conclusions and perspectives**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

14:45 - 15:55 **Type: Mini Oral session** **Sevilla Auditorium - Hall 9**
Title: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Chair(s): Edward Garon, US; Matthias Guckenberger, CH

14:45 - 14:50 **LBA57 - Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression**

M. Provencio Pulla[1], P. Forde[2], J. Spicer[3], C. Wang[4], S. Lu[5], T. Mitsudomi[6], M. Awad[7], E. Felip[8], S. Broderick[2], S.J. Swanson[7], J. Brahmer[2], K. Kerr[9], G. Saylors[10], F. Tanaka[11], K.-N. Chen[12], M. Tran[13], J.L. Cai[13], J. Mahmood[13], S. Meadows-Shropshire[13], N. Girard[14], [1]Hospital Universitario Puerta de Hierro, Madrid, ES, [2]The Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, [3]McGill University Health Centre, Montreal, CA, [4]Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, [5]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, [6]Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, JP, [7]Dana-Farber Cancer Institute, Boston, US, [8]Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, ES, [9]Aberdeen Royal Infirmary, Aberdeen, GB, [10]Charleston Oncology, Charleston, US, [11]University of Occupational and Environmental

Health, Kitakyushu, JP, [12]Peking University School of Oncology, Beijing Cancer Hospital, Beijing, CN, [13]Bristol Myers Squibb, Princeton, US, [14]Institut Curie, Paris, FR

14:50 - 14:55

1264MO - IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)

N. Altorki[1], M. Reck[2], H. Wakelee[3], E. Felip[4], E. Vallieres[5], R. Liersch[6], S. Oizumi[7], H. Tanaka[8], S. Novello[9], S. Mccune[10], H. Li[11], L. Molinero[12], S. Müller[12], E. Bennett[12], B. Gitlitz[12], V. Mcnally[13], M. Ballinger[12], B. Nabet[12], M. Srivastava[12], C. Zhou[14], [1]NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, [2]Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, DE, [3]Stanford University School of Medicine, Stanford Cancer Institute, Stanford, US, [4]Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, [5]Swedish Cancer Institute, Seattle, US, [6]Clemenshospital Muenster, Muenster, DE, [7]National Hospital Organization Hokkaido Cancer Center, Hokkaido University Hospital, Sapporo, JP, [8]Niigata Cancer Center Hospital, Niigata, JP, [9]University of Turin, AOU San Luigi Gonzaga, Orbassano, Turin, IT, [10]Northwest Georgia Oncology Centers, Marietta, US, [11]Hoffmann-La Roche Limited, Mississauga, CA, [12]Genentech, Inc., South San Francisco, US, [13]Roche Products Ltd, Welwyn Garden City, GB, [14]Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, CN

14:55 - 15:00

LBA58 - Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial

D. Yue[1], W. Wang[2], H. Liu[3], Q. Chen[4], C. Chen[5], J. Zhang[6], F. Bai[7], C. Wang[1], [1]Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, [2]Hunan Cancer Hospital, Hunan, CN, [3]Liaoning Cancer Hospital and Institute, Shenyang, CN, [4]Zhejiang Cancer Hospital, Hangzhou, CN, [5]Fujian Medical University Union Hospital, Fuzhou, CN, [6]BeiGene USA, Inc., San Mateo, US, [7]BeiGene (Shanghai) Co., Ltd., Shanghai, CN

15:00 - 15:05

LBA59 - Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial

M. Reck[1], D. Gale[2], D. Harpole[3], J. Taube[4], T. Mitsudomi[5], M. Hochmair[6], T. Winder[7], Z. Zhu[8], Z. Lai[9], R. Stewart[2], D. Hodgson[2], G. Doherty[2], J. Heymach[10], [1]Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, [2]AstraZeneca, Cambridge, GB, [3]Duke University Medical Center, Durham, US, [4]Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, US, [5]Kindai University Faculty of Medicine, Osaka-Sayama, JP, [6] Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, [7]Landeskrankenhaus Feldkirch, Feldkirch, AT, [8]AstraZeneca, Gaithersburg, US, [9]AstraZeneca, Waltham, US, [10]The University of Texas, M.D. Anderson Cancer Center, Houston, US

15:05 - 15:20

Invited Discussant LBA57, 1264MO, LBA58 and LBA59

E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

15:20 - 15:25

LBA61 - Durvalumab (durva) after sequential chemoradiotherapy (CRT) in

patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6

M. Garassino[1], J. Mazieres[2], M. Reck[3], C. Chouaid[4], H. Bischoff[5], N. Reinmuth[6], L. Cove-Smith[7], T. Mansy[8], D. Cortinovis[9], M.R. Migliorino[10], A. Delmonte[11], J. García Sanchez[12], L.E. Chara Velarde[13], R. Bernabe Caro[14], L. Paz-Ares[15], P. Chander[16], I. Diaz Perez[16], K. Foroutanpour[16], C. Faivre-Finn[17], [1]University of Chicago, Chicago, US, [2]Institut Universitaire du Cancer de Toulouse, Toulouse, FR, [3]Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, [4]Centre Hospitalier Intercommunal de Créteil, Créteil, FR, [5]Universitätsklinikum Heidelberg, Heidelberg, DE, [6]Asklepios Fachkliniken München-Gauting, and German Center for Lung Research (DZL), Gauting, DE, [7]The Christie NHS Foundation Trust and Manchester University Hospitals Foundation Trust, Manchester, GB, [8]James Cook University Hospital, Middlesbrough, GB, [9]Fondazione IRCCS San Gerardo dei Tintori, Monza, IT, [10]San Camillo-Forlanini Hospital, Rome, IT, [11]IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, IT, [12]Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana (FISABIO), Valencia, ES, [13]Hospital Universitario de Guadalajara, Guadalajara, ES, [14]Hospital Universitario Virgen del Rocio, Seville, ES, [15]Universidad Complutense, CiberOnc, CNIO and Hospital Universitario 12 de Octubre, Madrid, ES, [16]AstraZeneca, Gaithersburg, US, [17]The University of Manchester and The Christie NHS Foundation Trust, Manchester, GB

15:25 - 15:30

1292MO - A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A

R. Ko[1], A. Mouri[2], A. Kisohara[3], R. Morita[4], T. Nakagawa[5], T. Makiguchi[6], K. Isobe[7], N. Ishikawa[8], T. Kondo[9], M. Akiyama[10], A. Bessho[11], R. Honda[12], K. Yoshimura[13], H. Kagamu[2], S. Kato[14], K. Kobayashi[2], K. Kaira[2], [1]Shizuoka Cancer Center, Shizuoka, JP, [2]Saitama Medical University International Medical Center, Hidaka, JP, [3]Kasukabe medical center, Kasukabe,Saitama Prefecture, JP, [4]Akita Kousei Medical Center, Akita, JP, [5]Omagari Kosei Medical Center, Daisen, JP, [6]Hirosaki University Graduate School of Medicine, Hirosaki, JP, [7]Toho university Medical Center Oomori Hospital, Tokyo, JP, [8]Hiroshima Prefectural Hospital, Hiroshima, JP, [9]Kanagawa Cancer Center, Yokohama, JP, [10]Iwate Medical University, Shiwa-gun, JP, [11]Japanese Red Cross Okayama Hospital, Okayama, JP, [12]Asahi Gereral Hospital, Asahi, JP, [13]Hiroshima University Hospital, Hiroshima, JP, [14]International Medical Center, Saitama Medical University, Hidaka, JP

15:30 - 15:35

LBA62 - Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study

A.R. Filippi[1], M.R. Garcia Campelo[2], J.-B. Paoli[3], D. Kowalski[4], C. Bennati[5], P. Borghetti[6], D. Cortinovis[7], A. Delmonte[8], C. Genova[9], S. Van Hulst[10], R. Mroz[11], S. Nawrocki[12], I. Toledano[13], G. Tonini[14], I. Diaz Perez[15], N. Georgoulia[15], K. Foroutanpour[15], R. Dziadziuszko[16], [1]Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, IT, [2]University Hospital A Coruña, A Coruña, ES, [3]Hôpital Privé Clairval, Marseille, FR, [4]Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, [5]S Maria delle Croci Hospital, AUSL della Romagna, Ravenna, IT, [6]ASST Spedali Civili and University of Brescia, Brescia, IT, [7]Fondazione IRCCS San Gerardo dei Tintori Monza, Monza, IT, [8]IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, IT, [9]IRCCS Ospedale Policlinico San Martino/University of Genoa, Genova, IT,

[10]University Hospital of Nîmes, Nîmes, FR, [11]Medical University of Bialystok, Bialystok, PL, [12]University of Warmia and Mazury in Olsztyn, Olsztyn, PL, [13]CCGM, Clinique Clémentville, Montpellier, FR, [14]Fondazione Policlinico Universitario Campus Bio-Medico/Università Campus Bio-Medico di Roma, Rome, IT, [15]AstraZeneca, Gaithersburg, US, [16]Medical University of Gdansk, Gdansk, PL

15:35 - 15:40

1293MO - Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial

F. Bozorgmehr[1], E. Buchmeier[2], M. Hammer-Hellmig[2], U. Nestle[3], C. Meyer Zum Bueschenfelde[4], F. Weykamp[5], J. Claßen[6], P. Schuett[7], T. Riedel[8], T. Wehler[9], S. Hey-Koch[9], T. Overbeck[10], J. Alt[11], H. Schmidberger[12], R. Behnisch[13], I. Chung[1], M. Thomas[1], S. Rieken[14], [1]Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, DE, [2]Klinikum Köln-Merheim, Köln, DE, [3]Kliniken Maria Hilf, Mönchengladbach, DE, [4]St. Vincentius Hospital Medizinische Klinik II, Karlsruhe, DE, [5]University Hospital Heidelberg, Heidelberg University, Heidelberg, DE, [6]ViDia Karlsruhe Diakonissenkrankenhaus, Karlsruhe, DE, [7]Onkologische Schwerpunktpraxis, Gütersloh, DE, [8]Radioonkologische Praxis, Gütersloh, DE, [9]Sana Klinikum Offenbach GmbH, Offenbach am Main, DE, [10]University Medical Center Göttingen, Göttingen University, Goettingen, DE, [11]University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, DE, [12]Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, [13]Heidelberg University Hospital, Heidelberg, DE, [14]Universitätsmedizin Göttingen, Goettingen, DE

15:40 - 15:55

Invited Discussant LBA61, 1292MO, LBA62 and 1293MO

M. Guckenberger, USZ - University Hospital Zürich, Zurich, CH

14:45 - 16:15	**Type: Special symposium** **Title: Long term survivors in the era of immunotherapy of cancer** Chair(s): Teresa Amaral, DE; Michiel van der Heijden, NL	**Bilbao Auditorium - NCC**

14:45 - 15:05 **Long-term toxicity of immunotherapeutics**

D. Mcdermott, Beth Israel Deaconess Medical Center, Boston, US

15:05 - 15:25 **Quality of life in IO-treated long-term survivors**

L. Van De Poll-Franse, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:25 - 15:45 **Cognitive defects in long term IO**

A. Rogiers, CHU Brugmann UVB, Brussels, BE

15:45 - 16:05 **Ideal duration of IT: How to define it and what are the implications**

T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

16:05 - 16:15 **Discussion**

14:45 - 16:15	**Type: Special session** **Title: Artificial Intelligence in prognostication** Chair(s): Sanjay Aneja, US; Anne Vincent-Salomon, FR	**Granada Auditorium - Hall 3**

14:45 - 15:10 **AI for breast cancer prognostication**

A. Vincent-Salomon, Institut Curie, Paris, FR

15:10 - 15:35 **Biomarkers of response to drugs and radiotherapy**

B. Haibe-Kains, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

15:35 - 16:00 **Digital pathology for immuno-oncology**

M. Salto-Tellez, Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, GB

16:00 - 16:15 **Q&A and Discussion**

14:45 - 16:15	**Type: Special session** **Title: How do we best monitor patients during follow-up?** Chair(s): Christian Rolfo, US; Paolo Bossi, IT	**Valencia Auditorium - Hall 10**

14:45 - 14:50 **Introduction**

C. Rolfo, Icahn School of Medicine at Mount Sinai, New York, US

14:50 - 15:05 **Minimalist or maximalist? From literature to real-world data**

P. Zola, Università di Torino, Torino, IT

15:05 - 15:20 **Radiological imaging vs clinical examination: When less is more**

R. Maroldi, Università degli Studi di Brescia - Facoltà di Medicina e Chirurgia, Brescia, IT

15:20 - 15:35 **Liquid biopsy may improve a tailored follow up**

C. Rolfo, Icahn School of Medicine at Mount Sinai, New York, US

15:35 - 15:50 **The patient's perspective and expectations**

A. Cardone, Cancer Patients Europe, Brussels, BE

15:50 - 16:05 **It is not just survival: Rehabilitation, quality of life and late toxicities**

F. Jansen, Amsterdam University Medical Centers UMC, Amsterdam, NL

16:05 - 16:15 **Discussion**

14:45 - 16:15	**Type: Educational session** **Title: Bringing together thyroid cancer and neuroendocrine tumours** Chair(s): Eric Baudin, FR; Emily Bergsland, US	**Salamanca Auditorium - Hall 3**

14:45 - 15:05 **State-of-the-art in the treatment of advanced neuroendocrine tumours**

E. Bergsland, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

15:05 - 15:25 **State-of-the-art in the treatment of advanced thyroid cancer**

C. Spitzweg, LMU Klinikum der Universität München, Munich, DE

15:25 - 15:45 **What we could learn from each tumour type to improve the management of both**

E. Baudin, Gustave Roussy - Cancer Campus, Villejuif, FR

15:45 - 16:05 **Future directions on targeted agents and beyond in thyroid and neuroendocrine tumours**

E. Grande Pulido, MD Anderson Cancer Center Madrid, Madrid, ES

16:05 - 16:15 **Discussion**

14:45 - 16:15	**Type: Educational session** **Title: Genetic predisposition in patients with sarcoma** Chair(s): Nadia Hindi, ES; Tom Wei-Wu Chen, TW	**Málaga Auditorium - Hall 10**

14:45 - 15:05 **When and why to test a patient with sarcoma for hereditary predisposition**

D. Thomas, Garvan Institute of Medical Research, Sydney, AU

15:05 - 15:20 **How to use radiology in patients with hereditary syndromes**

C. Messiou, The Royal Marsden Hospital - Chelsea, London, GB

15:20 - 15:35 **How to treat bone, soft tissue and GIST patients with a hereditary predisposition: A surgeon's perspective**

S. Bonvalot, Institut Curie, Paris, FR

15:35 - 15:50 **How to treat bone, soft tissue and GIST patients with a hereditary predisposition: A medical oncologist's perspective**

W. Van Der Graaf, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:50 - 16:05 **How to treat sarcoma patients with a hereditary predisposition: A radiation oncologist's perspective**

B. Timmermann, University Hospital Essen - Westdeutsches Protonentherapiezentrum, Essen, DE

16:05 - 16:15 **Discussion**

15:00 - 16:00	**Type: Controversy session** **Title: Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients?** Chair(s): Andres Cervantes, ES	**Burgos Auditorium - Hall 3**

15:00 - 15:05 **Welcome and “set the scene”**

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

15:05 - 15:20 **Yes**

S. Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

15:20 - 15:35 **No**

D. Sebag-Montefiore, St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, GB

15:35 - 15:40 **First voting**

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

15:40 - 15:55 **Perspective from the Chair**

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

15:55 - 16:00 **Second voting**

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

15:00 - 16:15	**Type: Multidisciplinary session** **Title: Management of (very) high-risk localised PCA: How hard should you look and how long should we treat?** Chair(s): Gwenaëlle Gravis, FR; Boris Hadaschik, DE	**Santander Auditorium - Hall 9**

15:00 - 15:05 **Presentation of case/condition**

B. Hadaschik, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

15:05 - 15:15 **Usefulness and limitations of PSMA imaging/PET in high-risk localised disease**

K. Goffin, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:15 - 15:30 **Dose intensification and field expansion of EBRT**

A. Bossi, Gustave Roussy - Cancer Campus, Villejuif, FR

15:30 - 15:45 **Delineating staging pelvic LND before RT and positioning primary prostatectomy**

D. Tilki, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

15:45 - 16:00 **How much systemic treatment is needed and how long?**

G. Gravis, IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR

16:00 - 16:15 **Q&A and Discussion**

15:00 - 15:45	**Type: Challenge your Expert** **Title: Checkpoint inhibition and beyond: New approaches in advanced gastric oesophageal cancer** Chair(s): Tania Fleitas, ES	**Toledo Auditorium - Hall 3**

15:00 - 15:20 **Presentation by Expert**

S.-E. Al-Batran, Nordwest-Krankenhaus, Frankfurt am Main, DE

15:20 - 15:45 **Discussion led by Chair**

T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES

15:00 - 15:45	**Type: Challenge your Expert** **Title: Challenges in the management of Waldenström's macroglobulinemia** Chair(s): Meletios Dimopoulos, GR	**Oviedo Auditorium - Hall 7**

15:00 - 15:20 **Presentation by Expert**

A. Tedeschi, ASST Grande Ospedale Metropolitano Niguarda, Milan, IT

15:20 - 15:45 **Discussion led by Chair**

M. Dimopoulos, Alexandra Hospital, Athens, GR

15:00 - 16:15	**Type: Multidisciplinary session** **Title: Challenging common problems in neuro-oncology** Chair(s): Enrico Franceschi, IT; Emma van Kessel, NL	**León Auditorium - Hall 7**

15:00 - 15:15 **Presentation of case: Low-grade glioma**

E. Van Kessel, UMC - University Medical Center Utrecht, Utrecht, NL

15:15 - 15:30 **Upfront and salvage surgery for low grade gliomas: Do tumour mutations need different strategies?**

A. Jakola, University of Gothenburg - The Sahlgrenska Academy, Göteborg, SE

15:30 - 15:45 **Radiotherapy for low grade gliomas with and without mutations: Wait or treat?**

H. Shih, MGH - Massachusetts General Hospital, Boston, US

15:45 - 16:00 **The optimal radiochemotherapeutic combination for low grade gliomas: Lessons from trials**

E. Franceschi, Ospedale Bellaria Carlo Alberto Pizzardi, Bologna, IT

16:00 - 16:15 **Discussion**

15:00 - 15:45	**Type: Challenge your Expert** **Title: Alcohol consumption and cancer risk: The sobering facts about alcohol and cancer** Chair(s): Gilberto Morgan, SE	**Cádiz Auditorium - NCC**

15:00 - 15:20 **Presentation by Expert**

I. Soerjomataram, IARC - International Agency for Research on Cancer, Lyon, FR

15:20 - 15:45 **Discussion led by Chair**

G. Morgan, Skane University Hospital, Lund, SE

15:00 - 16:00 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: YCN/YO collaborative session

Chair(s): Nikolina Dodlek, HR

15:00 - 15:15 **Personalised cancer care: The physician's perspective**

P. Aftimos, Institute Jules Bordet, Anderlecht, BE

15:15 - 15:30 **Nursing in clinical trials**

H. Mccallig, University Hospital Limerick, Limerick, IE

15:30 - 15:40 **CN60 - Dynamics and processes in the perception of colorectal cancer patients facing skin toxicity due to an EGFR-inhibitor**

M. De Kegel[1], K. Geboes[2], S. De Meyer[2], P. Vandecandelaere[3], E. Pape[4], [1]Ghent University - Campus Ufo, Gent, BE, [2]UZ Gent - University Hospital Ghent, Gent, BE, [3]AZ Delta Campus Rumbeke, Roeselare, BE, [4]UZ Gent - Universitair Ziekenhuis Gent, Gent, BE

15:40 - 15:50 **CN61 - Recognizing and managing immune checkpoint: Related symptoms with expert advice from dedicated oncology nurse**

A. Muratovic, S. Sopaj, U. Janzic, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, SI

15:50 - 16:00 **Q&A and discussion**

16:00 - 17:00 **Type: Young Oncologists session** **Pamplona Auditorium - Hall 9**
Title: YO Clinical Case Discussion sessions

16:00 - 16:00 **Table 1: Immunotherapy in patients with autoimmune disease**

C. Robert[1], A. Starzer[2], [1]Institut Gustave Roussy, Villejuif, Cedex, FR, [2]Medizinische Universitaet Wien, Vienna, AT

16:00 - 16:00 **Table 2: Integration of liquid biopsy in decision making in the management of patients with colon cancer**

A. De Stefano[1], E. Mariamidze[2], [1]Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, [2]Todua Clinic, Tbilisi, GE

16:00 - 16:00 **Table 3: HER2+ breast cancer with brain metastases**

E. De Azambuja[1], P. Mando[2], [1]Institute Jules Bordet, Brussels, BE, [2]CEMIC - Centro de Educacion Medica e Investigacones Clinicas Dr Norberto Quirno, Buenos Aires, AR

16:00 - 16:00 **Table 4: Molecular profiling for cancer of unknown primary**

N. Cook[1], K. Punie[2], [1]The Christie NHS Foundation Trust, Manchester, GB, [2]UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

16:00 - 16:00 **Table 5: Rare sarcomas and the importance of centralised and multidisciplinary care**

K. Kozak[1], P. Sobczuk[2], [1]Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, [2]Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

16:15 - 16:30 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: EONS closing session

16:15 - 16:20 **EONS Poster Awards**

16:20 - 16:25 **ECND 2023 winners**

16:25 - 16:30 **Closing remarks and Farewell**

16:30 - 18:00 **Type: Educational session** **Granada Auditorium - Hall 3**
Title: Adjuvant / neoadjuvant therapy of operable NSCLC in 2023
Chair(s): Heather Wakelee, US; Jarushka Naidoo, IE

16:30 - 16:55 **Current standard of care in adjuvant / neoadjuvant therapy of operable NSCLC**
H. Wakelee, Standford University, Stanford, US

16:55 - 17:20 **Predictive biomarkers for adjuvant / neoadjuvant IO**
N. Girard, Institut Curie, Paris, FR

17:20 - 17:45 **Management of relapse on/after perioperative IO**
M. Frueh, Kantonsspital St. Gallen, St. Gallen, CH

17:45 - 18:00 **Discussion**

16:30 - 18:05 **Type: Mini Oral session** **Cádiz Auditorium - NCC**
Title: Mini oral session - Policy and preventive strategies
Chair(s): James McKay, FR; Tit Albreht, SI; Wendy Tse Yared, BE

16:30 - 16:35 **1692MO - Is project Orbis successful? The Swiss perspective**
M. Pavic, Q. Li, E. Atiek, A. Wolfer, U.-P. Rohr, Swissmedic Swiss Agency for Therapeutic Products, Bern, CH

16:35 - 16:40 **1693MO - The high burden of long-term and late health-related problems among adolescent and young adult cancer survivors: Results of the SURVAYA study**
S. Janssen[1], C. Vlooswijk[2], R. Van Leeuwen[3], S. Kaal[4], J. Kerst[1], J. Tromp[5], M. Bos[6], T. Van Der Hulle[7], R.I. Lalisang[8], J. Nuver[9], M. Kouwenhoven[5], W. Van Der Graaf[1], O. Husson[1], [1]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [2]IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL, [3]UMC - University Medical Center Utrecht, Utrecht, NL, [4]Radboud University Medical Center, Nijmegen, Nijmegen, NL, [5]Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, [6]Erasmus MC - University Medical Center, Rotterdam, NL, [7]LUMC - Universitair Medisch Centrum, Leiden, NL, [8]Maastricht University Medical Center (MUMC), Maastricht, NL, [9]University Medical Center Groningen - umcg, Groningen, NL

16:40 - 16:45 **1694MO - Socio-economic consequences among adolescent and young adult cancer patients: A European perspective**
S. Janssen[1], J. Vancoppenolle[1], N. Franzen[1], W. Van Der Graaf[1], O. Husson[1], V. Retel[1], W. Van Harten[2], [1]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [2]University of Twente, Enschede, NL

16:45 - 16:50 **1695MO - Cancer care during armed conflict: Factors associated with adult**

patient transfer for treatment abroad during the war in Ukraine

I. Huivaniuk[1], D. Kizub[2], V. Kopetskyi[1], A. Dzhemiliev[3], A. Kacharian[1], V. Strilka[1], A. Beznosenko[1], N. Melnitchouk[4], [1]National Cancer Institute of the Ministry of Health of Ukraine, Kiev, UA, [2]MD Anderson Cancer Center, Houston, US, [3]Brigham and Women's Hospital, Boston, US, [4]Harvard Medical School, Boston, US

16:50 - 17:05 **Invited Discussant 1692MO, 1693MO, 1694MO and 1695MO**

J. Mckay, IARC - International Agency for Research on Cancer, Lyon, FR

17:05 - 17:10 **1759MO - Clinical breast examination for early diagnosis of breast cancer: An Egyptian nationwide study**

H. Azim[1], L. Kassem[1], K. Shohdy[1], Y. Safwat[1], E. Khallaf[1], S. Naguib[1], M. Hegazy[2], A. Selim[1], N. Hussein[3], A. Abdelaziz[4], H. El Ghazaly[4], M. Hassany[3], A. Abdelaziz[1], A. Kandil[5], B.A. El Sayed[3], T. Hashem[6], S. Eid[7], A. Morsy[3], K. Abdelghaffar[3], H. Zaid[3], [1]Cairo University, Giza, EG, [2]Mansoura University, Mansoura, EG, [3]Ministry of Health and Population, Cairo, EG, [4]Ain Shams University, Cairo, EG, [5]Alexandria University, Alexandria, EG, [6]Menoufia University, Shebeen El-Kom, EG, [7]Assiut University, Assiut, EG

17:10 - 17:15 **1696MO - Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending**

D. Michaeli[1], C. Michaeli[2], [1]Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, DE, [2]UMM - Universitaetsklinikum Mannheim, Mannheim, DE

17:15 - 17:20 **1697MO - Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases**

J.C. Michaeli[1], C. Michaeli[2], D. Michaeli[3], [1]LMU University Hospital, LMU Munich, Munich, DE, [2]UMM - Universitaetsklinikum Mannheim, Mannheim, DE, [3]Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, DE

17:20 - 17:35 **Invited Discussant 1759MO, 1696MO and 1697MO**

T. Albreht, National Institute of Public Health of Slovenia - Nacionalni institut za javno zdravje, Ljubljana, SI

17:35 - 17:40 **1698MO - E-cigarette use among us ever-smoking cancer survivors and its implications on lung cancer screening**

Q. Wang[1], M. Hsu[1], C. Wen[2], A. Dowlati[1], Y. Zhang[3], C. Jiang[4], D. Bruno[1], Y. Li[5], L. Deng[4], L. Chiec[1], G. Dutcher[1], C.Y. Kong[2], [1]University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, US, [2]Icahn School of Medicine at Mount Sinai, New York, US, [3]Ascension Providence Hospital, Southfield, US, [4]Roswell Park Comprehensive Cancer Center, Buffalo, US, [5]UBC - The University of British Columbia, Vancouver, CA

17:40 - 17:45 **1699MO - Intervening factors for participation and non-participation in colorectal cancer screening in Spain**

M.L. Amador[1], D. De Haro[2], B. Fernández Sánchez[1], M. Lopez[3], M. Blanco Álvarez[1], A.

Fernández Marcos[1], [1]Headquarters Spanish Association Against Cancer (AECC), Madrid, ES, [2]AECC - Asociación Española Contra El Cáncer, MADRID, ES, [3]Asociación Española Contra el Cáncer, MADRID, ES

17:45 - 17:50 **1700MO - Knowledge of cancer risk factors and risk-reduction in 20 high- and middle-income countries**

P. Carrera, S. Calderazzo, DKFZ - German Cancer Research Center, Heidelberg, DE

17:50 - 18:05 **Invited Discussant 1698MO, 1699MO and 1700MO**

W. Tse Yared, Association of European Cancer Leagues, Brussels, BE

16:30 - 18:15 **Type: Proffered Paper session** **Madrid Auditorium - Hall 6**
Title: Presidential 3

Chair(s): Fabrice André, FR; Karin Jordan, DE

16:30 - 16:42 **LBA11 - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial**

A. Bardia[1], K. Jhaveri[2], S.-A. Im[3], S. Pernas Simon[4], M. De Laurentiis[5], S. Wang[6], N. Martinez[7], G. Santos Borges[8], D. Cescon[9], M. Hattori[10], Y.-S. Lu[11], E. Hamilton[12], Q.Y. Zhang[13], J. Tsurutani[14], K. Kalinsky[15], L. Xu[16], N. Denduluri[17], H. Rugo[18], B. Xu[19], B. Pistilli[20], [1]Massachusetts General Hospital Cancer Center, Boston, US, [2]Memorial Sloan Kettering Cancer Center, New York, US, [3]Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, [4]Institut Català d'Oncologia, IDIBELL, L'Hospitalet, L'Hospitalet de Llobregat, ES, [5]Istituto Nazionale Tumori Napoli IRCCS "Fondazione Pascale", Napoli, IT, [6]Cancer Center of SunYet-sen University, Guangzhou, CN, [7]Ramón y Cajal University Hospital, Madrid, ES, [8]Catarina Pesquisa Clínica, Santa Catarina, BR, [9]Princess Margaret Cancer Centre/UHN, Toronto, CA, [10]Aichi Cancer Center, Nagoya, JP, [11]National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, TW, [12]Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, [13]Harbin Medical University Cancer Hospital, Harbin, CN, [14]Showa University Hospital, Tokyo, JP, [15]Winship Cancer Institute at Emory University, Atlanta, US, [16]AstraZeneca, New York, US, [17]AstraZeneca, Arlington, US, [18]University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, US, [19]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, [20]Gustave Roussy Cancer Center, Villejuif, FR

16:42 - 16:54 **LBA12 - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01**

M.-J. Ahn[1], A. Lisberg[2], L. Paz-Ares[3], R. Cornelissen[4], N. Girard[5], E. Pons-Tostivint[6], D. Vicente Baz[7], S. Sugawara[8], M. Cobo Dols[9], M. Pérol[10], C. Mascaux[11], E. Poddubskaya[12], S. Kitazono[13], H. Hayashi[14], J. Sands[15], R. Hall[16], Y. Zhang[17], H. Zebger-Gong[18], D. Uema[17], I. Okamoto[19], [1]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [2]Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, [3]Hospital Universitario 12 de Octubre, Madrid, ES, [4]Erasmus MC Cancer Institute,

Rotterdam, NL, [5]Institut Curie, Paris, FR, [6]University Hospital Nantes, Nantes, FR, [7]Hospital Universitario Virgen Macarena, Seville, ES, [8]Sendai Kousei Hospital, Sendai, JP, [9]Regional and Virgen de la Victoria University Hospitals, Malaga, ES, [10]Léon Bérard Cancer Centre, Lyon, FR, [11]Hôpitaux Universitaires de Strasbourg (CHRU), Strasbourg, FR, [12]Vitamed LLC, Moscow, RU, [13]The Cancer Institute Hospital of JFCR, Tokyo, JP, [14]Kindai University, Osaka, JP, [15]Dana-Farber Cancer Institute, Boston, US, [16]University of Virginia Health System, Charlottesville, US, [17]Daiichi Sankyo, Inc, Basking Ridge, US, [18]Daiichi Sankyo Europe GmbH, Munich, DE, [19]Kyushu University, Fukuoka, JP

16:54 - 17:04 **Invited Discussant LBA11 and LBA12**

S. Chandarlapaty, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

17:04 - 17:10 **Q&A**

17:10 - 17:22 **LBA13 - Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)**

O. Sartor[1], D. Castellano Gauna[2], K. Herrmann[3], J. De Bono[4], N. Shore[5], K.N. Chi[6], M. Crosby[7], J.M. Piulats[8], A. Flechon[9], X. Wei[10], H. Mahammedi[11], G. Roubaud[12], H. Studentova[13], S. Ghebremariam[14], E. Kpamegan[14], T. Kreisl[14], N. Delgoshaie[15], K. Lehnhoff[15], M. Morris[16], K. Fizazi[17], [1]Mayo Clinic - Rochester, Rochester, US, [2]Hospital Universitario 12 de Octubre, Madrid, ES, [3]University of Duisburg-Essen and German cancer consortium (DKTK), partner site University Hospital Essen, Essen, DE, [4]The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, [5]Carolina Urologic Research Center/GenesisCare US, Myrtle Beach, US, [6]BC Cancer and Vancouver Prostate Centre, Vancouver, CA, [7]Veterens Prostate Cancer Awareness Inc, Washington DC, US, [8]ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, [9]Centre Leon Berard, Lyon, FR, [10]Dana Farber Cancer Institute, Boston, US, [11]Centre Jean PERRIN, Clermont-Ferrand, Cedex, FR, [12]Institute Bergonié, Bordeaux, FR, [13]FN Olomouc/ University Hospital Olomouc, Olomouc, CZ, [14]Novartis Pharmaceuticals Corporation, East Hanover, US, [15]Novartis International AG - Basel, Basel, CH, [16]MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, [17]Gustave Roussy, University Paris Saclay, Villejuif, FR

17:22 - 17:30 **Invited Discussant LBA13**

C. Sweeney, The University of Adelaide, Adelaide, AU

17:30 - 17:35 **Q&A**

17:35 - 17:47 **LBA14 - Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial**

B.C. Cho[1], E. Felip[2], A. Spira[3], N. Girard[4], J.-S. Lee[5], S.-H. Lee[6], Y. Ostapenko[7], P. Danchaivijitr[8], B. Liu[9], A. Alip[10], E. Korbenfeld[11], J. Dias[12], T. Sun[13], M. Martinez[13], J.

Bauml[14], M. Shreeve[15], S. Sethi[14], R. Knoblauch[14], H. Hayashi[16], S. Lu[17], [1]Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, [2]Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, [3]Virginia Cancer Specialists, Fairfax, US, [4]Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, FR, [5]Seoul National University Bundang Hospital, Seongnam, KR, [6]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [7]National Cancer Institute, Kyiv, UA, [8]Siriraj Hospital, Mahidol University, Bangkok, TH, [9]Harbin Medical University Cancer Hospital, Harbin, CN, [10]University Malaya Medical Centre, Kuala Lumpur, MY, [11]Hospital Britanico de Buenos Aires, Buenos Aires, AR, [12]Barretos Cancer Hospital, Barretos, BR, [13]Janssen R&D, Raritan, US, [14]Janssen R&D, Spring House, US, [15]Janssen R&D, San Diego, US, [16]Kindai University Faculty of Medicine, Osaka, JP, [17]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN

17:47 - 17:59

LBA15 - Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial

A. Passaro[1], B.C. Cho[2], Y. Wang[3], B. Melosky[4], R. Califano[5], S.-H. Lee[6], N. Girard[7], K. Reckamp[8], T. Takahashi[9], E. Felip[10], R.D. Gentzler[11], S. Popat[12], W. Nassib William Junior[13], T. Sun[14], S. Shah[15], B. Diorio[16], R. Knoblauch[15], J. Bauml[15], M.R. Garcia Campelo[17], J. Wang[18], [1]European Institute of Oncology, IRCCS, Milan, IT, [2]Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, [3]West China Hospital, Sichuan University, Chengdu, CN, [4]British Columbia Cancer Agency, Vancouver, CA, [5]Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, GB, [6]Sungkyunkwan University School of Medicine, Seoul, KR, [7]Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, FR, [8]Cedars-Sinai Medical Center, Los Angeles, US, [9]Shizuoka Cancer Center, Nagaizumi, JP, [10]Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, [11]University of Virginia Cancer Center, Charlottesville, US, [12]Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, GB, [13]Beneficência Portuguesa de São Paulo and Grupo Oncoclínicas, São Paulo, BR, [14]Janssen R&D, Raritan, US, [15]Janssen R&D, Spring House, US, [16]Janssen R&D, Titusville, US, [17]University Hospital A Coruña, A Coruña, ES, [18]Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

17:59 - 18:09

Invited Discussant LBA14 and LBA15

Z. Piotrowska, MGH - Massachusetts General Hospital, Boston, US

18:09 - 18:15

Q&A

16:30 - 18:00 **Type: Mini Oral session** **Valencia Auditorium - Hall 10**
Title: Mini oral session - Developmental therapeutics

Chair(s): Pamela Munster, US; Ulrik Lassen, DK; Philippe Cassier, FR

16:30 - 16:35

656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study

H. Yao[1], M.H. Ryu[2], J. Park[3], M. Voskoboynik[4], J.H. Kim[5], K. Liu[6], M. Barve[7], A. Acuna-

Villaorduna[8], S.-A. Im[9], A.C. Roy[10], L.-Y. Bai[11], C.-J. Yen[12], J. Zhang[13], V. Ganju[14], L. Wu[15], M. Yan[16], L. Bao[17], Y. Zhao[1], S. Rong[18], E. Song[1], [1]Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, [2]Asan Medical Center, Seoul, KR, [3]Macquarie University, Sydney, AU, [4]Alfred Health, Melbourne, AU, [5]Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, [6]Hunan Cancer Hospital, Changsha, CN, [7]Mary Crowley Cancer Research, Dallas, US, [8]Montefiore-Einstein Center for Cancer Care, Bronx, US, [9]Seoul National University, Seoul, KR, [10]Southern Oncology Clinical Research Unit, Adelaide, AU, [11]China Medical University Hospital, Taichung, TW, [12]National Cheng Kung University Hospital, Tainan, TW, [13]Fudan University Shanghai Cancer Center, Shanghai, CN, [14]PASO Medical, Melbourne, AU, [15]Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, [16]Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, [17]HuBei Cancer Hospital, Wuhan, CN, [18]Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, CN

16:35 - 16:40

657MO - Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors

B. Li[1], K.-W. Lee[2], M. Pegram[3], M. Sharma[4], J. Lee[5], A. Spira[6], Y.-K. Kang[7], K. Moore[8], D. Rasco[9], G. Hanna[10], B. Weinberg[11], T. Yu[12], M. Alonso[12], J. Ptacek[12], M. Yin[12], C. Tapia[12], L. Xu[12], E. Perez[12], E. Dumbrava[13], [1]Memorial Sloan Kettering Cancer Center, New York, US, [2]Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si, KR, [3]Stanford Comprehensive Cancer Institute, Stanford, US, [4]START Midwest, Grand Rapids, US, [5]Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, [6]Virginia Cancer Specialist, Fairfax, US, [7]Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, [8]Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, [9]South Texas Accelerated Research Therapeutics (START), San Antonio, US, [10]Dana Farber Cancer Institute, Boston, US, [11]Lombardi Cancer Center Georgetown University, Washington, US, [12]Bolt Biotherapeutics, Inc., Redwood City, US, [13]The University of Texas M. D. Anderson Cancer Center, Houston, US

16:40 - 16:45

LBA34 - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study

F. Meric-Bernstam[1], V. Makker[2], A. Oaknin[3], D.-Y. Oh[4], S. Banerjee[5], A. Gonzalez Martin[6], K. Jung[7], I. Lugowska[8], L. Manso[9], A. Manzano[10], B. Melichar[11], S. Siena[12], D. Stroyakovskiy[13], A. Fielding[14], Y. Ma[15], S. Puvvada[14], J.-Y. Lee[16], [1]University of Texas MD Anderson Cancer Center, Houston, US, [2]Memorial Sloan-Kettering Cancer Center, New York City, US, [3]Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, ES, [4]Seoul National University Hospital, Seoul, KR, [5]The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, [6]Cancer Center Clínica Universidad de Navarra, Madrid, ES, [7]Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, [8]Maria Sklodowska-Curie National Research Institute and Oncology Centre, Warsaw, PL, [9]Hospital Universitario 12 de Octubre, Madrid, ES, [10]Hospital Clinico San Carlos, Madrid, ES, [11]University Hospital, Palacký University Medical School, Olomouc, CZ, [12]Università degli Studi di Milano, Piazza Ospedale Maggiore, Milan, IT, [13]Moscow City Oncology Hospital No. 62, Moscow, RU, [14]AstraZeneca, Gaithersburg, MD, US, [15]AstraZeneca, Cambridge, GB, [16]Yonsei University College of Medicine, Seoul, KR

16:45 - 16:50

658MO - Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors

Q. Zhou[1], Y.-L. Wu[1], J. Li[2], A. Liu[2], J. Cui[3], Y. Kuboki[4], N. Yamamoto[5], S.-W. Han[6], G. Lin[7], J.-M. Sun[8], L. Wu[9], Z. Zhu[10], J. Shuang[10], F. Qiu[10], W. Shi[10], [1]Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CN, [2]The Second Affiliated Hospital of Nanchang University, Nanchang, CN, [3]The First Hospital of Jilin University, Changchun, CN, [4]National Cancer Center Hospital East, Kashiwa, JP, [5]National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, [6]Seoul National University Hospital, Seoul, KR, [7]Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, [8]Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, [9]Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, [10]Jiangsu Hengrui Pharmaceuticals, Co., Ltd, Shanghai, CN

16:50 - 17:05

Invited Discussant 656MO, 657MO, LBA34 and 658MO

P. Munster, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

17:05 - 17:10

659MO - Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors

J. Zhang[1], R. Liu[1], S. Gao[1], X. Li[2], J. Chen[3], X. Yao[4], Y. Fang[5], R. Li[6], M. Zhang[7], F. Qiu[8], Y. Li[9], T. Liu[10], H. Huang[11], X. Zhang[12], H. Guo[13], B. Hu[14], J.-Y. Liu[15], Q. Yang[16], P. Zhao[17], P. Wang[18], [1]Fudan University Shanghai Cancer Center, Shanghai, CN, [2]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, [3]Yantai Yuhunagding Hospital, Yantai, CN, [4]Tianjin Cancer Hospital, Tianjin, CN, [5]Affiliated Cancer Hospital of Chongqing University, Chongqing, CN, [6]Chongqing University Cancer Hospital, Chongqing, CN, [7]The Second Hospital of Anhui Medical University, Hefei, CN, [8]The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN, [9]Shenyang Tenth People's Hospital, Shenyang, CN, [10]Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, [11]The First Affiliated Hospital of Wenzhou Medical University - Nanbaixiang Site, Wenzhou, CN, [12]Wuhan Union Hospital, Wuhan, CN, [13]The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN, [14]Liaoning Cancer Hospital and Institute, Shenyang, CN, [15]West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, [16]The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, [17]The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, CN, [18]Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, CN

17:10 - 17:15

660MO - First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)

C. Perez[1], J. Henry[2], N. Lakhani[3], J. Call[4], E. Hamilton[5], G. Colon-Otero[6], J. Diamond[7], B. O'Neil[8], A. Kalyan[9], G. Sonpavde[10], I. Moreno[11], A. Awan[12], E. Fontana[13], P. Xu[14], F. Zhang[14], N. Nazarenko[14], A. Patnaik[15], [1]University of Central Florida Lake Nona Cancer Center, Orlando, US, [2]Sarah Cannon Research Institute at HealthONE, Denver, US, [3]START Midwest, Grand Rapids, US, [4]START Mountain Region, West Valley City, US, [5]Tennessee Oncology, Nashville, US, [6]Mayo Clinic, Jacksonville, US, [7]University of Colorado, Aurora, US, [8]Community Health Network, Indianapolis, US, [9]Northwestern University, Chicago, US, [10]AdventHealth Cancer Institute, Celebration, US, [11]Centro

Integral Oncológico Clara Campal, Madrid, ES, [12]Ottawa Hospital Research Institute, Ottawa, CA, [13]Sarah Cannon Research Institute SCRI UK, London, GB, [14]Seagen Inc., Bothell, US, [15]START San Antonio, San Antonio, US

17:15 - 17:30 **Invited Discussant 659MO and 660MO**

U. Lassen, Rigshospitalet, Copenhagen, DK

17:30 - 17:35 **LBA35 - BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac)**

J. Haanen[1], W. Alsdorf[2], C. Koenecke[3], E. Wagner-Drouet[4], P. Borchmann[5], D. Heudobler[6], A. Busse[7], S. Klobuch[1], N. Kutsch[8], F. Müller[9], C. Bokemeyer[10], A. Desuki[11], F. Lueke[6], T. Ho[12], K. Vemuri[12], L. Preussner[13], B. Rengstl[13], Ö. Türeci[13], U. Sahin[13], [1]NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, [2]University Medical Center Hamburg-Eppendorf, Hamburg, DE, [3]MHH - Medizinische Hochschule Hannover, Hannover, DE, [4]University Medical Center Mainz, Mainz, DE, [5]University Hospital Cologne, Köln, DE, [6]UKR - University Hospital Regensburg, Regensburg, DE, [7]Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, [8]University Hospital of Cologne, Cologne, DE, [9]Universitätsklinikums Erlangen, Erlangen, DE, [10]UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, [11]Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, [12]BioNTech US, Cambridge, US, [13]BioNTech SE, Mainz, DE

17:35 - 17:40 **661MO - Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation**

T.W. Kim[1], J. Lee[2], S.J. Shin[3], S.-W. Han[4], Y.J. Kim[5], J.-S. Kim[6], S.Y. Oh[7], D.H. Lee[1], M.H. Kim[3], S. Kim[2], Y. Hong[8], S. Kim[8], T. Kim[8], B. Lee[8], J. Eng-Wong[9], Y. Yan[9], C. Chou[9], Y.S. Noh[8], [1]Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, [2]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, [3]Yonsei University College of Medicine, Seoul, KR, [4]Seoul National University Hospital, Seoul, KR, [5]Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, [6]Boramae Medical Center, Seoul, KR, [7]Dong-A University College of Medicine, Busan, KR, [8]Hanmi Pharmaceutical Co., Ltd, Seoul, KR, [9]Genentech, Inc., South San Francisco, US

17:40 - 17:45 **662MO - Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors**

C.-C. Lin[1], J. Grewal[2], J. Baranda[3], R. Schneider[4], J. Zhang[5], L.-Y. Bai[6], Y.-M. Yeh[7], D. Sommerhalder[8], G. Li[9], L. Shen[10], H.-C. Hsu[11], O. Alese[12], R. Yin[13], C.-Y. Hsieh[14], S.X. Cai[14], Y.E. Tian[14], H. Xia[15], B. Li[14], M. Zhang[14], C. Zhang[14], [1]NTUH - National Taiwan University Hospital, Taipei City, TW, [2]Norton Cancer Institute, Louisville, US, [3]University of Kansas Clinical Research Center, Kansas City, US, [4]Mary Crowley Cancer Research Center, Dallas, US, [5]Fudan University Shanghai Cancer Center, Shanghai, CN, [6]China Medical University Hospital , New Taipei City, TW, [7]NCKUH - National Cheng Kung University Hospital, Tainan City, TW, [8]NEXT Oncology, San Antonio, US, [9]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, [10]Beijing Cancer Hospital, Beijing, CN, [11]Chang Gung Medical Foundation - Linkou

Chang Gung Memorial Hospital, Taoyuan City, TW, [12]Emory University Hospital, Atlanta, US, [13]West China Second University Hospital, Sichuan University/ West China Women's and Children's Hospital, Chengdu, CN, [14]IMPACT Therapeutics, Inc. (Shanghai), Shanghai, CN, [15]Impact Therapeutics, Shanghai, CN

17:45 - 18:00 **Invited Discussant LBA35, 661MO and 662MO**

P. Cassier, Centre Léon Bérard, Lyon, FR

16:30 - 18:00 **Type: Educational session** **Málaga Auditorium - Hall 10**
Title: Advances in the management of locally advanced NPC

Chair(s): Brigette Ma, HK; Lisa Licitra, IT

16:30 - 16:50 **Recent advances in the clinical application of plasma EBV DNA in individualizing treatment of LA-NPC**

M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

16:50 - 17:10 **Navigating the undulating landscape of radiotherapy escalation/ de-escalation in the treatment of LA-NPC**

Q.-T. Le, Stanford University, Stanford, US

17:10 - 17:30 **Induction versus adjuvant chemotherapy in LA-NPC: Deciphering the latest evidence for the practicing oncologist**

P. Blanchard, Institut Gustave Roussy, Villejuif, Cedex, FR

17:30 - 17:50 **How to transfer results from endemic to non-endemic settings**

L. Licitra, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

17:50 - 18:00 **Q&A and Discussion**

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: GSK - The Need for Better Patient Outcomes: Latest Investigational Approaches for dMMR/MSI-H CRC** Chair(s): Jenny Seligmann, GB	**Burgos Auditorium - Hall 3**

18:30 - 18:45 **The Need for New Approaches in Locally Advanced dMMR/MSI-H CRC**

J. Seligmann, The University of Leeds, Leeds, GB

18:45 - 19:05 **Locally Advanced dMMR/MSI-H Rectal Cancer: New Approaches Under Investigation**

A. Parikh, MGH - Massachusetts General Hospital, Boston, US

19:05 - 19:25 **Locally Advanced dMMR/MSI-H Colon Cancer: New Approaches Under Investigation**

V. Heinemann, LMU Klinikum der Universität München, Munich, DE

19:25 - 19:45 **The Multidisciplinary Approach to Locally Advanced dMMR/MSI-H CRC: Reducing the Patient Burden**

J. Seligmann, The University of Leeds, Leeds, GB

19:45 - 20:00 **Q&A | Panel Discussion**

J. Seligmann[1], V. Heinemann[2], A. Parikh[3], [1]The University of Leeds, Leeds, GB, [2]LMU Klinikum der Universität München, Munich, DE, [3]MGH - Massachusetts General Hospital, Boston, US

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: Stemline. A Menarini Group Company - Current and upcoming treatment strategies after CDK4/6 inhibitors for patients with ER+/HER2- advanced breast cancer** Chair(s): Antonio Llombart Cussac, ES	**Valencia Auditorium - Hall 10**

18:30 - 18:40 **Welcome and introductions**

A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES

18:40 - 19:10 **The current and future treatment landscape for ER+/HER2- metastatic breast cancer**

V. Kaklamani, Mays Cancer Center - UT Health San Antonio MD Anderson Cancer Center, San Antonio, US

19:10 - 19:30 **Emerging biomarkers in breast cancer: Implementing liquid biopsy ESR1 mutation testing**

V. Mueller, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

19:30 - 19:40 **Key takeaways**

A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES

19:40 - 20:00 **Q&A**

A. Llombart Cussac[1], V. Kaklamani[2], V. Mueller[3], [1]Hospital Arnau de Vilanova, Valencia, ES, [2]Mays Cancer Center - UT Health San Antonio MD Anderson Cancer Center, San Antonio, US, [3]UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: F. Hoffmann-La Roche LTD - Shaping the future of personalised healthcare for cancer patients** Chair(s): Vivek Subbiah, US	**Salamanca Auditorium - Hall 3**

18:30 - 18:35 **Understanding the patient's perspective**

T. Knott, Sarah Jennifer Knott Foundation, Dublin, IE

18:35 - 18:45 **CUPISCO as an innovative example in precision oncology**

L. Mileshkin, Peter MacCallum Cancer Center, Melbourne, AU

18:45 - 18:55 **Changing the trajectory for cancer patients with liquid biopsy**

B. Westphalen, LMU Klinikum der Universität München, Munich, DE

18:55 - 19:10 **Panel discussion: including Q&A: Considerations for future clinical decision making**

T. Knott[1], L. Mileshkin[2], B. Westphalen[3], A. Krämer[4], V. Subbiah[5], [1]Sarah Jennifer Knott Foundation, Dublin, IE, [2]Peter MacCallum Cancer Center, Melbourne, AU, [3]LMU Klinikum der Universität München, Munich, DE, [4]German Cancer Research Center (DKFZ) and University of Heidelberg, Heidelberg, DE, [5]The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US

19:10 - 19:20 **Translating scientific evidence into drug approvals**

V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US

19:20 - 19:30 **Shaping public healthcare systems to accelerate treatment access**

D. Thomas, Garvan Institute of Medical Research, Sydney, AU

19:30 - 19:55 **Panel discussion including Q&A: Considerations for our future healthcare systems**

V. Subbiah[1], D. Thomas[2], V. Muthu[3], [1]The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US, [2]Garvan Institute of Medical Research, Sydney, AU, [3]Marivek LTD, London, GB

19:55 - 20:00 **Call to action**

V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Nashville, NV, US

18:30 - 20:00 **Type: Industry Satellite Symposium** **Málaga Auditorium - Hall 10**
Title: AbbVie Inc. - The Future of ADCs in NSCLC
Chair(s): Federico Cappuzzo, IT

18:30 - 18:35 **Welcome and Introduction**

F. Cappuzzo, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT

18:35 - 19:00 **An introduction to ADCs in the treatment of NSCLC**

B. Besse, Institut Gustave Roussy, Villejuif, FR

19:00 - 19:25 **The emerging role for ADCs in the NSCLC treatment landscape**

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

19:25 - 19:55 **Panel discussion and Q&A**

F. Cappuzzo[1], B. Besse[2], E. Felip[3], [1]IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT, [2]Institut Gustave Roussy, Villejuif, FR, [3]Vall d'Hebron University Hospital, Barcelona, ES

19:55 - 20:00 **Closing**

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: F. Hoffmann-La Roche LTD - HER future: Pathways to better care for women with HER2+ breast cancer** Chair(s): Matteo Lambertini, IT	**Santander Auditorium - Hall 9**

18:30 - 18:33 **Welcome and introduction**

M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

18:33 - 18:53 **Delivering women-centric cancer care for optimal outcomes**

M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

18:53 - 19:13 **Changing the SCript: Rewriting the patient experience with subcutaneous formulations of HER2-targeted antibodies**

J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US

19:13 - 19:33 **Decentralised cancer care: Providing healthcare closer to home**

S.C. Lee, Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG

19:33 - 20:00 **Live Q&A, discussion and closing remarks**

M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: Pfizer Oncology - ALK+ NSCLC: Maximising the potential for patients throughout their treatment journey** Chair(s): Geoffrey Liu, CA	**Toledo Auditorium - Hall 3**

18:30 - 18:35 **Welcome and introduction**

G. Liu, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

18:35 - 19:55 **Follow a fictional patient on their ALK+ NSCLC treatment journey: Diagnosis, Treatment selection, 1L treatment, Experiencing adverse events, Beyond progression**

G. Liu[1], M.R. Garcia Campelo[2], M. Dietrich[3], [1]UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, [2]CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, [3]Florida Cancer Specialists & Research Institute - Lake Mary Cancer Center, Orlando, US

19:55 - 20:00 **Meeting close**

G. Liu, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: MSD - Immune Checkpoint Inhibitors & beyond: Evolving treatment landscape of Kidney Cancer** Chair(s): Toni Choueiri, US	**Oviedo Auditorium - Hall 7**

18:30 - 18:35 **Welcome**

T. Choueiri, Dana Farber Cancer Institute, Boston, US

18:35 - 18:55 **Management of post-nephrectomy RCC patients: Adjuvant treatment options and Patient case discussion**

J. Bedke[1], T. Choueiri[2], [1]Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, [2]Dana Farber Cancer Institute, Boston, US

18:55 - 19:00 **Q&A**

J. Bedke[1], T. Choueiri[2], [1]Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, [2]Dana Farber Cancer Institute, Boston, US

19:00 - 19:20 **First line advanced RCC treatment landscape: current standard of care, treatment decision making for both clear-cell and non-clear cell RCC treatment options and Patient Case discussion**

L. Albiges[1], T. Choueiri[2], [1]Institut Gustave Roussy, Villejuif, Cedex, FR, [2]Dana Farber Cancer Institute, Boston, US

19:20 - 19:35 **2L+ treatment options for advanced RCC patients post IO and/or TKI: Current treatment options & Patient case discussion**

C. Suarez Rodriguez[1], T. Choueiri[2], [1]Vall d'Hebron University Hospital, Barcelona, ES, [2]Dana Farber Cancer Institute, Boston, US

19:35 - 20:00 **Expert Panel & Q&A**

T. Choueiri[1], J. Bedke[2], L. Albiges[3], C. Suarez Rodriguez[4], [1]Dana Farber Cancer Institute, Boston, US, [2]Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, [3]Institut Gustave Roussy, Villejuif, Cedex, FR, [4]Vall d'Hebron University Hospital, Barcelona, ES

18:30 - 20:00	**Type: Industry Satellite Symposium** **Title: Daiichi Sankyo AstraZeneca - From Bench to Bedside: Interdisciplinary Management of HER2-Low Breast Cancer in the Clinic** Chair(s): Eva Ciruelos, ES	**León Auditorium - Hall 7**

18:30 - 18:35 **Welcome & Introduction**

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

18:35 - 18:55 **Inside the HER2 Expression Spectrum**

P. Sinn, University Hospital Heidelberg, Heidelberg, DE

18:55 - 19:15 **Treatment of HR+ Metastatic Breast Cancer: Considerations**

V. Guarneri, University of Padua, Padova, IT

19:15 - 19:35 **Optimising Patient Management in the Real-World**

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

19:35 - 19:55 **Panel Discussion and Q&A**

E. Ciruelos[1], V. Guarneri[2], P. Sinn[3], [1]Hospital Universitario 12 de Octubre, Madrid, ES, [2]University of Padua, Padova, IT, [3]University Hospital Heidelberg, Heidelberg, DE

19:55 - 20:00 **Wrap-up and Meeting Close**

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

24.10.2023

09:00 - 12:40 **Type: Scientific Congress highlights** **Barcelona Auditorium - Hall 9**
Title: Scientific Congress Highlights 1
Chair(s): Fabrice André, FR; Silke Gillessen, CH

09:00 - 09:20 **Breast cancer, early stage**
A.H. Partridge, Dana Farber Cancer Institute, Boston, US

09:20 - 09:40 **Breast cancer, metastatic**
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

09:40 - 10:00 **Gynaecological cancers**
A. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES

10:00 - 10:20 **CNS tumours**
A.S. Berghoff, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

10:20 - 10:40 **Policy and preventive strategies**
J. Martin-Moreno, Hospital Clinico Universitario de Valencia, Valencia, ES

10:40 - 11:00 **Break**

11:00 - 11:20 **Basic science & translational research**
K. Rouschop, Maastricht University, Maastricht, NL

11:20 - 11:40 **Developmental therapeutics**
L. Siu, Princess Margaret Cancer Centre, Toronto, CA

11:40 - 12:00 **GU prostate**
M. Gizzi, GHdC - Grand Hopital de Charleroi - Site Notre Dame, Charleroi, BE

12:00 - 12:20 **GU non-prostate**
P. Grivas, University of Washington, Seattle, US

12:20 - 12:40 **Investigational immunotherapy**
J. Hassel, NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE

09:00 - 12:40 **Type: Scientific Congress highlights** **Sevilla Auditorium - Hall 9**
Title: Scientific Congress Highlights 2
Chair(s): Andres Cervantes, ES; Solange Peters, CH

09:00 - 09:20 **Melanoma and other skin tumours**
I. Marquez-Rodas, Hospital General Universitario Gregorio Marañon - Fundación Investigación Biomedica, Madrid, ES

09:20 - 09:40 **Sarcoma**
C.M. Valverde Morales, Vall d'Hebron University Hospital, Barcelona, ES

09:40 - 10:00 **Head and neck cancer**
P. Bossi, IRCCS Humanitas Research Hospital, Rozzano, IT

10:00 - 10:20 **Supportive and palliative care**
C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

10:20 - 10:40 **Haematological malignancies**
D. Rossi, EOC - Amministrazione IOSI, Bellinzona, CH

10:40 - 11:00 **Break**

11:00 - 11:20 **GI, lower digestive**
S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG

11:20 - 11:30 **GI, upper digestive: HPB**
A. Ko, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

11:30 - 11:40 **GI, upper digestive: Gastroesophageal**
T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES

11:40 - 12:00 **NETs and endocrine tumours**
C. De La Fouchardiere, IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR

12:00 - 12:20 **Non-metastatic NSCLC and other thoracic malignancies**
J. Naidoo, Beaumont Hospital, Dublin, IE

12:20 - 12:40 **NSCLC, metastatic**
G. Pasello, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT